{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Coursework #3\n",
    "## Advanced Data Manipulations, Creating Visualisations, and Flask\n",
    "\n",
    "Harinath Selvaraj </br>\n",
    "\n",
    "##### ******* Libraries to be Installed ******* \n",
    "seaborn </br>\n",
    "matplotlib</br>\n",
    "altair</br>\n",
    "pandas</br>\n",
    "numpy</br>\n",
    "mysql"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import mysql.connector as sql\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import datetime\n",
    "import altair as alt\n",
    "import seaborn as sns\n",
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "db_connection = sql.connect(host='localhost', database='PYTHON_DB', user='root', password='root')\n",
    "df = pd.read_sql('SELECT * FROM scraped', con=db_connection)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Section 1 - Data Cleanups"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Checking the data Information"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 398 entries, 0 to 397\n",
      "Data columns (total 20 columns):\n",
      "id             398 non-null int64\n",
      "last_scrape    398 non-null datetime64[ns]\n",
      "url            398 non-null object\n",
      "rr_start       366 non-null object\n",
      "rr_end         398 non-null object\n",
      "rr_outcome     398 non-null object\n",
      "rr_dates       398 non-null object\n",
      "rr_multiple    398 non-null int64\n",
      "drug_name      398 non-null object\n",
      "trade_name     398 non-null object\n",
      "indication     398 non-null object\n",
      "ncpe_year      398 non-null int64\n",
      "eu_market      383 non-null object\n",
      "company        398 non-null object\n",
      "orphan         398 non-null int64\n",
      "earliest       398 non-null object\n",
      "latest         398 non-null object\n",
      "ema_url        398 non-null object\n",
      "ta_list        398 non-null object\n",
      "rr_status      398 non-null object\n",
      "dtypes: datetime64[ns](1), int64(4), object(15)\n",
      "memory usage: 62.3+ KB\n"
     ]
    }
   ],
   "source": [
    "df.info()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "All columns have totally 398 values except the below two columns </br>\n",
    "- 'rr_start' has 366 values\n",
    "- 'eu_market' hsa 383 values"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Getting all rows which has NULLS in the column - 'rr_start'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>last_scrape</th>\n",
       "      <th>url</th>\n",
       "      <th>rr_start</th>\n",
       "      <th>rr_end</th>\n",
       "      <th>rr_outcome</th>\n",
       "      <th>rr_dates</th>\n",
       "      <th>rr_multiple</th>\n",
       "      <th>drug_name</th>\n",
       "      <th>trade_name</th>\n",
       "      <th>indication</th>\n",
       "      <th>ncpe_year</th>\n",
       "      <th>eu_market</th>\n",
       "      <th>company</th>\n",
       "      <th>orphan</th>\n",
       "      <th>earliest</th>\n",
       "      <th>latest</th>\n",
       "      <th>ema_url</th>\n",
       "      <th>ta_list</th>\n",
       "      <th>rr_status</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>2176</td>\n",
       "      <td>2018-12-13 16:25:58</td>\n",
       "      <td>http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/</td>\n",
       "      <td>None</td>\n",
       "      <td>2013-04-10</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Agomelatine (Valdoxan®)</td>\n",
       "      <td>Valdoxan</td>\n",
       "      <td>Economic evaluation of Agomelatine (Valdoxan®)...</td>\n",
       "      <td>2009</td>\n",
       "      <td>2009-02-19</td>\n",
       "      <td>Les</td>\n",
       "      <td>0</td>\n",
       "      <td>2009-09-03</td>\n",
       "      <td>2009-12-11</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Depressive Disorder, Major</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>2209</td>\n",
       "      <td>2018-12-13 16:28:11</td>\n",
       "      <td>http://www.ncpe.ie/drugs/boceprevir-victrelis/</td>\n",
       "      <td>None</td>\n",
       "      <td>2015-12-22</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Boceprevir (Victrelis®)</td>\n",
       "      <td>Victrelis</td>\n",
       "      <td>Economic evaluation of Boceprevir (Victrelis®)...</td>\n",
       "      <td>2012</td>\n",
       "      <td>2011-07-18</td>\n",
       "      <td>Merck</td>\n",
       "      <td>0</td>\n",
       "      <td>2011-08-19</td>\n",
       "      <td>2012-01-17</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Hepatitis C, Chronic</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>2234</td>\n",
       "      <td>2018-12-13 16:29:44</td>\n",
       "      <td>http://www.ncpe.ie/drugs/certolizumab-pegol-ci...</td>\n",
       "      <td>None</td>\n",
       "      <td>2017-11-27</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Certolizumab pegol (Cimzia®)</td>\n",
       "      <td>Cimzia</td>\n",
       "      <td>Cost-effectiveness of certolizumab pegol (Cimz...</td>\n",
       "      <td>2010</td>\n",
       "      <td>2009-10-01</td>\n",
       "      <td>UCB</td>\n",
       "      <td>0</td>\n",
       "      <td>2010-03-13</td>\n",
       "      <td>2010-09-02</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Arthritis, Rheumatoid</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>2248</td>\n",
       "      <td>2018-12-13 16:30:51</td>\n",
       "      <td>http://www.ncpe.ie/drugs/dabigatran-etexilate-...</td>\n",
       "      <td>None</td>\n",
       "      <td>2014-06-13</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Dabigatran etexilate (Pradaxa®) – for the prev...</td>\n",
       "      <td>Pradaxa</td>\n",
       "      <td>Dabigatran etexilate (Pradaxa®) for the Preven...</td>\n",
       "      <td>2012</td>\n",
       "      <td>2008-03-17</td>\n",
       "      <td>Boehringer</td>\n",
       "      <td>0</td>\n",
       "      <td>2010-11-02</td>\n",
       "      <td>2012-10-03</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Arthroplasty, Replacement; Venous Thromboembolism</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>2249</td>\n",
       "      <td>2018-12-13 16:30:57</td>\n",
       "      <td>http://www.ncpe.ie/drugs/dabigatran-etexilate-...</td>\n",
       "      <td>None</td>\n",
       "      <td>2014-06-13</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Dabigatran Etexilate (Pradaxa®) for the Primar...</td>\n",
       "      <td>Pradaxa</td>\n",
       "      <td>Economic Evaluation of the Cost Effectiveness ...</td>\n",
       "      <td>2008</td>\n",
       "      <td>2008-03-17</td>\n",
       "      <td>Boehringer</td>\n",
       "      <td>0</td>\n",
       "      <td>2008-07-01</td>\n",
       "      <td>2008-09-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Arthroplasty, Replacement; Venous Thromboembolism</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>100</th>\n",
       "      <td>2264</td>\n",
       "      <td>2018-12-13 16:32:04</td>\n",
       "      <td>http://www.ncpe.ie/drugs/denosumab-prolia/</td>\n",
       "      <td>None</td>\n",
       "      <td>2013-01-04</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Denosumab (Prolia®)</td>\n",
       "      <td>Prolia</td>\n",
       "      <td>The Cost-effectiveness of Denosumab (Prolia®) ...</td>\n",
       "      <td>2010</td>\n",
       "      <td>2010-05-26</td>\n",
       "      <td>Amgen</td>\n",
       "      <td>0</td>\n",
       "      <td>2010-05-27</td>\n",
       "      <td>2010-07-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Bone Resorption; Osteoporosis, Postmenopausal</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>101</th>\n",
       "      <td>2265</td>\n",
       "      <td>2018-12-13 16:32:08</td>\n",
       "      <td>http://www.ncpe.ie/drugs/denosumab-xgeva-3/</td>\n",
       "      <td>None</td>\n",
       "      <td>2013-01-04</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Denosumab (Xgeva®)</td>\n",
       "      <td>Xgeva</td>\n",
       "      <td>Cost-effectiveness of denosumab (Xgeva®) for t...</td>\n",
       "      <td>2011</td>\n",
       "      <td>2011-07-13</td>\n",
       "      <td>Amgen</td>\n",
       "      <td>0</td>\n",
       "      <td>2011-08-15</td>\n",
       "      <td>2011-12-08</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Fractures, Bone; Neoplasm Metastasis</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>113</th>\n",
       "      <td>2277</td>\n",
       "      <td>2018-12-13 16:32:53</td>\n",
       "      <td>http://www.ncpe.ie/drugs/eculizumab-soliris/</td>\n",
       "      <td>None</td>\n",
       "      <td>2017-11-24</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Eculizumab (Soliris®)</td>\n",
       "      <td>Soliris</td>\n",
       "      <td>An Economic Evaluation of Eculizumab (Soliris®...</td>\n",
       "      <td>2013</td>\n",
       "      <td>2007-06-20</td>\n",
       "      <td>Alexion</td>\n",
       "      <td>1</td>\n",
       "      <td>2010-01-01</td>\n",
       "      <td>2013-10-14</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Hemoglobinuria, Paroxysmal</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>137</th>\n",
       "      <td>2301</td>\n",
       "      <td>2018-12-13 16:34:36</td>\n",
       "      <td>http://www.ncpe.ie/drugs/evolocumab-repatha/</td>\n",
       "      <td>None</td>\n",
       "      <td>2011-10-14</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Evolocumab (Repatha®)</td>\n",
       "      <td>Repatha</td>\n",
       "      <td>Evolocumab (Repatha®) is indicated for both pr...</td>\n",
       "      <td>2018</td>\n",
       "      <td>2015-07-17</td>\n",
       "      <td>Amgen</td>\n",
       "      <td>0</td>\n",
       "      <td>2016-01-01</td>\n",
       "      <td>2018-05-16</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Dyslipidemias; Hypercholesterolemia</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>146</th>\n",
       "      <td>2310</td>\n",
       "      <td>2018-12-13 16:35:12</td>\n",
       "      <td>http://www.ncpe.ie/drugs/gefitinib-iressa/</td>\n",
       "      <td>None</td>\n",
       "      <td>2017-08-15</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Gefitinib (Iressa®)</td>\n",
       "      <td>Iressa</td>\n",
       "      <td>A review of the economic evaluation of oral ge...</td>\n",
       "      <td>2010</td>\n",
       "      <td>2009-06-24</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>0</td>\n",
       "      <td>2010-06-16</td>\n",
       "      <td>2010-11-05</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>149</th>\n",
       "      <td>2313</td>\n",
       "      <td>2018-12-13 16:35:25</td>\n",
       "      <td>http://www.ncpe.ie/drugs/glucosamine-sulfate-d...</td>\n",
       "      <td>None</td>\n",
       "      <td>2017-08-17</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Glucosamine sulfate (Dona®)</td>\n",
       "      <td>Dona</td>\n",
       "      <td>Economic evalution of glucosamine sulfate (Don...</td>\n",
       "      <td>2009</td>\n",
       "      <td>1996-10-04</td>\n",
       "      <td>CIS</td>\n",
       "      <td>0</td>\n",
       "      <td>2009-04-01</td>\n",
       "      <td>2009-06-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Radionuclide Imaging; Ovarian Neoplasms</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>154</th>\n",
       "      <td>2318</td>\n",
       "      <td>2018-12-13 16:35:54</td>\n",
       "      <td>http://www.ncpe.ie/drugs/golimumab-simponi/</td>\n",
       "      <td>None</td>\n",
       "      <td>2013-10-31</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Golimumab (Simponi®)</td>\n",
       "      <td>Simponi</td>\n",
       "      <td>Cost-effectiveness of golimumab (Simponi®) in ...</td>\n",
       "      <td>2010</td>\n",
       "      <td>2009-10-01</td>\n",
       "      <td>Janssen</td>\n",
       "      <td>0</td>\n",
       "      <td>2009-11-20</td>\n",
       "      <td>2010-06-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Arthritis, Psoriatic; Spondylitis, Ankylosing;...</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>172</th>\n",
       "      <td>2336</td>\n",
       "      <td>2018-12-13 16:37:07</td>\n",
       "      <td>http://www.ncpe.ie/drugs/infliximab-inflectra/</td>\n",
       "      <td>None</td>\n",
       "      <td>2010-01-15</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Infliximab (Inflectra®)</td>\n",
       "      <td>Inflectra</td>\n",
       "      <td>Inflectra® is a biosimilar product indicated f...</td>\n",
       "      <td>2013</td>\n",
       "      <td>2013-09-09</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>0</td>\n",
       "      <td>2013-09-10</td>\n",
       "      <td>2013-09-20</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Arthritis, Psoriatic; Spondylitis, Ankylosing;...</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>194</th>\n",
       "      <td>2358</td>\n",
       "      <td>2018-12-13 16:38:50</td>\n",
       "      <td>http://www.ncpe.ie/drugs/lapatinib-tyverb/</td>\n",
       "      <td>None</td>\n",
       "      <td>2017-10-31</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Lapatinib (Tyverb®)</td>\n",
       "      <td>Tyverb</td>\n",
       "      <td>Cost-effectiveness of Lapatinib (Tyverb®) for ...</td>\n",
       "      <td>2008</td>\n",
       "      <td>2008-06-10</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>0</td>\n",
       "      <td>2008-01-01</td>\n",
       "      <td>2008-01-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Breast Neoplasms</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>222</th>\n",
       "      <td>2386</td>\n",
       "      <td>2018-12-13 16:40:43</td>\n",
       "      <td>http://www.ncpe.ie/drugs/melatonin-circadin/</td>\n",
       "      <td>None</td>\n",
       "      <td>2014-01-27</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Melatonin (Circadin®)</td>\n",
       "      <td>Circadin</td>\n",
       "      <td>A Review of the Economic Evaluation of Prolong...</td>\n",
       "      <td>2008</td>\n",
       "      <td>2007-06-29</td>\n",
       "      <td>RAD</td>\n",
       "      <td>0</td>\n",
       "      <td>2008-08-01</td>\n",
       "      <td>2008-10-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Sleep Initiation and Maintenance Disorders</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>234</th>\n",
       "      <td>2398</td>\n",
       "      <td>2018-12-13 16:41:30</td>\n",
       "      <td>http://www.ncpe.ie/drugs/natalizumab-tysabri/</td>\n",
       "      <td>None</td>\n",
       "      <td>2017-03-28</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Natalizumab (Tysabri®)</td>\n",
       "      <td>Tysabri</td>\n",
       "      <td>Economic Evaluation of Natalizumab (Tysabri®)...</td>\n",
       "      <td>2007</td>\n",
       "      <td>2006-06-27</td>\n",
       "      <td>Biogen</td>\n",
       "      <td>0</td>\n",
       "      <td>2007-01-01</td>\n",
       "      <td>2007-03-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Multiple Sclerosis</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>235</th>\n",
       "      <td>2399</td>\n",
       "      <td>2018-12-13 16:41:35</td>\n",
       "      <td>http://www.ncpe.ie/drugs/ncpe-inhaled-insulin-...</td>\n",
       "      <td>None</td>\n",
       "      <td>2017-03-28</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Inhaled insulin (Exubera®)</td>\n",
       "      <td>Exubera</td>\n",
       "      <td>In April 2006, Pfizer submitted a report on th...</td>\n",
       "      <td>2006</td>\n",
       "      <td>2006-01-24</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>0</td>\n",
       "      <td>2006-03-01</td>\n",
       "      <td>2006-03-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Diabetes Mellitus</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>239</th>\n",
       "      <td>2403</td>\n",
       "      <td>2018-12-13 16:41:51</td>\n",
       "      <td>http://www.ncpe.ie/drugs/nilotinib-tasigna/</td>\n",
       "      <td>None</td>\n",
       "      <td>2010-10-22</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Nilotinib (Tasigna®) CML resistant/intolerant ...</td>\n",
       "      <td>Tasigna</td>\n",
       "      <td>Cost-effectiveness of Nilotinib (Tasigna®) for...</td>\n",
       "      <td>2008</td>\n",
       "      <td>2007-11-19</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>1</td>\n",
       "      <td>2008-01-01</td>\n",
       "      <td>2008-02-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>252</th>\n",
       "      <td>2416</td>\n",
       "      <td>2018-12-13 16:42:51</td>\n",
       "      <td>http://www.ncpe.ie/drugs/nivolumab-plus-ipilim...</td>\n",
       "      <td>None</td>\n",
       "      <td>2018-12-11</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Nivolumab plus ipilimumab (Opdivo® plus Yervoy®)</td>\n",
       "      <td>Opdivo plus Yervoy</td>\n",
       "      <td>Opdivo® plus Yervoy® Is indicated for the trea...</td>\n",
       "      <td>2017</td>\n",
       "      <td>2009-10-10</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>0</td>\n",
       "      <td>2016-06-27</td>\n",
       "      <td>2017-10-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Influenza, Human; Immunization; Disease Outbreaks</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>267</th>\n",
       "      <td>2431</td>\n",
       "      <td>2018-12-13 16:44:08</td>\n",
       "      <td>http://www.ncpe.ie/drugs/omalizumab-xolair-for...</td>\n",
       "      <td>None</td>\n",
       "      <td>2018-10-01</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Omalizumab (Xolair®) for the treatment of seve...</td>\n",
       "      <td>Xolair</td>\n",
       "      <td>Omalizumab is indicated as an add-on therapy t...</td>\n",
       "      <td>2015</td>\n",
       "      <td>2005-10-25</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>0</td>\n",
       "      <td>2014-08-22</td>\n",
       "      <td>2015-06-25</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Asthma; Urticaria</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>269</th>\n",
       "      <td>2433</td>\n",
       "      <td>2018-12-13 16:44:19</td>\n",
       "      <td>http://www.ncpe.ie/drugs/oral-oxycodonenaloxon...</td>\n",
       "      <td>None</td>\n",
       "      <td>2014-04-25</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Oxycodone/naloxone (Targin®)</td>\n",
       "      <td>Targin</td>\n",
       "      <td>Cost-effectiveness of oral oxycodone/naloxone ...</td>\n",
       "      <td>2010</td>\n",
       "      <td>1996-10-04</td>\n",
       "      <td>CIS</td>\n",
       "      <td>0</td>\n",
       "      <td>2010-05-05</td>\n",
       "      <td>2010-10-19</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Radionuclide Imaging; Ovarian Neoplasms</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>300</th>\n",
       "      <td>2464</td>\n",
       "      <td>2018-12-13 16:46:38</td>\n",
       "      <td>http://www.ncpe.ie/drugs/prasugrel-efient/</td>\n",
       "      <td>None</td>\n",
       "      <td>2013-12-01</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Prasugrel (Efient®)</td>\n",
       "      <td>Efient</td>\n",
       "      <td>Economic Evaluation of Prasugrel (Efient®) for...</td>\n",
       "      <td>2010</td>\n",
       "      <td>2009-02-24</td>\n",
       "      <td>Daiichi</td>\n",
       "      <td>0</td>\n",
       "      <td>2009-07-01</td>\n",
       "      <td>2010-02-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Acute Coronary Syndrome; Angina, Unstable; Myo...</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>301</th>\n",
       "      <td>2465</td>\n",
       "      <td>2018-12-13 16:46:46</td>\n",
       "      <td>http://www.ncpe.ie/drugs/pregabalin-lyrica-2/</td>\n",
       "      <td>None</td>\n",
       "      <td>2013-12-01</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Pregabalin (Lyrica®) for the treatment of neur...</td>\n",
       "      <td>Lyrica</td>\n",
       "      <td>Lyrica® is indicated for the treatment of peri...</td>\n",
       "      <td>2015</td>\n",
       "      <td>2004-07-05</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>0</td>\n",
       "      <td>2013-09-30</td>\n",
       "      <td>2015-06-12</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Epilepsy; Anxiety Disorders; Neuralgia</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>302</th>\n",
       "      <td>2466</td>\n",
       "      <td>2018-12-13 16:46:52</td>\n",
       "      <td>http://www.ncpe.ie/drugs/pregabalin-lyrica-for...</td>\n",
       "      <td>None</td>\n",
       "      <td>2013-12-01</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Pregabalin (Lyrica®) for the treatment of Gene...</td>\n",
       "      <td>Lyrica</td>\n",
       "      <td>Pregabalin (Lyrica®) for the treatment of Gene...</td>\n",
       "      <td>2014</td>\n",
       "      <td>2004-07-05</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>0</td>\n",
       "      <td>2014-09-12</td>\n",
       "      <td>2014-12-15</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Epilepsy; Anxiety Disorders; Neuralgia</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>316</th>\n",
       "      <td>2480</td>\n",
       "      <td>2018-12-13 16:47:48</td>\n",
       "      <td>http://www.ncpe.ie/drugs/rimonabant-acomplia-2/</td>\n",
       "      <td>None</td>\n",
       "      <td>2016-07-11</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Rimonabant (Acomplia®)</td>\n",
       "      <td>Acomplia</td>\n",
       "      <td>In June 2006, Sanofi-Aventis submitted an eval...</td>\n",
       "      <td>2006</td>\n",
       "      <td>2006-06-19</td>\n",
       "      <td>sanofi-aventis</td>\n",
       "      <td>0</td>\n",
       "      <td>2006-06-01</td>\n",
       "      <td>2006-06-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>324</th>\n",
       "      <td>2488</td>\n",
       "      <td>2018-12-13 16:48:30</td>\n",
       "      <td>http://www.ncpe.ie/drugs/rivaroxaban-xarelto/</td>\n",
       "      <td>None</td>\n",
       "      <td>2017-11-21</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Rivaroxaban (Xarelto®) for the Primary Prevent...</td>\n",
       "      <td>Xarelto</td>\n",
       "      <td>Cost Effectiveness of Rivaroxaban (Xarelto®) f...</td>\n",
       "      <td>2008</td>\n",
       "      <td>2008-09-30</td>\n",
       "      <td>Bayer</td>\n",
       "      <td>0</td>\n",
       "      <td>2008-04-01</td>\n",
       "      <td>2008-09-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Arthroplasty, Replacement; Venous Thromboembolism</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>325</th>\n",
       "      <td>2489</td>\n",
       "      <td>2018-12-13 16:48:33</td>\n",
       "      <td>http://www.ncpe.ie/drugs/roflumilast-daxas/</td>\n",
       "      <td>None</td>\n",
       "      <td>2017-11-21</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Roflumilast (Daxas®)</td>\n",
       "      <td>Daxas</td>\n",
       "      <td>Cost Effectiveness of Roflumilast (Daxas®) for...</td>\n",
       "      <td>2010</td>\n",
       "      <td>2010-07-05</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>0</td>\n",
       "      <td>2010-06-11</td>\n",
       "      <td>2010-11-03</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Pulmonary Disease, Chronic Obstructive</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>327</th>\n",
       "      <td>2491</td>\n",
       "      <td>2018-12-13 16:48:43</td>\n",
       "      <td>http://www.ncpe.ie/drugs/romiplostim-nplate/</td>\n",
       "      <td>None</td>\n",
       "      <td>2017-06-12</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Romiplostim (Nplate®)</td>\n",
       "      <td>Nplate</td>\n",
       "      <td>Romiplostim (Nplate®) is indicated for the tre...</td>\n",
       "      <td>2015</td>\n",
       "      <td>2009-02-04</td>\n",
       "      <td>Amgen</td>\n",
       "      <td>1</td>\n",
       "      <td>2015-04-02</td>\n",
       "      <td>2015-05-27</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Purpura, Thrombocytopenic, Idiopathic</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>354</th>\n",
       "      <td>2518</td>\n",
       "      <td>2018-12-13 16:50:49</td>\n",
       "      <td>http://www.ncpe.ie/drugs/sublingual-immunother...</td>\n",
       "      <td>None</td>\n",
       "      <td>2013-05-17</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Sublingual Immunotherapy (Grazax®)</td>\n",
       "      <td>Grazax</td>\n",
       "      <td>A Review of the Cost-Effectiveness of Sublingu...</td>\n",
       "      <td>2007</td>\n",
       "      <td>1996-10-04</td>\n",
       "      <td>CIS</td>\n",
       "      <td>0</td>\n",
       "      <td>2007-09-01</td>\n",
       "      <td>2007-09-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Radionuclide Imaging; Ovarian Neoplasms</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>355</th>\n",
       "      <td>2519</td>\n",
       "      <td>2018-12-13 16:50:50</td>\n",
       "      <td>http://www.ncpe.ie/drugs/suboxone-buprenorphin...</td>\n",
       "      <td>None</td>\n",
       "      <td>2013-05-17</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Buprenorphine/naloxone (Suboxone®)</td>\n",
       "      <td>Suboxone</td>\n",
       "      <td>An economic evaluation of suboxone for the man...</td>\n",
       "      <td>2014</td>\n",
       "      <td>2006-09-26</td>\n",
       "      <td>Indivior</td>\n",
       "      <td>0</td>\n",
       "      <td>2007-11-01</td>\n",
       "      <td>2014-05-22</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Opioid-Related Disorders</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>357</th>\n",
       "      <td>2521</td>\n",
       "      <td>2018-12-13 16:50:59</td>\n",
       "      <td>http://www.ncpe.ie/drugs/sunitinib-sutent/</td>\n",
       "      <td>None</td>\n",
       "      <td>2016-03-22</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Sunitinib (Sutent®)</td>\n",
       "      <td>Sutent</td>\n",
       "      <td>In September 2006, Pfizer Healthcare Ireland s...</td>\n",
       "      <td>2006</td>\n",
       "      <td>2006-07-19</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>0</td>\n",
       "      <td>2006-09-01</td>\n",
       "      <td>2006-09-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Gastrointestinal Stromal Tumors; Carcinoma, Re...</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387</th>\n",
       "      <td>2551</td>\n",
       "      <td>2018-12-13 16:53:23</td>\n",
       "      <td>http://www.ncpe.ie/drugs/ustekinumab-stelara/</td>\n",
       "      <td>None</td>\n",
       "      <td>2017-01-11</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>0</td>\n",
       "      <td>Ustekinumab (Stelara®)</td>\n",
       "      <td>Stelara</td>\n",
       "      <td>Cost-effectiveness of Ustekinumab (Stelara®) i...</td>\n",
       "      <td>2009</td>\n",
       "      <td>2009-01-15</td>\n",
       "      <td>Janssen-Cilag</td>\n",
       "      <td>0</td>\n",
       "      <td>2009-07-01</td>\n",
       "      <td>2009-11-01</td>\n",
       "      <td>https://www.ema.europa.eu/en/medicines/human/E...</td>\n",
       "      <td>Psoriasis; Arthritis, Psoriatic; Crohn Disease</td>\n",
       "      <td>RR not conducted</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       id         last_scrape  \\\n",
       "12   2176 2018-12-13 16:25:58   \n",
       "45   2209 2018-12-13 16:28:11   \n",
       "70   2234 2018-12-13 16:29:44   \n",
       "84   2248 2018-12-13 16:30:51   \n",
       "85   2249 2018-12-13 16:30:57   \n",
       "100  2264 2018-12-13 16:32:04   \n",
       "101  2265 2018-12-13 16:32:08   \n",
       "113  2277 2018-12-13 16:32:53   \n",
       "137  2301 2018-12-13 16:34:36   \n",
       "146  2310 2018-12-13 16:35:12   \n",
       "149  2313 2018-12-13 16:35:25   \n",
       "154  2318 2018-12-13 16:35:54   \n",
       "172  2336 2018-12-13 16:37:07   \n",
       "194  2358 2018-12-13 16:38:50   \n",
       "222  2386 2018-12-13 16:40:43   \n",
       "234  2398 2018-12-13 16:41:30   \n",
       "235  2399 2018-12-13 16:41:35   \n",
       "239  2403 2018-12-13 16:41:51   \n",
       "252  2416 2018-12-13 16:42:51   \n",
       "267  2431 2018-12-13 16:44:08   \n",
       "269  2433 2018-12-13 16:44:19   \n",
       "300  2464 2018-12-13 16:46:38   \n",
       "301  2465 2018-12-13 16:46:46   \n",
       "302  2466 2018-12-13 16:46:52   \n",
       "316  2480 2018-12-13 16:47:48   \n",
       "324  2488 2018-12-13 16:48:30   \n",
       "325  2489 2018-12-13 16:48:33   \n",
       "327  2491 2018-12-13 16:48:43   \n",
       "354  2518 2018-12-13 16:50:49   \n",
       "355  2519 2018-12-13 16:50:50   \n",
       "357  2521 2018-12-13 16:50:59   \n",
       "387  2551 2018-12-13 16:53:23   \n",
       "\n",
       "                                                   url rr_start      rr_end  \\\n",
       "12    http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/     None  2013-04-10   \n",
       "45      http://www.ncpe.ie/drugs/boceprevir-victrelis/     None  2015-12-22   \n",
       "70   http://www.ncpe.ie/drugs/certolizumab-pegol-ci...     None  2017-11-27   \n",
       "84   http://www.ncpe.ie/drugs/dabigatran-etexilate-...     None  2014-06-13   \n",
       "85   http://www.ncpe.ie/drugs/dabigatran-etexilate-...     None  2014-06-13   \n",
       "100         http://www.ncpe.ie/drugs/denosumab-prolia/     None  2013-01-04   \n",
       "101        http://www.ncpe.ie/drugs/denosumab-xgeva-3/     None  2013-01-04   \n",
       "113       http://www.ncpe.ie/drugs/eculizumab-soliris/     None  2017-11-24   \n",
       "137       http://www.ncpe.ie/drugs/evolocumab-repatha/     None  2011-10-14   \n",
       "146         http://www.ncpe.ie/drugs/gefitinib-iressa/     None  2017-08-15   \n",
       "149  http://www.ncpe.ie/drugs/glucosamine-sulfate-d...     None  2017-08-17   \n",
       "154        http://www.ncpe.ie/drugs/golimumab-simponi/     None  2013-10-31   \n",
       "172     http://www.ncpe.ie/drugs/infliximab-inflectra/     None  2010-01-15   \n",
       "194         http://www.ncpe.ie/drugs/lapatinib-tyverb/     None  2017-10-31   \n",
       "222       http://www.ncpe.ie/drugs/melatonin-circadin/     None  2014-01-27   \n",
       "234      http://www.ncpe.ie/drugs/natalizumab-tysabri/     None  2017-03-28   \n",
       "235  http://www.ncpe.ie/drugs/ncpe-inhaled-insulin-...     None  2017-03-28   \n",
       "239        http://www.ncpe.ie/drugs/nilotinib-tasigna/     None  2010-10-22   \n",
       "252  http://www.ncpe.ie/drugs/nivolumab-plus-ipilim...     None  2018-12-11   \n",
       "267  http://www.ncpe.ie/drugs/omalizumab-xolair-for...     None  2018-10-01   \n",
       "269  http://www.ncpe.ie/drugs/oral-oxycodonenaloxon...     None  2014-04-25   \n",
       "300         http://www.ncpe.ie/drugs/prasugrel-efient/     None  2013-12-01   \n",
       "301      http://www.ncpe.ie/drugs/pregabalin-lyrica-2/     None  2013-12-01   \n",
       "302  http://www.ncpe.ie/drugs/pregabalin-lyrica-for...     None  2013-12-01   \n",
       "316    http://www.ncpe.ie/drugs/rimonabant-acomplia-2/     None  2016-07-11   \n",
       "324      http://www.ncpe.ie/drugs/rivaroxaban-xarelto/     None  2017-11-21   \n",
       "325        http://www.ncpe.ie/drugs/roflumilast-daxas/     None  2017-11-21   \n",
       "327       http://www.ncpe.ie/drugs/romiplostim-nplate/     None  2017-06-12   \n",
       "354  http://www.ncpe.ie/drugs/sublingual-immunother...     None  2013-05-17   \n",
       "355  http://www.ncpe.ie/drugs/suboxone-buprenorphin...     None  2013-05-17   \n",
       "357         http://www.ncpe.ie/drugs/sunitinib-sutent/     None  2016-03-22   \n",
       "387      http://www.ncpe.ie/drugs/ustekinumab-stelara/     None  2017-01-11   \n",
       "\n",
       "    rr_outcome rr_dates  rr_multiple  \\\n",
       "12                                 0   \n",
       "45                                 0   \n",
       "70                                 0   \n",
       "84                                 0   \n",
       "85                                 0   \n",
       "100                                0   \n",
       "101                                0   \n",
       "113                                0   \n",
       "137                                0   \n",
       "146                                0   \n",
       "149                                0   \n",
       "154                                0   \n",
       "172                                0   \n",
       "194                                0   \n",
       "222                                0   \n",
       "234                                0   \n",
       "235                                0   \n",
       "239                                0   \n",
       "252                                0   \n",
       "267                                0   \n",
       "269                                0   \n",
       "300                                0   \n",
       "301                                0   \n",
       "302                                0   \n",
       "316                                0   \n",
       "324                                0   \n",
       "325                                0   \n",
       "327                                0   \n",
       "354                                0   \n",
       "355                                0   \n",
       "357                                0   \n",
       "387                                0   \n",
       "\n",
       "                                             drug_name          trade_name  \\\n",
       "12                             Agomelatine (Valdoxan®)            Valdoxan   \n",
       "45                             Boceprevir (Victrelis®)           Victrelis   \n",
       "70                        Certolizumab pegol (Cimzia®)              Cimzia   \n",
       "84   Dabigatran etexilate (Pradaxa®) – for the prev...             Pradaxa   \n",
       "85   Dabigatran Etexilate (Pradaxa®) for the Primar...             Pradaxa   \n",
       "100                                Denosumab (Prolia®)              Prolia   \n",
       "101                                 Denosumab (Xgeva®)               Xgeva   \n",
       "113                              Eculizumab (Soliris®)             Soliris   \n",
       "137                              Evolocumab (Repatha®)             Repatha   \n",
       "146                                Gefitinib (Iressa®)              Iressa   \n",
       "149                        Glucosamine sulfate (Dona®)                Dona   \n",
       "154                               Golimumab (Simponi®)             Simponi   \n",
       "172                            Infliximab (Inflectra®)           Inflectra   \n",
       "194                                Lapatinib (Tyverb®)              Tyverb   \n",
       "222                              Melatonin (Circadin®)            Circadin   \n",
       "234                             Natalizumab (Tysabri®)             Tysabri   \n",
       "235                         Inhaled insulin (Exubera®)             Exubera   \n",
       "239  Nilotinib (Tasigna®) CML resistant/intolerant ...             Tasigna   \n",
       "252   Nivolumab plus ipilimumab (Opdivo® plus Yervoy®)  Opdivo plus Yervoy   \n",
       "267  Omalizumab (Xolair®) for the treatment of seve...              Xolair   \n",
       "269                       Oxycodone/naloxone (Targin®)              Targin   \n",
       "300                                Prasugrel (Efient®)              Efient   \n",
       "301  Pregabalin (Lyrica®) for the treatment of neur...              Lyrica   \n",
       "302  Pregabalin (Lyrica®) for the treatment of Gene...              Lyrica   \n",
       "316                             Rimonabant (Acomplia®)            Acomplia   \n",
       "324  Rivaroxaban (Xarelto®) for the Primary Prevent...             Xarelto   \n",
       "325                               Roflumilast (Daxas®)               Daxas   \n",
       "327                              Romiplostim (Nplate®)              Nplate   \n",
       "354                 Sublingual Immunotherapy (Grazax®)              Grazax   \n",
       "355                 Buprenorphine/naloxone (Suboxone®)            Suboxone   \n",
       "357                                Sunitinib (Sutent®)              Sutent   \n",
       "387                             Ustekinumab (Stelara®)             Stelara   \n",
       "\n",
       "                                            indication  ncpe_year   eu_market  \\\n",
       "12   Economic evaluation of Agomelatine (Valdoxan®)...       2009  2009-02-19   \n",
       "45   Economic evaluation of Boceprevir (Victrelis®)...       2012  2011-07-18   \n",
       "70   Cost-effectiveness of certolizumab pegol (Cimz...       2010  2009-10-01   \n",
       "84   Dabigatran etexilate (Pradaxa®) for the Preven...       2012  2008-03-17   \n",
       "85   Economic Evaluation of the Cost Effectiveness ...       2008  2008-03-17   \n",
       "100  The Cost-effectiveness of Denosumab (Prolia®) ...       2010  2010-05-26   \n",
       "101  Cost-effectiveness of denosumab (Xgeva®) for t...       2011  2011-07-13   \n",
       "113  An Economic Evaluation of Eculizumab (Soliris®...       2013  2007-06-20   \n",
       "137  Evolocumab (Repatha®) is indicated for both pr...       2018  2015-07-17   \n",
       "146  A review of the economic evaluation of oral ge...       2010  2009-06-24   \n",
       "149  Economic evalution of glucosamine sulfate (Don...       2009  1996-10-04   \n",
       "154  Cost-effectiveness of golimumab (Simponi®) in ...       2010  2009-10-01   \n",
       "172  Inflectra® is a biosimilar product indicated f...       2013  2013-09-09   \n",
       "194  Cost-effectiveness of Lapatinib (Tyverb®) for ...       2008  2008-06-10   \n",
       "222  A Review of the Economic Evaluation of Prolong...       2008  2007-06-29   \n",
       "234   Economic Evaluation of Natalizumab (Tysabri®)...       2007  2006-06-27   \n",
       "235  In April 2006, Pfizer submitted a report on th...       2006  2006-01-24   \n",
       "239  Cost-effectiveness of Nilotinib (Tasigna®) for...       2008  2007-11-19   \n",
       "252  Opdivo® plus Yervoy® Is indicated for the trea...       2017  2009-10-10   \n",
       "267  Omalizumab is indicated as an add-on therapy t...       2015  2005-10-25   \n",
       "269  Cost-effectiveness of oral oxycodone/naloxone ...       2010  1996-10-04   \n",
       "300  Economic Evaluation of Prasugrel (Efient®) for...       2010  2009-02-24   \n",
       "301  Lyrica® is indicated for the treatment of peri...       2015  2004-07-05   \n",
       "302  Pregabalin (Lyrica®) for the treatment of Gene...       2014  2004-07-05   \n",
       "316  In June 2006, Sanofi-Aventis submitted an eval...       2006  2006-06-19   \n",
       "324  Cost Effectiveness of Rivaroxaban (Xarelto®) f...       2008  2008-09-30   \n",
       "325  Cost Effectiveness of Roflumilast (Daxas®) for...       2010  2010-07-05   \n",
       "327  Romiplostim (Nplate®) is indicated for the tre...       2015  2009-02-04   \n",
       "354  A Review of the Cost-Effectiveness of Sublingu...       2007  1996-10-04   \n",
       "355  An economic evaluation of suboxone for the man...       2014  2006-09-26   \n",
       "357  In September 2006, Pfizer Healthcare Ireland s...       2006  2006-07-19   \n",
       "387  Cost-effectiveness of Ustekinumab (Stelara®) i...       2009  2009-01-15   \n",
       "\n",
       "             company  orphan    earliest      latest  \\\n",
       "12               Les       0  2009-09-03  2009-12-11   \n",
       "45             Merck       0  2011-08-19  2012-01-17   \n",
       "70               UCB       0  2010-03-13  2010-09-02   \n",
       "84        Boehringer       0  2010-11-02  2012-10-03   \n",
       "85        Boehringer       0  2008-07-01  2008-09-01   \n",
       "100            Amgen       0  2010-05-27  2010-07-01   \n",
       "101            Amgen       0  2011-08-15  2011-12-08   \n",
       "113          Alexion       1  2010-01-01  2013-10-14   \n",
       "137            Amgen       0  2016-01-01  2018-05-16   \n",
       "146      AstraZeneca       0  2010-06-16  2010-11-05   \n",
       "149              CIS       0  2009-04-01  2009-06-01   \n",
       "154          Janssen       0  2009-11-20  2010-06-01   \n",
       "172           Pfizer       0  2013-09-10  2013-09-20   \n",
       "194         Novartis       0  2008-01-01  2008-01-01   \n",
       "222              RAD       0  2008-08-01  2008-10-01   \n",
       "234           Biogen       0  2007-01-01  2007-03-01   \n",
       "235           Pfizer       0  2006-03-01  2006-03-01   \n",
       "239         Novartis       1  2008-01-01  2008-02-01   \n",
       "252  GlaxoSmithKline       0  2016-06-27  2017-10-01   \n",
       "267         Novartis       0  2014-08-22  2015-06-25   \n",
       "269              CIS       0  2010-05-05  2010-10-19   \n",
       "300          Daiichi       0  2009-07-01  2010-02-01   \n",
       "301           Pfizer       0  2013-09-30  2015-06-12   \n",
       "302           Pfizer       0  2014-09-12  2014-12-15   \n",
       "316   sanofi-aventis       0  2006-06-01  2006-06-01   \n",
       "324            Bayer       0  2008-04-01  2008-09-01   \n",
       "325      AstraZeneca       0  2010-06-11  2010-11-03   \n",
       "327            Amgen       1  2015-04-02  2015-05-27   \n",
       "354              CIS       0  2007-09-01  2007-09-01   \n",
       "355         Indivior       0  2007-11-01  2014-05-22   \n",
       "357           Pfizer       0  2006-09-01  2006-09-01   \n",
       "387    Janssen-Cilag       0  2009-07-01  2009-11-01   \n",
       "\n",
       "                                               ema_url  \\\n",
       "12   https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "45   https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "70   https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "84   https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "85   https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "100  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "101  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "113  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "137  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "146  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "149  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "154  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "172  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "194  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "222  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "234  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "235  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "239  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "252  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "267  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "269  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "300  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "301  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "302  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "316  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "324  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "325  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "327  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "354  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "355  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "357  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "387  https://www.ema.europa.eu/en/medicines/human/E...   \n",
       "\n",
       "                                               ta_list         rr_status  \n",
       "12                          Depressive Disorder, Major  RR not conducted  \n",
       "45                                Hepatitis C, Chronic  RR not conducted  \n",
       "70                               Arthritis, Rheumatoid  RR not conducted  \n",
       "84   Arthroplasty, Replacement; Venous Thromboembolism  RR not conducted  \n",
       "85   Arthroplasty, Replacement; Venous Thromboembolism  RR not conducted  \n",
       "100      Bone Resorption; Osteoporosis, Postmenopausal  RR not conducted  \n",
       "101               Fractures, Bone; Neoplasm Metastasis  RR not conducted  \n",
       "113                         Hemoglobinuria, Paroxysmal  RR not conducted  \n",
       "137                Dyslipidemias; Hypercholesterolemia  RR not conducted  \n",
       "146                     Carcinoma, Non-Small-Cell Lung  RR not conducted  \n",
       "149            Radionuclide Imaging; Ovarian Neoplasms  RR not conducted  \n",
       "154  Arthritis, Psoriatic; Spondylitis, Ankylosing;...  RR not conducted  \n",
       "172  Arthritis, Psoriatic; Spondylitis, Ankylosing;...  RR not conducted  \n",
       "194                                   Breast Neoplasms  RR not conducted  \n",
       "222         Sleep Initiation and Maintenance Disorders  RR not conducted  \n",
       "234                                 Multiple Sclerosis  RR not conducted  \n",
       "235                                  Diabetes Mellitus  RR not conducted  \n",
       "239   Leukemia, Myelogenous, Chronic, BCR-ABL Positive  RR not conducted  \n",
       "252  Influenza, Human; Immunization; Disease Outbreaks  RR not conducted  \n",
       "267                                  Asthma; Urticaria  RR not conducted  \n",
       "269            Radionuclide Imaging; Ovarian Neoplasms  RR not conducted  \n",
       "300  Acute Coronary Syndrome; Angina, Unstable; Myo...  RR not conducted  \n",
       "301             Epilepsy; Anxiety Disorders; Neuralgia  RR not conducted  \n",
       "302             Epilepsy; Anxiety Disorders; Neuralgia  RR not conducted  \n",
       "316                                            Obesity  RR not conducted  \n",
       "324  Arthroplasty, Replacement; Venous Thromboembolism  RR not conducted  \n",
       "325             Pulmonary Disease, Chronic Obstructive  RR not conducted  \n",
       "327              Purpura, Thrombocytopenic, Idiopathic  RR not conducted  \n",
       "354            Radionuclide Imaging; Ovarian Neoplasms  RR not conducted  \n",
       "355                           Opioid-Related Disorders  RR not conducted  \n",
       "357  Gastrointestinal Stromal Tumors; Carcinoma, Re...  RR not conducted  \n",
       "387     Psoriasis; Arthritis, Psoriatic; Crohn Disease  RR not conducted  "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['rr_start'].isna()]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "There are 32 rows which has NULL for 'rr_start'."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Logic to populate the NULL in 'rr_start': </br>\n",
    "\n",
    "- Store the data which has NOT NULL values for 'rr_start' in a separate dataframe - 'df_skip_na_rr_start'\n",
    "- Find the mean of the diffrence between 'rr_end' and 'rr_start' dates\n",
    "- Use the mean value to populate the NULL values in 'rr_start' date\n",
    "\n",
    "Below is the code which performs the above mentioned operations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_skip_na_rr_start = df[df['rr_start'].isna() == False]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Timedelta('32 days 01:30:29.508196')"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "mean_days  = (df_skip_na_rr_start['rr_end'] - df_skip_na_rr_start['rr_start']).mean()\n",
    "mean_days"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "On an average, there is 32 days difference between 'rr_start' and 'rr_end' dates. This can be used to populate the missing 'rr_start' date. \n",
    "\n",
    "Logic for populating : For NULL values of 'rr_start' date, The calculated date will be ('rr_end' - 'mean_days')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Taking an example of a row to visually see the changes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "id                                                          2176\n",
       "last_scrape                                  2018-12-13 16:25:58\n",
       "url             http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/\n",
       "rr_start                                                    None\n",
       "rr_end                                                2013-04-10\n",
       "rr_outcome                                                      \n",
       "rr_dates                                                        \n",
       "rr_multiple                                                    0\n",
       "drug_name                                Agomelatine (Valdoxan®)\n",
       "trade_name                                              Valdoxan\n",
       "indication     Economic evaluation of Agomelatine (Valdoxan®)...\n",
       "ncpe_year                                                   2009\n",
       "eu_market                                             2009-02-19\n",
       "company                                                      Les\n",
       "orphan                                                         0\n",
       "earliest                                              2009-09-03\n",
       "latest                                                2009-12-11\n",
       "ema_url        https://www.ema.europa.eu/en/medicines/human/E...\n",
       "ta_list                               Depressive Disorder, Major\n",
       "rr_status                                       RR not conducted\n",
       "Name: 12, dtype: object"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.iloc[12]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The value of 'rr_start' is NULL in the above result. It should be converted to '2013-04-10' minus 32 days"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The below code will fill NULLs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "values = {'rr_start' : df['rr_end'] -  pd.to_timedelta(mean_days, unit='d')}\n",
    "df =df.fillna(value=values)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "After Changes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "id                                                          2176\n",
       "last_scrape                                  2018-12-13 16:25:58\n",
       "url             http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/\n",
       "rr_start                                              2013-03-09\n",
       "rr_end                                                2013-04-10\n",
       "rr_outcome                                                      \n",
       "rr_dates                                                        \n",
       "rr_multiple                                                    0\n",
       "drug_name                                Agomelatine (Valdoxan®)\n",
       "trade_name                                              Valdoxan\n",
       "indication     Economic evaluation of Agomelatine (Valdoxan®)...\n",
       "ncpe_year                                                   2009\n",
       "eu_market                                             2009-02-19\n",
       "company                                                      Les\n",
       "orphan                                                         0\n",
       "earliest                                              2009-09-03\n",
       "latest                                                2009-12-11\n",
       "ema_url        https://www.ema.europa.eu/en/medicines/human/E...\n",
       "ta_list                               Depressive Disorder, Major\n",
       "rr_status                                       RR not conducted\n",
       "Name: 12, dtype: object"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.iloc[12]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 398 entries, 0 to 397\n",
      "Data columns (total 20 columns):\n",
      "id             398 non-null int64\n",
      "last_scrape    398 non-null datetime64[ns]\n",
      "url            398 non-null object\n",
      "rr_start       398 non-null object\n",
      "rr_end         398 non-null object\n",
      "rr_outcome     398 non-null object\n",
      "rr_dates       398 non-null object\n",
      "rr_multiple    398 non-null int64\n",
      "drug_name      398 non-null object\n",
      "trade_name     398 non-null object\n",
      "indication     398 non-null object\n",
      "ncpe_year      398 non-null int64\n",
      "eu_market      383 non-null object\n",
      "company        398 non-null object\n",
      "orphan         398 non-null int64\n",
      "earliest       398 non-null object\n",
      "latest         398 non-null object\n",
      "ema_url        398 non-null object\n",
      "ta_list        398 non-null object\n",
      "rr_status      398 non-null object\n",
      "dtypes: datetime64[ns](1), int64(4), object(15)\n",
      "memory usage: 62.3+ KB\n"
     ]
    }
   ],
   "source": [
    "df.info()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Column 'eu_market' \n",
    "\n",
    "There are 15 NaT entries in the column - 'eu_market'."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/anaconda3/lib/python3.6/site-packages/ipykernel_launcher.py:1: UserWarning: Boolean Series key will be reindexed to match DataFrame index.\n",
      "  \"\"\"Entry point for launching an IPython kernel.\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>last_scrape</th>\n",
       "      <th>url</th>\n",
       "      <th>rr_start</th>\n",
       "      <th>rr_end</th>\n",
       "      <th>rr_outcome</th>\n",
       "      <th>rr_dates</th>\n",
       "      <th>rr_multiple</th>\n",
       "      <th>drug_name</th>\n",
       "      <th>trade_name</th>\n",
       "      <th>indication</th>\n",
       "      <th>ncpe_year</th>\n",
       "      <th>eu_market</th>\n",
       "      <th>company</th>\n",
       "      <th>orphan</th>\n",
       "      <th>earliest</th>\n",
       "      <th>latest</th>\n",
       "      <th>ema_url</th>\n",
       "      <th>ta_list</th>\n",
       "      <th>rr_status</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2168</td>\n",
       "      <td>2018-12-13 16:24:49</td>\n",
       "      <td>http://www.ncpe.ie/drugs/aceclofenac-vitafen/</td>\n",
       "      <td>2016-12-21</td>\n",
       "      <td>2017-01-24</td>\n",
       "      <td>Following a resubmission of the rapid review a...</td>\n",
       "      <td>2016-12-21, 2017-01-24</td>\n",
       "      <td>0</td>\n",
       "      <td>Aceclofenac (Vitafen®)</td>\n",
       "      <td>Vitafen</td>\n",
       "      <td>Aceclofenac (Vitafen®) is indicated for the re...</td>\n",
       "      <td>2017</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2016-07-22</td>\n",
       "      <td>2017-11-01</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>HTA recommended at submitted price</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>2183</td>\n",
       "      <td>2018-12-13 16:26:29</td>\n",
       "      <td>http://www.ncpe.ie/drugs/amsacrine-amsidine/</td>\n",
       "      <td>2017-01-10</td>\n",
       "      <td>2017-02-15</td>\n",
       "      <td>Full Pharmacoeconomic Evaluation not Recommended</td>\n",
       "      <td>2017-01-10, 2017-02-15</td>\n",
       "      <td>0</td>\n",
       "      <td>Amsacrine (Amsidine®)</td>\n",
       "      <td>Amsidine</td>\n",
       "      <td>Amsidine® is indicated for the induction and m...</td>\n",
       "      <td>2017</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2017-01-10</td>\n",
       "      <td>2017-02-15</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>No HTA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>2196</td>\n",
       "      <td>2018-12-13 16:27:24</td>\n",
       "      <td>http://www.ncpe.ie/drugs/azelastine-hydrochlor...</td>\n",
       "      <td>2013-02-12</td>\n",
       "      <td>2013-02-28</td>\n",
       "      <td>Full Pharmacoeconomic Assessment not Recommended.</td>\n",
       "      <td>2013-02-12, 2013-02-28</td>\n",
       "      <td>0</td>\n",
       "      <td>Azelastine hydrochloride and fluticasone propi...</td>\n",
       "      <td>Dymista</td>\n",
       "      <td>Indicated for symptomatic treatment of moderat...</td>\n",
       "      <td>2013</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2013-02-12</td>\n",
       "      <td>2013-02-28</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>No HTA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>155</th>\n",
       "      <td>2319</td>\n",
       "      <td>2018-12-13 16:35:56</td>\n",
       "      <td>http://www.ncpe.ie/drugs/grass-pollen-allergen...</td>\n",
       "      <td>2011-10-11</td>\n",
       "      <td>2011-09-26</td>\n",
       "      <td>Full Pharmacoeconomic Evaluation not Recommended</td>\n",
       "      <td>2011-10-11, 2011-09-26</td>\n",
       "      <td>0</td>\n",
       "      <td>Grass pollen allergen extract (Oralair®)</td>\n",
       "      <td>Oralair</td>\n",
       "      <td>Grass pollen allegen extract (Oralair®) for t...</td>\n",
       "      <td>2011</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2011-09-26</td>\n",
       "      <td>2011-10-01</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>No HTA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>171</th>\n",
       "      <td>2335</td>\n",
       "      <td>2018-12-13 16:37:04</td>\n",
       "      <td>http://www.ncpe.ie/drugs/indacaterol-onbrez/</td>\n",
       "      <td>2010-01-15</td>\n",
       "      <td>2010-01-15</td>\n",
       "      <td>Full Pharmacoeconomic Evaluation not Recommended.</td>\n",
       "      <td>2010-01-15</td>\n",
       "      <td>0</td>\n",
       "      <td>Indacaterol (Onbrez®)</td>\n",
       "      <td>Onbrez</td>\n",
       "      <td>Review of Indacaterol (Onbrez®) for the treatm...</td>\n",
       "      <td>2010</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2010-01-15</td>\n",
       "      <td>2010-01-15</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>No HTA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>175</th>\n",
       "      <td>2339</td>\n",
       "      <td>2018-12-13 16:37:21</td>\n",
       "      <td>http://www.ncpe.ie/drugs/insulin-aspart-novora...</td>\n",
       "      <td>2014-07-22</td>\n",
       "      <td>2014-08-28</td>\n",
       "      <td>Full pharmacoeconomic evaluation recommended a...</td>\n",
       "      <td>2014-07-22, 2014-08-28</td>\n",
       "      <td>0</td>\n",
       "      <td>Insulin aspart (NovoRapid® FlexTouch ®)</td>\n",
       "      <td>NovoRapid FlexTouch</td>\n",
       "      <td>Insulin aspart (NovoRapid® FlexTouch ®) is ind...</td>\n",
       "      <td>2014</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2014-07-22</td>\n",
       "      <td>2014-08-28</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>HTA recommended at submitted price</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>202</th>\n",
       "      <td>2366</td>\n",
       "      <td>2018-12-13 16:39:28</td>\n",
       "      <td>http://www.ncpe.ie/drugs/levodopa-20mgml-carbi...</td>\n",
       "      <td>2013-03-13</td>\n",
       "      <td>2013-04-16</td>\n",
       "      <td>Full Pharmacoeconomic Evaluation Recommended.</td>\n",
       "      <td>2013-03-13, 2013-04-16</td>\n",
       "      <td>0</td>\n",
       "      <td>Levodopa 20mg/ml + carbidopa monohydrate 5mg i...</td>\n",
       "      <td>Duodopa</td>\n",
       "      <td>For the treatment of advanced levodopa-respons...</td>\n",
       "      <td>2018</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2013-03-13</td>\n",
       "      <td>2018-12-05</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>HTA recommended at submitted price</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>205</th>\n",
       "      <td>2369</td>\n",
       "      <td>2018-12-13 16:39:44</td>\n",
       "      <td>http://www.ncpe.ie/drugs/levonorgestrel-intrau...</td>\n",
       "      <td>2013-03-07</td>\n",
       "      <td>2013-03-25</td>\n",
       "      <td>Full Pharmacoeconomic Assessment Not Recommended</td>\n",
       "      <td>2013-03-07, 2013-03-25</td>\n",
       "      <td>0</td>\n",
       "      <td>Levonorgestrel intrauterine system LNG-IUS (Ja...</td>\n",
       "      <td>Jaydess</td>\n",
       "      <td>Levonorgestrel Intrauterine System LNG-IUS (Ja...</td>\n",
       "      <td>2013</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2013-03-07</td>\n",
       "      <td>2013-03-25</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>No HTA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>206</th>\n",
       "      <td>2370</td>\n",
       "      <td>2018-12-13 16:39:46</td>\n",
       "      <td>http://www.ncpe.ie/drugs/lidocaine-5-plasters-...</td>\n",
       "      <td>2010-09-09</td>\n",
       "      <td>2010-10-22</td>\n",
       "      <td>Full Pharmacoeconomic Evaluation Recommended.</td>\n",
       "      <td>2010-09-09, 2010-10-22</td>\n",
       "      <td>0</td>\n",
       "      <td>Lidocaine 5% plasters (Versatis®)</td>\n",
       "      <td>Versatis</td>\n",
       "      <td>Symptomatic relief of neuropathic pain associa...</td>\n",
       "      <td>2015</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2010-09-09</td>\n",
       "      <td>2015-09-24</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>HTA recommended at submitted price</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>217</th>\n",
       "      <td>2381</td>\n",
       "      <td>2018-12-13 16:40:24</td>\n",
       "      <td>http://www.ncpe.ie/drugs/lotemax-0-5-eye-drops...</td>\n",
       "      <td>2011-11-15</td>\n",
       "      <td>2011-12-05</td>\n",
       "      <td>Full Pharmacoeconomic Evaluation not Recommended</td>\n",
       "      <td>2011-11-15, 2011-12-05</td>\n",
       "      <td>0</td>\n",
       "      <td>Lotemax 0.5% eye drops suspension (Loteprednol)</td>\n",
       "      <td>Loteprednol</td>\n",
       "      <td>Indicated for treatment of post-operative inf...</td>\n",
       "      <td>2011</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2011-11-15</td>\n",
       "      <td>2011-12-05</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>No HTA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>224</th>\n",
       "      <td>2388</td>\n",
       "      <td>2018-12-13 16:40:51</td>\n",
       "      <td>http://www.ncpe.ie/drugs/methoxyflurane-penthrox/</td>\n",
       "      <td>2015-11-23</td>\n",
       "      <td>2015-12-18</td>\n",
       "      <td>Full Pharmacoeconomic Evaluation Not Recommended</td>\n",
       "      <td>2015-11-23, 2015-12-18</td>\n",
       "      <td>0</td>\n",
       "      <td>Methoxyflurane (Penthrox®)</td>\n",
       "      <td>Penthrox</td>\n",
       "      <td>Penthrox® is indicated for the emergency relie...</td>\n",
       "      <td>2015</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2015-11-23</td>\n",
       "      <td>2015-12-18</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>No HTA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>272</th>\n",
       "      <td>2436</td>\n",
       "      <td>2018-12-13 16:44:40</td>\n",
       "      <td>http://www.ncpe.ie/drugs/ozenoxacin-dubine/</td>\n",
       "      <td>2018-11-12</td>\n",
       "      <td>2018-12-13</td>\n",
       "      <td>A full HTA is not recommended. The NCPE recomm...</td>\n",
       "      <td>2018-11-12, 2018-12-13</td>\n",
       "      <td>0</td>\n",
       "      <td>Ozenoxacin (Dubine®)</td>\n",
       "      <td>Dubine</td>\n",
       "      <td>Ozenoxacin (Dubine®) 10mg/g cream for the shor...</td>\n",
       "      <td>2018</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2018-11-12</td>\n",
       "      <td>2018-12-13</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>292</th>\n",
       "      <td>2456</td>\n",
       "      <td>2018-12-13 16:46:09</td>\n",
       "      <td>http://www.ncpe.ie/drugs/phenylephrine-hydroch...</td>\n",
       "      <td>2016-11-18</td>\n",
       "      <td>2016-12-19</td>\n",
       "      <td>Reimbursement not recommended at the submitted...</td>\n",
       "      <td>2016-11-18, 2016-12-19</td>\n",
       "      <td>0</td>\n",
       "      <td>Phenylephrine Hydrochloride, Tropicamide &amp; Lid...</td>\n",
       "      <td>Fydrane</td>\n",
       "      <td>Fydrane® is indicated for cataract surgery to ...</td>\n",
       "      <td>2016</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2016-11-18</td>\n",
       "      <td>2016-12-19</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Reimbursement not recommended</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>328</th>\n",
       "      <td>2492</td>\n",
       "      <td>2018-12-13 16:48:47</td>\n",
       "      <td>http://www.ncpe.ie/drugs/ropivacaine-readyfusor/</td>\n",
       "      <td>2018-11-09</td>\n",
       "      <td>2018-12-13</td>\n",
       "      <td>A full HTA is not recommended. The NCPE recomm...</td>\n",
       "      <td>2018-11-09, 2018-12-13</td>\n",
       "      <td>0</td>\n",
       "      <td>Ropivacaine Readyfusor®</td>\n",
       "      <td>Ropivacaine Readyfusor</td>\n",
       "      <td>Ropivacaine Readyfusor for acute, postoperativ...</td>\n",
       "      <td>2018</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2018-11-09</td>\n",
       "      <td>2018-12-13</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385</th>\n",
       "      <td>2549</td>\n",
       "      <td>2018-12-13 16:53:12</td>\n",
       "      <td>http://www.ncpe.ie/drugs/urea-glucorx-allpresan/</td>\n",
       "      <td>2018-07-09</td>\n",
       "      <td>2018-07-24</td>\n",
       "      <td>Full pharmacoeconomic assessment is not recomm...</td>\n",
       "      <td>2018-07-09, 2018-07-24</td>\n",
       "      <td>0</td>\n",
       "      <td>Urea (GlucoRx Allpresan®)</td>\n",
       "      <td>GlucoRx Allpresan</td>\n",
       "      <td>GlucoRx Allpresan® Diabetic Foam Cream for the...</td>\n",
       "      <td>2018</td>\n",
       "      <td>None</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>0</td>\n",
       "      <td>2018-07-09</td>\n",
       "      <td>2018-07-24</td>\n",
       "      <td></td>\n",
       "      <td>Unknown</td>\n",
       "      <td>No HTA at submitted price</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       id         last_scrape  \\\n",
       "4    2168 2018-12-13 16:24:49   \n",
       "19   2183 2018-12-13 16:26:29   \n",
       "32   2196 2018-12-13 16:27:24   \n",
       "155  2319 2018-12-13 16:35:56   \n",
       "171  2335 2018-12-13 16:37:04   \n",
       "175  2339 2018-12-13 16:37:21   \n",
       "202  2366 2018-12-13 16:39:28   \n",
       "205  2369 2018-12-13 16:39:44   \n",
       "206  2370 2018-12-13 16:39:46   \n",
       "217  2381 2018-12-13 16:40:24   \n",
       "224  2388 2018-12-13 16:40:51   \n",
       "272  2436 2018-12-13 16:44:40   \n",
       "292  2456 2018-12-13 16:46:09   \n",
       "328  2492 2018-12-13 16:48:47   \n",
       "385  2549 2018-12-13 16:53:12   \n",
       "\n",
       "                                                   url    rr_start  \\\n",
       "4        http://www.ncpe.ie/drugs/aceclofenac-vitafen/  2016-12-21   \n",
       "19        http://www.ncpe.ie/drugs/amsacrine-amsidine/  2017-01-10   \n",
       "32   http://www.ncpe.ie/drugs/azelastine-hydrochlor...  2013-02-12   \n",
       "155  http://www.ncpe.ie/drugs/grass-pollen-allergen...  2011-10-11   \n",
       "171       http://www.ncpe.ie/drugs/indacaterol-onbrez/  2010-01-15   \n",
       "175  http://www.ncpe.ie/drugs/insulin-aspart-novora...  2014-07-22   \n",
       "202  http://www.ncpe.ie/drugs/levodopa-20mgml-carbi...  2013-03-13   \n",
       "205  http://www.ncpe.ie/drugs/levonorgestrel-intrau...  2013-03-07   \n",
       "206  http://www.ncpe.ie/drugs/lidocaine-5-plasters-...  2010-09-09   \n",
       "217  http://www.ncpe.ie/drugs/lotemax-0-5-eye-drops...  2011-11-15   \n",
       "224  http://www.ncpe.ie/drugs/methoxyflurane-penthrox/  2015-11-23   \n",
       "272        http://www.ncpe.ie/drugs/ozenoxacin-dubine/  2018-11-12   \n",
       "292  http://www.ncpe.ie/drugs/phenylephrine-hydroch...  2016-11-18   \n",
       "328   http://www.ncpe.ie/drugs/ropivacaine-readyfusor/  2018-11-09   \n",
       "385   http://www.ncpe.ie/drugs/urea-glucorx-allpresan/  2018-07-09   \n",
       "\n",
       "         rr_end                                         rr_outcome  \\\n",
       "4    2017-01-24  Following a resubmission of the rapid review a...   \n",
       "19   2017-02-15   Full Pharmacoeconomic Evaluation not Recommended   \n",
       "32   2013-02-28  Full Pharmacoeconomic Assessment not Recommended.   \n",
       "155  2011-09-26   Full Pharmacoeconomic Evaluation not Recommended   \n",
       "171  2010-01-15  Full Pharmacoeconomic Evaluation not Recommended.   \n",
       "175  2014-08-28  Full pharmacoeconomic evaluation recommended a...   \n",
       "202  2013-04-16      Full Pharmacoeconomic Evaluation Recommended.   \n",
       "205  2013-03-25   Full Pharmacoeconomic Assessment Not Recommended   \n",
       "206  2010-10-22      Full Pharmacoeconomic Evaluation Recommended.   \n",
       "217  2011-12-05   Full Pharmacoeconomic Evaluation not Recommended   \n",
       "224  2015-12-18   Full Pharmacoeconomic Evaluation Not Recommended   \n",
       "272  2018-12-13  A full HTA is not recommended. The NCPE recomm...   \n",
       "292  2016-12-19  Reimbursement not recommended at the submitted...   \n",
       "328  2018-12-13  A full HTA is not recommended. The NCPE recomm...   \n",
       "385  2018-07-24  Full pharmacoeconomic assessment is not recomm...   \n",
       "\n",
       "                   rr_dates  rr_multiple  \\\n",
       "4    2016-12-21, 2017-01-24            0   \n",
       "19   2017-01-10, 2017-02-15            0   \n",
       "32   2013-02-12, 2013-02-28            0   \n",
       "155  2011-10-11, 2011-09-26            0   \n",
       "171              2010-01-15            0   \n",
       "175  2014-07-22, 2014-08-28            0   \n",
       "202  2013-03-13, 2013-04-16            0   \n",
       "205  2013-03-07, 2013-03-25            0   \n",
       "206  2010-09-09, 2010-10-22            0   \n",
       "217  2011-11-15, 2011-12-05            0   \n",
       "224  2015-11-23, 2015-12-18            0   \n",
       "272  2018-11-12, 2018-12-13            0   \n",
       "292  2016-11-18, 2016-12-19            0   \n",
       "328  2018-11-09, 2018-12-13            0   \n",
       "385  2018-07-09, 2018-07-24            0   \n",
       "\n",
       "                                             drug_name  \\\n",
       "4                               Aceclofenac (Vitafen®)   \n",
       "19                               Amsacrine (Amsidine®)   \n",
       "32   Azelastine hydrochloride and fluticasone propi...   \n",
       "155           Grass pollen allergen extract (Oralair®)   \n",
       "171                              Indacaterol (Onbrez®)   \n",
       "175            Insulin aspart (NovoRapid® FlexTouch ®)   \n",
       "202  Levodopa 20mg/ml + carbidopa monohydrate 5mg i...   \n",
       "205  Levonorgestrel intrauterine system LNG-IUS (Ja...   \n",
       "206                  Lidocaine 5% plasters (Versatis®)   \n",
       "217    Lotemax 0.5% eye drops suspension (Loteprednol)   \n",
       "224                         Methoxyflurane (Penthrox®)   \n",
       "272                               Ozenoxacin (Dubine®)   \n",
       "292  Phenylephrine Hydrochloride, Tropicamide & Lid...   \n",
       "328                            Ropivacaine Readyfusor®   \n",
       "385                          Urea (GlucoRx Allpresan®)   \n",
       "\n",
       "                 trade_name  \\\n",
       "4                   Vitafen   \n",
       "19                 Amsidine   \n",
       "32                  Dymista   \n",
       "155                 Oralair   \n",
       "171                  Onbrez   \n",
       "175     NovoRapid FlexTouch   \n",
       "202                 Duodopa   \n",
       "205                 Jaydess   \n",
       "206                Versatis   \n",
       "217             Loteprednol   \n",
       "224                Penthrox   \n",
       "272                  Dubine   \n",
       "292                 Fydrane   \n",
       "328  Ropivacaine Readyfusor   \n",
       "385       GlucoRx Allpresan   \n",
       "\n",
       "                                            indication  ncpe_year eu_market  \\\n",
       "4    Aceclofenac (Vitafen®) is indicated for the re...       2017      None   \n",
       "19   Amsidine® is indicated for the induction and m...       2017      None   \n",
       "32   Indicated for symptomatic treatment of moderat...       2013      None   \n",
       "155   Grass pollen allegen extract (Oralair®) for t...       2011      None   \n",
       "171  Review of Indacaterol (Onbrez®) for the treatm...       2010      None   \n",
       "175  Insulin aspart (NovoRapid® FlexTouch ®) is ind...       2014      None   \n",
       "202  For the treatment of advanced levodopa-respons...       2018      None   \n",
       "205  Levonorgestrel Intrauterine System LNG-IUS (Ja...       2013      None   \n",
       "206  Symptomatic relief of neuropathic pain associa...       2015      None   \n",
       "217   Indicated for treatment of post-operative inf...       2011      None   \n",
       "224  Penthrox® is indicated for the emergency relie...       2015      None   \n",
       "272  Ozenoxacin (Dubine®) 10mg/g cream for the shor...       2018      None   \n",
       "292  Fydrane® is indicated for cataract surgery to ...       2016      None   \n",
       "328  Ropivacaine Readyfusor for acute, postoperativ...       2018      None   \n",
       "385  GlucoRx Allpresan® Diabetic Foam Cream for the...       2018      None   \n",
       "\n",
       "     company  orphan    earliest      latest ema_url  ta_list  \\\n",
       "4    Unknown       0  2016-07-22  2017-11-01          Unknown   \n",
       "19   Unknown       0  2017-01-10  2017-02-15          Unknown   \n",
       "32   Unknown       0  2013-02-12  2013-02-28          Unknown   \n",
       "155  Unknown       0  2011-09-26  2011-10-01          Unknown   \n",
       "171  Unknown       0  2010-01-15  2010-01-15          Unknown   \n",
       "175  Unknown       0  2014-07-22  2014-08-28          Unknown   \n",
       "202  Unknown       0  2013-03-13  2018-12-05          Unknown   \n",
       "205  Unknown       0  2013-03-07  2013-03-25          Unknown   \n",
       "206  Unknown       0  2010-09-09  2015-09-24          Unknown   \n",
       "217  Unknown       0  2011-11-15  2011-12-05          Unknown   \n",
       "224  Unknown       0  2015-11-23  2015-12-18          Unknown   \n",
       "272  Unknown       0  2018-11-12  2018-12-13          Unknown   \n",
       "292  Unknown       0  2016-11-18  2016-12-19          Unknown   \n",
       "328  Unknown       0  2018-11-09  2018-12-13          Unknown   \n",
       "385  Unknown       0  2018-07-09  2018-07-24          Unknown   \n",
       "\n",
       "                              rr_status  \n",
       "4    HTA recommended at submitted price  \n",
       "19                               No HTA  \n",
       "32                               No HTA  \n",
       "155                              No HTA  \n",
       "171                              No HTA  \n",
       "175  HTA recommended at submitted price  \n",
       "202  HTA recommended at submitted price  \n",
       "205                              No HTA  \n",
       "206  HTA recommended at submitted price  \n",
       "217                              No HTA  \n",
       "224                              No HTA  \n",
       "272                             Unknown  \n",
       "292       Reimbursement not recommended  \n",
       "328                             Unknown  \n",
       "385           No HTA at submitted price  "
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['eu_market'].isna().sort_values(inplace=False, na_position='last')]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Logic to populate the NULL in 'eu_market': </br>\n",
    "\n",
    "- Store the data which has NOT NULL values for 'rr_start' in a separate dataframe - 'df_skip_na_eu_market'\n",
    "- Find the mean of the diffrence between 'rr_start' and 'eu_market' dates\n",
    "- Use the mean value to populate the NULL values in 'eu_market' date\n",
    "\n",
    "Below is the code which performs the above mentioned operations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_skip_na_eu_market = df[df['eu_market'].isna() == False]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Timedelta('1083 days 19:06:44.177545')"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "mean_days_eu_market  = (df_skip_na_eu_market['rr_start'] - df_skip_na_eu_market['eu_market']).mean()\n",
    "mean_days_eu_market"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "On an average, there is 1083 days difference between 'rr_start' and 'eu_market' dates. This can be used to populate the missing 'eu_market' date. \n",
    "\n",
    "Logic for populating : For NULL values of 'eu_market' date, The calculated date will be ('rr_start' - 'mean_days_eu_market')\n",
    "\n",
    "Taking an example of a row to visually see the changes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "id                                                          2168\n",
       "last_scrape                                  2018-12-13 16:24:49\n",
       "url                http://www.ncpe.ie/drugs/aceclofenac-vitafen/\n",
       "rr_start                                              2016-12-21\n",
       "rr_end                                                2017-01-24\n",
       "rr_outcome     Following a resubmission of the rapid review a...\n",
       "rr_dates                                  2016-12-21, 2017-01-24\n",
       "rr_multiple                                                    0\n",
       "drug_name                                 Aceclofenac (Vitafen®)\n",
       "trade_name                                               Vitafen\n",
       "indication     Aceclofenac (Vitafen®) is indicated for the re...\n",
       "ncpe_year                                                   2017\n",
       "eu_market                                                   None\n",
       "company                                                  Unknown\n",
       "orphan                                                         0\n",
       "earliest                                              2016-07-22\n",
       "latest                                                2017-11-01\n",
       "ema_url                                                         \n",
       "ta_list                                                  Unknown\n",
       "rr_status                     HTA recommended at submitted price\n",
       "Name: 4, dtype: object"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.iloc[4]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The value of 'eu_market' is NULL in the above result. It should be converted to '2016-12-21' minus 1083 days"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The below code will fill NULLs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "values = {'eu_market' : df['rr_start'] -  pd.to_timedelta(mean_days_eu_market, unit='d')}\n",
    "df =df.fillna(value=values)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "After Changes - "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "id                                                          2168\n",
       "last_scrape                                  2018-12-13 16:24:49\n",
       "url                http://www.ncpe.ie/drugs/aceclofenac-vitafen/\n",
       "rr_start                                              2016-12-21\n",
       "rr_end                                                2017-01-24\n",
       "rr_outcome     Following a resubmission of the rapid review a...\n",
       "rr_dates                                  2016-12-21, 2017-01-24\n",
       "rr_multiple                                                    0\n",
       "drug_name                                 Aceclofenac (Vitafen®)\n",
       "trade_name                                               Vitafen\n",
       "indication     Aceclofenac (Vitafen®) is indicated for the re...\n",
       "ncpe_year                                                   2017\n",
       "eu_market                                             2014-01-03\n",
       "company                                                  Unknown\n",
       "orphan                                                         0\n",
       "earliest                                              2016-07-22\n",
       "latest                                                2017-11-01\n",
       "ema_url                                                         \n",
       "ta_list                                                  Unknown\n",
       "rr_status                     HTA recommended at submitted price\n",
       "Name: 4, dtype: object"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.iloc[4]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 398 entries, 0 to 397\n",
      "Data columns (total 20 columns):\n",
      "id             398 non-null int64\n",
      "last_scrape    398 non-null datetime64[ns]\n",
      "url            398 non-null object\n",
      "rr_start       398 non-null object\n",
      "rr_end         398 non-null object\n",
      "rr_outcome     398 non-null object\n",
      "rr_dates       398 non-null object\n",
      "rr_multiple    398 non-null int64\n",
      "drug_name      398 non-null object\n",
      "trade_name     398 non-null object\n",
      "indication     398 non-null object\n",
      "ncpe_year      398 non-null int64\n",
      "eu_market      398 non-null object\n",
      "company        398 non-null object\n",
      "orphan         398 non-null int64\n",
      "earliest       398 non-null object\n",
      "latest         398 non-null object\n",
      "ema_url        398 non-null object\n",
      "ta_list        398 non-null object\n",
      "rr_status      398 non-null object\n",
      "dtypes: datetime64[ns](1), int64(4), object(15)\n",
      "memory usage: 62.3+ KB\n"
     ]
    }
   ],
   "source": [
    "df.info()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now, all columns have 398 values."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Changing the datatype - </br>The below columns has datatype - object. Since it stores dates, it has to be converted to datatype - 'date'\n",
    "rr_dates, rr_start, rr_end, eu_market, earliest, latest"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Changing the datatype of \"rr_start\" from object to datetime"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['rr_start'] =  pd.to_datetime(df['rr_start'], format='%Y-%m-%d')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Changing the datatype of \"rr_end\" from object to datetime"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['rr_end'] =  pd.to_datetime(df['rr_end'], format='%Y-%m-%d')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Changing the datatype of \"earliest\" from object to datetime"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['earliest'] =  pd.to_datetime(df['earliest'], format='%Y-%m-%d')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Changing the datatype of \"latest\" from object to datetime"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['latest'] =  pd.to_datetime(df['latest'], format='%Y-%m-%d')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Why I can't drop column - RR_DATES ?\n",
    "\n",
    "The values in the column - 'rr_dates' are already present in the columns - 'rr_start' and 'rr_end' however for some rows, it has more than 2 dates. Those corresponding rows has rr_multiple = 1. Therefore, it can't be deleted"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Code to get the NaT values in column - eu_market"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Converting the column 'eu_market' to datetime"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['eu_market'] =  pd.to_datetime(df['eu_market'], format='%Y-%m-%d')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "There are many duplicates in rr_outcome column. Therefore, the below operations were performed<br />\n",
    "Convert to lower case<br />\n",
    "Remove full stop<br />\n",
    "Trim the text<br />"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### The below code is used to check the unique values in the column - rr_outcome"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Full Pharmacoeconomic Assessment Recommended',\n",
       "       'A full pharmacoeconomic assessment is recommended',\n",
       "       'Full Pharmacoeconomic Evaluation Recommended.',\n",
       "       'Following a resubmission of the rapid review a full pharmacoeconomic evaluation is recommended at the submitted price.',\n",
       "       'Full Pharmacoeconomic Evaluation Not Recommended',\n",
       "       'Full Pharmacoeconomic Evaluation Recommended at submitted price.',\n",
       "       'Full Pharmacoeconomic Evaluation not Recommended',\n",
       "       'Full HTA not recommended',\n",
       "       'Full Pharmacoeconomic Evaluation Recommended', '',\n",
       "       'Full pharmacoeconomic evaluation recommended',\n",
       "       'Full HTA Recommended',\n",
       "       'Full Pharmacoeconomic Evaluation not Recommended.',\n",
       "       'Full pharmacoeconomic evaluation not recommended',\n",
       "       'Full pharmacoeconomic assessment recommended',\n",
       "       'A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of  axi-cel compared with the current standard of care.\\n ',\n",
       "       'Full Pharmacoeconomic Assessment not Recommended.',\n",
       "       'Full Pharmacoeconomic Evaluation Recommended at the Submitted Price',\n",
       "       'Full pharamcoeconomic assessment recommended at the submitted price',\n",
       "       'Full pharmacoeconomic assessment not recommended. The NCPE recommends that Biktarvy® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.',\n",
       "       'Full Pharmacoeconomic Evaluation Not Recommended.  The NCPE cannot recommend reimbursement of Blinctyo® at this point in time.',\n",
       "       'At the current price a full HTA would be required.',\n",
       "       'A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brigatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\\n ',\n",
       "       'Full Pharmacoeconomic Evaluation Recommended at the submitted price.',\n",
       "       'Full pharmacoeconomic assessment recommended at submitted price',\n",
       "       'Full HTA recommended',\n",
       "       'Full pharmacoeconomic assessment not recommended',\n",
       "       'Full pharmacoeconomic assessment\\nrecommended',\n",
       "       'Full pharmacoeconomic evaluation recommended at the submitted price',\n",
       "       'Full Pharmacoeconomic Evaluation not recommended',\n",
       "       'Full Pharmacoeconomic Evaluation Recommended at the Submitted Price ',\n",
       "       'Full Pharmacoeconomic Evaluation recommended at the Submitted Price.',\n",
       "       'A full pharmacoeconomic evaluation is recommended.',\n",
       "       'A Full pharmacoeconomic assessment is recommended',\n",
       "       'Full Pharmacoeconomic Evaluation Not Recommended.',\n",
       "       'Full pharmacoeconomic assessment recommended at the submitted price',\n",
       "       'Full pharmacoeconomic Evaluation Recommended',\n",
       "       'A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of darvadstrocel compared with the current standard of care.',\n",
       "       'A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Sativex® compared with the current standard of care.',\n",
       "       ' Full Pharmacoeconomic Assessment Recommended',\n",
       "       'Following assessment of the applicant’s submission, the NCPE recommends that dinutuximab beta (Qarziba®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Goods) Act 2013.',\n",
       "       'A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Juluca® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\\n ',\n",
       "       'A full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with currently available therapies.',\n",
       "       'Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.',\n",
       "       'A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care.',\n",
       "       'Reimbursement not recommended',\n",
       "       'Full Pharmacoeconomic Evaluation recommended',\n",
       "       'A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy™ Ellipta™ be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\\n ',\n",
       "       'Full pharmacoeconomic assessment recommended at submitted price\\n',\n",
       "       'A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of gemtuzumab ozogamicin compared with the current standard of care.',\n",
       "       'A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Glycerol Phenylbutyrate (Ravicti®) be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.',\n",
       "       'Reimbursement not recommended at the submitted price',\n",
       "       'Full pharmacoeconomic evaluation recommended at the submitted price.',\n",
       "       'Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.  ',\n",
       "       'Full Pharmacoeconomic Evaluation Not Recommended. ',\n",
       "       'Full Pharmaoeconomic Evaluation Recommended',\n",
       "       'A Full pharmacoeconomic assessment is not recommended. The NCPE recommends that ixekizumab not be considered for reimbursement at the submitted price. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013',\n",
       "       'Full Pharmacoeconomic Assessment Not Recommended',\n",
       "       'A full pharmacoeconomic evaluation is recommended at the submitted price.\\n ',\n",
       "       'A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.',\n",
       "       'Full pharmacoeconomic evaluation recommended at the submitted price. ',\n",
       "       'A Full Pharmacoeconomic Assessment is recommended',\n",
       "       'A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.',\n",
       "       'A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of niraparib compared with the current standard of care',\n",
       "       'A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.',\n",
       "       'Full Pharmacoeconomic Evaluation Recommended ',\n",
       "       'Full pharmacoeconomic assessment is recommended',\n",
       "       'Full Pharmacoeconomic assessment recommended',\n",
       "       'The NCPE recommend  a full HTA to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.',\n",
       "       'Full Pharmacoeconomic Evaluation Not Recommended for this indication.',\n",
       "       'A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations compared with the current standard of care.',\n",
       "       'A full HTA is not recommended. The NCPE recommends that ozenoxacin cream not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\\n \\n ',\n",
       "       'A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.',\n",
       "       'A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies',\n",
       "       'A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of pertuzumab compared with the current standard of care.',\n",
       "       'Pharmacoeconomic Evaluation Recommended',\n",
       "       'Following NCPE assessment of the company submission, the NCPE recommends that ribociclib (in combination with an aromatase inhibitor) for the treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic BC as initial endocrine-based therapy, not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.',\n",
       "       'Reimbursement Not Recommeded',\n",
       "       'Full HTA recommended at the current price.',\n",
       "       'A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Rivaroxaban compared with the current standard of care.',\n",
       "       'A full HTA is not recommended. The NCPE recommends that Ropivicaine Readyfusor not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.',\n",
       "       'Reimbursement not recommended.',\n",
       "       'Full pharmacoeconomic assessment recommended at the submitted price.',\n",
       "       'A full pharmacoeconomic assessment is recommended on the basis of the proposed price, relative to currently available therapies.',\n",
       "       'Full Pharmacoeconomic Assessment Recommended.',\n",
       "       'Full pharmacoeconomic assessment not recommended when used in triple therapy with peg-interferon and ribavirin.',\n",
       "       ' Full pharmacoeconomic assessment not recommended',\n",
       "       'A full pharmacoeconomic assessment is not recommended until additional efficacy and/or safety data is submitted. On the basis of current evidence, the NCPE recommends that tafamidis not be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.',\n",
       "       'A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.',\n",
       "       'Full Pharmacoeconomic Evaluation Recommended at theSubmitted Price.',\n",
       "       'A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tofacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.',\n",
       "       'Reimursement not recommended at the submitted price',\n",
       "       'Full Pharmacoeconomic Evaluation Not Recommended ',\n",
       "       'Full pharmacoeconomic assessment is not recommended. The NCPE recommends that GlucoRx Allpresan Diabetic Foam Cream not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.',\n",
       "       'A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax compared with the current standard of care.',\n",
       "       'Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies.'],\n",
       "      dtype=object)"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['rr_outcome'].unique()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Before Changes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0         Full Pharmacoeconomic Assessment Recommended\n",
       "1    A full pharmacoeconomic assessment is recommended\n",
       "2        Full Pharmacoeconomic Evaluation Recommended.\n",
       "3        Full Pharmacoeconomic Evaluation Recommended.\n",
       "4    Following a resubmission of the rapid review a...\n",
       "Name: rr_outcome, dtype: object"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['rr_outcome'].head(5)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Code Change"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "scrolled": false
   },
   "outputs": [],
   "source": [
    "df['rr_outcome'] = df['rr_outcome'].str.lower().str.replace('.','').str.replace('\\n','').str.replace('a full','full').str.strip()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "After Changes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0         full pharmacoeconomic assessment recommended\n",
       "1      full pharmacoeconomic assessment is recommended\n",
       "2         full pharmacoeconomic evaluation recommended\n",
       "3         full pharmacoeconomic evaluation recommended\n",
       "4    following a resubmission of the rapid review f...\n",
       "Name: rr_outcome, dtype: object"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['rr_outcome'].head(5)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Section 2 - Five Data Visualization"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### 1) Amount of Drugs registered Year-wise in NCPE Website"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Plotting Type : Altair Barplot"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.vegalite.v2+json": {
       "$schema": "https://vega.github.io/schema/vega-lite/v2.6.0.json",
       "config": {
        "view": {
         "height": 300,
         "width": 400
        }
       },
       "data": {
        "name": "data-a91e9a5d15f18c51b67216ebfeb79a06"
       },
       "datasets": {
        "data-a91e9a5d15f18c51b67216ebfeb79a06": [
         {
          "company": "",
          "drug_name": "Abatacept (Orencia®)",
          "earliest": "2012-11-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/orencia",
          "eu_market": "2007-05-21T00:00:00",
          "id": 2164,
          "indication": "Subcutaneous Abatacept (Orencia®) in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.",
          "last_scrape": "2018-12-13T16:24:32",
          "latest": "2015-11-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2012-11-28, 2012-12-21",
          "rr_end": "2012-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2012-11-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Unknown",
          "trade_name": "Orencia",
          "url": "http://www.ncpe.ie/drugs/abatacept-orencia/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Abiraterone acetate (Zytiga®) for mHSPC",
          "earliest": "2018-10-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga",
          "eu_market": "2011-09-05T00:00:00",
          "id": 2165,
          "indication": "Abiraterone acetate (Zytiga®) for the treatment of newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).",
          "last_scrape": "2018-12-13T16:24:36",
          "latest": "2018-11-15T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-10-03, 2018-11-15",
          "rr_end": "2018-11-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_start": "2018-10-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Zytiga",
          "url": "http://www.ncpe.ie/drugs/abiraterone-acetate-zytiga-for-mhspc/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Abiraterone acetate (Zytiga®) for mCRPC post ADT",
          "earliest": "2013-01-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga",
          "eu_market": "2011-09-05T00:00:00",
          "id": 2166,
          "indication": "Pharmacoeconomic evaluation of Abiratone acetate (Zytiga®) for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated",
          "last_scrape": "2018-12-13T16:24:41",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2013-01-03, 2013-02-01",
          "rr_end": "2013-02-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-01-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Zytiga",
          "url": "http://www.ncpe.ie/drugs/abiratone-acetate-zytiga-for-mcrpc-post-adt/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Abiraterone Acetate (Zytiga®) for mCRPC",
          "earliest": "2011-10-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga",
          "eu_market": "2011-09-05T00:00:00",
          "id": 2167,
          "indication": "Pharmacoeconomic evaluation and resource implications of Zytiga ® (abiraterone acetate) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel-based chemotherapy.",
          "last_scrape": "2018-12-13T16:24:46",
          "latest": "2014-04-01T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2011-10-21, 2011-11-02",
          "rr_end": "2011-11-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-10-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Zytiga",
          "url": "http://www.ncpe.ie/drugs/abiratone-acetate-zytiga/"
         },
         {
          "company": "Unknown",
          "drug_name": "Aceclofenac (Vitafen®)",
          "earliest": "2016-07-22T00:00:00",
          "ema_url": "",
          "eu_market": "2014-01-03T00:00:00",
          "id": 2168,
          "indication": "Aceclofenac (Vitafen®) is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.",
          "last_scrape": "2018-12-13T16:24:49",
          "latest": "2017-11-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-12-21, 2017-01-24",
          "rr_end": "2017-01-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "following a resubmission of the rapid review full pharmacoeconomic evaluation is recommended at the submitted price",
          "rr_start": "2016-12-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Unknown",
          "trade_name": "Vitafen",
          "url": "http://www.ncpe.ie/drugs/aceclofenac-vitafen/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Aclidinium bromide (Eklira Genuair®)",
          "earliest": "2012-10-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair",
          "eu_market": "2012-07-20T00:00:00",
          "id": 2169,
          "indication": "Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)",
          "last_scrape": "2018-12-13T16:24:56",
          "latest": "2012-10-26T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-10-23, 2012-10-26",
          "rr_end": "2012-10-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2012-10-23T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Pulmonary Disease, Chronic Obstructive",
          "trade_name": "Eklira Genuair",
          "url": "http://www.ncpe.ie/drugs/aclidinium-bromide-eklira-genuair/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Aclidinium bromide / formoterol fumarate dihydrate (Brimica®  Genuair®)",
          "earliest": "2015-01-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair",
          "eu_market": "2014-11-19T00:00:00",
          "id": 2170,
          "indication": "Brimica® Genuair® is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.",
          "last_scrape": "2018-12-13T16:25:00",
          "latest": "2015-02-09T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-01-05, 2015-02-09",
          "rr_end": "2015-02-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at submitted price",
          "rr_start": "2015-01-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Pulmonary Disease, Chronic Obstructive",
          "trade_name": "Brimica Genuair",
          "url": "http://www.ncpe.ie/drugs/aclidinium-bromide-formoterol-fumarate-dihydrate-brimica-genuair/"
         },
         {
          "company": "AbbVie",
          "drug_name": "Adalimumab (Humira®)",
          "earliest": "2011-05-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/humira",
          "eu_market": "2003-09-07T00:00:00",
          "id": 2171,
          "indication": "Economic evaluation of Adalimumab (Humira®) in combination with methotrexate for polyarticular juvenile idiopathic arthritis in children and adolescents (4-17yrs) in patients who have had an inadequate response to DMARDs.  Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate.",
          "last_scrape": "2018-12-13T16:25:37",
          "latest": "2011-06-02T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-05-20, 2011-06-02",
          "rr_end": "2011-06-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-05-20T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid",
          "trade_name": "Humira",
          "url": "http://www.ncpe.ie/drugs/adalimumab-humira/"
         },
         {
          "company": "Menarini",
          "drug_name": "Adenuric (Febuxostat®)",
          "earliest": "2009-12-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric",
          "eu_market": "2008-04-21T00:00:00",
          "id": 2172,
          "indication": "NCPE review of Adenuric (Febuxostat®) a xanthine oxidase inhibitor for the treatment of gout.",
          "last_scrape": "2018-12-13T16:25:40",
          "latest": "2009-12-08T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "2009-12-08",
          "rr_end": "2009-12-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2009-12-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Gout",
          "trade_name": "Febuxostat",
          "url": "http://www.ncpe.ie/drugs/adenuric-febuxostat/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Afatinib (Giotrif®)",
          "earliest": "2013-10-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif",
          "eu_market": "2013-09-25T00:00:00",
          "id": 2173,
          "indication": "GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).",
          "last_scrape": "2018-12-13T16:25:45",
          "latest": "2013-10-13T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-10-01, 2013-10-13",
          "rr_end": "2013-10-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta not recommended",
          "rr_start": "2013-10-01T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Giotrif",
          "url": "http://www.ncpe.ie/drugs/afatinib-giotrif/"
         },
         {
          "company": "Bayer",
          "drug_name": "Aflibercept (Eylea®)",
          "earliest": "2012-12-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/eylea",
          "eu_market": "2012-11-21T00:00:00",
          "id": 2174,
          "indication": "Aflibercept (Eylea®) is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).",
          "last_scrape": "2018-12-13T16:25:49",
          "latest": "2012-12-21T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-12-10, 2012-12-21",
          "rr_end": "2012-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2012-12-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Wet Macular Degeneration; Macular Edema; Diabetes Complications",
          "trade_name": "Eylea",
          "url": "http://www.ncpe.ie/drugs/aflibercept-eylea/"
         },
         {
          "company": "Sanofi-Aventis",
          "drug_name": "Aflibercept (Zaltrap®)",
          "earliest": "2013-03-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zaltrap",
          "eu_market": "2013-02-01T00:00:00",
          "id": 2175,
          "indication": "Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.",
          "last_scrape": "2018-12-13T16:25:52",
          "latest": "2014-02-12T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-03-21, 2013-04-10",
          "rr_end": "2013-04-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-03-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Colorectal Neoplasms",
          "trade_name": "Zaltrap",
          "url": "http://www.ncpe.ie/drugs/aflibercept-zaltrap/"
         },
         {
          "company": "Les",
          "drug_name": "Agomelatine (Valdoxan®)",
          "earliest": "2009-09-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan",
          "eu_market": "2009-02-19T00:00:00",
          "id": 2176,
          "indication": "Economic evaluation of Agomelatine (Valdoxan®) for the treatment of major depressive disorder.",
          "last_scrape": "2018-12-13T16:25:58",
          "latest": "2009-12-11T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-04-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2013-03-09T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Depressive Disorder, Major",
          "trade_name": "Valdoxan",
          "url": "http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/"
         },
         {
          "company": "Roche",
          "drug_name": "Alectinib (Alecensa®)",
          "earliest": "2017-01-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa",
          "eu_market": "2017-02-16T00:00:00",
          "id": 2177,
          "indication": "Alectinib (Alecensa ®) for the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with crizotinib.",
          "last_scrape": "2018-12-13T16:26:06",
          "latest": "2018-12-05T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04",
          "rr_end": "2017-12-04T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2017-01-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Alecensa",
          "url": "http://www.ncpe.ie/drugs/alectinib-alecensa/"
         },
         {
          "company": "Sanofi",
          "drug_name": "Alemtuzumab (Lemtrada®)",
          "earliest": "2013-11-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada",
          "eu_market": "2013-09-12T00:00:00",
          "id": 2178,
          "indication": "Alemtuzumab (Lemtrada®) is indicated for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features",
          "last_scrape": "2018-12-13T16:26:12",
          "latest": "2014-06-25T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-11-08, 2013-12-02",
          "rr_end": "2013-12-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta recommended",
          "rr_start": "2013-11-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Lemtrada",
          "url": "http://www.ncpe.ie/drugs/alemtuzumab-lemtrada/"
         },
         {
          "company": "sanofi-aventis",
          "drug_name": "Alirocumab (Praluent®)",
          "earliest": "2015-10-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/praluent",
          "eu_market": "2015-09-23T00:00:00",
          "id": 2179,
          "indication": "Praluent® is indicated for both primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.",
          "last_scrape": "2018-12-13T16:26:14",
          "latest": "2018-03-20T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2015-10-13, 2015-11-02",
          "rr_end": "2015-11-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-10-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Dyslipidemias",
          "trade_name": "Praluent",
          "url": "http://www.ncpe.ie/drugs/alirocumab-praluent/"
         },
         {
          "company": "Takeda",
          "drug_name": "Alogliptin (Vipidia®)",
          "earliest": "2013-09-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia",
          "eu_market": "2013-09-18T00:00:00",
          "id": 2180,
          "indication": "Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.",
          "last_scrape": "2018-12-13T16:26:16",
          "latest": "2013-10-30T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-09-27, 2013-10-30",
          "rr_end": "2013-10-30T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta not recommended",
          "rr_start": "2013-09-27T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Vipidia",
          "url": "http://www.ncpe.ie/drugs/alogliptin-vipidia/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Ambrisentan (Volibris®)",
          "earliest": "2008-10-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/volibris",
          "eu_market": "2008-04-20T00:00:00",
          "id": 2181,
          "indication": "Cost Effectiveness of ambrisentan (Volibris®) in the treatment of patients with Functional Class II or III pulmonary arterial hypertension.",
          "last_scrape": "2018-12-13T16:26:21",
          "latest": "2014-07-04T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-05-27, 2014-07-04",
          "rr_end": "2014-07-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-05-27T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hypertension, Pulmonary",
          "trade_name": "Volibris",
          "url": "http://www.ncpe.ie/drugs/ambrisentan-volibris/"
         },
         {
          "company": "CIS",
          "drug_name": "Amifampridine (Firdapse®)",
          "earliest": "2011-11-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2182,
          "indication": "For Lambert Eaton Myasthenic Syndrome (LEMS).  This high cost drug is likely to require a full HTA due to significant budget impact.",
          "last_scrape": "2018-12-13T16:26:23",
          "latest": "2011-12-09T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-11-07, 2011-12-09",
          "rr_end": "2011-12-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-11-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Firdapse",
          "url": "http://www.ncpe.ie/drugs/amifampridine-firdapse/"
         },
         {
          "company": "Unknown",
          "drug_name": "Amsacrine (Amsidine®)",
          "earliest": "2017-01-10T00:00:00",
          "ema_url": "",
          "eu_market": "2014-01-23T00:00:00",
          "id": 2183,
          "indication": "Amsidine® is indicated for the induction and maintenance of remission in acute leukaemia of adults.",
          "last_scrape": "2018-12-13T16:26:29",
          "latest": "2017-02-15T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-01-10, 2017-02-15",
          "rr_end": "2017-02-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2017-01-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Amsidine",
          "url": "http://www.ncpe.ie/drugs/amsacrine-amsidine/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Apixaban (Eliquis®) for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and",
          "earliest": "2014-07-29T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis",
          "eu_market": "2011-05-18T00:00:00",
          "id": 2184,
          "indication": "Apixaban (Eliquis®) for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.",
          "last_scrape": "2018-12-13T16:26:35",
          "latest": "2014-08-10T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-07-29, 2014-08-10",
          "rr_end": "2014-08-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-07-29T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Arthroplasty; Venous Thromboembolism",
          "trade_name": "Eliquis",
          "url": "http://www.ncpe.ie/drugs/apixaban-eliquis-for-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe-in-adults/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Apixaban (Eliquis®) for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee",
          "earliest": "2011-10-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis",
          "eu_market": "2011-05-18T00:00:00",
          "id": 2185,
          "indication": "Apixaban (Eliquis®) for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery.",
          "last_scrape": "2018-12-13T16:26:39",
          "latest": "2012-06-19T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-10-19, 2011-11-02",
          "rr_end": "2011-11-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-10-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthroplasty; Venous Thromboembolism",
          "trade_name": "Eliquis",
          "url": "http://www.ncpe.ie/drugs/apixaban-eliquis/"
         },
         {
          "company": "Celgene",
          "drug_name": "Apremilast (Otezla®) for moderate to severe chronic plaque psoriasis.",
          "earliest": "2015-02-24T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/otezla",
          "eu_market": "2015-01-15T00:00:00",
          "id": 2186,
          "indication": "Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light (PUVA).",
          "last_scrape": "2018-12-13T16:26:45",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2015-02-24, 2015-04-03",
          "rr_end": "2015-04-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-02-24T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Psoriatic; Psoriasis",
          "trade_name": "Otezla",
          "url": "http://www.ncpe.ie/drugs/apremilast-otezla-for-moderate-to-severe-chronic-plaque-psoriasis/"
         },
         {
          "company": "Celgene",
          "drug_name": "Apremilast (Otezla®) for psoriatic arthritis.",
          "earliest": "2015-02-24T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/otezla",
          "eu_market": "2015-01-15T00:00:00",
          "id": 2187,
          "indication": "Apremilist (Otezla®), alone or in combination with DMARDs, for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.",
          "last_scrape": "2018-12-13T16:26:47",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2015-02-24, 2015-04-03",
          "rr_end": "2015-04-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-02-24T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Psoriatic; Psoriasis",
          "trade_name": "Otezla",
          "url": "http://www.ncpe.ie/drugs/apremilast-otezla-for-psoriatic-arthritis/"
         },
         {
          "company": "Otsuka",
          "drug_name": "Aripiprazole (Abilify Maintena®)",
          "earliest": "2014-07-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena",
          "eu_market": "2013-11-14T00:00:00",
          "id": 2188,
          "indication": "Aripiprazole (Abilify Maintena®) for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole",
          "last_scrape": "2018-12-13T16:26:49",
          "latest": "2014-08-06T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-07-02, 2014-08-06",
          "rr_end": "2014-08-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-07-02T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Schizophrenia",
          "trade_name": "Abilify Maintena",
          "url": "http://www.ncpe.ie/drugs/aripiprazole-abilify-maintena/"
         },
         {
          "company": "Organon",
          "drug_name": "Asenapine (Sycrest®)",
          "earliest": "2011-08-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/sycrest",
          "eu_market": "2010-09-01T00:00:00",
          "id": 2189,
          "indication": "Asenapine (Sycrest®) for the treatment of moderate to severe manic episodes associated with biopolar 1 disorder in adults.",
          "last_scrape": "2018-12-13T16:26:55",
          "latest": "2011-09-06T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-08-17, 2011-09-06",
          "rr_end": "2011-09-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-08-17T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Bipolar Disorder",
          "trade_name": "Sycrest",
          "url": "http://www.ncpe.ie/drugs/asenapine-sycrest/"
         },
         {
          "company": "Roche",
          "drug_name": "Atezolizumab (Tecentriq®)",
          "earliest": "2017-08-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq",
          "eu_market": "2017-09-21T00:00:00",
          "id": 2190,
          "indication": "Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab.",
          "last_scrape": "2018-12-13T16:27:00",
          "latest": "2018-09-20T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-08-08, 2017-10-09",
          "rr_end": "2017-10-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-08-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Tecentriq",
          "url": "http://www.ncpe.ie/drugs/atezolizumab-tecentriq/"
         },
         {
          "company": "Menarini",
          "drug_name": "Avanafil (Spedra®)",
          "earliest": "2014-02-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/spedra",
          "eu_market": "2013-06-21T00:00:00",
          "id": 2191,
          "indication": "Avanafil (Spedra®) is indicated for the treatment of erectile dysfunction in adult men.",
          "last_scrape": "2018-12-13T16:27:05",
          "latest": "2014-03-12T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-02-19, 2014-03-12",
          "rr_end": "2014-03-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-02-19T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Erectile Dysfunction",
          "trade_name": "Spedra",
          "url": "http://www.ncpe.ie/drugs/avanafil-spedra/"
         },
         {
          "company": "Merck",
          "drug_name": "Avelumab (Bavencio®)",
          "earliest": "2017-10-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio",
          "eu_market": "2017-09-18T00:00:00",
          "id": 2192,
          "indication": "Avelumab (Bavencio®) is indicated for the treatment of adults with metastatic Merkel Cell Carcinoma.",
          "last_scrape": "2018-12-13T16:27:06",
          "latest": "2018-10-08T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-10-17, 2017-11-21",
          "rr_end": "2017-11-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-10-17T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Neuroendocrine Tumors",
          "trade_name": "Bavencio",
          "url": "http://www.ncpe.ie/drugs/avelumab-bavencio/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Aspirin 81mg/Esomeprazole 20mg (Axanum®)",
          "earliest": "2012-04-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2193,
          "indication": "Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.",
          "last_scrape": "2018-12-13T16:27:08",
          "latest": "2012-04-20T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-04-12, 2012-04-20",
          "rr_end": "2012-04-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2012-04-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Axanum",
          "url": "http://www.ncpe.ie/drugs/axanum-aspirin-81mgesomeprazole-20mg/"
         },
         {
          "company": "Kite",
          "drug_name": "Axicabtagene Ciloleucel (Yescarta®)",
          "earliest": "2018-09-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta",
          "eu_market": "2018-08-23T00:00:00",
          "id": 2194,
          "indication": "Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.",
          "last_scrape": "2018-12-13T16:27:14",
          "latest": "2018-10-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-09-10, 2018-10-18",
          "rr_end": "2018-10-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of  axi-cel compared with the current standard of care",
          "rr_start": "2018-09-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse",
          "trade_name": "Yescarta",
          "url": "http://www.ncpe.ie/drugs/axicabtagene-ciloleucel-yescarta/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Axitinib (Inlyta®)",
          "earliest": "2012-11-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta",
          "eu_market": "2012-09-03T00:00:00",
          "id": 2195,
          "indication": "For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine",
          "last_scrape": "2018-12-13T16:27:23",
          "latest": "2012-11-19T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-11-07, 2012-11-19",
          "rr_end": "2012-11-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2012-11-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Renal Cell",
          "trade_name": "Inlyta",
          "url": "http://www.ncpe.ie/drugs/axitinib-inlyta/"
         },
         {
          "company": "Unknown",
          "drug_name": "Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista®)",
          "earliest": "2013-02-12T00:00:00",
          "ema_url": "",
          "eu_market": "2010-02-25T00:00:00",
          "id": 2196,
          "indication": "Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.",
          "last_scrape": "2018-12-13T16:27:24",
          "latest": "2013-02-28T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-02-12, 2013-02-28",
          "rr_end": "2013-02-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_start": "2013-02-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Dymista",
          "url": "http://www.ncpe.ie/drugs/azelastine-hydrochloride-and-fluticasone-propionate-nasal-spray-dymista/"
         },
         {
          "company": "Takeda",
          "drug_name": "Azilsartan (Edarbi®)",
          "earliest": "2012-01-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi",
          "eu_market": "2011-12-07T00:00:00",
          "id": 2197,
          "indication": "Edarbi is indicated for the treatment of essential hypertension in adults.",
          "last_scrape": "2018-12-13T16:27:25",
          "latest": "2012-01-11T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-01-10, 2012-01-11",
          "rr_end": "2012-01-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2012-01-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hypertension",
          "trade_name": "Edarbi",
          "url": "http://www.ncpe.ie/drugs/azilsartan-edarbi/"
         },
         {
          "company": "Eli",
          "drug_name": "Baricitinib (Olumiant®)",
          "earliest": "2017-06-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant",
          "eu_market": "2017-02-12T00:00:00",
          "id": 2198,
          "indication": "Baricitinib (Olumiant®) is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate.",
          "last_scrape": "2018-12-13T16:27:27",
          "latest": "2017-11-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-06-14, 2017-07-13",
          "rr_end": "2017-07-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2017-06-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Rheumatoid",
          "trade_name": "Olumiant",
          "url": "http://www.ncpe.ie/drugs/baricitinib-olumiant/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Bazedoxifene (Conbriza®)",
          "earliest": "2011-09-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza",
          "eu_market": "2009-04-17T00:00:00",
          "id": 2199,
          "indication": "Bazedoxifene (Conbriza®) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.  A significant reduction in the incidence of verterbral fractures has been demonstrated; efficacy on hip fractures has not been established.",
          "last_scrape": "2018-12-13T16:27:33",
          "latest": "2011-11-02T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-09-20, 2011-11-02",
          "rr_end": "2011-11-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-09-20T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Osteoporosis, Postmenopausal",
          "trade_name": "Conbriza",
          "url": "http://www.ncpe.ie/drugs/bazedoxifene-conbriza/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Bedaquiline (Sirturo®)",
          "earliest": "2015-01-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo",
          "eu_market": "2014-03-05T00:00:00",
          "id": 2200,
          "indication": "Bedaquiline (Sirturo®) is indicated for use as part of an appropriate combination regimen for pulmonary MDR‑TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.",
          "last_scrape": "2018-12-13T16:27:36",
          "latest": "2015-02-20T00:00:00",
          "ncpe_year": 2015,
          "orphan": 1,
          "rr_dates": "2015-01-23, 2015-02-20",
          "rr_end": "2015-02-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-01-23T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Tuberculosis, Multidrug-Resistant",
          "trade_name": "Sirturo",
          "url": "http://www.ncpe.ie/drugs/bedaquiline-sirturo/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Belatacept (Nulojix®)",
          "earliest": "2011-11-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/nulojix",
          "eu_market": "2011-06-17T00:00:00",
          "id": 2201,
          "indication": "Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.\n",
          "last_scrape": "2018-12-13T16:27:37",
          "latest": "2012-01-23T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-11-15, 2012-01-23",
          "rr_end": "2012-01-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-11-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Graft Rejection; Kidney Transplantation",
          "trade_name": "Nulojix",
          "url": "http://www.ncpe.ie/drugs/belatacept-nulojix/"
         },
         {
          "company": "Glaxo",
          "drug_name": "Belimumab (Benlysta®)",
          "earliest": "2011-08-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta",
          "eu_market": "2011-07-13T00:00:00",
          "id": 2202,
          "indication": "Cost-effectiveness of Belimumab (Benlysta®)",
          "last_scrape": "2018-12-13T16:27:40",
          "latest": "2011-08-11T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-08-11, 2011-08-11",
          "rr_end": "2011-08-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-08-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lupus Erythematosus, Systemic",
          "trade_name": "Benlysta",
          "url": "http://www.ncpe.ie/drugs/belimumab-benlysta/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Bendamustine (Levact®)",
          "earliest": "2011-03-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2203,
          "indication": "Bendamustine (Levact®) for the treatment of Chronic Lymphocytic Leukaemia (CLL)",
          "last_scrape": "2018-12-13T16:27:46",
          "latest": "2012-11-20T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-03-21, 2011-03-01",
          "rr_end": "2011-03-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-03-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Levact",
          "url": "http://www.ncpe.ie/drugs/bendamustine-levact/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Benralizumab (Fasenra®)",
          "earliest": "2018-01-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra",
          "eu_market": "2018-01-08T00:00:00",
          "id": 2204,
          "indication": "Benralizumab (Fasenra®) is indicated as add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.",
          "last_scrape": "2018-12-13T16:27:50",
          "latest": "2018-02-14T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-01-15, 2018-02-14",
          "rr_end": "2018-02-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharamcoeconomic assessment recommended at the submitted price",
          "rr_start": "2018-01-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Asthma",
          "trade_name": "Fasenra",
          "url": "http://www.ncpe.ie/drugs/benralizumab-fasenra/"
         },
         {
          "company": "Merck",
          "drug_name": "Bezlotoxumab (Zinplava®)",
          "earliest": "2017-05-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava",
          "eu_market": "2017-01-18T00:00:00",
          "id": 2205,
          "indication": "Bezlotoxumab (Zinplava®) is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.",
          "last_scrape": "2018-12-13T16:27:56",
          "latest": "2017-06-14T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-05-11, 2017-06-14",
          "rr_end": "2017-06-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2017-05-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Enterocolitis, Pseudomembranous",
          "trade_name": "Zinplava",
          "url": "http://www.ncpe.ie/drugs/bezlotoxumab-zinplava/"
         },
         {
          "company": "Gilead",
          "drug_name": "Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®)",
          "earliest": "2018-04-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy",
          "eu_market": "2018-06-21T00:00:00",
          "id": 2206,
          "indication": "Biktarvy® for the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.",
          "last_scrape": "2018-12-13T16:27:58",
          "latest": "2018-12-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-04-30, 2018-06-07",
          "rr_end": "2018-06-07T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended the ncpe recommends that biktarvy® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the health (pricing and supply of medical goods act) 2013",
          "rr_start": "2018-04-30T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "HIV Infections",
          "trade_name": "Biktarvy",
          "url": "http://www.ncpe.ie/drugs/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy/"
         },
         {
          "company": "CIS",
          "drug_name": "Bilastine (Drynol®)",
          "earliest": "2011-03-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2207,
          "indication": " Bilastine (Drynol®) for the Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria.",
          "last_scrape": "2018-12-13T16:28:01",
          "latest": "2011-03-23T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-03-10, 2011-03-23",
          "rr_end": "2011-03-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-03-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Drynol",
          "url": "http://www.ncpe.ie/drugs/bilastine-drynol/"
         },
         {
          "company": "Amgen",
          "drug_name": "Blinatumomab (Blincyto®)",
          "earliest": "2015-12-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto",
          "eu_market": "2015-11-23T00:00:00",
          "id": 2208,
          "indication": "Blincyto® is indicated for the treatment of adults with Philadelphia chromosome negative (Ph-) relapsed or refractory\nB-precursor acute lymphoblastic leukaemia.",
          "last_scrape": "2018-12-13T16:28:05",
          "latest": "2018-04-16T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2015-12-08, 2015-12-22",
          "rr_end": "2015-12-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended  the ncpe cannot recommend reimbursement of blinctyo® at this point in time",
          "rr_start": "2015-12-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
          "trade_name": "Blincyto",
          "url": "http://www.ncpe.ie/drugs/blinatumomab-blincyto/"
         },
         {
          "company": "Merck",
          "drug_name": "Boceprevir (Victrelis®)",
          "earliest": "2011-08-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis",
          "eu_market": "2011-07-18T00:00:00",
          "id": 2209,
          "indication": "Economic evaluation of Boceprevir (Victrelis®) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.",
          "last_scrape": "2018-12-13T16:28:11",
          "latest": "2012-01-17T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2015-12-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2015-11-20T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Victrelis",
          "url": "http://www.ncpe.ie/drugs/boceprevir-victrelis/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Bosentan (Tracleer®)",
          "earliest": "2014-06-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer",
          "eu_market": "2002-05-14T00:00:00",
          "id": 2210,
          "indication": "Bosentan (Tracleer®) is indicated for the treatment pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO Functional Class (FC) III and WHO FC II.  It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.",
          "last_scrape": "2018-12-13T16:28:16",
          "latest": "2014-07-04T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-06-27, 2014-07-04",
          "rr_end": "2014-07-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-06-27T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Scleroderma, Systemic; Hypertension, Pulmonary",
          "trade_name": "Tracleer",
          "url": "http://www.ncpe.ie/drugs/bosentan-tracleer/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Bosutinib (Bosulif®)",
          "earliest": "2013-08-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif",
          "eu_market": "2013-03-26T00:00:00",
          "id": 2211,
          "indication": "Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.",
          "last_scrape": "2018-12-13T16:28:18",
          "latest": "2013-09-18T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-08-09, 2013-09-18",
          "rr_end": "2013-09-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "at the current price full hta would be required",
          "rr_start": "2013-08-09T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid",
          "trade_name": "Bosulif",
          "url": "http://www.ncpe.ie/drugs/bosutinib-bosulif/"
         },
         {
          "company": "Takeda",
          "drug_name": "Brentuximab vedotin (Adcetris®) for CD30+ cutaneous T-cell lymphoma (CTCL)",
          "earliest": "2018-02-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris",
          "eu_market": "2012-10-25T00:00:00",
          "id": 2212,
          "indication": "Brentuximab vedotin (Adcetris®) for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy. This is a license extension.",
          "last_scrape": "2018-12-13T16:28:19",
          "latest": "2018-03-06T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-02-07, 2018-03-06",
          "rr_end": "2018-03-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2018-02-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lymphoma, Non-Hodgkin; Hodgkin Disease",
          "trade_name": "Adcetris",
          "url": "http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris-for-cd30-cutaneous-t-cell-lymphoma-ctcl/"
         },
         {
          "company": "Takeda",
          "drug_name": "Brentuximab vedotin (Adcetris®)",
          "earliest": "2012-11-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris",
          "eu_market": "2012-10-25T00:00:00",
          "id": 2213,
          "indication": "Brentuximab vedotin (Adcetris®) indicated for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.",
          "last_scrape": "2018-12-13T16:28:23",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 1,
          "rr_dates": "2012-11-28, 2012-12-21",
          "rr_end": "2012-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2012-11-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lymphoma, Non-Hodgkin; Hodgkin Disease",
          "trade_name": "Adcetris",
          "url": "http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris/"
         },
         {
          "company": "Takeda",
          "drug_name": "Brigatinib (Alunbrig®)",
          "earliest": "2018-11-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig",
          "eu_market": "2018-11-22T00:00:00",
          "id": 2214,
          "indication": "Brigatinib (Alunbrig ®) is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.",
          "last_scrape": "2018-12-13T16:28:29",
          "latest": "2018-12-11T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-11-19, 2018-12-11",
          "rr_end": "2018-12-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of brigatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies",
          "rr_start": "2018-11-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Alunbrig",
          "url": "http://www.ncpe.ie/drugs/brigatinib-alunbrig/"
         },
         {
          "company": "Galderma",
          "drug_name": "Brimonidine 3.3 mg/g gel (Mirvaso®)",
          "earliest": "2014-04-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso",
          "eu_market": "2014-02-20T00:00:00",
          "id": 2215,
          "indication": "Brimonidine 3.3 mg/g gel (Mirvaso®) is indicated for the treatment of facial erythema of rosacea in adult patients.",
          "last_scrape": "2018-12-13T16:28:30",
          "latest": "2014-04-09T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-04-09",
          "rr_end": "2014-04-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-04-09T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Skin Diseases",
          "trade_name": "Mirvaso",
          "url": "http://www.ncpe.ie/drugs/brimonidine-3-3-mgg-gel-mirvaso/"
         },
         {
          "company": "CIS",
          "drug_name": "Brivaracetam (Briviact®)",
          "earliest": "2016-02-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2216,
          "indication": "Brivaracetam (Briviact®) is indicated as adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.",
          "last_scrape": "2018-12-13T16:28:36",
          "latest": "2016-03-22T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-02-15, 2016-03-22",
          "rr_end": "2016-03-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2016-02-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Briviact",
          "url": "http://www.ncpe.ie/drugs/brivaracetam-briviact/"
         },
         {
          "company": "LEO",
          "drug_name": "Brodalumab (Kyntheum®)",
          "earliest": "2017-07-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum",
          "eu_market": "2017-07-17T00:00:00",
          "id": 2217,
          "indication": "Brodalumab (Kyntheum®) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.",
          "last_scrape": "2018-12-13T16:28:40",
          "latest": "2018-01-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-07-25, 2017-08-29",
          "rr_end": "2017-08-29T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at submitted price",
          "rr_start": "2017-07-25T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Psoriasis",
          "trade_name": "Kyntheum",
          "url": "http://www.ncpe.ie/drugs/brodalumab-kyntheum/"
         },
         {
          "company": "Pharmaxis",
          "drug_name": "Mannitol Dry Powder (Bronchitol®)",
          "earliest": "2012-09-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol",
          "eu_market": "2012-04-13T00:00:00",
          "id": 2218,
          "indication": "Bronchitol® – Mannitol dry powder for inhalation for the treatment of cystic fibrosis (CF)",
          "last_scrape": "2018-12-13T16:28:44",
          "latest": "2014-08-29T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2012-09-11, 2012-09-21",
          "rr_end": "2012-09-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta recommended",
          "rr_start": "2012-09-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystic Fibrosis",
          "trade_name": "Bronchitol",
          "url": "http://www.ncpe.ie/drugs/bronchitol/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar ®)",
          "earliest": "2016-05-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2219,
          "indication": "Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.",
          "last_scrape": "2018-12-13T16:28:46",
          "latest": "2016-06-21T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-05-17, 2016-06-21",
          "rr_end": "2016-06-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2016-05-17T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Enstilar",
          "url": "http://www.ncpe.ie/drugs/c-drugs/calcipotriol-and-betamethasone-dipropionate-cutaneous-foam-enstilar/"
         },
         {
          "company": "Shire",
          "drug_name": "C1inhibitor (human) (Cinryze®)",
          "earliest": "2012-10-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze",
          "eu_market": "2011-06-15T00:00:00",
          "id": 2220,
          "indication": "C1inhibitor (human) (Cinryze® 500 Units powder and solvent for solution for injection)",
          "last_scrape": "2018-12-13T16:28:53",
          "latest": "2012-11-14T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-10-22, 2012-11-14",
          "rr_end": "2012-11-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_start": "2012-10-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Angioedemas, Hereditary",
          "trade_name": "Cinryze",
          "url": "http://www.ncpe.ie/drugs/c1inhibitor-human-cinryze/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Cabozantinib (Cabometyx®)",
          "earliest": "2017-03-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2221,
          "indication": "Cabozantinib (Cabometyx®) is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.",
          "last_scrape": "2018-12-13T16:28:55",
          "latest": "2018-07-03T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-03-20, 2017-04-25",
          "rr_end": "2017-04-25T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessmentrecommended",
          "rr_start": "2017-03-20T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Cabometyx",
          "url": "http://www.ncpe.ie/drugs/cabozantinib-cabometyx/"
         },
         {
          "company": "Ipsen",
          "drug_name": "Cabozantinib (Cometriq®)",
          "earliest": "2014-07-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq",
          "eu_market": "2014-03-21T00:00:00",
          "id": 2222,
          "indication": "Cabozantinib (COMETRIQ®) is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.",
          "last_scrape": "2018-12-13T16:28:58",
          "latest": "2014-08-12T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-07-10, 2014-08-12",
          "rr_end": "2014-08-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2014-07-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Thyroid Neoplasms",
          "trade_name": "Cometriq",
          "url": "http://www.ncpe.ie/drugs/cabozantinib-cometriq/"
         },
         {
          "company": "CIS",
          "drug_name": "Camellia sinensis, folium (green tea leaf) (Catephen 10%®)",
          "earliest": "2015-05-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2223,
          "indication": "Catephen 10%® is indicated for the cutaneous treatment of external genital and perianal warts (condylomataacuminata) in immunocompetent patients from the age of 18 years.",
          "last_scrape": "2018-12-13T16:29:01",
          "latest": "2015-07-10T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-05-26, 2015-07-10",
          "rr_end": "2015-07-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-05-26T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Catephen 10%",
          "url": "http://www.ncpe.ie/drugs/camellia-sinensis-folium-green-tea-leaf-catephen-10/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Canagliflozin (Invokana®)",
          "earliest": "2013-11-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/invokana",
          "eu_market": "2013-11-15T00:00:00",
          "id": 2224,
          "indication": "Canagliflozin (Invokana®) is indicated for the treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin",
          "last_scrape": "2018-12-13T16:29:04",
          "latest": "2014-12-01T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-11-25, 2013-12-02",
          "rr_end": "2013-12-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta recommended",
          "rr_start": "2013-11-25T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Invokana",
          "url": "http://www.ncpe.ie/drugs/canagliflozin-invokana/"
         },
         {
          "company": "Grunenthal",
          "drug_name": "Capsaicin 8%w/w patch (Qutenza®)",
          "earliest": "2012-06-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza",
          "eu_market": "2009-05-15T00:00:00",
          "id": 2225,
          "indication": "Capsaicin 8% w/w patch (Qutenza®) for peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.",
          "last_scrape": "2018-12-13T16:29:09",
          "latest": "2012-06-28T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-06-15, 2012-06-28",
          "rr_end": "2012-06-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2012-06-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Neuralgia",
          "trade_name": "Qutenza",
          "url": "http://www.ncpe.ie/drugs/capsaicin-8ww-patch-qutenza/"
         },
         {
          "company": "sanofi-aventis",
          "drug_name": "Cabazitaxel (Jevtana®)",
          "earliest": "2011-06-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana",
          "eu_market": "2011-03-17T00:00:00",
          "id": 2226,
          "indication": "Economic Evaluation of cabazitaxel (Jevtana®) for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen.",
          "last_scrape": "2018-12-13T16:29:11",
          "latest": "2014-03-01T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2011-06-02, 2011-06-09",
          "rr_end": "2011-06-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-06-02T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Jevtana",
          "url": "http://www.ncpe.ie/drugs/carbazitaxel-jevtana-for-prostate-cancer/"
         },
         {
          "company": "Amgen",
          "drug_name": "Carfilzomib (Kyprolis®)",
          "earliest": "2015-12-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis",
          "eu_market": "2015-11-19T00:00:00",
          "id": 2227,
          "indication": "Kyprolis® (in combination with lenalidomide and dexamethasone) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.",
          "last_scrape": "2018-12-13T16:29:16",
          "latest": "2018-09-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2015-12-07, 2016-01-06",
          "rr_end": "2016-01-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-12-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Myeloma",
          "trade_name": "Kyprolis",
          "url": "http://www.ncpe.ie/drugs/carfilzomib-kyprolis/"
         },
         {
          "company": "Neovii",
          "drug_name": "Catumaxomab (Removab®)",
          "earliest": "2011-08-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/removab",
          "eu_market": "2009-04-20T00:00:00",
          "id": 2228,
          "indication": "Catumazomab (Removab®) for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.",
          "last_scrape": "2018-12-13T16:29:22",
          "latest": "2011-09-06T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-08-05, 2011-09-06",
          "rr_end": "2011-09-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-08-05T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Ascites; Cancer",
          "trade_name": "Removab",
          "url": "http://www.ncpe.ie/drugs/catumaxomab-removab/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Ceftaroline (Zinforo®)",
          "earliest": "2012-10-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo",
          "eu_market": "2012-08-22T00:00:00",
          "id": 2229,
          "indication": "For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP).",
          "last_scrape": "2018-12-13T16:29:25",
          "latest": "2012-10-12T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-10-08, 2012-10-12",
          "rr_end": "2012-10-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2012-10-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia",
          "trade_name": "Zinforo",
          "url": "http://www.ncpe.ie/drugs/ceftaroline-zinforo/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Ceftazidime-avibactam (CEF-AVI)(Zavicefta®)",
          "earliest": "2017-05-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta",
          "eu_market": "2016-06-23T00:00:00",
          "id": 2230,
          "indication": "Ceftazidime-avibactam (CEF-AVI)(Zavicefta®) is indicated for the treatment of CIAI, cUTI, HAP (including VAP) and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.",
          "last_scrape": "2018-12-13T16:29:29",
          "latest": "2017-11-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-05-17, 2017-06-13",
          "rr_end": "2017-06-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2017-05-17T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections",
          "trade_name": "Zavicefta",
          "url": "http://www.ncpe.ie/drugs/ceftazidime-avibactam-cef-avizavicefta/"
         },
         {
          "company": "Merck",
          "drug_name": "Ceftolozane/tazobactam (Zerbaxa®)",
          "earliest": "2016-03-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa",
          "eu_market": "2015-09-18T00:00:00",
          "id": 2231,
          "indication": "Zerbaxa® is indicated for the treatment of complicated urinary tract infections (cUTI), acute pyelonephritis and complicated intra-abdominal infections (cIAI) in adults.",
          "last_scrape": "2018-12-13T16:29:34",
          "latest": "2016-09-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-03-03, 2016-04-26",
          "rr_end": "2016-04-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2016-03-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Bacterial Infections",
          "trade_name": "Zerbaxa",
          "url": "http://www.ncpe.ie/drugs/ceftolozanetazobactam-zerbaxa/"
         },
         {
          "company": "Novartis",
          "drug_name": "Ceritinib (Zykadia®)",
          "earliest": "2015-05-29T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia",
          "eu_market": "2015-05-06T00:00:00",
          "id": 2232,
          "indication": "Zykadia® is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.",
          "last_scrape": "2018-12-13T16:29:36",
          "latest": "2015-07-22T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-05-29, 2015-07-22",
          "rr_end": "2015-07-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2015-05-29T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Zykadia",
          "url": "http://www.ncpe.ie/drugs/ceritinib-zykadia/"
         },
         {
          "company": "BioMarin",
          "drug_name": "Cerliponase alfa (Brineura®)",
          "earliest": "2017-10-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/brineura",
          "eu_market": "2017-05-30T00:00:00",
          "id": 2233,
          "indication": "Cerliponase alfa (Brineura®) is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.",
          "last_scrape": "2018-12-13T16:29:40",
          "latest": "2018-08-02T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-10-11, 2017-11-27",
          "rr_end": "2017-11-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation is recommended",
          "rr_start": "2017-10-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Neuronal Ceroid-Lipofuscinoses",
          "trade_name": "Brineura",
          "url": "http://www.ncpe.ie/drugs/cerliponase-alfa-brineura/"
         },
         {
          "company": "UCB",
          "drug_name": "Certolizumab pegol (Cimzia®)",
          "earliest": "2010-03-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0",
          "eu_market": "2009-10-01T00:00:00",
          "id": 2234,
          "indication": "Cost-effectiveness of certolizumab pegol (Cimzia®) for the treatment of moderate to severe rheumatoid arthritis.",
          "last_scrape": "2018-12-13T16:29:44",
          "latest": "2010-09-02T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-11-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2017-10-26T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Arthritis, Rheumatoid",
          "trade_name": "Cimzia",
          "url": "http://www.ncpe.ie/drugs/certolizumab-pegol-cimzia/"
         },
         {
          "company": "Santen",
          "drug_name": "Ciclosporin 1mg/ml eye drops (Ikervis®)",
          "earliest": "2015-01-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis",
          "eu_market": "2015-03-19T00:00:00",
          "id": 2235,
          "indication": "Ikervis® is indicated for the treatment of severe keratitis in adult patients with dry eye disease (DED), which has not improved despite treatment with tear substitutes.",
          "last_scrape": "2018-12-13T16:29:49",
          "latest": "2016-01-18T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2015-01-07, 2016-01-18",
          "rr_end": "2016-01-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-01-07T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Corneal Diseases",
          "trade_name": "Ikervis",
          "url": "http://www.ncpe.ie/drugs/ciclosporin-1mgml-eye-drops-ikervis/"
         },
         {
          "company": "Merck",
          "drug_name": "Cladribine (Mavenclad®)",
          "earliest": "2017-08-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad",
          "eu_market": "2017-08-22T00:00:00",
          "id": 2236,
          "indication": "Cladribine (Mavenclad®) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features",
          "last_scrape": "2018-12-13T16:29:54",
          "latest": "2018-09-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-08-22, 2017-09-18",
          "rr_end": "2017-09-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_start": "2017-08-22T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Mavenclad",
          "url": "http://www.ncpe.ie/drugs/cladribine-mavenclad/"
         },
         {
          "company": "CIS",
          "drug_name": "Clindamycin 1% with tretinoin 0.025% (Treclinac®)",
          "earliest": "2014-04-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2237,
          "indication": "Clindamycin 1% with tretinoin 0.025% (Treclinac®) is indicated for the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older.",
          "last_scrape": "2018-12-13T16:29:58",
          "latest": "2014-05-06T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-04-08, 2014-05-06",
          "rr_end": "2014-05-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-04-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Treclinac",
          "url": "http://www.ncpe.ie/drugs/clindamycin-1-with-tretinoin-0-025-treclinac/"
         },
         {
          "company": "Roche",
          "drug_name": "Cobimetinib (Cotellic®)",
          "earliest": "2016-04-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic",
          "eu_market": "2015-11-20T00:00:00",
          "id": 2238,
          "indication": "Cotellic® is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
          "last_scrape": "2018-12-13T16:30:02",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-04-19, 2016-04-26",
          "rr_end": "2016-04-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-04-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma",
          "trade_name": "Cotellic",
          "url": "http://www.ncpe.ie/drugs/cobimetinib-cotellic/"
         },
         {
          "company": "Genzyme",
          "drug_name": "Colesevelam (Cholestagel®)",
          "earliest": "2010-10-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cholestagel",
          "eu_market": "2004-03-09T00:00:00",
          "id": 2239,
          "indication": "Cost-effectiveness of Colesevelam (Cholestagel®)",
          "last_scrape": "2018-12-13T16:30:03",
          "latest": "2010-10-22T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-10-19, 2010-10-22",
          "rr_end": "2010-10-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2010-10-19T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hypercholesterolemia",
          "trade_name": "Cholestagel",
          "url": "http://www.ncpe.ie/drugs/colesevelam-cholestagel/"
         },
         {
          "company": "Teva",
          "drug_name": "Colistimethate sodium (Colobreathe®)",
          "earliest": "2013-06-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe",
          "eu_market": "2012-02-13T00:00:00",
          "id": 2240,
          "indication": "Colistimethate sodium (colobreathe®) is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.",
          "last_scrape": "2018-12-13T16:30:06",
          "latest": "2013-06-28T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-06-07, 2013-06-28",
          "rr_end": "2013-06-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2013-06-07T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Cystic Fibrosis",
          "trade_name": "Colobreathe",
          "url": "http://www.ncpe.ie/drugs/colistimethate-sodium-colobreathe/"
         },
         {
          "company": "Swedish",
          "drug_name": "Collagenase Clostridium Histolyticum (Xiapex®)",
          "earliest": "2011-05-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex",
          "eu_market": "2011-02-28T00:00:00",
          "id": 2241,
          "indication": " Collagenase Clostridium Histolyticum (Xiapex®) is indicated for the treatment of Dupuytren’s contracture in adult patients with a palpable cord.",
          "last_scrape": "2018-12-13T16:30:17",
          "latest": "2011-06-09T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-05-20, 2011-06-09",
          "rr_end": "2011-06-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-05-20T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Dupuytren Contracture",
          "trade_name": "Xiapex",
          "url": "http://www.ncpe.ie/drugs/collagenase-clostridium-histolyticum-xiapex/"
         },
         {
          "company": "Merck",
          "drug_name": "Corifollitropin alfa (Elonva®)",
          "earliest": "2010-09-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/elonva",
          "eu_market": "2010-01-25T00:00:00",
          "id": 2242,
          "indication": "Cost-effectiveness of Corifollitropin alfa (Elonva®).",
          "last_scrape": "2018-12-13T16:30:20",
          "latest": "2010-10-22T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-10-22, 2010-09-01",
          "rr_end": "2010-09-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2010-10-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Reproductive Techniques, Assisted; Ovulation Induction",
          "trade_name": "Elonva",
          "url": "http://www.ncpe.ie/drugs/corifollitropin-alfa-elonva/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Crizotinib (Xalkori®) for first line ALK+ NSCLC",
          "earliest": "2017-02-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori",
          "eu_market": "2012-10-23T00:00:00",
          "id": 2243,
          "indication": "Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
          "last_scrape": "2018-12-13T16:30:24",
          "latest": "2017-04-24T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-02-06, 2017-04-24",
          "rr_end": "2017-04-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2017-02-06T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Xalkori",
          "url": "http://www.ncpe.ie/drugs/crizotinib-xalkori-for-first-line-alk-nsclc/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Crizotinib (Xalkori®) for ROS1 NSCLC",
          "earliest": "2017-02-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori",
          "eu_market": "2012-10-23T00:00:00",
          "id": 2244,
          "indication": "Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).",
          "last_scrape": "2018-12-13T16:30:29",
          "latest": "2017-04-24T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-02-06, 2017-04-24",
          "rr_end": "2017-04-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2017-02-06T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Xalkori",
          "url": "http://www.ncpe.ie/drugs/crizotinib-xalkori-for-ros1-nsclc/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Crizotinib (Xalkori®)",
          "earliest": "2013-01-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori",
          "eu_market": "2012-10-23T00:00:00",
          "id": 2245,
          "indication": "For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd–line treatment setting)",
          "last_scrape": "2018-12-13T16:30:34",
          "latest": "2015-08-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2013-01-09, 2013-01-31",
          "rr_end": "2013-01-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-01-09T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Xalkori",
          "url": "http://www.ncpe.ie/drugs/crizotinib-xalkori/"
         },
         {
          "company": "Chiesi",
          "drug_name": "Cysteamine bitartrate delayed-release (Procysbi®)",
          "earliest": "2015-12-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi",
          "eu_market": "2013-09-05T00:00:00",
          "id": 2246,
          "indication": "Procysbi® for the treatment of proven nephropathic cystinosis.",
          "last_scrape": "2018-12-13T16:30:37",
          "latest": "2017-11-15T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2015-12-01, 2015-12-15",
          "rr_end": "2015-12-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at the submitted price",
          "rr_start": "2015-12-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystinosis",
          "trade_name": "Procysbi",
          "url": "http://www.ncpe.ie/drugs/cysteamine-bitartrate-procysbi/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Dabigatran Etexilate (Pradaxa®) for the treatment of DVT and PE",
          "earliest": "2014-05-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa",
          "eu_market": "2008-03-17T00:00:00",
          "id": 2247,
          "indication": "Dabigatran etexilate (Pradaxa®) is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.",
          "last_scrape": "2018-12-13T16:30:43",
          "latest": "2014-06-13T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-05-09, 2014-06-13",
          "rr_end": "2014-06-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-05-09T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Pradaxa",
          "url": "http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-2/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Dabigatran etexilate (Pradaxa®) – for the prevention of stroke and systematic embolisom in atrial fibrillation",
          "earliest": "2010-11-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa",
          "eu_market": "2008-03-17T00:00:00",
          "id": 2248,
          "indication": "Dabigatran etexilate (Pradaxa®) for the Prevention of Stroke and Systemic Embolism in Adult Patients with Atrial Fibrillation",
          "last_scrape": "2018-12-13T16:30:51",
          "latest": "2012-10-03T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2014-06-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2014-05-12T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Pradaxa",
          "url": "http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-for-the-prevention-of-stroke-and-systematic-embolisom-in-atrial-fibrillation/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Dabigatran Etexilate (Pradaxa®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement",
          "earliest": "2008-07-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa",
          "eu_market": "2008-03-17T00:00:00",
          "id": 2249,
          "indication": "Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate (Pradaxa®) for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have undergone Total Hip Replacement or Total Knee Surgery.",
          "last_scrape": "2018-12-13T16:30:57",
          "latest": "2008-09-01T00:00:00",
          "ncpe_year": 2008,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2014-06-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2014-05-12T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Pradaxa",
          "url": "http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-vte-prevention/"
         },
         {
          "company": "Novartis",
          "drug_name": "Dabrafenib (Tafinlar®)",
          "earliest": "2013-09-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar",
          "eu_market": "2013-08-26T00:00:00",
          "id": 2250,
          "indication": "Dabrafenib (Tafinlar® ) is indicated for the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation.",
          "last_scrape": "2018-12-13T16:30:59",
          "latest": "2014-06-24T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-09-11, 2013-10-02",
          "rr_end": "2013-10-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-09-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma",
          "trade_name": "Tafinlar",
          "url": "http://www.ncpe.ie/drugs/dabrafenib-tafinlar/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Daclatasvir (Daklinza®)",
          "earliest": "2014-08-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza",
          "eu_market": "2014-08-22T00:00:00",
          "id": 2251,
          "indication": "Daclatasvir (Daklinza®) is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (genotype 1,3 and 4). ",
          "last_scrape": "2018-12-13T16:31:02",
          "latest": "2015-05-29T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-08-05, 2014-09-12",
          "rr_end": "2014-09-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-08-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Daklinza",
          "url": "http://www.ncpe.ie/drugs/daclatasvir-daklinza/"
         },
         {
          "company": "Biogen",
          "drug_name": "Daclizumab (Zinbryta®)",
          "earliest": "2016-09-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta",
          "eu_market": "2016-07-01T00:00:00",
          "id": 2252,
          "indication": "Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.",
          "last_scrape": "2018-12-13T16:31:08",
          "latest": "2018-03-07T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-09-26, 2016-11-23",
          "rr_end": "2016-11-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2016-09-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Zinbryta",
          "url": "http://www.ncpe.ie/drugs/daclizumab-zinbryta/"
         },
         {
          "company": "Allergan",
          "drug_name": "Dalbavancin (Xydalba®)",
          "earliest": "2017-03-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xydalba",
          "eu_market": "2015-02-19T00:00:00",
          "id": 2253,
          "indication": "Dalbavancin (Xydalba®) is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.",
          "last_scrape": "2018-12-13T16:31:12",
          "latest": "2017-11-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-03-07, 2017-04-28",
          "rr_end": "2017-04-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at the submitted price",
          "rr_start": "2017-03-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Soft Tissue Infections; Skin Diseases, Bacterial",
          "trade_name": "Xydalba",
          "url": "http://www.ncpe.ie/drugs/dalbavancin-xydalba/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Dapagliflozin (Forxiga®)",
          "earliest": "2012-10-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga",
          "eu_market": "2012-11-11T00:00:00",
          "id": 2254,
          "indication": "Dapagliflozin (Forxiga®) is indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as:\nMonotherapy\nWhen diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.\nAdd-on combination therapy\nIn combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.",
          "last_scrape": "2018-12-13T16:31:18",
          "latest": "2013-12-31T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2012-10-10, 2012-10-22",
          "rr_end": "2012-10-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2012-10-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Forxiga",
          "url": "http://www.ncpe.ie/drugs/dapagliflozin-forxiga/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Daratumumab (Darzalex®)",
          "earliest": "2016-05-31T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex",
          "eu_market": "2017-04-28T00:00:00",
          "id": 2255,
          "indication": "Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.",
          "last_scrape": "2018-12-13T16:31:21",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2016-05-31, 2016-06-14",
          "rr_end": "2016-06-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-05-31T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Myeloma",
          "trade_name": "Darzalex",
          "url": "http://www.ncpe.ie/drugs/daratumumab-darzalex/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza®)",
          "earliest": "2017-09-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza",
          "eu_market": "2017-09-20T00:00:00",
          "id": 2256,
          "indication": "Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza®) is indicated for the treatment of HIV-1 in adults and adolescents.",
          "last_scrape": "2018-12-13T16:31:25",
          "latest": "2017-10-26T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-09-27, 2017-10-26",
          "rr_end": "2017-10-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_start": "2017-09-27T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "HIV Infections",
          "trade_name": "Symtuza",
          "url": "http://www.ncpe.ie/drugs/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Darunavir & cobicistat (Rezolsta®)",
          "earliest": "2014-12-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta",
          "eu_market": "2014-11-19T00:00:00",
          "id": 2257,
          "indication": "Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.",
          "last_scrape": "2018-12-13T16:31:30",
          "latest": "2015-01-08T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-12-02, 2015-01-08",
          "rr_end": "2015-01-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-12-02T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "HIV Infections",
          "trade_name": "Rezolsta",
          "url": "http://www.ncpe.ie/drugs/darunavir-cobicistat-rezolsta/"
         },
         {
          "company": "Takeda",
          "drug_name": "Darvadstrocel (Alofisel®)",
          "earliest": "2018-06-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel",
          "eu_market": "2018-03-23T00:00:00",
          "id": 2258,
          "indication": "Darvadstrocel (Alofisel®) for the treatment of complex perianal fistulae in adult patients with non-active/ mildly active luminal Crohn’s Disease when fistulae have shown an inadequate response to at least one conventional or biologic therapy and should be used after conditioning of fistula.",
          "last_scrape": "2018-12-13T16:31:35",
          "latest": "2018-07-31T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-06-14, 2018-07-17",
          "rr_end": "2018-07-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of darvadstrocel compared with the current standard of care",
          "rr_start": "2018-06-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Rectal Fistula",
          "trade_name": "Alofisel",
          "url": "http://www.ncpe.ie/drugs/darvadstrocel-alofisel/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Decitabine (Dacogen®)",
          "earliest": "2012-11-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen",
          "eu_market": "2012-09-20T00:00:00",
          "id": 2259,
          "indication": "Decitabine (Dacogen®) is indicated for AML in patients who are >65yrs who are not candidates for standard induction therapy",
          "last_scrape": "2018-12-13T16:31:40",
          "latest": "2013-12-05T00:00:00",
          "ncpe_year": 2013,
          "orphan": 1,
          "rr_dates": "2012-11-08, 2012-12-13",
          "rr_end": "2012-12-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2012-11-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid",
          "trade_name": "Dacogen",
          "url": "http://www.ncpe.ie/drugs/decitabine-dacogen/"
         },
         {
          "company": "Gentium",
          "drug_name": "Defibrotide (Defitelio®)",
          "earliest": "2014-05-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio",
          "eu_market": "2013-10-18T00:00:00",
          "id": 2260,
          "indication": "Defibrotide (Defitelio®) indicated in adults, children and infants (>1month) for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy.",
          "last_scrape": "2018-12-13T16:31:44",
          "latest": "2014-07-10T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-05-12, 2014-07-10",
          "rr_end": "2014-07-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2014-05-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hepatic Veno-Occlusive Disease",
          "trade_name": "Defitelio",
          "url": "http://www.ncpe.ie/drugs/defibrotide-defitelio/"
         },
         {
          "company": "Ferring",
          "drug_name": "Degarelix (Firmagon®)",
          "earliest": "2009-10-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon",
          "eu_market": "2009-02-17T00:00:00",
          "id": 2261,
          "indication": "Cost-effectiveness of Degarelix (Firmagon®)",
          "last_scrape": "2018-12-13T16:31:47",
          "latest": "2009-10-15T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "2009-10-15",
          "rr_end": "2009-10-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2009-10-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Firmagon",
          "url": "http://www.ncpe.ie/drugs/degarelix-firmagon/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex®)",
          "earliest": "2018-02-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2262,
          "indication": "Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex®) which is indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.",
          "last_scrape": "2018-12-13T16:31:52",
          "latest": "2018-04-20T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-02-12, 2018-04-03",
          "rr_end": "2018-04-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of sativex® compared with the current standard of care",
          "rr_start": "2018-02-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Sativex",
          "url": "http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-cannabidiol-thc-cbd-sativex/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex®)",
          "earliest": "2012-12-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2263,
          "indication": "For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy",
          "last_scrape": "2018-12-13T16:31:59",
          "latest": "2014-09-26T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2012-12-05, 2013-01-04",
          "rr_end": "2013-01-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2012-12-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Sativex",
          "url": "http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-thccannabidiol-cbd-sativex/"
         },
         {
          "company": "Amgen",
          "drug_name": "Denosumab (Prolia®)",
          "earliest": "2010-05-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/prolia",
          "eu_market": "2010-05-26T00:00:00",
          "id": 2264,
          "indication": "The Cost-effectiveness of Denosumab (Prolia®) for the Prevention of Osteoporotic Fractures in Postmenopausal Women.",
          "last_scrape": "2018-12-13T16:32:04",
          "latest": "2010-07-01T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-01-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2012-12-03T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Bone Resorption; Osteoporosis, Postmenopausal",
          "trade_name": "Prolia",
          "url": "http://www.ncpe.ie/drugs/denosumab-prolia/"
         },
         {
          "company": "Amgen",
          "drug_name": "Denosumab (Xgeva®)",
          "earliest": "2011-08-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva",
          "eu_market": "2011-07-13T00:00:00",
          "id": 2265,
          "indication": "Cost-effectiveness of denosumab (Xgeva®) for the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland.",
          "last_scrape": "2018-12-13T16:32:08",
          "latest": "2011-12-08T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-01-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2012-12-03T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Fractures, Bone; Neoplasm Metastasis",
          "trade_name": "Xgeva",
          "url": "http://www.ncpe.ie/drugs/denosumab-xgeva-3/"
         },
         {
          "company": "Allergan",
          "drug_name": "Dexamethasone Intravitreal Implant (Ozurdex®)",
          "earliest": "2010-11-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex",
          "eu_market": "2010-07-26T00:00:00",
          "id": 2266,
          "indication": "Cost-effectiveness of Ozurdex® in the treatment of macular oedema following Retinal Vein Occlusion.",
          "last_scrape": "2018-12-13T16:32:12",
          "latest": "2012-03-16T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2010-11-12, 2010-12-16",
          "rr_end": "2010-12-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2010-11-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Macular Edema; Uveitis",
          "trade_name": "Ozurdex",
          "url": "http://www.ncpe.ie/drugs/dexamethasone-intravitreal-implant-ozurdex/"
         },
         {
          "company": "Orion",
          "drug_name": "Dexmedetomidine (Dexdor®)",
          "earliest": "2011-07-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/dexdor",
          "eu_market": "2011-09-15T00:00:00",
          "id": 2267,
          "indication": "Dexmedetomidine (Dexdor®) for the treatemnt of ICU adult patients requiring light to moderate sedation.",
          "last_scrape": "2018-12-13T16:32:15",
          "latest": "2011-09-06T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-07-08, 2011-09-06",
          "rr_end": "2011-09-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-07-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Conscious Sedation",
          "trade_name": "Dexdor",
          "url": "http://www.ncpe.ie/drugs/dexmedetomidine-dexdor/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Dienogest (Visanne®)",
          "earliest": "2010-09-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2268,
          "indication": "Dienogest (Visanne®) for the Treatment of Endometriosis",
          "last_scrape": "2018-12-13T16:32:21",
          "latest": "2010-10-04T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-09-17, 2010-10-04",
          "rr_end": "2010-10-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2010-09-17T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Visanne",
          "url": "http://www.ncpe.ie/drugs/dienogest-visanne/"
         },
         {
          "company": "Almirall",
          "drug_name": "Dimethyl fumarate (Skilarence®)",
          "earliest": "2018-01-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence",
          "eu_market": "2017-06-23T00:00:00",
          "id": 2269,
          "indication": "Dimethyl fumarate (Skilarence®) for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.",
          "last_scrape": "2018-12-13T16:32:24",
          "latest": "2018-02-06T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-01-15, 2018-02-06",
          "rr_end": "2018-02-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2018-01-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Psoriasis",
          "trade_name": "Skilarence",
          "url": "http://www.ncpe.ie/drugs/dimethyl-fumarate-skilarence/"
         },
         {
          "company": "Biogen",
          "drug_name": "Dimethyl fumarate (Tecfidera®)",
          "earliest": "2014-02-04T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera",
          "eu_market": "2014-01-30T00:00:00",
          "id": 2270,
          "indication": "Dimethyl fumarate (Tecfidera®) is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (MS).",
          "last_scrape": "2018-12-13T16:32:26",
          "latest": "2015-04-14T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-02-04, 2014-03-06",
          "rr_end": "2014-03-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-02-04T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Tecfidera",
          "url": "http://www.ncpe.ie/drugs/dimethyl-fumarate-tecfidera/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Dinutuximab beta (Qarziba®)",
          "earliest": "2017-10-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13",
          "eu_market": "2009-12-09T00:00:00",
          "id": 2271,
          "indication": "Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ≥ 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.",
          "last_scrape": "2018-12-13T16:32:29",
          "latest": "2018-10-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-10-19, 2017-11-23",
          "rr_end": "2017-11-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "following assessment of the applicant’s submission, the ncpe recommends that dinutuximab beta (qarziba®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments this recommendation should be considered while also having regard to the criteria specified in the health (pricing and supply of goods) act 2013",
          "rr_start": "2017-10-19T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "Pneumococcal Infections; Immunization",
          "trade_name": "Qarziba",
          "url": "http://www.ncpe.ie/drugs/dinutuximab-beta-dinutuximab-beta-eusa/"
         },
         {
          "company": "ViiV",
          "drug_name": "Dolutegravir/Rilpivirine (Juluca®)",
          "earliest": "2018-06-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/juluca",
          "eu_market": "2018-05-16T00:00:00",
          "id": 2272,
          "indication": "Dolutegravir/rilpivirine (Juluca®)is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.",
          "last_scrape": "2018-12-13T16:32:34",
          "latest": "2018-10-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-06-08, 2018-07-12",
          "rr_end": "2018-07-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is not recommended the ncpe recommends that juluca® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the health (pricing and supply of medical goods) act 2013",
          "rr_start": "2018-06-08T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "HIV Infections",
          "trade_name": "Juluca",
          "url": "http://www.ncpe.ie/drugs/dolutegravir-rilpivirine-juluca/"
         },
         {
          "company": "ViiV",
          "drug_name": "Dolutegravir (Tivicay®)",
          "earliest": "2014-02-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay",
          "eu_market": "2014-01-16T00:00:00",
          "id": 2273,
          "indication": "Dolutegravir (Tivicay®) is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age.",
          "last_scrape": "2018-12-13T16:32:36",
          "latest": "2014-03-13T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-02-10, 2014-03-13",
          "rr_end": "2014-03-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-02-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "HIV Infections",
          "trade_name": "Tivicay",
          "url": "http://www.ncpe.ie/drugs/dolutegravir-tivicay/"
         },
         {
          "company": "Sanofi-aventis",
          "drug_name": "Dronedarone (Multaq®)",
          "earliest": "2010-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0",
          "eu_market": "2009-11-25T00:00:00",
          "id": 2274,
          "indication": "Rapid Review",
          "last_scrape": "2018-12-13T16:32:39",
          "latest": "2010-01-12T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-01-12, 2010-01-01",
          "rr_end": "2010-01-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2010-01-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Atrial Fibrillation",
          "trade_name": "Multaq",
          "url": "http://www.ncpe.ie/drugs/dronedarone-multaq/"
         },
         {
          "company": "Eli",
          "drug_name": "Dulaglutide (Trulicity®)",
          "earliest": "2015-03-04T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity",
          "eu_market": "2014-11-21T00:00:00",
          "id": 2275,
          "indication": "Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.",
          "last_scrape": "2018-12-13T16:32:42",
          "latest": "2015-04-29T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-03-04, 2015-04-29",
          "rr_end": "2015-04-29T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_start": "2015-03-04T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Trulicity",
          "url": "http://www.ncpe.ie/drugs/dulaglutide-trulicity/"
         },
         {
          "company": "sanofi-aventis",
          "drug_name": "Dupilumab (Dupixent®)",
          "earliest": "2017-11-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent",
          "eu_market": "2017-09-27T00:00:00",
          "id": 2276,
          "indication": "Dupilumab (Dupixent®) is indicated for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.",
          "last_scrape": "2018-12-13T16:32:46",
          "latest": "2018-06-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-11-13, 2017-11-24",
          "rr_end": "2017-11-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-11-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Dermatitis, Atopic",
          "trade_name": "Dupixent",
          "url": "http://www.ncpe.ie/drugs/dupilumab-dupixent/"
         },
         {
          "company": "Alexion",
          "drug_name": "Eculizumab (Soliris®)",
          "earliest": "2010-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/soliris",
          "eu_market": "2007-06-20T00:00:00",
          "id": 2277,
          "indication": "An Economic Evaluation of Eculizumab (Soliris®) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in the Irish healthcare setting.",
          "last_scrape": "2018-12-13T16:32:53",
          "latest": "2013-10-14T00:00:00",
          "ncpe_year": 2013,
          "orphan": 1,
          "rr_dates": "",
          "rr_end": "2017-11-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2017-10-23T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Hemoglobinuria, Paroxysmal",
          "trade_name": "Soliris",
          "url": "http://www.ncpe.ie/drugs/eculizumab-soliris/"
         },
         {
          "company": "Daiichi",
          "drug_name": "Edoxaban (Lixiana®)",
          "earliest": "2015-06-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2278,
          "indication": "Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.",
          "last_scrape": "2018-12-13T16:32:55",
          "latest": "2015-07-10T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-06-26, 2015-07-10",
          "rr_end": "2015-07-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-06-26T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Stroke; Venous Thromboembolism",
          "trade_name": "Lixiana",
          "url": "http://www.ncpe.ie/drugs/edoxaban-lixiana/"
         },
         {
          "company": "Merck",
          "drug_name": "Elbasvir/Grazoprevir (Zepatier®)",
          "earliest": "2016-08-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier",
          "eu_market": "2016-07-22T00:00:00",
          "id": 2279,
          "indication": "Elbasvir 50mg/100mg grazoprevir (EBR/GZR)(Zepatier®) is indicated for the treatment of genotypes 1 and 4 chronic HCV infection in patients with Child-Turcotte-Pugh score A (CTPA).",
          "last_scrape": "2018-12-13T16:33:00",
          "latest": "2016-10-13T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-08-10, 2016-10-13",
          "rr_end": "2016-10-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2016-08-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Zepatier",
          "url": "http://www.ncpe.ie/drugs/elbasvirgrazoprevir-zepatier-2/"
         },
         {
          "company": "Genzyme",
          "drug_name": "Eliglustat (Cerdelga®)",
          "earliest": "2016-03-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga",
          "eu_market": "2015-01-19T00:00:00",
          "id": 2280,
          "indication": "Eliglustat (Cerdelga®) is indicated for the long-term treatment of adult patients with Gaucher disease type 1.",
          "last_scrape": "2018-12-13T16:33:03",
          "latest": "2018-09-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2016-03-21, 2016-05-17",
          "rr_end": "2016-05-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_start": "2016-03-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Gaucher Disease",
          "trade_name": "Cerdelga",
          "url": "http://www.ncpe.ie/drugs/eliglustat-cerdelga/"
         },
         {
          "company": "BioMarin",
          "drug_name": "Elosulfase alfa (Vimizim®)",
          "earliest": "2015-03-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vimizim",
          "eu_market": "2014-04-27T00:00:00",
          "id": 2281,
          "indication": "Elosulfase alfa (Vimzim®) is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome, MPS IVA) in patients of all ages.",
          "last_scrape": "2018-12-13T16:33:05",
          "latest": "2018-04-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2015-03-30, 2015-05-08",
          "rr_end": "2015-05-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-03-30T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Mucopolysaccharidosis IV",
          "trade_name": "Vimizim",
          "url": "http://www.ncpe.ie/drugs/elosulfase-alfa-vimizim/"
         },
         {
          "company": "Novartis",
          "drug_name": "Eltrombopag (Revolade®) for Thrombocytopenia in HCV",
          "earliest": "2014-01-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/revolade",
          "eu_market": "2010-03-11T00:00:00",
          "id": 2282,
          "indication": "Eltrombopag (Revolade®) is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy",
          "last_scrape": "2018-12-13T16:33:12",
          "latest": "2014-02-13T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-01-10, 2014-02-13",
          "rr_end": "2014-02-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-01-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Purpura, Thrombocytopenic, Idiopathic",
          "trade_name": "Revolade",
          "url": "http://www.ncpe.ie/drugs/eltrombopag-revolade-2/"
         },
         {
          "company": "Novartis",
          "drug_name": "Eltrombopag (Revolade®) for Severe Aplastic Anaemia (SAA)",
          "earliest": "2016-02-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/revolade",
          "eu_market": "2010-03-11T00:00:00",
          "id": 2283,
          "indication": "Revolade® for the treatment adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation.",
          "last_scrape": "2018-12-13T16:33:17",
          "latest": "2016-03-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 1,
          "rr_dates": "2016-02-05, 2016-03-01",
          "rr_end": "2016-03-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2016-02-05T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Purpura, Thrombocytopenic, Idiopathic",
          "trade_name": "Revolade",
          "url": "http://www.ncpe.ie/drugs/eltrombopag-revolade-3/"
         },
         {
          "company": "Novartis",
          "drug_name": "Eltrombopag (Revolade®) for ITP",
          "earliest": "2010-07-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/revolade",
          "eu_market": "2010-03-11T00:00:00",
          "id": 2284,
          "indication": "Cost-effectiveness of eltrombopag (Revolade®) for the treatment of chronic immune thrombocytopenic purpura (ITP).",
          "last_scrape": "2018-12-13T16:33:23",
          "latest": "2018-04-16T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-12-04, 2018-04-16, 2017-12-01",
          "rr_end": "2017-12-01T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with currently available therapies",
          "rr_start": "2017-12-04T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Purpura, Thrombocytopenic, Idiopathic",
          "trade_name": "Revolade",
          "url": "http://www.ncpe.ie/drugs/eltrombopag-revolade/"
         },
         {
          "company": "Gilead",
          "drug_name": "Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya®)",
          "earliest": "2015-11-24T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya",
          "eu_market": "2015-11-19T00:00:00",
          "id": 2285,
          "indication": "Genvoya® is indicated for the treatment of adults and adolescents infected with human immunodeficiency virus – 1 (HIV-1).",
          "last_scrape": "2018-12-13T16:33:26",
          "latest": "2016-01-05T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2015-11-24, 2016-01-05",
          "rr_end": "2016-01-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-11-24T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "HIV Infections",
          "trade_name": "Genvoya",
          "url": "http://www.ncpe.ie/drugs/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Empagliflozin (Jardiance®)",
          "earliest": "2014-05-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance",
          "eu_market": "2014-05-22T00:00:00",
          "id": 2286,
          "indication": "Add-on combination therapy ",
          "last_scrape": "2018-12-13T16:33:32",
          "latest": "2014-06-12T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-05-22, 2014-06-12",
          "rr_end": "2014-06-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-05-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Jardiance",
          "url": "http://www.ncpe.ie/drugs/empagliflozin-jardiance/"
         },
         {
          "company": "Gilead",
          "drug_name": "Emtricitabine / tenofovir disoproxil fumarate (Truvada®)",
          "earliest": "2017-06-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/truvada",
          "eu_market": "2005-02-20T00:00:00",
          "id": 2287,
          "indication": "Truvada® is indicated in combination with safer sex practices for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.",
          "last_scrape": "2018-12-13T16:33:37",
          "latest": "2017-07-19T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-06-12, 2017-07-18",
          "rr_end": "2017-07-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-06-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "HIV Infections",
          "trade_name": "Truvada",
          "url": "http://www.ncpe.ie/drugs/emtricitabine-tenofovir-disoproxil-fumarate-truvada/"
         },
         {
          "company": "CIS",
          "drug_name": "Emtricitabine/tenofovir disoproxil (TEVA®)",
          "earliest": "2017-12-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2288,
          "indication": "Emtricitabine/tenofovir disoproxil (TEVA®) for pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk.",
          "last_scrape": "2018-12-13T16:33:43",
          "latest": "2017-12-21T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-12-11, 2017-12-21",
          "rr_end": "2017-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-12-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "TEVA",
          "url": "http://www.ncpe.ie/drugs/emtricitabine-tenovir-disoproxil-teva/"
         },
         {
          "company": "Gilead",
          "drug_name": "Emtricitabine/tenofovir alafenamide (Descovy®)",
          "earliest": "2016-04-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/descovy",
          "eu_market": "2016-04-21T00:00:00",
          "id": 2289,
          "indication": "Descovy® (F/TAF) is licensed in combination with other antiretroviral agents (ARVs) for the treatment of adults and adolescents (≥12 years; body weight ≥35 kg) infected with human immunodeficiency virus (HIV) type 1.",
          "last_scrape": "2018-12-13T16:33:48",
          "latest": "2016-04-26T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-04-26, 2016-04-26",
          "rr_end": "2016-04-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2016-04-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "HIV Infections",
          "trade_name": "Descovy",
          "url": "http://www.ncpe.ie/drugs/emtricitabinetenofovir-alafenamide-descovy/"
         },
         {
          "company": "Astellas",
          "drug_name": "Enzalutamide (Xtandi®) on or after chemotherapy",
          "earliest": "2013-06-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi",
          "eu_market": "2013-06-21T00:00:00",
          "id": 2290,
          "indication": "Enzalutamide (Xtandi®) is indicated for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.",
          "last_scrape": "2018-12-13T16:33:52",
          "latest": "2014-04-10T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-06-28, 2013-07-10",
          "rr_end": "2013-07-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-06-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Xtandi",
          "url": "http://www.ncpe.ie/drugs/enzalutamide-xtandi/"
         },
         {
          "company": "CIS",
          "drug_name": "Epoprostenol (Veletri®)",
          "earliest": "2016-12-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2291,
          "indication": "Veletri® is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH associated with connective tissue diseases) in patients with WHO FC III–IV symptoms to improve exercise capacity.",
          "last_scrape": "2018-12-13T16:33:59",
          "latest": "2017-02-06T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-12-13, 2017-02-06",
          "rr_end": "2017-02-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2016-12-13T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Veletri",
          "url": "http://www.ncpe.ie/drugs/epoprostenol-veletri/"
         },
         {
          "company": "Novartis",
          "drug_name": "Erenumab (Aimovig®)",
          "earliest": "2018-07-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig",
          "eu_market": "2018-07-26T00:00:00",
          "id": 2292,
          "indication": "Erenumab (Aimovig®)  is indicated for the treatment of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig®.",
          "last_scrape": "2018-12-13T16:34:03",
          "latest": "2018-08-15T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-07-19, 2018-08-15",
          "rr_end": "2018-08-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care",
          "rr_start": "2018-07-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Migraine Disorders",
          "trade_name": "Aimovig",
          "url": "http://www.ncpe.ie/drugs/erenumab-aimovig/"
         },
         {
          "company": "Eisai",
          "drug_name": "Eribulin (Halaven®)",
          "earliest": "2011-02-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/halaven",
          "eu_market": "2011-03-17T00:00:00",
          "id": 2293,
          "indication": "Eribulin (Halaven®) for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.",
          "last_scrape": "2018-12-13T16:34:07",
          "latest": "2014-12-01T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2011-03-11, 2011-02-09",
          "rr_end": "2011-02-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-03-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms; Liposarcoma",
          "trade_name": "Halaven",
          "url": "http://www.ncpe.ie/drugs/eribulin-halaven/"
         },
         {
          "company": "BIAL",
          "drug_name": "Eslicarbazepine (Zebinix®)",
          "earliest": "2009-08-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix",
          "eu_market": "2009-04-21T00:00:00",
          "id": 2294,
          "indication": "Eslicarbazepine (Zebinix®) for the treatment of Epilepsy",
          "last_scrape": "2018-12-13T16:34:09",
          "latest": "2009-09-01T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "2009-09-01, 2009-08-01",
          "rr_end": "2009-08-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2009-09-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Epilepsy",
          "trade_name": "Zebinix",
          "url": "http://www.ncpe.ie/drugs/eslicarbazepine-zebinix/"
         },
         {
          "company": "Samsung",
          "drug_name": "Etanercept (Benepali®)",
          "earliest": "2016-03-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/benepali",
          "eu_market": "2016-01-13T00:00:00",
          "id": 2295,
          "indication": "Benepali® is a biosimilar of the TNF-α inhibitor Etanercept (Enbrel®) for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, axial spondylitis and plaque psoriasis.",
          "last_scrape": "2018-12-13T16:34:12",
          "latest": "2016-05-10T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-03-22, 2016-05-10",
          "rr_end": "2016-05-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2016-03-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis",
          "trade_name": "Benepali",
          "url": "http://www.ncpe.ie/drugs/etanercept-benepali/"
         },
         {
          "company": "Amgen",
          "drug_name": "Etelcalcetide (Parsabiv®)",
          "earliest": "2017-06-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv",
          "eu_market": "2016-11-11T00:00:00",
          "id": 2296,
          "indication": "Etelcalcitide (Parsabiv®) is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis.",
          "last_scrape": "2018-12-13T16:34:15",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-06-14, 2017-09-01",
          "rr_end": "2017-09-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at the submitted price",
          "rr_start": "2017-06-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hyperparathyroidism, Secondary",
          "trade_name": "Parsabiv",
          "url": "http://www.ncpe.ie/drugs/etelcalcetide-parsabiv/"
         },
         {
          "company": "Alfasigma",
          "drug_name": "Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim®)",
          "earliest": "2012-05-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim",
          "eu_market": "2011-10-27T00:00:00",
          "id": 2297,
          "indication": "Eurartesim® (Piperaquine tetraphosphate/dihidroartemisinin) for uncomplicated malaria caused by the Plasmodium falciparum parasite",
          "last_scrape": "2018-12-13T16:34:21",
          "latest": "2012-05-28T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-05-22, 2012-05-28",
          "rr_end": "2012-05-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2012-05-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Malaria",
          "trade_name": "Eurartesim",
          "url": "http://www.ncpe.ie/drugs/eurartesim-piperaquine-tetraphosphatedihidroartemisinin/"
         },
         {
          "company": "Novartis",
          "drug_name": "Everolimus (Afinitor®)",
          "earliest": "2012-09-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor",
          "eu_market": "2009-08-02T00:00:00",
          "id": 2298,
          "indication": "Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor",
          "last_scrape": "2018-12-13T16:34:24",
          "latest": "2012-10-12T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-09-21, 2012-10-12",
          "rr_end": "2012-10-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2012-09-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms",
          "trade_name": "Afinitor",
          "url": "http://www.ncpe.ie/drugs/everolimus-afinitor/"
         },
         {
          "company": "Novartis",
          "drug_name": "Everolimus (Votubia ®) for refractory seizures associated with tuberous sclerosis complex (TSC)",
          "earliest": "2017-04-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/votubia",
          "eu_market": "2011-09-02T00:00:00",
          "id": 2299,
          "indication": "Everolimus (Votubia®) is indicated for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC.",
          "last_scrape": "2018-12-13T16:34:26",
          "latest": "2017-04-26T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2017-04-19, 2017-04-26",
          "rr_end": "2017-04-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2017-04-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Tuberous Sclerosis",
          "trade_name": "Votubia",
          "url": "http://www.ncpe.ie/drugs/everolimus-votubia-for-refractory-seizures-associated-with-tuberous-sclerosis-complex-tsc/"
         },
         {
          "company": "Novartis",
          "drug_name": "Everolimus (Votubia®)",
          "earliest": "2011-09-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/votubia",
          "eu_market": "2011-09-02T00:00:00",
          "id": 2300,
          "indication": "Everolimus (Votubia®) for the treatment of patients aged 3 years and older with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery",
          "last_scrape": "2018-12-13T16:34:29",
          "latest": "2011-10-14T00:00:00",
          "ncpe_year": 2011,
          "orphan": 1,
          "rr_dates": "2011-09-30, 2011-10-14",
          "rr_end": "2011-10-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-09-30T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Tuberous Sclerosis",
          "trade_name": "Votubia",
          "url": "http://www.ncpe.ie/drugs/everolimus-votubia/"
         },
         {
          "company": "Amgen",
          "drug_name": "Evolocumab (Repatha®)",
          "earliest": "2016-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/repatha",
          "eu_market": "2015-07-17T00:00:00",
          "id": 2301,
          "indication": "Evolocumab (Repatha®) is indicated for both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia.",
          "last_scrape": "2018-12-13T16:34:36",
          "latest": "2018-05-16T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2011-10-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2011-09-12T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Dyslipidemias; Hypercholesterolemia",
          "trade_name": "Repatha",
          "url": "http://www.ncpe.ie/drugs/evolocumab-repatha/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Exenatide (Bydureon®)",
          "earliest": "2011-05-31T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon",
          "eu_market": "2011-06-17T00:00:00",
          "id": 2302,
          "indication": "Exenatide (Bydureon®) for the treatment of type II diabetes mellitus combined with Metformin, Sulphonylurea, Thiazolidinedione, Metform and SU and Metformn and TZD in adults who have not acheived glycaemic control on maximally tolerated doses of these oral therapies.",
          "last_scrape": "2018-12-13T16:34:41",
          "latest": "2011-06-09T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-05-31, 2011-06-09",
          "rr_end": "2011-06-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-05-31T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Bydureon",
          "url": "http://www.ncpe.ie/drugs/exenatide-bydureon/"
         },
         {
          "company": "Blogen",
          "drug_name": "Fampridine (Fampyra®)",
          "earliest": "2011-09-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra",
          "eu_market": "2011-07-20T00:00:00",
          "id": 2303,
          "indication": "Fampridine (Fampyra®) for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).",
          "last_scrape": "2018-12-13T16:34:44",
          "latest": "2012-08-17T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-09-11, 2011-09-01",
          "rr_end": "2011-09-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-09-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Fampyra",
          "url": "http://www.ncpe.ie/drugs/fampridine-fampyra/"
         },
         {
          "company": "Shield",
          "drug_name": "Ferric maltol (Feraccru®)",
          "earliest": "2016-08-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/feraccru",
          "eu_market": "2016-02-18T00:00:00",
          "id": 2304,
          "indication": "Ferric maltol indicated for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients.",
          "last_scrape": "2018-12-13T16:34:48",
          "latest": "2016-09-06T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-08-12, 2016-09-06",
          "rr_end": "2016-09-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "reimbursement not recommended",
          "rr_start": "2016-08-12T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "Anemia, Iron-Deficiency",
          "trade_name": "Feraccru",
          "url": "http://www.ncpe.ie/drugs/ferric-maltol-feraccru_/"
         },
         {
          "company": "Astellas",
          "drug_name": "Fidaxomicin (Dificlir®)",
          "earliest": "2012-03-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir",
          "eu_market": "2011-12-05T00:00:00",
          "id": 2305,
          "indication": "Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.",
          "last_scrape": "2018-12-13T16:34:51",
          "latest": "2013-02-05T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2012-03-09, 2012-03-23",
          "rr_end": "2012-03-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2012-03-09T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Clostridium Infections",
          "trade_name": "Dificlir",
          "url": "http://www.ncpe.ie/drugs/fidaxomicin-dificlir/"
         },
         {
          "company": "Novartis",
          "drug_name": "Fingolimod (Gilenya®)",
          "earliest": "2010-12-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya",
          "eu_market": "2011-03-17T00:00:00",
          "id": 2306,
          "indication": "Cost effectiveness of Fingolimod (Gilenya®) for the treatment of highly active relapsing-remitting multiple sclerosis.",
          "last_scrape": "2018-12-13T16:34:56",
          "latest": "2011-09-22T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-01-10, 2010-12-03",
          "rr_end": "2010-12-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-01-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Gilenya",
          "url": "http://www.ncpe.ie/drugs/fingolimod-gilenya-4/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Fluocinolone acetonide (Iluvien®)",
          "earliest": "2016-02-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2307,
          "indication": "Iluvien® is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema (DMO) considered insufficiently responsive to available therapies.",
          "last_scrape": "2018-12-13T16:35:01",
          "latest": "2016-03-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-02-15, 2016-03-01",
          "rr_end": "2016-03-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2016-02-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Iluvien",
          "url": "http://www.ncpe.ie/drugs/fluocinolone-acetonide-iluvien/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Fluticasone furoate/ umeclidinium/ vilantero (Trelegy™ Ellipta™)",
          "earliest": "2018-04-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta",
          "eu_market": "2017-11-15T00:00:00",
          "id": 2308,
          "indication": "Trelegy™ Ellipta™ which is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.",
          "last_scrape": "2018-12-13T16:35:05",
          "latest": "2018-06-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-04-30, 2018-06-18",
          "rr_end": "2018-06-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is not recommended the ncpe recommends that trelegy™ ellipta™ be considered for reimbursement in accordance with the criteria specified in the health (pricing and supply of medical goods) act 2013",
          "rr_start": "2018-04-30T00:00:00",
          "rr_status": "Reimbursement without HTA",
          "ta_list": "Pulmonary Disease, Chronic Obstructive",
          "trade_name": "Trelegy Ellipta",
          "url": "http://www.ncpe.ie/drugs/fluticasone-furoate-umeclidinium-vilantero-trelegy-ellipta/"
         },
         {
          "company": "Ferring",
          "drug_name": "Follitropin delta (Rekovelle®)",
          "earliest": "2017-07-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle",
          "eu_market": "2016-12-12T00:00:00",
          "id": 2309,
          "indication": "Follitropin delta (Rekovelle ®) is indicated for controlled ovarian stimulation (COS) for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle",
          "last_scrape": "2018-12-13T16:35:09",
          "latest": "2019-02-01T00:00:00",
          "ncpe_year": 2019,
          "orphan": 0,
          "rr_dates": "2017-07-25, 2017-08-15",
          "rr_end": "2017-08-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at submitted price",
          "rr_start": "2017-07-25T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Anovulation",
          "trade_name": "Rekovelle",
          "url": "http://www.ncpe.ie/drugs/follitropin-delta-rekovelle/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Gefitinib (Iressa®)",
          "earliest": "2010-06-16T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/iressa",
          "eu_market": "2009-06-24T00:00:00",
          "id": 2310,
          "indication": "A review of the economic evaluation of oral gefitinib (Iressa®) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR.",
          "last_scrape": "2018-12-13T16:35:12",
          "latest": "2010-11-05T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-08-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2017-07-14T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Iressa",
          "url": "http://www.ncpe.ie/drugs/gefitinib-iressa/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Gemtuzumab ozogamicin (Mylotarg®)",
          "earliest": "2018-06-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0",
          "eu_market": "2018-04-19T00:00:00",
          "id": 2311,
          "indication": "Gemtuzumab ozogamicin (Mylotarg®) which is indicated for combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia.",
          "last_scrape": "2018-12-13T16:35:15",
          "latest": "2018-07-31T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-06-21, 2018-07-17",
          "rr_end": "2018-07-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of gemtuzumab ozogamicin compared with the current standard of care",
          "rr_start": "2018-06-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid, Acute",
          "trade_name": "Mylotarg",
          "url": "http://www.ncpe.ie/drugs/gemtuzumab-ozogamicin-mylotarg/"
         },
         {
          "company": "AbbVie",
          "drug_name": "Glecaprevir/Pibrentasvir (Maviret®)",
          "earliest": "2017-07-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/maviret",
          "eu_market": "2017-07-26T00:00:00",
          "id": 2312,
          "indication": "Glecaprevir/pibrentasvir (Maviret®) is licensed for the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic GT1-6.",
          "last_scrape": "2018-12-13T16:35:19",
          "latest": "2017-08-17T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-07-11, 2017-08-17",
          "rr_end": "2017-08-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_start": "2017-07-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Maviret",
          "url": "http://www.ncpe.ie/drugs/glecaprevirpibrentasvir-maviret/"
         },
         {
          "company": "CIS",
          "drug_name": "Glucosamine sulfate (Dona®)",
          "earliest": "2009-04-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2313,
          "indication": "Economic evalution of glucosamine sulfate (Dona®) for the treatment of oestoarthritis in the Irish Healthcare setting.",
          "last_scrape": "2018-12-13T16:35:25",
          "latest": "2009-06-01T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-08-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2017-07-16T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Dona",
          "url": "http://www.ncpe.ie/drugs/glucosamine-sulfate-dona/"
         },
         {
          "company": "Horizon",
          "drug_name": "Glycerol Phenylbutyrate (Ravicti®)",
          "earliest": "2018-03-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti",
          "eu_market": "2015-11-26T00:00:00",
          "id": 2314,
          "indication": "Glycerol phenylbutyrate (Ravicti®) which is indicated for use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs).",
          "last_scrape": "2018-12-13T16:35:32",
          "latest": "2018-06-20T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-03-26, 2018-06-20",
          "rr_end": "2018-06-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is not recommended the ncpe recommends that glycerol phenylbutyrate (ravicti®) be considered for reimbursement in accordance with the criteria specified in the health (pricing and supply of medical goods) act 2013",
          "rr_start": "2018-03-26T00:00:00",
          "rr_status": "Reimbursement without HTA",
          "ta_list": "Urea Cycle Disorders, Inborn",
          "trade_name": "Ravicti",
          "url": "http://www.ncpe.ie/drugs/glycerol-phenylbutyrate-ravicti/"
         },
         {
          "company": "Novartis",
          "drug_name": "Glycopyrronium bromide (Seebri Breezhaler®)",
          "earliest": "2012-08-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler",
          "eu_market": "2012-09-28T00:00:00",
          "id": 2315,
          "indication": "Seebri Breezhaler® is indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).",
          "last_scrape": "2018-12-13T16:35:38",
          "latest": "2012-08-17T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-08-12, 2012-08-17",
          "rr_end": "2012-08-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2012-08-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Pulmonary Disease, Chronic Obstructive",
          "trade_name": "Seebri Breezhaler",
          "url": "http://www.ncpe.ie/drugs/glycopyrronium-bromide-seebri-breezhaler/"
         },
         {
          "company": "Proveca",
          "drug_name": "Glycopyrronium bromide (Sialanar®)",
          "earliest": "2017-03-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar",
          "eu_market": "2016-09-15T00:00:00",
          "id": 2316,
          "indication": "Glycopyrronium bromide (Sialanar®) is indicated for symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders",
          "last_scrape": "2018-12-13T16:35:40",
          "latest": "2017-03-13T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-03-07, 2017-03-13",
          "rr_end": "2017-03-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2017-03-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Sialorrhea",
          "trade_name": "Sialanar",
          "url": "http://www.ncpe.ie/drugs/glypyrronium-bromide-sialanar/"
         },
         {
          "company": "Janssen",
          "drug_name": "Golimumab (Simponi®) for UC",
          "earliest": "2013-10-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/simponi",
          "eu_market": "2009-10-01T00:00:00",
          "id": 2317,
          "indication": "Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.",
          "last_scrape": "2018-12-13T16:35:47",
          "latest": "2013-10-31T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-10-11, 2013-10-31",
          "rr_end": "2013-10-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta not recommended",
          "rr_start": "2013-10-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid",
          "trade_name": "Simponi",
          "url": "http://www.ncpe.ie/drugs/golimumab-simponi-2/"
         },
         {
          "company": "Janssen",
          "drug_name": "Golimumab (Simponi®)",
          "earliest": "2009-11-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/simponi",
          "eu_market": "2009-10-01T00:00:00",
          "id": 2318,
          "indication": "Cost-effectiveness of golimumab (Simponi®) in the treatment of moderate to severe rheumatoid arthritis.",
          "last_scrape": "2018-12-13T16:35:54",
          "latest": "2010-06-01T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-10-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2013-09-29T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid",
          "trade_name": "Simponi",
          "url": "http://www.ncpe.ie/drugs/golimumab-simponi/"
         },
         {
          "company": "Unknown",
          "drug_name": "Grass pollen allergen extract (Oralair®)",
          "earliest": "2011-09-26T00:00:00",
          "ema_url": "",
          "eu_market": "2008-10-23T00:00:00",
          "id": 2319,
          "indication": " Grass pollen allegen extract (Oralair®) for the treatment of allergic grass pollen rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms confirmed by a positive cutaneous test and/or a positive titre of the specific IgE to the grass pollen.",
          "last_scrape": "2018-12-13T16:35:56",
          "latest": "2011-10-01T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-10-11, 2011-09-26",
          "rr_end": "2011-09-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-10-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Oralair",
          "url": "http://www.ncpe.ie/drugs/grass-pollen-allergen-extract-oralair/"
         },
         {
          "company": "Shire",
          "drug_name": "Guanfacine hydrochloride (Intuniv®)",
          "earliest": "2015-12-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv",
          "eu_market": "2015-09-17T00:00:00",
          "id": 2320,
          "indication": "Intuniv® is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.  It must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.",
          "last_scrape": "2018-12-13T16:36:00",
          "latest": "2015-12-18T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-12-01, 2015-12-18",
          "rr_end": "2015-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-12-01T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Attention Deficit Disorder with Hyperactivity",
          "trade_name": "Intuniv",
          "url": "http://www.ncpe.ie/drugs/guanfacine-hydrochloride-intuniv/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Guselkumab (Tremfya®)",
          "earliest": "2017-12-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya",
          "eu_market": "2017-11-10T00:00:00",
          "id": 2321,
          "indication": "Guselkumab (Tremfya®) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.",
          "last_scrape": "2018-12-13T16:36:02",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-12-01, 2018-02-06",
          "rr_end": "2018-02-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at the submitted price",
          "rr_start": "2017-12-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Psoriasis",
          "trade_name": "Tremfya",
          "url": "http://www.ncpe.ie/drugs/guselkumab-tremfya/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Human alpha1-proteinase inhibitor (A1PI) (Prolastin®)",
          "earliest": "2017-05-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2322,
          "indication": "Human A1PI (Prolastin ®)  is indicated for long-term augmentation therapy in subjects with alpha1-proteinase inhibitor deficiency (phenotypes PiZZ, PiZ(null), Pi (null,null) and PiSZ) within the limits of moderate airflow obstruction (FEV1 35-60%) and the evaluation of the clinical condition (disability).",
          "last_scrape": "2018-12-13T16:36:07",
          "latest": "2017-06-08T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-05-05, 2017-06-08",
          "rr_end": "2017-06-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2017-05-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Prolastin",
          "url": "http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-a1pi-prolastin/"
         },
         {
          "company": "CSL",
          "drug_name": "Human alpha1-proteinase inhibitor (Respreeza®)",
          "earliest": "2016-01-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza",
          "eu_market": "2015-08-20T00:00:00",
          "id": 2323,
          "indication": "Respreeza® is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null, null), PiSZ). Patients are to be under optimal pharmacologic and nonpharmacological treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.",
          "last_scrape": "2018-12-13T16:36:14",
          "latest": "2017-01-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-01-20, 2016-02-05",
          "rr_end": "2016-02-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-01-20T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Genetic Diseases, Inborn; Lung Diseases",
          "trade_name": "Respreeza",
          "url": "http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-respreeza/"
         },
         {
          "company": "CIS",
          "drug_name": "Hyaluronic acid and co enzyme Q10 (VisuXL®)",
          "earliest": "2017-11-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2324,
          "indication": "Cross linked hyaluronic acid and co enzyme Q10 (VisuXL®) for the treatment of dry eye disease and the treatment of post-surgical intervention following elective surgery and trauma.",
          "last_scrape": "2018-12-13T16:36:17",
          "latest": "2017-11-30T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-11-06, 2017-11-30",
          "rr_end": "2017-11-30T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "reimbursement not recommended at the submitted price",
          "rr_start": "2017-11-06T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "VisuXL",
          "url": "http://www.ncpe.ie/drugs/hyaluronic-acid-and-co-enzyme-q10-visuxl/"
         },
         {
          "company": "Shire",
          "drug_name": "Modified Release Hydrocortisone  (Plenadren®)",
          "earliest": "2013-08-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren",
          "eu_market": "2011-11-03T00:00:00",
          "id": 2325,
          "indication": "Modified release hydrocortisone (Plenadren®) for the treatment of adrenal insufficiency in adults.",
          "last_scrape": "2018-12-13T16:36:22",
          "latest": "2018-01-11T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-11-08, 2018-01-11, 2017-11-01",
          "rr_end": "2017-11-01T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "reimbursement not recommended at the submitted price",
          "rr_start": "2017-11-08T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "Adrenal Insufficiency",
          "trade_name": "Plenadren",
          "url": "http://www.ncpe.ie/drugs/hydrocortisone-plenadren/"
         },
         {
          "company": "Addmedica",
          "drug_name": "Hydroxycarbamide (Siklos®)",
          "earliest": "2011-08-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/siklos",
          "eu_market": "2007-06-29T00:00:00",
          "id": 2326,
          "indication": " Hydroxycarbamide (Siklos®) is indicated for use in the prevention of painful, recurrent vaso-occlusive crises, including acute chest syndrome, in adults, adolescents and children over 2 years of age suffering from symptomatic sickle-cell disease.",
          "last_scrape": "2018-12-13T16:36:27",
          "latest": "2011-09-06T00:00:00",
          "ncpe_year": 2011,
          "orphan": 1,
          "rr_dates": "2011-08-22, 2011-09-06",
          "rr_end": "2011-09-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-08-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Anemia, Sickle Cell",
          "trade_name": "Siklos",
          "url": "http://www.ncpe.ie/drugs/hydroxcarbamide-siklos/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Ibrutinib (Imbruvica®) for previously untreated CLL",
          "earliest": "2016-08-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica",
          "eu_market": "2014-10-21T00:00:00",
          "id": 2327,
          "indication": "Ibrutinib (Imbruvica®), as a single agent, is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This indication is an extension to the original licence in the relapsed/refractory setting.",
          "last_scrape": "2018-12-13T16:36:32",
          "latest": "2016-08-24T00:00:00",
          "ncpe_year": 2016,
          "orphan": 1,
          "rr_dates": "2016-08-02, 2016-08-24",
          "rr_end": "2016-08-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-08-02T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Imbruvica",
          "url": "http://www.ncpe.ie/drugs/ibrutinib-imbruivca-for-previously-untreated-cll/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Ibrutinib (Imbruvica®) for MCL",
          "earliest": "2014-11-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica",
          "eu_market": "2014-10-21T00:00:00",
          "id": 2328,
          "indication": "Ibrutinib (Imbruvica®) is indicated in the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).",
          "last_scrape": "2018-12-13T16:36:36",
          "latest": "2015-10-06T00:00:00",
          "ncpe_year": 2015,
          "orphan": 1,
          "rr_dates": "2014-11-07, 2014-12-18",
          "rr_end": "2014-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-11-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Imbruvica",
          "url": "http://www.ncpe.ie/drugs/ibrutinib-imbruvica-for-mcl/"
         },
         {
          "company": "Shire",
          "drug_name": "Icatibant (Firazyr®)",
          "earliest": "2013-07-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr",
          "eu_market": "2008-07-11T00:00:00",
          "id": 2329,
          "indication": "Icatibant (Firazyr®) indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (type I and II HAE).",
          "last_scrape": "2018-12-13T16:36:40",
          "latest": "2013-07-01T00:00:00",
          "ncpe_year": 2013,
          "orphan": 1,
          "rr_dates": "2013-07-01, 2013-07-01",
          "rr_end": "2013-07-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2013-07-01T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Angioedemas, Hereditary",
          "trade_name": "Firazyr",
          "url": "http://www.ncpe.ie/drugs/icatibant-firazyr/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Idarucizumab (Praxbind®)",
          "earliest": "2015-12-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind",
          "eu_market": "2015-11-20T00:00:00",
          "id": 2330,
          "indication": "Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:",
          "last_scrape": "2018-12-13T16:36:43",
          "latest": "2015-12-18T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-12-11, 2015-12-18",
          "rr_end": "2015-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-12-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hemorrhage",
          "trade_name": "Praxbind",
          "url": "http://www.ncpe.ie/drugs/idarucizumab-praxbind/"
         },
         {
          "company": "Santhera",
          "drug_name": "Idebenone (Raxone®)",
          "earliest": "2016-02-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/raxone",
          "eu_market": "2015-09-08T00:00:00",
          "id": 2331,
          "indication": "Raxone® is indicated for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON).",
          "last_scrape": "2018-12-13T16:36:50",
          "latest": "2018-08-28T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2016-02-10, 2016-04-14",
          "rr_end": "2016-04-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_start": "2016-02-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Optic Atrophy, Hereditary, Leber",
          "trade_name": "Raxone",
          "url": "http://www.ncpe.ie/drugs/idebenone-raxone/"
         },
         {
          "company": "Gilead",
          "drug_name": "Idelalisib (Zydelig®)",
          "earliest": "2014-12-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig",
          "eu_market": "2014-09-18T00:00:00",
          "id": 2332,
          "indication": "Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.",
          "last_scrape": "2018-12-13T16:36:56",
          "latest": "2016-12-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2014-12-08, 2014-12-30",
          "rr_end": "2014-12-30T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-12-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Zydelig",
          "url": "http://www.ncpe.ie/drugs/idelalisib-zydelig/"
         },
         {
          "company": "Meda",
          "drug_name": "Imiquimod 3.75% (Zyclara®)",
          "earliest": "2013-09-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara",
          "eu_market": "2012-08-23T00:00:00",
          "id": 2333,
          "indication": "Imiquimod 3.75%(Zyclara®) indicated for topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.",
          "last_scrape": "2018-12-13T16:36:59",
          "latest": "2013-09-18T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-09-10, 2013-09-18",
          "rr_end": "2013-09-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2013-09-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Keratosis; Keratosis, Actinic",
          "trade_name": "Zyclara",
          "url": "http://www.ncpe.ie/drugs/imiquimod-zyclara/"
         },
         {
          "company": "CIS",
          "drug_name": "Incobotulinum Toxin Type A (Xeomin®)",
          "earliest": "2014-02-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2334,
          "indication": "Incobotulinum Toxin Type A (Xeomin®) is indicated for the symptomatic treatment of blepharospasm, cervical dystonia of a predominantly rotational form (spasmodic torticollis) and of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults.",
          "last_scrape": "2018-12-13T16:37:01",
          "latest": "2014-03-05T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-02-07, 2014-03-05",
          "rr_end": "2014-03-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-02-07T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Xeomin",
          "url": "http://www.ncpe.ie/drugs/incobotulinum-toxin-type-a-xeomin/"
         },
         {
          "company": "Unknown",
          "drug_name": "Indacaterol (Onbrez®)",
          "earliest": "2010-01-15T00:00:00",
          "ema_url": "",
          "eu_market": "2007-01-28T00:00:00",
          "id": 2335,
          "indication": "Review of Indacaterol (Onbrez®) for the treatment of COPD.",
          "last_scrape": "2018-12-13T16:37:04",
          "latest": "2010-01-15T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-01-15",
          "rr_end": "2010-01-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2010-01-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Onbrez",
          "url": "http://www.ncpe.ie/drugs/indacaterol-onbrez/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Infliximab (Inflectra®)",
          "earliest": "2013-09-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra",
          "eu_market": "2013-09-09T00:00:00",
          "id": 2336,
          "indication": "Inflectra® is a biosimilar product indicated for Rheumatoid Arthritis, Adult Crohn’s disease, Paediatric Crohn’s disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis.",
          "last_scrape": "2018-12-13T16:37:07",
          "latest": "2013-09-20T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2010-01-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2009-12-14T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid",
          "trade_name": "Inflectra",
          "url": "http://www.ncpe.ie/drugs/infliximab-inflectra/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Inotuzumab ozogamicin (Besponsa®)",
          "earliest": "2017-07-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa",
          "eu_market": "2017-06-28T00:00:00",
          "id": 2337,
          "indication": "Inotuzumab ozogamicin (Besponsa®) is indicated as monotherapy for the treatment of adults with relapsed or refractory (R/R) CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).",
          "last_scrape": "2018-12-13T16:37:09",
          "latest": "2018-09-14T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-07-03, 2017-09-08",
          "rr_end": "2017-09-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-07-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
          "trade_name": "Besponsa",
          "url": "http://www.ncpe.ie/drugs/inotuzumab-ozogamicin-besponsa/"
         },
         {
          "company": "Novo",
          "drug_name": "Insulin aspart (Fiasp®)",
          "earliest": "2017-05-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/fiasp",
          "eu_market": "2017-01-09T00:00:00",
          "id": 2338,
          "indication": "Insulin aspart (Fiasp®) is indicated for the treatment of diabetes mellitus in adults.",
          "last_scrape": "2018-12-13T16:37:16",
          "latest": "2017-06-14T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-05-17, 2017-06-14",
          "rr_end": "2017-06-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2017-05-17T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus",
          "trade_name": "Fiasp",
          "url": "http://www.ncpe.ie/drugs/insulin-aspart-fiasp/"
         },
         {
          "company": "Unknown",
          "drug_name": "Insulin aspart (NovoRapid® FlexTouch ®)",
          "earliest": "2014-07-22T00:00:00",
          "ema_url": "",
          "eu_market": "2011-08-04T00:00:00",
          "id": 2339,
          "indication": "Insulin aspart (NovoRapid® FlexTouch ®) is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.",
          "last_scrape": "2018-12-13T16:37:21",
          "latest": "2014-08-28T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-07-22, 2014-08-28",
          "rr_end": "2014-08-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2014-07-22T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Unknown",
          "trade_name": "NovoRapid FlexTouch",
          "url": "http://www.ncpe.ie/drugs/insulin-aspart-novorapid-flextouch/"
         },
         {
          "company": "Novo",
          "drug_name": "Insulin Degludec (Tresiba®)",
          "earliest": "2012-12-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba",
          "eu_market": "2013-01-20T00:00:00",
          "id": 2340,
          "indication": "Treatment of diabetes mellitus",
          "last_scrape": "2018-12-13T16:37:25",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2012-12-17, 2013-01-04",
          "rr_end": "2013-01-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2012-12-17T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Diabetes Mellitus",
          "trade_name": "Tresiba",
          "url": "http://www.ncpe.ie/drugs/insulin-degludec-tresiba/"
         },
         {
          "company": "Novo",
          "drug_name": "Insulin degludec/liraglutide (IDegLira) (Xultophy®)",
          "earliest": "2016-09-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy",
          "eu_market": "2014-09-18T00:00:00",
          "id": 2341,
          "indication": "IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.",
          "last_scrape": "2018-12-13T16:37:30",
          "latest": "2016-10-17T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-09-19, 2016-10-17",
          "rr_end": "2016-10-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2016-09-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Xultophy",
          "url": "http://www.ncpe.ie/drugs/insulin-degludecliraglutide-ideglira-xultophy/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Insulin Glargine (Abasaglar®)",
          "earliest": "2015-09-04T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2342,
          "indication": "Abasaglar® is indicated in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.",
          "last_scrape": "2018-12-13T16:37:36",
          "latest": "2015-10-12T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-09-04, 2015-10-12",
          "rr_end": "2015-10-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-09-04T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Abasaglar",
          "url": "http://www.ncpe.ie/drugs/insulin-glargine-abasaglar/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Insulin Glargine U300 (Toujeo®)",
          "earliest": "2015-05-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2343,
          "indication": "Toujeo® is indicated for the treatment of diabetes mellitus in adults.",
          "last_scrape": "2018-12-13T16:37:40",
          "latest": "2015-07-02T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-05-14, 2015-07-02",
          "rr_end": "2015-07-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2015-05-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Toujeo",
          "url": "http://www.ncpe.ie/drugs/insulin-glargine-u300-toujeo/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Ipilimumab (Yervoy®)",
          "earliest": "2011-05-31T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy",
          "eu_market": "2011-07-12T00:00:00",
          "id": 2344,
          "indication": "Pharmacoeconomic evaluation of Ipilimumab (Yervoy®) for the treatment of advanced (unresectable or metastatic) melanoma in adult patients who have received prior therapy.",
          "last_scrape": "2018-12-13T16:37:43",
          "latest": "2013-09-01T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2011-05-31, 2011-06-09",
          "rr_end": "2011-06-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-05-31T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma",
          "trade_name": "Yervoy",
          "url": "http://www.ncpe.ie/drugs/ipilimumab-yervoy/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Iron (III) isomaltoside 1000 (Diafer®)",
          "earliest": "2015-10-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2345,
          "indication": "Diafer® is indicated in adults for the treatment of iron deficiency in patients with chronic kidney disease on dialysis, when oral iron preparations are ineffective or cannot be used.",
          "last_scrape": "2018-12-13T16:37:49",
          "latest": "2015-11-18T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-10-10, 2015-11-18",
          "rr_end": "2015-11-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-10-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Diafer",
          "url": "http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-diafer/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Iron (III) isomaltoside 1000 (Monover®)",
          "earliest": "2015-10-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2346,
          "indication": "Monover® is indicated in the treatment of Iron deficiency anaemia when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.",
          "last_scrape": "2018-12-13T16:37:52",
          "latest": "2015-11-18T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-10-10, 2015-11-18",
          "rr_end": "2015-11-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-10-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Monover",
          "url": "http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-monover/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Iron isomaltoside 1000 (MonoVer®)",
          "earliest": "2011-01-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2347,
          "indication": "MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.",
          "last_scrape": "2018-12-13T16:38:02",
          "latest": "2011-02-02T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-01-10, 2011-02-02",
          "rr_end": "2011-02-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-01-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "MonoVer",
          "url": "http://www.ncpe.ie/drugs/iron-isomaltoside-1000-monover/"
         },
         {
          "company": "Basilea",
          "drug_name": "Isavuconazole (Cresemba®) for the treatment of invasive aspergillosis.",
          "earliest": "2016-04-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba",
          "eu_market": "2015-10-15T00:00:00",
          "id": 2348,
          "indication": "Isavuconazole (Cresemba®) is indicated for the treatment of invasive aspergillosis",
          "last_scrape": "2018-12-13T16:38:07",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2016-04-11, 2016-05-11",
          "rr_end": "2016-05-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2016-04-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Aspergillosis",
          "trade_name": "Cresemba",
          "url": "http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-invasive-aspergillosis/"
         },
         {
          "company": "Basilea",
          "drug_name": "Isavuconazole (Cresemba®) for the treatment of mucormycosis",
          "earliest": "2016-04-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba",
          "eu_market": "2015-10-15T00:00:00",
          "id": 2349,
          "indication": "Isavuconazole (Cresemba®) is indicated in adults for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate.",
          "last_scrape": "2018-12-13T16:38:09",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2016-04-11, 2016-05-11",
          "rr_end": "2016-05-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2016-04-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Aspergillosis",
          "trade_name": "Cresemba",
          "url": "http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-mucormycosis/"
         },
         {
          "company": "Vertex",
          "drug_name": "Ivacaftor (Kalydeco®)",
          "earliest": "2012-08-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco",
          "eu_market": "2012-07-22T00:00:00",
          "id": 2350,
          "indication": "For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation",
          "last_scrape": "2018-12-13T16:38:15",
          "latest": "2013-01-21T00:00:00",
          "ncpe_year": 2013,
          "orphan": 1,
          "rr_dates": "2012-08-13, 2012-08-22",
          "rr_end": "2012-08-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2012-08-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystic Fibrosis",
          "trade_name": "Kalydeco",
          "url": "http://www.ncpe.ie/drugs/ivacaftor-kaldeco/"
         },
         {
          "company": "Vertex",
          "drug_name": "Ivacaftor (Kalydeco®) for patients with CF 2 years +",
          "earliest": "2015-11-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco",
          "eu_market": "2012-07-22T00:00:00",
          "id": 2351,
          "indication": "Kalydeco® is indicated for the treatment of children with CF aged 2 years and older and weighing less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.",
          "last_scrape": "2018-12-13T16:38:21",
          "latest": "2016-10-12T00:00:00",
          "ncpe_year": 2016,
          "orphan": 1,
          "rr_dates": "2015-11-19, 2015-12-18",
          "rr_end": "2015-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmaoeconomic evaluation recommended",
          "rr_start": "2015-11-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystic Fibrosis",
          "trade_name": "Kalydeco",
          "url": "http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-patients-with-cf-2-years/"
         },
         {
          "company": "Vertex",
          "drug_name": "Ivacaftor (Kalydeco®) for the treatment of CF patients with the R117H mutation.",
          "earliest": "2016-01-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco",
          "eu_market": "2012-07-22T00:00:00",
          "id": 2352,
          "indication": "Kalydeco® for the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene.",
          "last_scrape": "2018-12-13T16:38:24",
          "latest": "2017-01-05T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2016-01-14, 2016-02-10",
          "rr_end": "2016-02-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-01-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystic Fibrosis",
          "trade_name": "Kalydeco",
          "url": "http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-the-treatment-of-cf-patients-with-the-r117h-mutation/"
         },
         {
          "company": "Takeda",
          "drug_name": "Ixazomib (Ninlaro®)",
          "earliest": "2016-11-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro",
          "eu_market": "2016-11-21T00:00:00",
          "id": 2353,
          "indication": "Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.",
          "last_scrape": "2018-12-13T16:38:29",
          "latest": "2018-12-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2016-11-23, 2017-01-16",
          "rr_end": "2017-01-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2016-11-23T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Myeloma",
          "trade_name": "Ninlaro",
          "url": "http://www.ncpe.ie/drugs/ixazomib-ninlaro/"
         },
         {
          "company": "Eli",
          "drug_name": "Ixekizumab (Taltz®) for psoriatic arthritis",
          "earliest": "2018-10-16T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/taltz",
          "eu_market": "2016-04-25T00:00:00",
          "id": 2354,
          "indication": "Ixekizumab (Taltz®) is indicated for the treatment of active PsA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.",
          "last_scrape": "2018-12-13T16:38:34",
          "latest": "2018-11-19T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-10-16, 2018-11-19",
          "rr_end": "2018-11-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is not recommended the ncpe recommends that ixekizumab not be considered for reimbursement at the submitted price this recommendation should be considered while also having regard to the criteria specified in the health (pricing and supply of medical goods act) 2013",
          "rr_start": "2018-10-16T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "Psoriasis",
          "trade_name": "Taltz",
          "url": "http://www.ncpe.ie/drugs/ixekizumab-taltz-for-psoriatic-arthritis/"
         },
         {
          "company": "Eli",
          "drug_name": "Ixekizumab (Taltz®)",
          "earliest": "2016-06-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/taltz",
          "eu_market": "2016-04-25T00:00:00",
          "id": 2355,
          "indication": "Taltz® is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.",
          "last_scrape": "2018-12-13T16:38:37",
          "latest": "2016-09-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-06-28, 2016-07-26",
          "rr_end": "2016-07-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2016-06-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Psoriasis",
          "trade_name": "Taltz",
          "url": "http://www.ncpe.ie/drugs/ixekizumab-taltz/"
         },
         {
          "company": "CIS",
          "drug_name": "Lisdexamfetamine dimesylate (Tyvense®)",
          "earliest": "2013-02-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2356,
          "indication": "Lisdexamfetamine dimesylate (Tyvense®) for Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.",
          "last_scrape": "2018-12-13T16:38:39",
          "latest": "2013-02-28T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-02-09, 2013-02-28",
          "rr_end": "2013-02-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_start": "2013-02-09T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Tyvense",
          "url": "http://www.ncpe.ie/drugs/l/lisdexamfetamine-dimesylate-tyvense/"
         },
         {
          "company": "UCB",
          "drug_name": "Lacosamide (Vimpat ®)",
          "earliest": "2017-09-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat",
          "eu_market": "2008-08-29T00:00:00",
          "id": 2357,
          "indication": "Vimpat ® is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.  The Applicant is seeking reimbursement for an extension to the product license to cover children (≥4 years of age) and adolescents (≤ 15 years of age).",
          "last_scrape": "2018-12-13T16:38:44",
          "latest": "2017-10-31T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-09-11, 2017-10-31",
          "rr_end": "2017-10-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation is recommended at the submitted price",
          "rr_start": "2017-09-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Epilepsy",
          "trade_name": "Vimpat",
          "url": "http://www.ncpe.ie/drugs/lacosamide-vimpat/"
         },
         {
          "company": "Novartis",
          "drug_name": "Lapatinib (Tyverb®)",
          "earliest": "2008-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb",
          "eu_market": "2008-06-10T00:00:00",
          "id": 2358,
          "indication": "Cost-effectiveness of Lapatinib (Tyverb®) for the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer.",
          "last_scrape": "2018-12-13T16:38:50",
          "latest": "2008-01-01T00:00:00",
          "ncpe_year": 2008,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-10-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2017-09-29T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Tyverb",
          "url": "http://www.ncpe.ie/drugs/lapatinib-tyverb/"
         },
         {
          "company": "Gilead",
          "drug_name": "Ledipasvir/sofosbuvir (Harvoni®)",
          "earliest": "2014-11-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni",
          "eu_market": "2014-11-17T00:00:00",
          "id": 2359,
          "indication": "Ledipasvir/sofosbuvir (Harvoni®) is indicated for the treatment of Chronic Hepatitis C (CHC) infection (Genotye 1, 3 and 4)  in adults.",
          "last_scrape": "2018-12-13T16:38:56",
          "latest": "2015-11-20T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-11-14, 2014-12-18",
          "rr_end": "2014-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-11-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Harvoni",
          "url": "http://www.ncpe.ie/drugs/ledipasvirsofosbuvir-harvoni/"
         },
         {
          "company": "Celgene",
          "drug_name": "Lenalidomide (Revlimid®)",
          "earliest": "2015-10-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid",
          "eu_market": "2007-06-14T00:00:00",
          "id": 2360,
          "indication": "Revlimid® for the treatment of adult patients with previously untreated multiple myelomas (MM) who are not eligible for transplant (licence extension).",
          "last_scrape": "2018-12-13T16:39:05",
          "latest": "2018-01-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2015-10-05, 2015-11-20",
          "rr_end": "2015-11-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at submitted price",
          "rr_start": "2015-10-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes",
          "trade_name": "Revlimid",
          "url": "http://www.ncpe.ie/drugs/lenalidomide-revlimid/"
         },
         {
          "company": "Eisai",
          "drug_name": "Lenvatinib (Kisplyx®)",
          "earliest": "2017-05-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx",
          "eu_market": "2016-08-25T00:00:00",
          "id": 2361,
          "indication": "Lenvatinib (Kisplyx®) is Indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.",
          "last_scrape": "2018-12-13T16:39:07",
          "latest": "2017-05-18T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-05-05, 2017-05-18",
          "rr_end": "2017-05-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2017-05-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Renal Cell",
          "trade_name": "Kisplyx",
          "url": "http://www.ncpe.ie/drugs/lenvatinib-kisplyx/"
         },
         {
          "company": "Eisai",
          "drug_name": "Lenvatinib (Lenvima®) for HCC",
          "earliest": "2018-08-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima",
          "eu_market": "2015-05-28T00:00:00",
          "id": 2362,
          "indication": "Lenvatinib (Lenvima®) which is indicated as monotherapy for the treatment of adult patients with advanced or unresectable HCC who have received no prior systemic therapy.",
          "last_scrape": "2018-12-13T16:39:11",
          "latest": "2018-08-16T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-08-07, 2018-08-16",
          "rr_end": "2018-08-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies",
          "rr_start": "2018-08-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Thyroid Neoplasms",
          "trade_name": "Lenvima",
          "url": "http://www.ncpe.ie/drugs/lenvatinib-lenvima-2/"
         },
         {
          "company": "Eisai",
          "drug_name": "Lenvatinib (Lenvima®)",
          "earliest": "2015-05-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima",
          "eu_market": "2015-05-28T00:00:00",
          "id": 2363,
          "indication": "Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.",
          "last_scrape": "2018-12-13T16:39:15",
          "latest": "2015-07-09T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-05-05, 2015-07-09",
          "rr_end": "2015-07-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2015-05-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Thyroid Neoplasms",
          "trade_name": "Lenvima",
          "url": "http://www.ncpe.ie/drugs/lenvatinib-lenvima/"
         },
         {
          "company": "Grünenthal",
          "drug_name": "Lesinurad (Zurampic®)",
          "earliest": "2017-03-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic",
          "eu_market": "2016-02-18T00:00:00",
          "id": 2364,
          "indication": "Lesinurad (Zurampic®) for the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor.",
          "last_scrape": "2018-12-13T16:39:20",
          "latest": "2018-12-06T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-03-15, 2017-03-20",
          "rr_end": "2017-03-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-03-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hyperuricemia",
          "trade_name": "Zurampic",
          "url": "http://www.ncpe.ie/drugs/lesinurad-zurampic/"
         },
         {
          "company": "Merck",
          "drug_name": "Letermovir (Prevymis®)",
          "earliest": "2018-03-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis",
          "eu_market": "2018-01-08T00:00:00",
          "id": 2365,
          "indication": "Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).",
          "last_scrape": "2018-12-13T16:39:25",
          "latest": "2018-05-10T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-03-12, 2018-05-10",
          "rr_end": "2018-05-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_start": "2018-03-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cytomegalovirus Infections",
          "trade_name": "Prevymis",
          "url": "http://www.ncpe.ie/drugs/letermovir-prevymis/"
         },
         {
          "company": "Unknown",
          "drug_name": "Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa®)",
          "earliest": "2013-03-13T00:00:00",
          "ema_url": "",
          "eu_market": "2010-03-26T00:00:00",
          "id": 2366,
          "indication": "For the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa® administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.",
          "last_scrape": "2018-12-13T16:39:28",
          "latest": "2018-12-05T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2013-03-13, 2013-04-16",
          "rr_end": "2013-04-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-03-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Unknown",
          "trade_name": "Duodopa",
          "url": "http://www.ncpe.ie/drugs/levodopa-20mgml-carbidopa-monohydrate-5mg-intestinal-gel-duodopa/"
         },
         {
          "company": "Horizon",
          "drug_name": "Levofloxacin (Quinsair®)",
          "earliest": "2016-02-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair",
          "eu_market": "2015-03-25T00:00:00",
          "id": 2367,
          "indication": "Levofloxacin (Quinsair®) is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with Cystic Fibrosis.",
          "last_scrape": "2018-12-13T16:39:34",
          "latest": "2016-03-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-02-10, 2016-03-01",
          "rr_end": "2016-03-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2016-02-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystic Fibrosis; Respiratory Tract Infections",
          "trade_name": "Quinsair",
          "url": "http://www.ncpe.ie/drugs/levofloxacin-quinsair/"
         },
         {
          "company": "CIS",
          "drug_name": "Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena®)",
          "earliest": "2017-02-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2368,
          "indication": "Kyleena® (19.5mg levonorgestrel intrauterine delivery system; LNG IUS 12)  which is indicated for contraception for up to 5 years.",
          "last_scrape": "2018-12-13T16:39:39",
          "latest": "2017-03-16T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-02-08, 2017-03-16",
          "rr_end": "2017-03-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2017-02-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Kyleena",
          "url": "http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-delivery-system-lng-ius-12-kyleena/"
         },
         {
          "company": "Unknown",
          "drug_name": "Levonorgestrel intrauterine system LNG-IUS (Jaydess®)",
          "earliest": "2013-03-07T00:00:00",
          "ema_url": "",
          "eu_market": "2010-03-20T00:00:00",
          "id": 2369,
          "indication": "Levonorgestrel Intrauterine System LNG-IUS (Jaydess®) for contraception for up to three years.",
          "last_scrape": "2018-12-13T16:39:44",
          "latest": "2013-03-25T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-03-07, 2013-03-25",
          "rr_end": "2013-03-25T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_start": "2013-03-07T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Jaydess",
          "url": "http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-system-lng-ius-jaydess/"
         },
         {
          "company": "Unknown",
          "drug_name": "Lidocaine 5% plasters (Versatis®)",
          "earliest": "2010-09-09T00:00:00",
          "ema_url": "",
          "eu_market": "2007-09-22T00:00:00",
          "id": 2370,
          "indication": "Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).",
          "last_scrape": "2018-12-13T16:39:46",
          "latest": "2015-09-24T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2010-09-09, 2010-10-22",
          "rr_end": "2010-10-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2010-09-09T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Unknown",
          "trade_name": "Versatis",
          "url": "http://www.ncpe.ie/drugs/lidocaine-5-plasters-versatis/"
         },
         {
          "company": "Allergan",
          "drug_name": "Linaclotide (Constella®)",
          "earliest": "2013-05-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/constella",
          "eu_market": "2012-11-26T00:00:00",
          "id": 2371,
          "indication": "Linaclotide (Constella®) is indicated for the treatment of symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.",
          "last_scrape": "2018-12-13T16:39:51",
          "latest": "2013-06-28T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-05-28, 2013-06-28",
          "rr_end": "2013-06-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2013-05-28T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Irritable Bowel Syndrome",
          "trade_name": "Constella",
          "url": "http://www.ncpe.ie/drugs/linaclotide-clonstella/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Linagliptin (Trajenta®)",
          "earliest": "2011-08-18T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta",
          "eu_market": "2011-08-23T00:00:00",
          "id": 2372,
          "indication": "Lingagliptin (Trajenta®) for treatment of type 2 diabetes mellitus to improve glycaemic control in adults, as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment, as combination therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control, in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.",
          "last_scrape": "2018-12-13T16:39:54",
          "latest": "2011-09-06T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-08-18, 2011-09-06",
          "rr_end": "2011-09-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-08-18T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Trajenta",
          "url": "http://www.ncpe.ie/drugs/linagliptin-trajenta/"
         },
         {
          "company": "Sicor",
          "drug_name": "Lipegfilgrastim (Lonquex®)",
          "earliest": "2013-08-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex",
          "eu_market": "2013-07-25T00:00:00",
          "id": 2373,
          "indication": "Lonquex® is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).",
          "last_scrape": "2018-12-13T16:39:57",
          "latest": "2013-09-20T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-08-20, 2013-09-20",
          "rr_end": "2013-09-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2013-08-20T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Neutropenia",
          "trade_name": "Lonquex",
          "url": "http://www.ncpe.ie/drugs/lipegfilgrastim-lonquex/"
         },
         {
          "company": "Jazz",
          "drug_name": "Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos®)",
          "earliest": "2018-09-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos",
          "eu_market": "2018-08-23T00:00:00",
          "id": 2374,
          "indication": "Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos®) for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes.",
          "last_scrape": "2018-12-13T16:40:00",
          "latest": "2018-11-08T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-09-28, 2018-11-08",
          "rr_end": "2018-11-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_start": "2018-09-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid, Acute",
          "trade_name": "Vyxeos",
          "url": "http://www.ncpe.ie/drugs/liposomal-daunorubicin-and-cytarabine-cpx-351vyxeos/"
         },
         {
          "company": "Baxalta",
          "drug_name": "Liposomal irinotecan (Onivyde®)",
          "earliest": "2017-06-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-0",
          "eu_market": "2016-10-14T00:00:00",
          "id": 2375,
          "indication": "Liposomal irinotecan (Onivyde®) is indicated for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin in adult patients who have progressed following gemcitabine based therapy.",
          "last_scrape": "2018-12-13T16:40:06",
          "latest": "2017-07-13T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2017-06-13, 2017-07-13",
          "rr_end": "2017-07-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2017-06-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Pancreatic Neoplasms",
          "trade_name": "Onivyde",
          "url": "http://www.ncpe.ie/drugs/liposomal-irinotecan-nal-iri-onivyde/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Liquid Paraffin Ointment (VitA-POS Opthalmic®)",
          "earliest": "2014-01-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2376,
          "indication": "Liquid Paraffin Ointment (VitA-POS Opthalmic®) is indicated for the treatment of mild to moderate form of dry eye.",
          "last_scrape": "2018-12-13T16:40:09",
          "latest": "2014-01-27T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-01-15, 2014-01-27",
          "rr_end": "2014-01-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-01-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "VitA-POS Opthalmic",
          "url": "http://www.ncpe.ie/drugs/liquid-paraffin-ointment-vita-pos-opthalmic/"
         },
         {
          "company": "Novo",
          "drug_name": "Liraglutide (Victoza®)",
          "earliest": "2009-09-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/victoza",
          "eu_market": "2009-06-30T00:00:00",
          "id": 2377,
          "indication": "Victoza®  is indicated for treatment of adults with type 2 diabetes mellitus.",
          "last_scrape": "2018-12-13T16:40:13",
          "latest": "2018-10-30T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2009-09-01, 2009-10-07",
          "rr_end": "2009-10-07T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2009-09-01T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Victoza",
          "url": "http://www.ncpe.ie/drugs/liraglutide-victoza/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Lixisenatide (Lyxumia®)",
          "earliest": "2013-03-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13",
          "eu_market": "2009-12-09T00:00:00",
          "id": 2378,
          "indication": "Lixisenatide (Lyxumia®) for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.",
          "last_scrape": "2018-12-13T16:40:17",
          "latest": "2014-08-07T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-03-21, 2013-04-10",
          "rr_end": "2013-04-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-03-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Pneumococcal Infections; Immunization",
          "trade_name": "Lyxumia",
          "url": "http://www.ncpe.ie/drugs/lixisenatide-lyxumia/"
         },
         {
          "company": "Amryt",
          "drug_name": "Lomitapide (Lojuxta®)",
          "earliest": "2014-09-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta",
          "eu_market": "2013-07-31T00:00:00",
          "id": 2379,
          "indication": "Lojuxta® is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH).",
          "last_scrape": "2018-12-13T16:40:19",
          "latest": "2014-09-15T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-09-09, 2014-09-15",
          "rr_end": "2014-09-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-09-09T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hypercholesterolemia",
          "trade_name": "Lojuxta",
          "url": "http://www.ncpe.ie/drugs/lomitapide-lojuxta/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Lornoxicam (Xefo®)",
          "earliest": "2011-06-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13",
          "eu_market": "2009-12-09T00:00:00",
          "id": 2380,
          "indication": " Lornoxicam (Xefo®) for the Short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis",
          "last_scrape": "2018-12-13T16:40:22",
          "latest": "2011-07-07T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-06-23, 2011-07-07",
          "rr_end": "2011-07-07T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-06-23T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Pneumococcal Infections; Immunization",
          "trade_name": "Xefo",
          "url": "http://www.ncpe.ie/drugs/lornoxicam-xefo/"
         },
         {
          "company": "Unknown",
          "drug_name": "Lotemax 0.5% eye drops suspension (Loteprednol)",
          "earliest": "2011-11-15T00:00:00",
          "ema_url": "",
          "eu_market": "2008-11-27T00:00:00",
          "id": 2381,
          "indication": " Indicated for treatment of post-operative inflammation following ocular surgery.",
          "last_scrape": "2018-12-13T16:40:24",
          "latest": "2011-12-05T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-11-15, 2011-12-05",
          "rr_end": "2011-12-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-11-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Loteprednol",
          "url": "http://www.ncpe.ie/drugs/lotemax-0-5-eye-drops-suspension-loteprednol/"
         },
         {
          "company": "Ferrer",
          "drug_name": "Loxapine inhalation powder (Adasuve®)",
          "earliest": "2016-06-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve",
          "eu_market": "2013-02-20T00:00:00",
          "id": 2382,
          "indication": "Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.",
          "last_scrape": "2018-12-13T16:40:30",
          "latest": "2016-07-28T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-06-21, 2016-07-28",
          "rr_end": "2016-07-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-06-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Schizophrenia; Bipolar Disorder",
          "trade_name": "Adasuve",
          "url": "http://www.ncpe.ie/drugs/loxapine-inhalation-powder-adasuve/"
         },
         {
          "company": "Vertex",
          "drug_name": "Lumacaftor/ivacaftor (Orkambi®)",
          "earliest": "2015-11-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi",
          "eu_market": "2015-11-19T00:00:00",
          "id": 2383,
          "indication": "Orkambi® is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene.",
          "last_scrape": "2018-12-13T16:40:34",
          "latest": "2016-06-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2015-11-26, 2015-12-15",
          "rr_end": "2015-12-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-11-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystic Fibrosis",
          "trade_name": "Orkambi",
          "url": "http://www.ncpe.ie/drugs/lumacaftorivacaftor-orkambi/"
         },
         {
          "company": "Advanced",
          "drug_name": "Lutetium (177Lu) Oxodotreotide (Lutathera®)",
          "earliest": "2018-10-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera",
          "eu_market": "2017-09-26T00:00:00",
          "id": 2384,
          "indication": "Lutetium (177Lu) Oxodotreotide (Lutathera®) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.",
          "last_scrape": "2018-12-13T16:40:36",
          "latest": "2018-11-16T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-10-23, 2018-11-16",
          "rr_end": "2018-11-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_start": "2018-10-23T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Neuroendocrine Tumors",
          "trade_name": "Lutathera",
          "url": "http://www.ncpe.ie/drugs/lutetium-177lu-oxodotreotide-lutathera/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Macitentan (Opsumit®)",
          "earliest": "2014-01-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit",
          "eu_market": "2013-12-20T00:00:00",
          "id": 2385,
          "indication": "Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.",
          "last_scrape": "2018-12-13T16:40:41",
          "latest": "2014-01-27T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-01-10, 2014-01-27",
          "rr_end": "2014-01-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-01-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hypertension, Pulmonary",
          "trade_name": "Opsumit",
          "url": "http://www.ncpe.ie/drugs/macitentan-opsumit/"
         },
         {
          "company": "RAD",
          "drug_name": "Melatonin (Circadin®)",
          "earliest": "2008-08-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/circadin",
          "eu_market": "2007-06-29T00:00:00",
          "id": 2386,
          "indication": "A Review of the Economic Evaluation of Prolonged Release Melatonin (Circadin®) For The Short-Term Treatment of Primary Insomnia.",
          "last_scrape": "2018-12-13T16:40:43",
          "latest": "2008-10-01T00:00:00",
          "ncpe_year": 2008,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2014-01-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2013-12-26T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Sleep Initiation and Maintenance Disorders",
          "trade_name": "Circadin",
          "url": "http://www.ncpe.ie/drugs/melatonin-circadin/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Mepolizumab (Nucala®)",
          "earliest": "2016-03-16T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/nucala",
          "eu_market": "2015-12-01T00:00:00",
          "id": 2387,
          "indication": "Mepolizumab (Nucala®) is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.",
          "last_scrape": "2018-12-13T16:40:45",
          "latest": "2018-04-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-03-16, 2016-04-04",
          "rr_end": "2016-04-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-03-16T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Asthma",
          "trade_name": "Nucala",
          "url": "http://www.ncpe.ie/drugs/mepolizumab-nucala/"
         },
         {
          "company": "Unknown",
          "drug_name": "Methoxyflurane (Penthrox®)",
          "earliest": "2015-11-23T00:00:00",
          "ema_url": "",
          "eu_market": "2012-12-05T00:00:00",
          "id": 2388,
          "indication": "Penthrox® is indicated for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  It is an inhaled anesthetic with analgesic effects at sub-anesthetic doses.",
          "last_scrape": "2018-12-13T16:40:51",
          "latest": "2015-12-18T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-11-23, 2015-12-18",
          "rr_end": "2015-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-11-23T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Penthrox",
          "url": "http://www.ncpe.ie/drugs/methoxyflurane-penthrox/"
         },
         {
          "company": "Novartis",
          "drug_name": "Midostaurin (Rydapt®) for AML",
          "earliest": "2018-08-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt",
          "eu_market": "2017-09-18T00:00:00",
          "id": 2389,
          "indication": "Midostaurin (Rydapt®) is indicated in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.",
          "last_scrape": "2018-12-13T16:40:56",
          "latest": "2018-09-10T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-08-13, 2018-09-10",
          "rr_end": "2018-09-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care",
          "rr_start": "2018-08-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid, Acute; Mastocytosis",
          "trade_name": "Rydapt",
          "url": "http://www.ncpe.ie/drugs/midostaurin-rydapt-for-aml/"
         },
         {
          "company": "Novartis",
          "drug_name": "Midostaurin (Rydapt®) for ASM",
          "earliest": "2018-08-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt",
          "eu_market": "2017-09-18T00:00:00",
          "id": 2390,
          "indication": "Midostaurin (Rydapt®) is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL).",
          "last_scrape": "2018-12-13T16:41:02",
          "latest": "2018-09-10T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-08-13, 2018-09-10",
          "rr_end": "2018-09-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care",
          "rr_start": "2018-08-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid, Acute; Mastocytosis",
          "trade_name": "Rydapt",
          "url": "http://www.ncpe.ie/drugs/midostaurin-rydapt-for-asm/"
         },
         {
          "company": "Takeda",
          "drug_name": "Mifamurtide (Mepact®)",
          "earliest": "2010-06-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mepact",
          "eu_market": "2009-03-06T00:00:00",
          "id": 2391,
          "indication": "Mifamurtide (Meptact®) for the treatment of osteosarcoma.",
          "last_scrape": "2018-12-13T16:41:04",
          "latest": "2010-07-13T00:00:00",
          "ncpe_year": 2010,
          "orphan": 1,
          "rr_dates": "2010-06-22, 2010-07-13",
          "rr_end": "2010-07-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2010-06-22T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Osteosarcoma",
          "trade_name": "Mepact",
          "url": "http://www.ncpe.ie/drugs/mifamurtide-mepact/"
         },
         {
          "company": "Amicus",
          "drug_name": "Migalastat (Galafold®)",
          "earliest": "2016-07-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/galafold",
          "eu_market": "2016-05-25T00:00:00",
          "id": 2392,
          "indication": "Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.",
          "last_scrape": "2018-12-13T16:41:06",
          "latest": "2017-06-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2016-07-14, 2016-08-18",
          "rr_end": "2016-08-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-07-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Fabry Disease",
          "trade_name": "Galafold",
          "url": "http://www.ncpe.ie/drugs/migalastat-galafold/"
         },
         {
          "company": "Astellas",
          "drug_name": "Mirabegron (Betmiga®)",
          "earliest": "2012-12-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga",
          "eu_market": "2012-12-20T00:00:00",
          "id": 2393,
          "indication": "Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome",
          "last_scrape": "2018-12-13T16:41:13",
          "latest": "2013-03-12T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2012-12-19, 2013-03-12",
          "rr_end": "2013-03-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_start": "2012-12-19T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Urinary Bladder, Overactive",
          "trade_name": "Betmiga",
          "url": "http://www.ncpe.ie/drugs/mirabegron-betmiga/"
         },
         {
          "company": "Celgene",
          "drug_name": "Nab-paclitaxel (Abraxane®)",
          "earliest": "2014-01-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane",
          "eu_market": "2008-01-10T00:00:00",
          "id": 2394,
          "indication": "Nab-paclitaxel (Abraxane®) in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.",
          "last_scrape": "2018-12-13T16:41:15",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-01-23, 2014-03-02",
          "rr_end": "2014-03-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-01-23T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Abraxane",
          "url": "http://www.ncpe.ie/drugs/nab-paclitaxel-abraxane/"
         },
         {
          "company": "Lundbeck",
          "drug_name": "Nalmefene (Selincro®)",
          "earliest": "2013-06-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/selincro",
          "eu_market": "2013-02-24T00:00:00",
          "id": 2395,
          "indication": "Nalmefene (Selincro®) is indicated for the reduction of alcohol consumption in those aged ≥18 years with alcohol dependence, who do not require immediate detoxification.",
          "last_scrape": "2018-12-13T16:41:18",
          "latest": "2014-04-08T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-06-07, 2013-06-28",
          "rr_end": "2013-06-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-06-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Alcohol-Related Disorders",
          "trade_name": "Selincro",
          "url": "http://www.ncpe.ie/drugs/nalmefene-selincro/"
         },
         {
          "company": "Kyowa",
          "drug_name": "Naloxegel (Moventig®)",
          "earliest": "2015-02-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/moventig",
          "eu_market": "2014-12-07T00:00:00",
          "id": 2396,
          "indication": "Naloxegel (Moventiq®) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).",
          "last_scrape": "2018-12-13T16:41:24",
          "latest": "2015-04-13T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-02-10, 2015-04-13",
          "rr_end": "2015-04-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-02-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Constipation; Opioid-Related Disorders",
          "trade_name": "Moventig",
          "url": "http://www.ncpe.ie/drugs/naloxegel-moventig/"
         },
         {
          "company": "Orexigen",
          "drug_name": "Naltrexone / bupropion (Mysimba®)",
          "earliest": "2017-03-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba",
          "eu_market": "2015-03-26T00:00:00",
          "id": 2397,
          "indication": "Naltrexone / bupropion (Mysimba®) is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities.",
          "last_scrape": "2018-12-13T16:41:26",
          "latest": "2018-05-09T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-03-12, 2017-03-28",
          "rr_end": "2017-03-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_start": "2017-03-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Obesity; Overweight",
          "trade_name": "Mysimba",
          "url": "http://www.ncpe.ie/drugs/naltrexone-bupropion-mysimba/"
         },
         {
          "company": "Biogen",
          "drug_name": "Natalizumab (Tysabri®)",
          "earliest": "2007-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri",
          "eu_market": "2006-06-27T00:00:00",
          "id": 2398,
          "indication": " Economic Evaluation of Natalizumab (Tysabri®) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated.",
          "last_scrape": "2018-12-13T16:41:30",
          "latest": "2007-03-01T00:00:00",
          "ncpe_year": 2007,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-03-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2017-02-24T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Tysabri",
          "url": "http://www.ncpe.ie/drugs/natalizumab-tysabri/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Inhaled insulin (Exubera®)",
          "earliest": "2006-03-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/exubera",
          "eu_market": "2006-01-24T00:00:00",
          "id": 2399,
          "indication": "In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera®) versus sub-cutaneous insulin in patients with diabetes mellitus in support of their application for reimbursement under the Community Drug Schemes. The following reports were prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.",
          "last_scrape": "2018-12-13T16:41:35",
          "latest": "2006-03-01T00:00:00",
          "ncpe_year": 2006,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-03-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2017-02-24T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Diabetes Mellitus",
          "trade_name": "Exubera",
          "url": "http://www.ncpe.ie/drugs/ncpe-inhaled-insulin-exubera-assessment/"
         },
         {
          "company": "Novartis",
          "drug_name": "Nepafenac (Nevanac®)",
          "earliest": "2011-06-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac",
          "eu_market": "2007-12-11T00:00:00",
          "id": 2400,
          "indication": "Nepafenac (Nevanac®) for the prevention and treatment of postoperative pain and inflammation associated with cataract surgery.",
          "last_scrape": "2018-12-13T16:41:38",
          "latest": "2011-06-27T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-06-14, 2011-06-27",
          "rr_end": "2011-06-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-06-14T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Pain, Postoperative; Ophthalmologic Surgical Procedures",
          "trade_name": "Nevanac",
          "url": "http://www.ncpe.ie/drugs/nepafenac-nevanac-2/"
         },
         {
          "company": "Helsinn",
          "drug_name": "Netupitant/palonosetron (Akynzeo®)",
          "earliest": "2015-08-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo",
          "eu_market": "2015-05-27T00:00:00",
          "id": 2401,
          "indication": "Akynzeo® is indicated for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.",
          "last_scrape": "2018-12-13T16:41:41",
          "latest": "2015-10-13T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-08-26, 2015-10-13",
          "rr_end": "2015-10-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-08-26T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Vomiting; Cancer; Nausea",
          "trade_name": "Akynzeo",
          "url": "http://www.ncpe.ie/drugs/netupitantpalonosetron-akynzeo/"
         },
         {
          "company": "Novartis",
          "drug_name": "Nilotinib (Tasigna®) newly diagnosed CML",
          "earliest": "2010-10-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna",
          "eu_market": "2007-11-19T00:00:00",
          "id": 2402,
          "indication": "Nilotinib (Tasigna®) for the newly diagnosed Chronic Phase Philadelpha Chromosone positive CML.",
          "last_scrape": "2018-12-13T16:41:44",
          "latest": "2010-10-22T00:00:00",
          "ncpe_year": 2010,
          "orphan": 1,
          "rr_dates": "2010-10-06, 2010-10-22",
          "rr_end": "2010-10-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2010-10-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
          "trade_name": "Tasigna",
          "url": "http://www.ncpe.ie/drugs/nilotinib-tasigna-newly-diagnosed-cml/"
         },
         {
          "company": "Novartis",
          "drug_name": "Nilotinib (Tasigna®) CML resistant/intolerant to imatinib",
          "earliest": "2008-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna",
          "eu_market": "2007-11-19T00:00:00",
          "id": 2403,
          "indication": "Cost-effectiveness of Nilotinib (Tasigna®) for the treatment of chronic phase CML.",
          "last_scrape": "2018-12-13T16:41:51",
          "latest": "2008-02-01T00:00:00",
          "ncpe_year": 2008,
          "orphan": 1,
          "rr_dates": "",
          "rr_end": "2010-10-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2010-09-20T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
          "trade_name": "Tasigna",
          "url": "http://www.ncpe.ie/drugs/nilotinib-tasigna/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Nintedanib (Ofev®)",
          "earliest": "2015-01-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ofev",
          "eu_market": "2015-01-14T00:00:00",
          "id": 2404,
          "indication": "Nintedanib (Ofev®) indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).",
          "last_scrape": "2018-12-13T16:41:53",
          "latest": "2017-06-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2015-01-30, 2015-02-18",
          "rr_end": "2015-02-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-01-30T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Idiopathic Pulmonary Fibrosis",
          "trade_name": "Ofev",
          "url": "http://www.ncpe.ie/drugs/nintedanib-ofev/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Nintedanib (Vargatef®)",
          "earliest": "2015-01-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef",
          "eu_market": "2014-11-21T00:00:00",
          "id": 2405,
          "indication": "Nintedanib (Vargatef®) indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.",
          "last_scrape": "2018-12-13T16:41:56",
          "latest": "2017-02-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2015-01-02, 2015-02-10",
          "rr_end": "2015-02-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-01-02T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Vargatef",
          "url": "http://www.ncpe.ie/drugs/nintedanib-vargatef/"
         },
         {
          "company": "Tesaro",
          "drug_name": "Niraparib (Zejula®)",
          "earliest": "2018-06-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zejula",
          "eu_market": "2017-11-16T00:00:00",
          "id": 2406,
          "indication": "Niraparib (Zejula®) which is indicated as monotherapy for maintenance treatment of adult patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response [CR] or partial response [PR]) to platinum-based chemotherapy.",
          "last_scrape": "2018-12-13T16:42:00",
          "latest": "2018-06-27T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-06-01, 2018-06-21",
          "rr_end": "2018-06-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of niraparib compared with the current standard of care",
          "rr_start": "2018-06-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms",
          "trade_name": "Zejula",
          "url": "http://www.ncpe.ie/drugs/niraparib-zejula/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for Melanoma",
          "earliest": "2015-05-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2407,
          "indication": "Opdivo® is indicated as for monotherapy treatment for patients diagnosed with unresectable metastatic melanoma.",
          "last_scrape": "2018-12-13T16:42:06",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2015-05-28, 2015-07-16",
          "rr_end": "2015-07-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-05-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivio-for-melanoma/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for non-squamous NSCLC",
          "earliest": "2016-03-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2408,
          "indication": "Nivolumab (Opdivo®) is indicated for the treatment of adults with locally advanced or metastatic non-squamous NSCLC after prior chemotherapy.",
          "last_scrape": "2018-12-13T16:42:13",
          "latest": "2018-09-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-03-03, 2016-04-04",
          "rr_end": "2016-04-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-03-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivio-for-non-squamous-nsclc/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for NSCLC",
          "earliest": "2015-07-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2409,
          "indication": "Opdivo® is indicated for the treatment of locally advanced or metastatic squamous NSCLC after prior chemotherapy in adults.",
          "last_scrape": "2018-12-13T16:42:20",
          "latest": "2018-09-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2015-07-02, 2015-07-16",
          "rr_end": "2015-07-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-07-02T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivio-for-nsclc/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of adults with melanoma",
          "earliest": "2018-07-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2410,
          "indication": "Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of adults with melanoma  with involvement of lymph nodes or metastatic disease who have undergone complete resection.",
          "last_scrape": "2018-12-13T16:42:26",
          "latest": "2018-11-30T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-07-09, 2018-07-27",
          "rr_end": "2018-07-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care",
          "rr_start": "2018-07-09T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivo-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-melanoma/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for advanced renal cell carcinoma",
          "earliest": "2016-04-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2411,
          "indication": "Nivolumab (Opdivo®) is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults.",
          "last_scrape": "2018-12-13T16:42:31",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-04-27, 2016-05-16",
          "rr_end": "2016-05-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-04-27T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivo-for-advanced-renal-cell-carcinoma/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for classical Hodgkin Lymphoma",
          "earliest": "2016-11-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2412,
          "indication": "Nivolumab (Opdivo®) as monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.",
          "last_scrape": "2018-12-13T16:42:33",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-11-22, 2017-01-18",
          "rr_end": "2017-01-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2016-11-22T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivo-for-classical-hodgkin-lymphoma/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for head and neck cancer",
          "earliest": "2017-05-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2413,
          "indication": "Nivolumab (Opdivo®) for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy.",
          "last_scrape": "2018-12-13T16:42:36",
          "latest": "2018-04-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-05-03, 2017-05-30",
          "rr_end": "2017-05-30T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2017-05-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivo-for-head-and-neck-cancer/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for urothelial carcinoma",
          "earliest": "2017-06-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2414,
          "indication": "Nivolumab (Opdivo®) as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.",
          "last_scrape": "2018-12-13T16:42:41",
          "latest": "2018-09-12T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-06-28, 2017-08-10",
          "rr_end": "2017-08-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-06-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivo-for-urothelial-carcinoma/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®)",
          "earliest": "2018-11-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy",
          "eu_market": "2011-07-12T00:00:00",
          "id": 2415,
          "indication": "Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).",
          "last_scrape": "2018-12-13T16:42:46",
          "latest": "2018-12-11T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-11-28, 2018-12-11",
          "rr_end": "2018-12-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_start": "2018-11-28T00:00:00",
          "rr_status": "Unknown",
          "ta_list": "Melanoma",
          "trade_name": "Yervoy",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Nivolumab plus ipilimumab (Opdivo® plus Yervoy®)",
          "earliest": "2016-06-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2416,
          "indication": "Opdivo® plus Yervoy® Is indicated for the treatment of advanced melanoma.",
          "last_scrape": "2018-12-13T16:42:51",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2018-12-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2018-11-09T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Opdivo plus Yervoy",
          "url": "http://www.ncpe.ie/drugs/nivolumab-plus-ipilimumab-opdivio-plus-yervoy/"
         },
         {
          "company": "Teva",
          "drug_name": "Nomegestrol acetate/estradiol (Zoely®)",
          "earliest": "2011-12-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zoely",
          "eu_market": "2011-07-26T00:00:00",
          "id": 2417,
          "indication": "Nomegestrol acetate/estradiol (Zoely®) oral contraception",
          "last_scrape": "2018-12-13T16:42:56",
          "latest": "2012-01-03T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-12-08, 2012-01-03",
          "rr_end": "2012-01-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-12-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Contraception",
          "trade_name": "Zoely",
          "url": "http://www.ncpe.ie/drugs/nomace2-zoely/"
         },
         {
          "company": "Biogen",
          "drug_name": "Nusinersin (Spinraza®)",
          "earliest": "2017-07-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza",
          "eu_market": "2017-05-30T00:00:00",
          "id": 2418,
          "indication": "Nusinersen (Spinraza®) is indicated for the treatment of 5q spinal muscular atrophy (SMA)",
          "last_scrape": "2018-12-13T16:43:02",
          "latest": "2017-12-19T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2017-07-11, 2017-08-02",
          "rr_end": "2017-08-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2017-07-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Muscular Atrophy, Spinal",
          "trade_name": "Spinraza",
          "url": "http://www.ncpe.ie/drugs/nusinersin-spinraza/"
         },
         {
          "company": "Intercept",
          "drug_name": "Obeticholic acid (Ocaliva®)",
          "earliest": "2016-11-18T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva",
          "eu_market": "2016-12-12T00:00:00",
          "id": 2419,
          "indication": "Obeticholic acid is indicated for the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.",
          "last_scrape": "2018-12-13T16:43:07",
          "latest": "2017-10-31T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2016-11-18, 2016-12-21",
          "rr_end": "2016-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2016-11-18T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Liver Cirrhosis, Biliary",
          "trade_name": "Ocaliva",
          "url": "http://www.ncpe.ie/drugs/obeticholic-acid-ocaliva/"
         },
         {
          "company": "Roche",
          "drug_name": "Obinutuzumab (Gazyvaro®) for Follicular Lymphoma",
          "earliest": "2016-05-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro",
          "eu_market": "2014-07-22T00:00:00",
          "id": 2420,
          "indication": "Obinutuzumab (in combination with bendamustine) followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.",
          "last_scrape": "2018-12-13T16:43:10",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2016-05-11, 2016-05-31",
          "rr_end": "2016-05-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-05-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Gazyvaro",
          "url": "http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-follicular-lymphoma/"
         },
         {
          "company": "Roche",
          "drug_name": "Obinutuzumab (Gazyvaro®) for previously untreated advanced follicular lymphoma",
          "earliest": "2017-08-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro",
          "eu_market": "2014-07-22T00:00:00",
          "id": 2421,
          "indication": "Obinutuzumab (Gazyvaro®) in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.",
          "last_scrape": "2018-12-13T16:43:15",
          "latest": "2018-05-03T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-08-08, 2017-09-13",
          "rr_end": "2017-09-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-08-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Gazyvaro",
          "url": "http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-previously-untreated-advanced-follicular-lymphoma/"
         },
         {
          "company": "Roche",
          "drug_name": "Obinutuzumab (Gazyvaro®) for Lymphocytic Leukaemia",
          "earliest": "2014-08-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro",
          "eu_market": "2014-07-22T00:00:00",
          "id": 2422,
          "indication": "Obinutuzumab (Gazyvaro®) in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia and with comorbidities making them unsuitable for full-dose fludarabine based therapy.",
          "last_scrape": "2018-12-13T16:43:21",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 1,
          "rr_dates": "2014-08-08, 2014-09-11",
          "rr_end": "2014-09-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-08-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Gazyvaro",
          "url": "http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro/"
         },
         {
          "company": "Roche",
          "drug_name": "Ocrelizumab (Ocrevus®) for PPMS",
          "earliest": "2017-11-29T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus",
          "eu_market": "2018-01-08T00:00:00",
          "id": 2423,
          "indication": "Ocrelizumab (Ocrevus®) is indicated for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.",
          "last_scrape": "2018-12-13T16:43:24",
          "latest": "2018-10-04T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-11-29, 2017-12-14",
          "rr_end": "2017-12-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-11-29T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Ocrevus",
          "url": "http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-ppms/"
         },
         {
          "company": "Roche",
          "drug_name": "Ocrelizumab (Ocrevus®) for RMS",
          "earliest": "2017-11-29T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus",
          "eu_market": "2018-01-08T00:00:00",
          "id": 2424,
          "indication": "Ocrelizumab (Ocrevus®) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.",
          "last_scrape": "2018-12-13T16:43:30",
          "latest": "2018-08-29T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-11-29, 2017-12-14",
          "rr_end": "2017-12-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-11-29T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Ocrevus",
          "url": "http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-rms/"
         },
         {
          "company": "ThromboGenics",
          "drug_name": "Ocriplasmin (Jetrea®)",
          "earliest": "2013-06-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea",
          "eu_market": "2013-03-13T00:00:00",
          "id": 2425,
          "indication": "Ocriplasmin (Jetrea®) is a hospital only product licensed in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.",
          "last_scrape": "2018-12-13T16:43:34",
          "latest": "2013-07-09T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-06-12, 2013-07-09",
          "rr_end": "2013-07-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2013-06-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Retinal Diseases",
          "trade_name": "Jetrea",
          "url": "http://www.ncpe.ie/drugs/ocriplasmin-jetrea/"
         },
         {
          "company": "Novartis",
          "drug_name": "Ofatumumab (Arzerra®) (Previously untreated Chronic Lymphocytic Leukaemia)",
          "earliest": "2014-10-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra",
          "eu_market": "2010-04-19T00:00:00",
          "id": 2426,
          "indication": "Ofatumumab (Arzerra®) in combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.",
          "last_scrape": "2018-12-13T16:43:39",
          "latest": "2014-12-18T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-10-13, 2014-12-18",
          "rr_end": "2014-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2014-10-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Arzerra",
          "url": "http://www.ncpe.ie/drugs/ofatumumab-arzerra-previously-untreated-chronic-lymphocytic-leukaemia/"
         },
         {
          "company": "Novartis",
          "drug_name": "Ofatumumab (Arzerra®) (Refractory CLL)",
          "earliest": "2010-06-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra",
          "eu_market": "2010-04-19T00:00:00",
          "id": 2427,
          "indication": "Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.",
          "last_scrape": "2018-12-13T16:43:46",
          "latest": "2010-06-22T00:00:00",
          "ncpe_year": 2010,
          "orphan": 1,
          "rr_dates": "2010-06-22, 2010-06-01",
          "rr_end": "2010-06-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2010-06-22T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Arzerra",
          "url": "http://www.ncpe.ie/drugs/ofatumumab-arzerra/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Oladaterol (Striverdi®, Respimat®)",
          "earliest": "2014-04-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2428,
          "indication": "Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).",
          "last_scrape": "2018-12-13T16:43:52",
          "latest": "2014-05-02T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-04-07, 2014-05-02",
          "rr_end": "2014-05-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-04-07T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Striverdi, Respimat",
          "url": "http://www.ncpe.ie/drugs/oladaterol-striverdi-respimat/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Olaparib (Lynparza®)",
          "earliest": "2015-01-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza",
          "eu_market": "2014-12-16T00:00:00",
          "id": 2429,
          "indication": "Lynparza® is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.",
          "last_scrape": "2018-12-13T16:43:57",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2015-01-05, 2015-02-19",
          "rr_end": "2015-02-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-01-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Ovarian Neoplasms",
          "trade_name": "Lynparza",
          "url": "http://www.ncpe.ie/drugs/olaparib-lynparza-2/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Olaparib (Lynparza®) for platinum sensitive relapsed ovarian cancer",
          "earliest": "2018-09-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza",
          "eu_market": "2014-12-16T00:00:00",
          "id": 2430,
          "indication": "Olaparib (Lynparza®) monotherapy for the maintenance treatment of adult patients with PSR high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
          "last_scrape": "2018-12-13T16:44:03",
          "latest": "2018-10-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-09-19, 2018-10-01",
          "rr_end": "2018-10-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "the ncpe recommend  full hta to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care",
          "rr_start": "2018-09-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Ovarian Neoplasms",
          "trade_name": "Lynparza",
          "url": "http://www.ncpe.ie/drugs/olaparib-lynparza-for-platinum-sensitive-relapsed-ovarian-cancer/"
         },
         {
          "company": "Novartis",
          "drug_name": "Omalizumab (Xolair®) for the treatment of severe allergic asthma",
          "earliest": "2014-08-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xolair",
          "eu_market": "2005-10-25T00:00:00",
          "id": 2431,
          "indication": "Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1<80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.",
          "last_scrape": "2018-12-13T16:44:08",
          "latest": "2015-06-25T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2018-10-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2018-08-30T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Asthma; Urticaria",
          "trade_name": "Xolair",
          "url": "http://www.ncpe.ie/drugs/omalizumab-xolair-for-the-treatment-of-severe-allergic-asthma/"
         },
         {
          "company": "Novartis",
          "drug_name": "Omalizumab (Xolair®)",
          "earliest": "2014-03-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xolair",
          "eu_market": "2005-10-25T00:00:00",
          "id": 2432,
          "indication": "Omalizumab (Xolair®) is indicated as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment. ",
          "last_scrape": "2018-12-13T16:44:14",
          "latest": "2014-04-25T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-03-25, 2014-04-25",
          "rr_end": "2014-04-25T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended for this indication",
          "rr_start": "2014-03-25T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Asthma; Urticaria",
          "trade_name": "Xolair",
          "url": "http://www.ncpe.ie/drugs/omalizumab-xolair/"
         },
         {
          "company": "CIS",
          "drug_name": "Oxycodone/naloxone (Targin®)",
          "earliest": "2010-05-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2433,
          "indication": "Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin®) for severe pain, which can be adequately managed only with opioid analgesics.",
          "last_scrape": "2018-12-13T16:44:19",
          "latest": "2010-10-19T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2014-04-25T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2014-03-24T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Targin",
          "url": "http://www.ncpe.ie/drugs/oral-oxycodonenaloxone-targin/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Osimertinib (Tagrisso®) for the first-line treatment of metastatic NSCLC",
          "earliest": "2018-07-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso",
          "eu_market": "2016-02-01T00:00:00",
          "id": 2434,
          "indication": "Osimertinib (Tagrisso®) as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.",
          "last_scrape": "2018-12-13T16:44:22",
          "latest": "2018-08-07T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-07-19, 2018-08-07",
          "rr_end": "2018-08-07T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib for the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations compared with the current standard of care",
          "rr_start": "2018-07-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Tagrisso",
          "url": "http://www.ncpe.ie/drugs/osimertinib-tagrisso-for-the-first-line-treatment-of-metastatic-nsclc/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Osimertinib (Tagrisso®)",
          "earliest": "2016-02-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso",
          "eu_market": "2016-02-01T00:00:00",
          "id": 2435,
          "indication": "Osimertinib (Tagrisso®) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor [EGFR] T790M mutation positive non-small cell lung cancer [NSCLC].",
          "last_scrape": "2018-12-13T16:44:39",
          "latest": "2018-05-03T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-02-26, 2016-03-22, 2017-01-10",
          "rr_end": "2017-01-10T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2016-02-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Tagrisso",
          "url": "http://www.ncpe.ie/drugs/osimertinib-tagrisso/"
         },
         {
          "company": "Unknown",
          "drug_name": "Ozenoxacin (Dubine®)",
          "earliest": "2018-11-12T00:00:00",
          "ema_url": "",
          "eu_market": "2015-11-25T00:00:00",
          "id": 2436,
          "indication": "Ozenoxacin (Dubine®) 10mg/g cream for the short term treatment of non-bullous impetigo in adults, adolescents, children, and infants aged 6 months and older.",
          "last_scrape": "2018-12-13T16:44:40",
          "latest": "2018-12-13T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-11-12, 2018-12-13",
          "rr_end": "2018-12-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is not recommended the ncpe recommends that ozenoxacin cream not be considered for reimbursement at the submitted price  this recommendation should be considered while also having regard to the criteria specified in the health (pricing and supply of medical goods act) 2013",
          "rr_start": "2018-11-12T00:00:00",
          "rr_status": "Unknown",
          "ta_list": "Unknown",
          "trade_name": "Dubine",
          "url": "http://www.ncpe.ie/drugs/ozenoxacin-dubine/"
         },
         {
          "company": "Biogen",
          "drug_name": "Pegylated Interferon beta-1a (Plegridy ®)",
          "earliest": "2014-11-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy",
          "eu_market": "2014-07-17T00:00:00",
          "id": 2437,
          "indication": "Treatment of adult patients with relapsing remitting multiple sclerosis",
          "last_scrape": "2018-12-13T16:44:43",
          "latest": "2014-12-22T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-11-25, 2014-12-22",
          "rr_end": "2014-12-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-11-25T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Plegridy",
          "url": "http://www.ncpe.ie/drugs/p-drugs/pegylated-interferon-b-1a-plegridy/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Palbociclib (Ibrance®)",
          "earliest": "2016-09-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance",
          "eu_market": "2016-11-09T00:00:00",
          "id": 2438,
          "indication": "Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.",
          "last_scrape": "2018-12-13T16:44:47",
          "latest": "2017-07-28T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-09-10, 2016-09-28",
          "rr_end": "2016-09-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2016-09-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Ibrance",
          "url": "http://www.ncpe.ie/drugs/palbociclib-ibrance/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Paliperidone palmitate (Xeplion®)",
          "earliest": "2011-03-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xeplion",
          "eu_market": "2011-03-04T00:00:00",
          "id": 2439,
          "indication": "Paliperidone palmitate (Xeplion®) is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate, and a long acting injectable treatment is needed.",
          "last_scrape": "2018-12-13T16:44:53",
          "latest": "2011-03-23T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-03-11, 2011-03-23",
          "rr_end": "2011-03-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-03-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Schizophrenia",
          "trade_name": "Xeplion",
          "url": "http://www.ncpe.ie/drugs/paliperidone-palmitate-xeplion/"
         },
         {
          "company": "Novartis",
          "drug_name": "Panobinostat (Farydak®)",
          "earliest": "2016-01-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/farydak",
          "eu_market": "2015-08-28T00:00:00",
          "id": 2440,
          "indication": "Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.",
          "last_scrape": "2018-12-13T16:44:57",
          "latest": "2016-02-09T00:00:00",
          "ncpe_year": 2016,
          "orphan": 1,
          "rr_dates": "2016-01-26, 2016-02-09",
          "rr_end": "2016-02-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-01-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Myeloma",
          "trade_name": "Farydak",
          "url": "http://www.ncpe.ie/drugs/panobinostat-farydak/"
         },
         {
          "company": "AbbVie",
          "drug_name": "Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax®) with or without dasabuvir (Exviera®)",
          "earliest": "2014-12-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/exviera",
          "eu_market": "2015-01-14T00:00:00",
          "id": 2441,
          "indication": "Exviera® is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (CHC) in adults. Exviera® must not be administered as monotherapy. Depending on the patient population The recommended co-administered medicinal products for exviera® combination therapy are viekirax® or viekirax®   and ribavirin.",
          "last_scrape": "2018-12-13T16:45:01",
          "latest": "2016-02-10T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2014-12-21, 2015-01-13",
          "rr_end": "2015-01-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-12-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Exviera",
          "url": "http://www.ncpe.ie/drugs/paritaprevir-boosted-with-ritonavir-and-ombitasvir-vierkirax-with-or-without-dasabuvir-exviera/"
         },
         {
          "company": "Vifor",
          "drug_name": "Patiromer (Veltassa®)",
          "earliest": "2017-10-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/veltassa",
          "eu_market": "2017-07-19T00:00:00",
          "id": 2442,
          "indication": "Patiromer (Veltassa®) is indicated for the treatment of hyperkalaemia in adults.",
          "last_scrape": "2018-12-13T16:45:07",
          "latest": "2018-11-13T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-10-11, 2017-11-17",
          "rr_end": "2017-11-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessmentrecommended",
          "rr_start": "2017-10-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hyperkalemia",
          "trade_name": "Veltassa",
          "url": "http://www.ncpe.ie/drugs/patiromer-veltassa/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda®) 1L NSCLC with chemotherapy",
          "earliest": "2018-08-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2443,
          "indication": "Pembrolizumab (Keytruda®) is indicated in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.",
          "last_scrape": "2018-12-13T16:45:10",
          "latest": "2018-08-29T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-08-14, 2018-08-29",
          "rr_end": "2018-08-29T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care",
          "rr_start": "2018-08-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-1l-nsclc-with-chemotherapy/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda®) for Adjuvant melanoma",
          "earliest": "2018-11-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2444,
          "indication": "Pembrolizuma (Keytruda®) as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.",
          "last_scrape": "2018-12-13T16:45:15",
          "latest": "2018-12-07T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-11-19, 2018-12-07",
          "rr_end": "2018-12-07T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care",
          "rr_start": "2018-11-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-adjuvant-melanoma/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda ®) for Classical Hodgkin Lymphoma",
          "earliest": "2017-12-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2445,
          "indication": "Pembrolizumab (Keytruda®) is indicated as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.",
          "last_scrape": "2018-12-13T16:45:18",
          "latest": "2018-11-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-12-06, 2017-12-21",
          "rr_end": "2017-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at the submitted price",
          "rr_start": "2017-12-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-classical-hodgkin-lymphoma/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda®) for NSCLC (first line)",
          "earliest": "2016-12-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2446,
          "indication": "Keytruda® for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 (tumour proportion score [TPS] ≥ 50%) with no EGFR or ALK positive tumour mutations and no prior systemic therapy for advanced disease.",
          "last_scrape": "2018-12-13T16:45:23",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-12-19, 2017-01-10",
          "rr_end": "2017-01-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2016-12-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-first-line-nsclc/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda®) for NSCLC (second line)",
          "earliest": "2016-08-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2447,
          "indication": "Pembrolizumab (Keytruda®) is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving pembrolizumab.",
          "last_scrape": "2018-12-13T16:45:28",
          "latest": "2018-11-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-08-03, 2016-08-24",
          "rr_end": "2016-08-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2016-08-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-nsclc/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda®) for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.",
          "earliest": "2015-08-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2448,
          "indication": "Keytruda® for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.",
          "last_scrape": "2018-12-13T16:45:31",
          "latest": "2016-06-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2015-08-06, 2015-08-13",
          "rr_end": "2015-08-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-08-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-the-treatment-of-unresectable-or-advanced-metastatic-melanoma-in-adults-refractory-to-ipilimumab/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda ®) for Urothelial  Carcinoma 1L",
          "earliest": "2017-12-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2449,
          "indication": "Pembrolizumab (Keytruda®) is indicated for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.",
          "last_scrape": "2018-12-13T16:45:36",
          "latest": "2018-07-27T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27",
          "rr_end": "2018-07-27T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies",
          "rr_start": "2017-12-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-uc-1l/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda ®) for Urothelial Carcinoma 2L",
          "earliest": "2017-12-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2450,
          "indication": "Pembrolizumab (Keytruda ®) is indicated as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.",
          "last_scrape": "2018-12-13T16:45:38",
          "latest": "2018-12-05T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-12-06, 2017-12-21",
          "rr_end": "2017-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-12-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-urothelial-carcinoma-2l/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda®) for the first line treatment of unresectable or advanced metastatic melanoma in adults.",
          "earliest": "2015-08-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2451,
          "indication": "Keytruda® is indicated for the first line treatment of unresectable or advanced metastatic melanoma in adults.",
          "last_scrape": "2018-12-13T16:45:45",
          "latest": "2016-02-08T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2015-08-06, 2015-08-13",
          "rr_end": "2015-08-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-08-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda/"
         },
         {
          "company": "Eisai",
          "drug_name": "Perampanel (Fycompa®)",
          "earliest": "2013-07-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa",
          "eu_market": "2012-07-23T00:00:00",
          "id": 2452,
          "indication": "Perampanel (Fycompa®) indicated for treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. ",
          "last_scrape": "2018-12-13T16:45:50",
          "latest": "2013-07-01T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-07-01, 2013-07-01",
          "rr_end": "2013-07-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2013-07-01T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Epilepsies, Partial",
          "trade_name": "Fycompa",
          "url": "http://www.ncpe.ie/drugs/perampanel-fycompa/"
         },
         {
          "company": "Roche",
          "drug_name": "Pertuzumab  (Perjeta®) for Adjuvant HER2 positive breast cancer",
          "earliest": "2018-06-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta",
          "eu_market": "2013-03-04T00:00:00",
          "id": 2453,
          "indication": "Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.",
          "last_scrape": "2018-12-13T16:45:56",
          "latest": "2018-12-03T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-06-01, 2018-06-22",
          "rr_end": "2018-06-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of pertuzumab compared with the current standard of care",
          "rr_start": "2018-06-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Perjeta",
          "url": "http://www.ncpe.ie/drugs/pertuzumab-perjeta-for-her2-positive-breast-cancer/"
         },
         {
          "company": "Roche",
          "drug_name": "Pertuzumab (Perjeta®) in neoadjuvant HER2 positive breast cancer",
          "earliest": "2015-08-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta",
          "eu_market": "2013-03-04T00:00:00",
          "id": 2454,
          "indication": "Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.",
          "last_scrape": "2018-12-13T16:46:02",
          "latest": "2016-05-10T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2015-08-10, 2015-09-01",
          "rr_end": "2015-09-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-08-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Perjeta",
          "url": "http://www.ncpe.ie/drugs/pertuzumab-perjeta-in-neoadjuvant-her2-positive-breast-cancer/"
         },
         {
          "company": "Roche",
          "drug_name": "Pertuzumab (Perjeta®)",
          "earliest": "2013-01-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta",
          "eu_market": "2013-03-04T00:00:00",
          "id": 2455,
          "indication": "The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. ",
          "last_scrape": "2018-12-13T16:46:04",
          "latest": "2013-08-28T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-01-14, 2013-01-31",
          "rr_end": "2013-01-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "pharmacoeconomic evaluation recommended",
          "rr_start": "2013-01-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Perjeta",
          "url": "http://www.ncpe.ie/drugs/pertuzumab-perjeta/"
         },
         {
          "company": "Unknown",
          "drug_name": "Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane®)",
          "earliest": "2016-11-18T00:00:00",
          "ema_url": "",
          "eu_market": "2013-12-01T00:00:00",
          "id": 2456,
          "indication": "Fydrane® is indicated for cataract surgery to obtain mydriasis and intraocular anaesthesia, during the surgical procedure.",
          "last_scrape": "2018-12-13T16:46:09",
          "latest": "2016-12-19T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-11-18, 2016-12-19",
          "rr_end": "2016-12-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "reimbursement not recommended at the submitted price",
          "rr_start": "2016-11-18T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "Unknown",
          "trade_name": "Fydrane",
          "url": "http://www.ncpe.ie/drugs/phenylephrine-hydrochloride-tropicamide-lidocaine-hydrochloride-fydrane/"
         },
         {
          "company": "Roche",
          "drug_name": "Pirfenidone (Esbriet®)",
          "earliest": "2011-12-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet",
          "eu_market": "2011-02-27T00:00:00",
          "id": 2457,
          "indication": "Pirfenidone has been licensed by the European Medicines Agency (EMA) for the treatment of mild to moderate idiopathic pulmonary fibrosis.",
          "last_scrape": "2018-12-13T16:46:11",
          "latest": "2015-03-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 1,
          "rr_dates": "2011-12-15, 2012-01-05",
          "rr_end": "2012-01-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-12-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Idiopathic Pulmonary Fibrosis",
          "trade_name": "Esbriet",
          "url": "http://www.ncpe.ie/drugs/pirfenidone-esbriet/"
         },
         {
          "company": "CIS",
          "drug_name": "Pitavastatin (Livazo®)",
          "earliest": "2010-12-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2458,
          "indication": "Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.",
          "last_scrape": "2018-12-13T16:46:14",
          "latest": "2010-12-24T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-12-22, 2010-12-24",
          "rr_end": "2010-12-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2010-12-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Livazo",
          "url": "http://www.ncpe.ie/drugs/pitavastatin-livazo/"
         },
         {
          "company": "Bioprojet",
          "drug_name": "Pitolisant hydrochloride (Wakix®)",
          "earliest": "2017-06-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/wakix",
          "eu_market": "2016-03-31T00:00:00",
          "id": 2459,
          "indication": "Pitolisant hydrochloride (Wakix®) is indicated for the treatment of narcolepsy with or without cataplexy and should be initiated by a physician experienced in the treatment of sleep disorders.",
          "last_scrape": "2018-12-13T16:46:20",
          "latest": "2017-06-15T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2017-06-12, 2017-06-15",
          "rr_end": "2017-06-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2017-06-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Narcolepsy",
          "trade_name": "Wakix",
          "url": "http://www.ncpe.ie/drugs/pitolisant-wakix/"
         },
         {
          "company": "CTI",
          "drug_name": "Pixantrone (Pixuvri®)",
          "earliest": "2015-02-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri",
          "eu_market": "2012-05-10T00:00:00",
          "id": 2460,
          "indication": "Pixurvi® is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas (NHL).",
          "last_scrape": "2018-12-13T16:46:24",
          "latest": "2015-03-20T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-02-10, 2015-03-20",
          "rr_end": "2015-03-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-02-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Lymphoma, Non-Hodgkin",
          "trade_name": "Pixuvri",
          "url": "http://www.ncpe.ie/drugs/pixantrone-pixuvri/"
         },
         {
          "company": "Vifor",
          "drug_name": "Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro®)",
          "earliest": "2014-09-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro",
          "eu_market": "2014-08-26T00:00:00",
          "id": 2461,
          "indication": "Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro™) is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD).",
          "last_scrape": "2018-12-13T16:46:27",
          "latest": "2014-10-08T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-09-12, 2014-10-08",
          "rr_end": "2014-10-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-09-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hyperphosphatemia; Renal Dialysis",
          "trade_name": "Velphoro",
          "url": "http://www.ncpe.ie/drugs/polynuclear-ironiii-oxyhydroxide-pn-feooh-velphoro/"
         },
         {
          "company": "CIS",
          "drug_name": "Pomalidomide (Imnovid®)",
          "earliest": "2013-09-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2462,
          "indication": "Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.",
          "last_scrape": "2018-12-13T16:46:30",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2013-09-20, 2013-10-02",
          "rr_end": "2013-10-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-09-20T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Imnovid",
          "url": "http://www.ncpe.ie/drugs/pomalidomide-imnovid/"
         },
         {
          "company": "Incyte",
          "drug_name": "Ponatinib (Iclusig®)",
          "earliest": "2013-10-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig",
          "eu_market": "2013-07-01T00:00:00",
          "id": 2463,
          "indication": "Ponatinib (Iclusig®) Is indicated for patients in chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation and for Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) patients who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.",
          "last_scrape": "2018-12-13T16:46:32",
          "latest": "2016-01-05T00:00:00",
          "ncpe_year": 2016,
          "orphan": 1,
          "rr_dates": "2013-10-02, 2013-12-01",
          "rr_end": "2013-12-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta recommended",
          "rr_start": "2013-10-02T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid; Leukemia, Lymphoid",
          "trade_name": "Iclusig",
          "url": "http://www.ncpe.ie/drugs/ponatinib-iclusig/"
         },
         {
          "company": "Daiichi",
          "drug_name": "Prasugrel (Efient®)",
          "earliest": "2009-07-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/efient",
          "eu_market": "2009-02-24T00:00:00",
          "id": 2464,
          "indication": "Economic Evaluation of Prasugrel (Efient®) for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.",
          "last_scrape": "2018-12-13T16:46:38",
          "latest": "2010-02-01T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-12-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2013-10-30T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction",
          "trade_name": "Efient",
          "url": "http://www.ncpe.ie/drugs/prasugrel-efient/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Pregabalin (Lyrica®) for the treatment of neuropathic pain",
          "earliest": "2013-09-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica",
          "eu_market": "2004-07-05T00:00:00",
          "id": 2465,
          "indication": "Lyrica® is indicated for the treatment of peripheral and central neuropathic pain, generalised anxiety disorder and as adjunctive therapy for epilepsy.",
          "last_scrape": "2018-12-13T16:46:46",
          "latest": "2015-06-12T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-12-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2013-10-30T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Epilepsy; Anxiety Disorders; Neuralgia",
          "trade_name": "Lyrica",
          "url": "http://www.ncpe.ie/drugs/pregabalin-lyrica-2/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Pregabalin (Lyrica®) for the treatment of Generalised Anxiety Disorder",
          "earliest": "2014-09-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica",
          "eu_market": "2004-07-05T00:00:00",
          "id": 2466,
          "indication": "Pregabalin (Lyrica®) for the treatment of Generalised Anxiety Disorder.",
          "last_scrape": "2018-12-13T16:46:52",
          "latest": "2014-12-15T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-12-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2013-10-30T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Epilepsy; Anxiety Disorders; Neuralgia",
          "trade_name": "Lyrica",
          "url": "http://www.ncpe.ie/drugs/pregabalin-lyrica-for-the-treatment-of-generalised-anxiety-disorder/"
         },
         {
          "company": "Shire",
          "drug_name": "Prucalopride (Resolor®)",
          "earliest": "2011-01-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/resolor",
          "eu_market": "2009-10-14T00:00:00",
          "id": 2467,
          "indication": "Prucalopride (Resolor®) for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.",
          "last_scrape": "2018-12-13T16:46:58",
          "latest": "2011-03-01T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-03-11, 2011-01-17",
          "rr_end": "2011-01-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-03-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Constipation",
          "trade_name": "Resolor",
          "url": "http://www.ncpe.ie/drugs/prucalopride-resolor/"
         },
         {
          "company": "Bayer",
          "drug_name": "Radium-223 (Xofigo®)",
          "earliest": "2013-11-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo",
          "eu_market": "2013-11-13T00:00:00",
          "id": 2468,
          "indication": "Radium-223 (Xofigo®) is indicated for the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.  It is for use in the hospital setting.",
          "last_scrape": "2018-12-13T16:47:00",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2013-11-28, 2013-12-23",
          "rr_end": "2013-12-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-11-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Xofigo",
          "url": "http://www.ncpe.ie/drugs/radium-223-xofigo/"
         },
         {
          "company": "Eli",
          "drug_name": "Ramucirumab (Cyramza®)",
          "earliest": "2014-12-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza",
          "eu_market": "2014-12-19T00:00:00",
          "id": 2469,
          "indication": "Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.",
          "last_scrape": "2018-12-13T16:47:03",
          "latest": "2016-07-26T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2014-12-20, 2014-12-23",
          "rr_end": "2014-12-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-12-20T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Stomach Neoplasms",
          "trade_name": "Cyramza",
          "url": "http://www.ncpe.ie/drugs/ramucirumab-cyramza/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Ranolazine (Ranexa®)",
          "earliest": "2009-11-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2470,
          "indication": "Cost-effectiveness of Ranolazine (Ranexa®)",
          "last_scrape": "2018-12-13T16:47:06",
          "latest": "2009-11-19T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "2009-11-19",
          "rr_end": "2009-11-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2009-11-19T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Ranexa",
          "url": "http://www.ncpe.ie/drugs/ranolazine-ranexa/"
         },
         {
          "company": "GE",
          "drug_name": "Regadenoson (Rapiscan®)",
          "earliest": "2011-09-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan",
          "eu_market": "2010-09-06T00:00:00",
          "id": 2471,
          "indication": "Cost-effectiveness of Regadenoson (Rapiscan®)",
          "last_scrape": "2018-12-13T16:47:13",
          "latest": "2011-11-02T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-09-19, 2011-11-02",
          "rr_end": "2011-11-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-09-19T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Myocardial Perfusion Imaging",
          "trade_name": "Rapiscan",
          "url": "http://www.ncpe.ie/drugs/regadenoson-rapiscan/"
         },
         {
          "company": "Bayer",
          "drug_name": "Regorafenib (Stivarga®) for GIST",
          "earliest": "2014-09-18T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga",
          "eu_market": "2013-08-26T00:00:00",
          "id": 2472,
          "indication": "Regorafenib (Stivarga®) indicated for the treatment of patients with gastrointestinal stromal tumours (GIST) who have been previously treated with two tyrosine kinase inhibitors and have progressed or are intolerant to prior treatment with two TKI’s.",
          "last_scrape": "2018-12-13T16:47:17",
          "latest": "2014-10-06T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-09-18, 2014-10-06",
          "rr_end": "2014-10-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-09-18T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Colorectal Neoplasms",
          "trade_name": "Stivarga",
          "url": "http://www.ncpe.ie/drugs/regorafenib-stivarga-for-gist/"
         },
         {
          "company": "Teva",
          "drug_name": "Reslizumab (Cinqaero®)",
          "earliest": "2017-01-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero",
          "eu_market": "2016-08-15T00:00:00",
          "id": 2473,
          "indication": "Cinqaero® is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.",
          "last_scrape": "2018-12-13T16:47:23",
          "latest": "2017-03-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-01-23, 2017-03-01",
          "rr_end": "2017-03-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2017-01-23T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Asthma",
          "trade_name": "Cinqaero",
          "url": "http://www.ncpe.ie/drugs/reslizumab-cinqaero/"
         },
         {
          "company": "Glaxo",
          "drug_name": "Retigabine (Trobalt®)",
          "earliest": "2011-03-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt",
          "eu_market": "2011-03-27T00:00:00",
          "id": 2474,
          "indication": "Cost-effectiveness of Retigabine (Trobalt®)",
          "last_scrape": "2018-12-13T16:47:27",
          "latest": "2011-04-06T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-04-06, 2011-03-01",
          "rr_end": "2011-03-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-04-06T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Epilepsy",
          "trade_name": "Trobalt",
          "url": "http://www.ncpe.ie/drugs/retigabine-trobalt/"
         },
         {
          "company": "Novartis",
          "drug_name": "Ribociclib (Kisqali®)",
          "earliest": "2017-09-04T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali",
          "eu_market": "2017-08-22T00:00:00",
          "id": 2475,
          "indication": "Ribociclib (Kisqali®) in combination with an aromatase inhibitor (AI) is indicated for the treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine based therapy.",
          "last_scrape": "2018-12-13T16:47:29",
          "latest": "2018-08-13T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-09-04, 2017-09-19",
          "rr_end": "2017-09-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "following ncpe assessment of the company submission, the ncpe recommends that ribociclib (in combination with an aromatase inhibitor) for the treatment of postmenopausal women with hr+/her2- locally advanced or metastatic bc as initial endocrine-based therapy, not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments this recommendation should be considered while also having regard to the criteria specified in the health (pricing and supply of medical goods) act 2013",
          "rr_start": "2017-09-04T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Kisqali",
          "url": "http://www.ncpe.ie/drugs/ribociclib-kisqali/"
         },
         {
          "company": "CIS",
          "drug_name": "Rifaximin (Targaxan®)",
          "earliest": "2013-07-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2476,
          "indication": "Rifaximin (Targaxan®) is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age. ",
          "last_scrape": "2018-12-13T16:47:35",
          "latest": "2013-08-06T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-07-09, 2013-08-06",
          "rr_end": "2013-08-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2013-07-09T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Targaxan",
          "url": "http://www.ncpe.ie/drugs/rifaximin-targaxan-2/"
         },
         {
          "company": "Bayer",
          "drug_name": "Regorafenib (Stivarga®) for mCRC",
          "earliest": "2013-09-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga",
          "eu_market": "2013-08-26T00:00:00",
          "id": 2477,
          "indication": "Regorafenib (Stivarga®) is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.",
          "last_scrape": "2018-12-13T16:47:38",
          "latest": "2014-06-30T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-09-12, 2013-10-02",
          "rr_end": "2013-10-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-09-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Colorectal Neoplasms",
          "trade_name": "Stivarga",
          "url": "http://www.ncpe.ie/drugs/rigorafenib-stivarga/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Rilpivirine (Edurant®)",
          "earliest": "2011-12-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/edurant",
          "eu_market": "2011-11-28T00:00:00",
          "id": 2478,
          "indication": "Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml.",
          "last_scrape": "2018-12-13T16:47:42",
          "latest": "2012-01-06T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-12-14, 2012-01-06",
          "rr_end": "2012-01-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-12-14T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "HIV Infections",
          "trade_name": "Edurant",
          "url": "http://www.ncpe.ie/drugs/rilpivirine-edurant/"
         },
         {
          "company": "Gilead",
          "drug_name": "Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey®)",
          "earliest": "2016-06-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey",
          "eu_market": "2016-06-21T00:00:00",
          "id": 2479,
          "indication": "Odefsey® (R/F/TAF) is indicated for the treatment of adults and adolescents (≥ 12 years, body weight ≥35 kg) infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/ml.",
          "last_scrape": "2018-12-13T16:47:45",
          "latest": "2016-10-04T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-06-28, 2016-07-11",
          "rr_end": "2016-07-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "reimbursement not recommeded",
          "rr_start": "2016-06-28T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "HIV Infections",
          "trade_name": "Odefsey",
          "url": "http://www.ncpe.ie/drugs/rilpivirine-r-emtricitabine-f-tenofovir-alafenamide-taf-odefsey/"
         },
         {
          "company": "sanofi-aventis",
          "drug_name": "Rimonabant (Acomplia®)",
          "earliest": "2006-06-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia",
          "eu_market": "2006-06-19T00:00:00",
          "id": 2480,
          "indication": "In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant (in addition to diet and exercise) in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.",
          "last_scrape": "2018-12-13T16:47:48",
          "latest": "2006-06-01T00:00:00",
          "ncpe_year": 2006,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2016-07-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2016-06-09T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Obesity",
          "trade_name": "Acomplia",
          "url": "http://www.ncpe.ie/drugs/rimonabant-acomplia-2/"
         },
         {
          "company": "Bayer",
          "drug_name": "Riociguat (Adempas®)",
          "earliest": "2014-04-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adempas",
          "eu_market": "2014-03-27T00:00:00",
          "id": 2481,
          "indication": "Riociguat (Adempas®) is indicated for the treatment of Pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH).",
          "last_scrape": "2018-12-13T16:47:53",
          "latest": "2014-05-16T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-04-11, 2014-05-16",
          "rr_end": "2014-05-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta recommended at the current price",
          "rr_start": "2014-04-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hypertension, Pulmonary",
          "trade_name": "Adempas",
          "url": "http://www.ncpe.ie/drugs/riociguat-adempas/"
         },
         {
          "company": "Roche",
          "drug_name": "Rituximab (MabThera®)",
          "earliest": "2014-05-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera",
          "eu_market": "1998-06-02T00:00:00",
          "id": 2482,
          "indication": "Rituximab (MabThera®) subcutaneous formulation is indicated in adults for Non-Hodgkin’s lymphoma (NHL):",
          "last_scrape": "2018-12-13T16:47:59",
          "latest": "2014-09-22T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-05-26, 2014-09-22",
          "rr_end": "2014-09-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-05-26T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "MabThera",
          "url": "http://www.ncpe.ie/drugs/rituximab-mabthera/"
         },
         {
          "company": "Bayer",
          "drug_name": "Rivaroxaban (Xarelto®) for Atrial Fibrillation patients undergoing PCI",
          "earliest": "2017-11-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto",
          "eu_market": "2008-09-30T00:00:00",
          "id": 2483,
          "indication": "Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.",
          "last_scrape": "2018-12-13T16:48:05",
          "latest": "2017-11-21T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-11-20, 2017-11-21",
          "rr_end": "2017-11-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-11-20T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Xarelto",
          "url": "http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-atrial-fibrillation-patients-undergoing-pci/"
         },
         {
          "company": "Bayer",
          "drug_name": "Rivaroxaban (Xarelto®) for the Treatment of Deep Vein Thrombosis",
          "earliest": "2011-08-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto",
          "eu_market": "2008-09-30T00:00:00",
          "id": 2484,
          "indication": "Economic evaluation of Rivaroxaban (Xarelto®) for the Treatment of Deep Vein Thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.",
          "last_scrape": "2018-12-13T16:48:10",
          "latest": "2012-02-24T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-08-17, 2011-08-31",
          "rr_end": "2011-08-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-08-17T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Xarelto",
          "url": "http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-dvt/"
         },
         {
          "company": "Bayer",
          "drug_name": "Rivaroxaban (Xarelto®) for the Prevention of Stroke in Atrial Fibrillation",
          "earliest": "2011-08-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto",
          "eu_market": "2008-09-30T00:00:00",
          "id": 2485,
          "indication": "Cost Effectiveness of Rivaroxaban (Xarelto®) for the prevention of stroke in atrial fibrillation.",
          "last_scrape": "2018-12-13T16:48:15",
          "latest": "2012-06-19T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-08-17, 2011-08-31",
          "rr_end": "2011-08-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-08-17T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Xarelto",
          "url": "http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-spaf-2/"
         },
         {
          "company": "Bayer",
          "drug_name": "Rivaroxaban (Xarelto®) for the prevention of atherothrombotic events",
          "earliest": "2018-09-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto",
          "eu_market": "2008-09-30T00:00:00",
          "id": 2486,
          "indication": "Rivaroxaban (Xarelto®) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.",
          "last_scrape": "2018-12-13T16:48:18",
          "latest": "2018-10-11T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-09-26, 2018-10-11",
          "rr_end": "2018-10-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of rivaroxaban compared with the current standard of care",
          "rr_start": "2018-09-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Xarelto",
          "url": "http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-the-prevention-of-atherothrombotic-events/"
         },
         {
          "company": "Bayer",
          "drug_name": "Rivaroxaban (Xarelto®) low dose for prevention of recurrent venous thromboembolism",
          "earliest": "2017-11-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto",
          "eu_market": "2008-09-30T00:00:00",
          "id": 2487,
          "indication": "Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.",
          "last_scrape": "2018-12-13T16:48:25",
          "latest": "2017-11-21T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-11-20, 2017-11-21",
          "rr_end": "2017-11-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-11-20T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Xarelto",
          "url": "http://www.ncpe.ie/drugs/rivaroxaban-xarelto-low-dose-for-prevention-of-recurrent-venous-thromboembolism/"
         },
         {
          "company": "Bayer",
          "drug_name": "Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement",
          "earliest": "2008-04-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto",
          "eu_market": "2008-09-30T00:00:00",
          "id": 2488,
          "indication": "Cost Effectiveness of Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement.",
          "last_scrape": "2018-12-13T16:48:30",
          "latest": "2008-09-01T00:00:00",
          "ncpe_year": 2008,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-11-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2017-10-20T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Xarelto",
          "url": "http://www.ncpe.ie/drugs/rivaroxaban-xarelto/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Roflumilast (Daxas®)",
          "earliest": "2010-06-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/daxas",
          "eu_market": "2010-07-05T00:00:00",
          "id": 2489,
          "indication": "Cost Effectiveness of Roflumilast (Daxas®) for the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.",
          "last_scrape": "2018-12-13T16:48:33",
          "latest": "2010-11-03T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-11-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2017-10-20T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Pulmonary Disease, Chronic Obstructive",
          "trade_name": "Daxas",
          "url": "http://www.ncpe.ie/drugs/roflumilast-daxas/"
         },
         {
          "company": "Tesaro",
          "drug_name": "Rolapitant (Varuby®)",
          "earliest": "2017-05-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/varuby",
          "eu_market": "2017-04-19T00:00:00",
          "id": 2490,
          "indication": "Rolapitant (Varuby®)is indicated for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.",
          "last_scrape": "2018-12-13T16:48:40",
          "latest": "2017-06-12T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-05-15, 2017-06-12",
          "rr_end": "2017-06-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2017-05-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Vomiting; Nausea; Cancer",
          "trade_name": "Varuby",
          "url": "http://www.ncpe.ie/drugs/rolapitant-varuby/"
         },
         {
          "company": "Amgen",
          "drug_name": "Romiplostim (Nplate®)",
          "earliest": "2015-04-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/nplate",
          "eu_market": "2009-02-04T00:00:00",
          "id": 2491,
          "indication": "Romiplostim (Nplate®) is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.",
          "last_scrape": "2018-12-13T16:48:43",
          "latest": "2015-05-27T00:00:00",
          "ncpe_year": 2015,
          "orphan": 1,
          "rr_dates": "",
          "rr_end": "2017-06-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2017-05-11T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Purpura, Thrombocytopenic, Idiopathic",
          "trade_name": "Nplate",
          "url": "http://www.ncpe.ie/drugs/romiplostim-nplate/"
         },
         {
          "company": "Unknown",
          "drug_name": "Ropivacaine Readyfusor®",
          "earliest": "2018-11-09T00:00:00",
          "ema_url": "",
          "eu_market": "2015-11-22T00:00:00",
          "id": 2492,
          "indication": "Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.",
          "last_scrape": "2018-12-13T16:48:47",
          "latest": "2018-12-13T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-11-09, 2018-12-13",
          "rr_end": "2018-12-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is not recommended the ncpe recommends that ropivicaine readyfusor not be considered for reimbursement at the submitted price  this recommendation should be considered while also having regard to the criteria specified in the health (pricing and supply of medical goods act) 2013",
          "rr_start": "2018-11-09T00:00:00",
          "rr_status": "Unknown",
          "ta_list": "Unknown",
          "trade_name": "Ropivacaine Readyfusor",
          "url": "http://www.ncpe.ie/drugs/ropivacaine-readyfusor/"
         },
         {
          "company": "Novartis",
          "drug_name": "Ruxolitinib (Jakavi®) for Polycythaemia Vera",
          "earliest": "2015-04-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi",
          "eu_market": "2012-08-23T00:00:00",
          "id": 2493,
          "indication": "Jakavi® is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.",
          "last_scrape": "2018-12-13T16:48:50",
          "latest": "2016-08-16T00:00:00",
          "ncpe_year": 2016,
          "orphan": 1,
          "rr_dates": "2015-04-15, 2015-05-28",
          "rr_end": "2015-05-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-04-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Myeloproliferative Disorders",
          "trade_name": "Jakavi",
          "url": "http://www.ncpe.ie/drugs/ruxolitinib-jakavi-for-polycythaemia-vera/"
         },
         {
          "company": "Novartis",
          "drug_name": "Ruxolitinib (Jakavi®)",
          "earliest": "2012-08-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi",
          "eu_market": "2012-08-23T00:00:00",
          "id": 2494,
          "indication": "Ruxolitinib (Jakavi®) for the treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.",
          "last_scrape": "2018-12-13T16:48:55",
          "latest": "2013-07-09T00:00:00",
          "ncpe_year": 2013,
          "orphan": 1,
          "rr_dates": "2012-08-01, 2012-08-10",
          "rr_end": "2012-08-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2012-08-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Myeloproliferative Disorders",
          "trade_name": "Jakavi",
          "url": "http://www.ncpe.ie/drugs/ruxolitinib-jakavi/"
         },
         {
          "company": "Novartis",
          "drug_name": "Sacubitril/valsartan (Entresto®)",
          "earliest": "2015-11-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/entresto",
          "eu_market": "2015-11-19T00:00:00",
          "id": 2495,
          "indication": "Entresto® for the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients.",
          "last_scrape": "2018-12-13T16:48:58",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2015-11-06, 2015-11-30",
          "rr_end": "2015-11-30T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-11-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Heart Failure",
          "trade_name": "Entresto",
          "url": "http://www.ncpe.ie/drugs/sacubitrilvalsartan-entresto/"
         },
         {
          "company": "Zambon",
          "drug_name": "Safinamide methansulfonate (Xadago®)",
          "earliest": "2016-06-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xadago",
          "eu_market": "2015-02-23T00:00:00",
          "id": 2496,
          "indication": "Xadago® for the treatment of adult patients with idiopathic Parkinson’s disease.",
          "last_scrape": "2018-12-13T16:49:04",
          "latest": "2016-07-06T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-06-14, 2016-07-06",
          "rr_end": "2016-07-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "reimbursement not recommended",
          "rr_start": "2016-06-14T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "Parkinson Disease",
          "trade_name": "Xadago",
          "url": "http://www.ncpe.ie/drugs/safinamide-methansulfonate-xadago/"
         },
         {
          "company": "BioMarin",
          "drug_name": "Sapropterin (Kuvan®)",
          "earliest": "2009-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan",
          "eu_market": "2008-12-02T00:00:00",
          "id": 2497,
          "indication": "Sapropterin (Kuvan®) for the treatment of phenylketonuria (PKU).",
          "last_scrape": "2018-12-13T16:49:07",
          "latest": "2017-09-15T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2015-07-14, 2015-08-14, 2015-07-01",
          "rr_end": "2015-07-01T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2015-07-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Phenylketonurias",
          "trade_name": "Kuvan",
          "url": "http://www.ncpe.ie/drugs/sapropterin-kuvan/"
         },
         {
          "company": "sanofi-aventis",
          "drug_name": "Sarilumab (Kevzara®)",
          "earliest": "2017-08-18T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara",
          "eu_market": "2017-06-23T00:00:00",
          "id": 2498,
          "indication": "Sarilumab (Kevzara®) in combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARD). Sarilumab can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.",
          "last_scrape": "2018-12-13T16:49:11",
          "latest": "2017-10-04T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-08-18, 2017-10-04",
          "rr_end": "2017-10-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at the submitted price",
          "rr_start": "2017-08-18T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Rheumatoid",
          "trade_name": "Kevzara",
          "url": "http://www.ncpe.ie/drugs/sarilumab-kevzara/"
         },
         {
          "company": "Alexion",
          "drug_name": "Sebelipase alfa (Kanuma®)",
          "earliest": "2017-02-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kanuma",
          "eu_market": "2015-08-28T00:00:00",
          "id": 2499,
          "indication": "Sebelipase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.",
          "last_scrape": "2018-12-13T16:49:16",
          "latest": "2018-06-08T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-02-08, 2017-03-13",
          "rr_end": "2017-03-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_start": "2017-02-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lipid Metabolism, Inborn Errors",
          "trade_name": "Kanuma",
          "url": "http://www.ncpe.ie/drugs/sebelipase-alfa-kanuma/"
         },
         {
          "company": "Novartis",
          "drug_name": "Secukinumab (Cosentyx®) for Ankylosing Spondylitis",
          "earliest": "2015-12-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx",
          "eu_market": "2015-01-14T00:00:00",
          "id": 2500,
          "indication": "Cosentyx® is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy",
          "last_scrape": "2018-12-13T16:49:20",
          "latest": "2015-12-14T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-12-02, 2015-12-14",
          "rr_end": "2015-12-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-12-02T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing",
          "trade_name": "Cosentyx",
          "url": "http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-ankylosing-spondylitis/"
         },
         {
          "company": "Novartis",
          "drug_name": "Secukinumab (Cosentyx®) for Psoriatic Arthritis",
          "earliest": "2015-12-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx",
          "eu_market": "2015-01-14T00:00:00",
          "id": 2501,
          "indication": "Cosentyx® alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.",
          "last_scrape": "2018-12-13T16:49:25",
          "latest": "2015-12-15T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-12-02, 2015-12-15",
          "rr_end": "2015-12-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-12-02T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing",
          "trade_name": "Cosentyx",
          "url": "http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-psoriatic-arthritis/"
         },
         {
          "company": "Novartis",
          "drug_name": "Secukinumab (Cosentyx®)",
          "earliest": "2014-12-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx",
          "eu_market": "2015-01-14T00:00:00",
          "id": 2502,
          "indication": "Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.",
          "last_scrape": "2018-12-13T16:49:31",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-12-19, 2015-02-05",
          "rr_end": "2015-02-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-12-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing",
          "trade_name": "Cosentyx",
          "url": "http://www.ncpe.ie/drugs/secukinumab-cosentyx/"
         },
         {
          "company": "Janssen",
          "drug_name": "Selexipag (Uptravi®)",
          "earliest": "2016-11-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi",
          "eu_market": "2016-05-12T00:00:00",
          "id": 2503,
          "indication": "Selexipag (Uptravi®) is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.",
          "last_scrape": "2018-12-13T16:49:34",
          "latest": "2018-05-21T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-11-01, 2016-12-05",
          "rr_end": "2016-12-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2016-11-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hypertension, Pulmonary",
          "trade_name": "Uptravi",
          "url": "http://www.ncpe.ie/drugs/selexipag-uptravi/"
         },
         {
          "company": "Novo",
          "drug_name": "Semaglutide (Ozempic®)",
          "earliest": "2018-03-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic",
          "eu_market": "2018-02-08T00:00:00",
          "id": 2504,
          "indication": "Semaglutide (Ozempic®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:",
          "last_scrape": "2018-12-13T16:49:39",
          "latest": "2018-04-10T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-03-12, 2018-04-10",
          "rr_end": "2018-04-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended on the basis of the proposed price, relative to currently available therapies",
          "rr_start": "2018-03-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Diabetes Mellitus",
          "trade_name": "Ozempic",
          "url": "http://www.ncpe.ie/drugs/semaglutide-ozempic/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Sildenafil (Revatio®)",
          "earliest": "2014-04-16T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/revatio",
          "eu_market": "2005-10-28T00:00:00",
          "id": 2505,
          "indication": "Sildenafil (Revatio®) is indicated for:",
          "last_scrape": "2018-12-13T16:49:44",
          "latest": "2014-05-23T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-04-16, 2014-05-23",
          "rr_end": "2014-05-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-04-16T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hypertension, Pulmonary",
          "trade_name": "Revatio",
          "url": "http://www.ncpe.ie/drugs/sildenafil-revatio/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Simeprevir (Olysio®) in combination with Sofosbuvir",
          "earliest": "2014-05-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/olysio",
          "eu_market": "2014-05-14T00:00:00",
          "id": 2506,
          "indication": "Simeprevir (Olysio®) in combination with Sofosbuvir for the treatment of chronic hepatitis C (CHC) in adult patients who are intolerant to or ineligible for interferon therapy, and are in urgent need of treatment.",
          "last_scrape": "2018-12-13T16:49:49",
          "latest": "2015-03-13T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-05-27, 2014-07-11",
          "rr_end": "2014-07-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2014-05-27T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Olysio",
          "url": "http://www.ncpe.ie/drugs/simeprevir-olysio-in-combination-with-sofosbuvir/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Simeprevir (Olysio®)",
          "earliest": "2014-05-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/olysio",
          "eu_market": "2014-05-14T00:00:00",
          "id": 2507,
          "indication": "Simeprevir (Olysio®) is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients as part of a triple therapy regimen (co-administered with PegInterferon + Ribavirin) to treat hepatitis C virus (HCV) Genotypes 1 and 4 who are treatment naïve or have previously been treated.",
          "last_scrape": "2018-12-13T16:49:53",
          "latest": "2014-07-11T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-05-27, 2014-07-11",
          "rr_end": "2014-07-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended when used in triple therapy with peg-interferon and ribavirin",
          "rr_start": "2014-05-27T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Olysio",
          "url": "http://www.ncpe.ie/drugs/simeprevir-olysio/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb®)",
          "earliest": "2014-02-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2508,
          "indication": "Hyaneb® is particularly indicated in patients with cystic fibrosis and in patients with bronchiectasis.  Hyaneb® is classified as a medical device and carries a CE mark.",
          "last_scrape": "2018-12-13T16:50:00",
          "latest": "2014-03-19T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-02-10, 2014-03-19",
          "rr_end": "2014-03-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-02-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Hyaneb",
          "url": "http://www.ncpe.ie/drugs/sodium-chloride-70mgml-sodium-hyaluronate-1mgml-hyaneb/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Sodium Hyaluronate (Hyloforte® 0.2%)",
          "earliest": "2014-01-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2509,
          "indication": "Sodium Hyaluronate (Hyloforte® 0.2%) is indicated for the treatment of mild to moderate form of dry eye.",
          "last_scrape": "2018-12-13T16:50:06",
          "latest": "2014-01-27T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-01-15, 2014-01-27",
          "rr_end": "2014-01-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-01-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Hyloforte 0.2%",
          "url": "http://www.ncpe.ie/drugs/sodium-hyaluronate-hyloforte-0-2/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Sodium Hyaluronate (Hylotear® 0.1%)",
          "earliest": "2014-01-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2510,
          "indication": "Sodium Hyaluronate (Hylotear® 0.1%) is indicated for the treatment of mild to moderate form of dry eye.",
          "last_scrape": "2018-12-13T16:50:09",
          "latest": "2014-01-27T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-01-15, 2014-01-27",
          "rr_end": "2014-01-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-01-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Hylotear 0.1%",
          "url": "http://www.ncpe.ie/drugs/sodium-hyaluronate-hylotear-0-1/"
         },
         {
          "company": "Lucane",
          "drug_name": "Sodium phenylbutyrate (Pheburane®)",
          "earliest": "2013-07-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane",
          "eu_market": "2013-07-30T00:00:00",
          "id": 2511,
          "indication": "Sodium phenylbutyrate (Pheburane®) is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.",
          "last_scrape": "2018-12-13T16:50:15",
          "latest": "2013-08-06T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-07-17, 2013-08-06",
          "rr_end": "2013-08-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2013-07-17T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Carbamoyl-Phosphate Synthase I Deficiency Disease",
          "trade_name": "Pheburane",
          "url": "http://www.ncpe.ie/drugs/sodium-phenylbutyrate-pheburane/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Sofosbuvir (Solvaldi®)",
          "earliest": "2014-02-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13",
          "eu_market": "2009-12-09T00:00:00",
          "id": 2512,
          "indication": "Sofosbuvir (Solvaldi®) is indicated in combination with other medicinal products for the treatment of Chronic Hepatitis C in adults.",
          "last_scrape": "2018-12-13T16:50:18",
          "latest": "2014-10-24T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-02-12, 2014-03-10",
          "rr_end": "2014-03-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-02-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Pneumococcal Infections; Immunization",
          "trade_name": "Solvaldi",
          "url": "http://www.ncpe.ie/drugs/sofosbuvir-solvaldi/"
         },
         {
          "company": "Gilead",
          "drug_name": "Sofosbuvir/Velpatasvir (Epclusa®) chronic hepatitis C virus (HCV) – pangenotypic",
          "earliest": "2017-09-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa",
          "eu_market": "2016-07-06T00:00:00",
          "id": 2513,
          "indication": "Sofosbuvir/velpatasvir (Epclusa®) for the treatment of chronic hepatitis C virus (HCV) infection in adults. This indication covers all genotypes (GT1, 2, 3, 4, 5 and 6) i.e. pangenotypic.",
          "last_scrape": "2018-12-13T16:50:22",
          "latest": "2017-10-19T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-09-05, 2017-10-19",
          "rr_end": "2017-10-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_start": "2017-09-05T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Epclusa",
          "url": "http://www.ncpe.ie/drugs/sofosbuvirvelpatasvir-epclusa-chronic-hepatitis-c-virus-hcv-pangenotypic/"
         },
         {
          "company": "Gilead",
          "drug_name": "Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®)",
          "earliest": "2017-09-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi",
          "eu_market": "2017-07-26T00:00:00",
          "id": 2514,
          "indication": "Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®) is indicated the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic i.e. all genotypes (GT1, 2, 3, 4, 5 and 6).",
          "last_scrape": "2018-12-13T16:50:26",
          "latest": "2017-11-15T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-09-19, 2017-11-15",
          "rr_end": "2017-11-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_start": "2017-09-19T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Vosevi",
          "url": "http://www.ncpe.ie/drugs/sofosbuvirvelpatasvirvoxilaprevir-vosevi/"
         },
         {
          "company": "CIS",
          "drug_name": "St Johns Wort (Pacifa®)",
          "earliest": "2015-04-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2515,
          "indication": "Pacifa® is indicated for the short term treatment of mild depressive symptoms.",
          "last_scrape": "2018-12-13T16:50:32",
          "latest": "2015-05-29T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-04-14, 2015-05-29",
          "rr_end": "2015-05-29T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-04-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Pacifa",
          "url": "http://www.ncpe.ie/drugs/st-johns-wort-pafica/"
         },
         {
          "company": "Biocodex",
          "drug_name": "Stiripentol (Diacomit®)",
          "earliest": "2017-07-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit",
          "eu_market": "2007-01-03T00:00:00",
          "id": 2516,
          "indication": "Stiripentol (Diacomit®) for use in conjunction with clobazam and valproate as adjunctive therapy of\nrefractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy\n(SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and\nvalproate",
          "last_scrape": "2018-12-13T16:50:38",
          "latest": "2018-10-19T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-07-06, 2017-08-10",
          "rr_end": "2017-08-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-07-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Myoclonic Epilepsy, Juvenile",
          "trade_name": "Diacomit",
          "url": "http://www.ncpe.ie/drugs/stiripentol-diacomit/"
         },
         {
          "company": "Gilead",
          "drug_name": "Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild®)",
          "earliest": "2013-04-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/stribild",
          "eu_market": "2013-05-24T00:00:00",
          "id": 2517,
          "indication": "Indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®.",
          "last_scrape": "2018-12-13T16:50:43",
          "latest": "2013-12-06T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-04-28, 2013-05-17",
          "rr_end": "2013-05-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-04-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "HIV Infections",
          "trade_name": "Stribild",
          "url": "http://www.ncpe.ie/drugs/stribild-elvitegravircobicistatemtricitabinetenofovir-disoproxil-as-fumarate/"
         },
         {
          "company": "CIS",
          "drug_name": "Sublingual Immunotherapy (Grazax®)",
          "earliest": "2007-09-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2518,
          "indication": "A Review of the Cost-Effectiveness of Sublingual Immunotherapy (Grazax®) for the Prevention of Seasonal Grass Pollen-Induced Rhinoconjunctivitis.",
          "last_scrape": "2018-12-13T16:50:49",
          "latest": "2007-09-01T00:00:00",
          "ncpe_year": 2007,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-05-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2013-04-15T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Grazax",
          "url": "http://www.ncpe.ie/drugs/sublingual-immunotherapy-grazax/"
         },
         {
          "company": "Indivior",
          "drug_name": "Buprenorphine/naloxone (Suboxone®)",
          "earliest": "2007-11-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone",
          "eu_market": "2006-09-26T00:00:00",
          "id": 2519,
          "indication": "An economic evaluation of suboxone for the management of opiate addiction.",
          "last_scrape": "2018-12-13T16:50:50",
          "latest": "2014-05-22T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-05-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2013-04-15T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Opioid-Related Disorders",
          "trade_name": "Suboxone",
          "url": "http://www.ncpe.ie/drugs/suboxone-buprenorphinenaloxone/"
         },
         {
          "company": "Grünenthal",
          "drug_name": "Sufentanil (Zalviso®)",
          "earliest": "2016-03-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zalviso",
          "eu_market": "2015-09-18T00:00:00",
          "id": 2520,
          "indication": "Sufentanil (Zalviso®) is indicated for the management of acute moderate to severe post-operative pain in adult patients.",
          "last_scrape": "2018-12-13T16:50:54",
          "latest": "2018-06-27T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-03-14, 2016-03-22",
          "rr_end": "2016-03-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-03-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Pain, Postoperative",
          "trade_name": "Zalviso",
          "url": "http://www.ncpe.ie/drugs/sufentanil-zalviso/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Sunitinib (Sutent®)",
          "earliest": "2006-09-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/sutent",
          "eu_market": "2006-07-19T00:00:00",
          "id": 2521,
          "indication": "In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours (GIST). Data on the cost-effectiveness and budget impact of sutinitinib as second line treatment for patients with metastatic renal cell carcinoma (mRCC) was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.",
          "last_scrape": "2018-12-13T16:50:59",
          "latest": "2006-09-01T00:00:00",
          "ncpe_year": 2006,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2016-03-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2016-02-19T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors",
          "trade_name": "Sutent",
          "url": "http://www.ncpe.ie/drugs/sunitinib-sutent/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Tadalafil (Adcirca®)",
          "earliest": "2011-07-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2522,
          "indication": "Tadalafil (Adcirca®) is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as World Health Organisation (WHO) Functional Class (FC) II and III, to improve exercise capacity.",
          "last_scrape": "2018-12-13T16:51:04",
          "latest": "2014-05-23T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23",
          "rr_end": "2014-05-23T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-07-13T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Adcirca",
          "url": "http://www.ncpe.ie/drugs/tadalafil-adcirca-2/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Tafamadis meglumine (Vyndaqel®)",
          "earliest": "2018-03-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel",
          "eu_market": "2011-11-16T00:00:00",
          "id": 2523,
          "indication": "Tafamadis meglumine (Vyndaqel®) for the treatment of transthyretin amyloidosis in adult patients with stage I symptomatic polyneuropathy to delay peripheral neurologic impairment.",
          "last_scrape": "2018-12-13T16:51:09",
          "latest": "2018-05-10T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-03-12, 2018-05-10",
          "rr_end": "2018-05-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is not recommended until additional efficacy and/or safety data is submitted on the basis of current evidence, the ncpe recommends that tafamidis not be considered for reimbursement in accordance with the criteria specified in the health (pricing and supply of medical goods) act 2013",
          "rr_start": "2018-03-12T00:00:00",
          "rr_status": "No HTA until more evidence",
          "ta_list": "Amyloidosis",
          "trade_name": "Vyndaqel",
          "url": "http://www.ncpe.ie/drugs/tafamadis-meglumine-vyndaqel/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Tafluprost (Saflutan®)",
          "earliest": "2011-03-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2524,
          "indication": "Tafluoprost (Salflutan®) for the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension.",
          "last_scrape": "2018-12-13T16:51:15",
          "latest": "2011-03-25T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-03-11, 2011-03-25",
          "rr_end": "2011-03-25T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2011-03-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Saflutan",
          "url": "http://www.ncpe.ie/drugs/tafluprost-saflutan/"
         },
         {
          "company": "Amgen",
          "drug_name": "Talimogene Laherparepvec (Imlygic®)",
          "earliest": "2016-02-16T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic",
          "eu_market": "2015-12-16T00:00:00",
          "id": 2525,
          "indication": "Talimogene laherparepvec (Imlygic®) is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.",
          "last_scrape": "2018-12-13T16:51:24",
          "latest": "2016-03-14T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-02-16, 2016-03-14",
          "rr_end": "2016-03-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-02-16T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma",
          "trade_name": "Imlygic",
          "url": "http://www.ncpe.ie/drugs/talimogene-laherparepvec-imlygic/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Tapentadol (Palexia®)",
          "earliest": "2010-10-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2526,
          "indication": "Economic evaluation of oral tapentadol (Palexia®) for the management of adult patients with severe chronic/acute pain.",
          "last_scrape": "2018-12-13T16:51:28",
          "latest": "2011-04-08T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2010-10-19, 2010-10-22",
          "rr_end": "2010-10-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2010-10-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Palexia",
          "url": "http://www.ncpe.ie/drugs/tapentadol-palexia/"
         },
         {
          "company": "Merck",
          "drug_name": "Tedizolid phosphate (Sivextro®)",
          "earliest": "2015-05-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro",
          "eu_market": "2015-03-23T00:00:00",
          "id": 2527,
          "indication": "Tedizolid phosphate (Sivextro®) is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults",
          "last_scrape": "2018-12-13T16:51:34",
          "latest": "2015-07-07T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-05-07, 2015-07-07",
          "rr_end": "2015-07-07T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2015-05-07T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Soft Tissue Infections; Skin Diseases, Bacterial",
          "trade_name": "Sivextro",
          "url": "http://www.ncpe.ie/drugs/tedizolid-phosphate-sivextro/"
         },
         {
          "company": "Shire",
          "drug_name": "Teduglutide (Revestive®)",
          "earliest": "2017-03-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/revestive",
          "eu_market": "2012-08-30T00:00:00",
          "id": 2528,
          "indication": "Teduglutide (Revestive®) is indicated for the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation.",
          "last_scrape": "2018-12-13T16:51:38",
          "latest": "2018-03-16T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-03-13, 2017-04-12",
          "rr_end": "2017-04-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2017-03-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Malabsorption Syndromes",
          "trade_name": "Revestive",
          "url": "http://www.ncpe.ie/drugs/teduglutide-revestive/"
         },
         {
          "company": "Nordic",
          "drug_name": "Tegafur/Gimeracil/Oteracil (Teysuno®)",
          "earliest": "2012-02-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno",
          "eu_market": "2011-03-14T00:00:00",
          "id": 2529,
          "indication": "Teysuno is indicated in adults for the treatment of advanced gastric cancer.",
          "last_scrape": "2018-12-13T16:51:44",
          "latest": "2012-03-23T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-02-27, 2012-03-23",
          "rr_end": "2012-03-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2012-02-27T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Stomach Neoplasms",
          "trade_name": "Teysuno",
          "url": "http://www.ncpe.ie/drugs/tegafurgimeraciloteracil-teysuno/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Telaprevir (Incivo®)",
          "earliest": "2011-10-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/incivo",
          "eu_market": "2011-09-19T00:00:00",
          "id": 2530,
          "indication": "Economic evaluation of Telaprevir (Incivo®) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.",
          "last_scrape": "2018-12-13T16:51:48",
          "latest": "2012-01-19T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-10-28, 2011-11-02",
          "rr_end": "2011-11-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-10-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Incivo",
          "url": "http://www.ncpe.ie/drugs/telapravir/"
         },
         {
          "company": "Theravance",
          "drug_name": "Telavancin (Vibativ®)",
          "earliest": "2014-12-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vibativ-0",
          "eu_market": "2011-09-02T00:00:00",
          "id": 2531,
          "indication": "Indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA).  Vabitiv® should be used only in situations where it is known or suspected that other alternatives are not suitable.",
          "last_scrape": "2018-12-13T16:51:52",
          "latest": "2015-01-13T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-12-08, 2015-01-13",
          "rr_end": "2015-01-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-12-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Pneumonia, Bacterial; Cross Infection",
          "trade_name": "Vibativ",
          "url": "http://www.ncpe.ie/drugs/telavancin-vibativ/"
         },
         {
          "company": "Sanofi-aventis",
          "drug_name": "Teriflunomide (Aubagio®)",
          "earliest": "2013-08-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio",
          "eu_market": "2013-08-26T00:00:00",
          "id": 2532,
          "indication": "Aubagio® is indicated for the first line treatment of adult patients with relapsing remitting multiple sclerosis (MS).",
          "last_scrape": "2018-12-13T16:51:56",
          "latest": "2014-09-05T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-08-27, 2013-09-20",
          "rr_end": "2013-09-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-08-27T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Aubagio",
          "url": "http://www.ncpe.ie/drugs/teriflunomide-aubagio/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Ticagrelor (Brilique®)",
          "earliest": "2016-02-29T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/brilique",
          "eu_market": "2010-12-03T00:00:00",
          "id": 2533,
          "indication": "Ticagrelor (Brilique®) 60mg, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.",
          "last_scrape": "2018-12-13T16:51:58",
          "latest": "2016-05-04T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-02-29, 2016-05-04",
          "rr_end": "2016-05-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2016-02-29T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Peripheral Vascular Diseases; Acute Coronary Syndrome",
          "trade_name": "Brilique",
          "url": "http://www.ncpe.ie/drugs/ticagrelor-brilique-2/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Ticagrelor (Brilique®)",
          "earliest": "2010-11-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/brilique",
          "eu_market": "2010-12-03T00:00:00",
          "id": 2534,
          "indication": "Economic Evaluation of Ticagrelor (Brilique®) for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndrome (ACS) including patients managed medically, and those who are managed with PCI (Percutaneous Coronary Intervention) or CABG (Coronary Artery Bypass Graft).",
          "last_scrape": "2018-12-13T16:52:01",
          "latest": "2011-10-10T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2010-11-25, 2011-01-20",
          "rr_end": "2011-01-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2010-11-25T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Peripheral Vascular Diseases; Acute Coronary Syndrome",
          "trade_name": "Brilique",
          "url": "http://www.ncpe.ie/drugs/ticagrelor-brilique/"
         },
         {
          "company": "Novartis",
          "drug_name": "Tisagenlecleucel (Kymriah®) for ALL",
          "earliest": "2018-09-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah",
          "eu_market": "2018-08-22T00:00:00",
          "id": 2535,
          "indication": "Tisagenlecleucel (Kymriah®) for the treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.",
          "last_scrape": "2018-12-13T16:52:07",
          "latest": "2018-10-19T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-09-19, 2018-10-19",
          "rr_end": "2018-10-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care",
          "rr_start": "2018-09-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse",
          "trade_name": "Kymriah",
          "url": "http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-all/"
         },
         {
          "company": "Novartis",
          "drug_name": "Tisagenlecleucel (Kymriah®) for DLBCL",
          "earliest": "2018-09-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah",
          "eu_market": "2018-08-22T00:00:00",
          "id": 2536,
          "indication": "Tisagenlecleucel (Kymriah®) which is licensed for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.",
          "last_scrape": "2018-12-13T16:52:13",
          "latest": "2018-10-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-09-19, 2018-10-18",
          "rr_end": "2018-10-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care",
          "rr_start": "2018-09-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse",
          "trade_name": "Kymriah",
          "url": "http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-dlbcl/"
         },
         {
          "company": "CIS",
          "drug_name": "Tobramycin (TOBI Podhaler®)",
          "earliest": "2010-11-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2537,
          "indication": "Tobramycin (TOBI Podhaler®) for the suppressive therapy of chronic pulmonary infection due to Ps aeruginosa in adults and children aged 6 years and older with CF.",
          "last_scrape": "2018-12-13T16:52:19",
          "latest": "2010-11-03T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-11-10, 2010-11-03",
          "rr_end": "2010-11-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2010-11-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "TOBI Podhaler",
          "url": "http://www.ncpe.ie/drugs/tobramycin-tobi-podhaler/"
         },
         {
          "company": "Roche",
          "drug_name": "Tocilizumab SC (RoActemra®)",
          "earliest": "2014-04-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra",
          "eu_market": "2009-01-15T00:00:00",
          "id": 2538,
          "indication": "It is licensed for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.",
          "last_scrape": "2018-12-13T16:52:24",
          "latest": "2014-07-16T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-04-28, 2014-07-16",
          "rr_end": "2014-07-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at thesubmitted price",
          "rr_start": "2014-04-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid",
          "trade_name": "RoActemra",
          "url": "http://www.ncpe.ie/drugs/tocilizumab-sc-roactemra/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Tofacitinib (Xeljanz®) for Ulcerative Colitis",
          "earliest": "2018-07-16T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz",
          "eu_market": "2017-03-21T00:00:00",
          "id": 2539,
          "indication": "Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor).",
          "last_scrape": "2018-12-13T16:52:30",
          "latest": "2018-09-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-07-16, 2018-09-18",
          "rr_end": "2018-09-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of tofacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies",
          "rr_start": "2018-07-16T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Rheumatoid",
          "trade_name": "Xeljanz",
          "url": "http://www.ncpe.ie/drugs/tofacitinib-xeljanz-for-ulcerative-colitis/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Tofacitinib (Xeljanz®)",
          "earliest": "2017-03-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz",
          "eu_market": "2017-03-21T00:00:00",
          "id": 2540,
          "indication": "Tofacitinib (Xeljanz®) in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drug. Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.",
          "last_scrape": "2018-12-13T16:52:35",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-03-08, 2017-04-28",
          "rr_end": "2017-04-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2017-03-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Rheumatoid",
          "trade_name": "Xeljanz",
          "url": "http://www.ncpe.ie/drugs/tofacitinib-xeljanz/"
         },
         {
          "company": "Otsuka",
          "drug_name": "Tolvaptan (Jinarc®)",
          "earliest": "2016-01-04T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc",
          "eu_market": "2015-05-27T00:00:00",
          "id": 2541,
          "indication": "Jinarc®) to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1-3 at initiation of treatment with evidence of rapidly progressing disease.",
          "last_scrape": "2018-12-13T16:52:40",
          "latest": "2018-09-13T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-01-04, 2016-01-12",
          "rr_end": "2016-01-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_start": "2016-01-04T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Polycystic Kidney, Autosomal Dominant",
          "trade_name": "Jinarc",
          "url": "http://www.ncpe.ie/drugs/tolvaptan-jinarc/"
         },
         {
          "company": "CIS",
          "drug_name": "Tramadol hydrochloride/dexketoprofen (Skudexa®)",
          "earliest": "2017-10-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2542,
          "indication": "Tramadol hydrochloride/dexketoprofen (Skudexa ®) for the symptomatic short-term treatment of moderate to severe acute pain in adult patients whose pain is considered to require a combination of tramadol and dexketoprofen.",
          "last_scrape": "2018-12-13T16:52:45",
          "latest": "2017-12-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-10-17, 2017-12-01",
          "rr_end": "2017-12-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "reimursement not recommended at the submitted price",
          "rr_start": "2017-10-17T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Skudexa",
          "url": "http://www.ncpe.ie/drugs/tramadol-hydrochloridedexketoprofen-skudexa/"
         },
         {
          "company": "Novartis",
          "drug_name": "Trametinib (Mekinist®)",
          "earliest": "2015-11-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist",
          "eu_market": "2014-06-30T00:00:00",
          "id": 2543,
          "indication": "Mekinist® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
          "last_scrape": "2018-12-13T16:52:51",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2015-11-27, 2015-12-22",
          "rr_end": "2015-12-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2015-11-27T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma",
          "trade_name": "Mekinist",
          "url": "http://www.ncpe.ie/drugs/trametinib-mekinist/"
         },
         {
          "company": "Roche",
          "drug_name": "Trastuzumab emtansine (Kadcyla®)",
          "earliest": "2013-09-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla",
          "eu_market": "2013-11-15T00:00:00",
          "id": 2544,
          "indication": "Trastuzumab emtansine (Kadcyla®) is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination.",
          "last_scrape": "2018-12-13T16:52:56",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2013-09-25, 2013-10-24",
          "rr_end": "2013-10-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-09-25T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Kadcyla",
          "url": "http://www.ncpe.ie/drugs/trastuzumab-emtansine-kadcyla/"
         },
         {
          "company": "Les",
          "drug_name": "Trifluridine/tipiracil (Lonsurf®)",
          "earliest": "2016-06-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf",
          "eu_market": "2016-04-25T00:00:00",
          "id": 2545,
          "indication": "Trifluridine/tipiracil (Lonsurf®) is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.",
          "last_scrape": "2018-12-13T16:53:00",
          "latest": "2016-07-11T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-06-10, 2016-07-11",
          "rr_end": "2016-07-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2016-06-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Colorectal Neoplasms",
          "trade_name": "Lonsurf",
          "url": "http://www.ncpe.ie/drugs/trifluridinetipiracil-lonsurf/"
         },
         {
          "company": "Gedeon",
          "drug_name": "Ulipristal acetate (Esmya ®) intermittent treatment",
          "earliest": "2016-05-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/esmya",
          "eu_market": "2012-02-22T00:00:00",
          "id": 2546,
          "indication": "Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.",
          "last_scrape": "2018-12-13T16:53:04",
          "latest": "2016-05-31T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-05-17, 2016-05-31",
          "rr_end": "2016-05-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2016-05-17T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Leiomyoma",
          "trade_name": "Esmya",
          "url": "http://www.ncpe.ie/drugs/ulipristal-acetate-esmya-2/"
         },
         {
          "company": "Gedeon",
          "drug_name": "Ulipristal acetate (Esmya®) single course treatment",
          "earliest": "2013-09-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/esmya",
          "eu_market": "2012-02-22T00:00:00",
          "id": 2547,
          "indication": "Ulipristal acetate (Esmya®) is indicated for the pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.",
          "last_scrape": "2018-12-13T16:53:08",
          "latest": "2013-10-18T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-09-03, 2013-10-18",
          "rr_end": "2013-10-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2013-09-03T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Leiomyoma",
          "trade_name": "Esmya",
          "url": "http://www.ncpe.ie/drugs/ulipristal-acetate-esmya/"
         },
         {
          "company": "CIS",
          "drug_name": "Umeclidinium/vilanterol (Anoro®)",
          "earliest": "2014-06-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2548,
          "indication": "Umeclidinium/vilanterol (Anoro®) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.",
          "last_scrape": "2018-12-13T16:53:10",
          "latest": "2014-07-10T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-06-11, 2014-07-10",
          "rr_end": "2014-07-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_start": "2014-06-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Anoro",
          "url": "http://www.ncpe.ie/drugs/umeclidiniumvilanterol-anoro/"
         },
         {
          "company": "Unknown",
          "drug_name": "Urea (GlucoRx Allpresan®)",
          "earliest": "2018-07-09T00:00:00",
          "ema_url": "",
          "eu_market": "2015-07-22T00:00:00",
          "id": 2549,
          "indication": "GlucoRx Allpresan® Diabetic Foam Cream for the treatment of dry and sensitive foot skin (Basic) and very dry to chapped foot skin (Intensive) in patients with Diabetes Mellitus.",
          "last_scrape": "2018-12-13T16:53:12",
          "latest": "2018-07-24T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-07-09, 2018-07-24",
          "rr_end": "2018-07-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is not recommended the ncpe recommends that glucorx allpresan diabetic foam cream not be considered for reimbursement at the submitted price in accordance with the criteria specified in the health (pricing and supply of medical goods) act 2013",
          "rr_start": "2018-07-09T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "Unknown",
          "trade_name": "GlucoRx Allpresan",
          "url": "http://www.ncpe.ie/drugs/urea-glucorx-allpresan/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Ustekinumab (Stelara®) for Crohn’s Disease",
          "earliest": "2016-11-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/stelara",
          "eu_market": "2009-01-15T00:00:00",
          "id": 2550,
          "indication": "Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist or have medical contraindications to such therapies",
          "last_scrape": "2018-12-13T16:53:17",
          "latest": "2017-11-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-11-28, 2017-01-11",
          "rr_end": "2017-01-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_start": "2016-11-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Psoriasis; Arthritis, Psoriatic; Crohn Disease",
          "trade_name": "Stelara",
          "url": "http://www.ncpe.ie/drugs/ustekinumab-stelara-2/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Ustekinumab (Stelara®)",
          "earliest": "2009-07-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/stelara",
          "eu_market": "2009-01-15T00:00:00",
          "id": 2551,
          "indication": "Cost-effectiveness of Ustekinumab (Stelara®) in the treament of moderate to severe psoriasis.",
          "last_scrape": "2018-12-13T16:53:23",
          "latest": "2009-11-01T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-01-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_start": "2016-12-10T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Psoriasis; Arthritis, Psoriatic; Crohn Disease",
          "trade_name": "Stelara",
          "url": "http://www.ncpe.ie/drugs/ustekinumab-stelara/"
         },
         {
          "company": "Genzyme",
          "drug_name": "Vandetanib (Caprelsa®)",
          "earliest": "2013-06-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa",
          "eu_market": "2012-02-16T00:00:00",
          "id": 2552,
          "indication": "Vandetanib (Caprelsa®) for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.",
          "last_scrape": "2018-12-13T16:53:29",
          "latest": "2013-07-03T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-06-06, 2013-07-03",
          "rr_end": "2013-07-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-06-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Thyroid Neoplasms",
          "trade_name": "Caprelsa",
          "url": "http://www.ncpe.ie/drugs/vandetanib-caprelsa/"
         },
         {
          "company": "Takeda",
          "drug_name": "Vedolizumab (Entyvio®) in Crohn’s Disease",
          "earliest": "2014-09-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio",
          "eu_market": "2014-05-22T00:00:00",
          "id": 2553,
          "indication": "Vedolizumab (Entyvio®) indicated for the treatment of adult patients with moderately toseverely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.",
          "last_scrape": "2018-12-13T16:53:32",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2014-09-12, 2014-10-01",
          "rr_end": "2014-10-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-09-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Colitis, Ulcerative; Crohn Disease",
          "trade_name": "Entyvio",
          "url": "http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-crohns-disease/"
         },
         {
          "company": "Takeda",
          "drug_name": "Vedolizumab (Entyvio®) in Ulcerative Colitis",
          "earliest": "2014-09-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio",
          "eu_market": "2014-05-22T00:00:00",
          "id": 2554,
          "indication": "Vedolizumab (Entyvio®) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.",
          "last_scrape": "2018-12-13T16:53:39",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2014-09-12, 2014-10-01",
          "rr_end": "2014-10-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-09-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Colitis, Ulcerative; Crohn Disease",
          "trade_name": "Entyvio",
          "url": "http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-ulcerative-colitis/"
         },
         {
          "company": "CIS",
          "drug_name": "Velaglucerase Alfa (VPRIV®)",
          "earliest": "2011-04-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2555,
          "indication": "VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.",
          "last_scrape": "2018-12-13T16:53:45",
          "latest": "2011-06-20T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-04-26, 2011-06-20",
          "rr_end": "2011-06-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-04-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "VPRIV",
          "url": "http://www.ncpe.ie/drugs/velaglucerase-alfa-vpriv-2/"
         },
         {
          "company": "AbbVie",
          "drug_name": "Venetoclax (Venclyxto®) in combination with rituximab",
          "earliest": "2018-09-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto",
          "eu_market": "2016-12-04T00:00:00",
          "id": 2556,
          "indication": "Venetoclax (Venclyxto®) in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.",
          "last_scrape": "2018-12-13T16:53:49",
          "latest": "2018-10-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-09-26, 2018-10-18",
          "rr_end": "2018-10-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax compared with the current standard of care",
          "rr_start": "2018-09-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Venclyxto",
          "url": "http://www.ncpe.ie/drugs/venetoclax-venclyxto-in-combination-with-rituximab/"
         },
         {
          "company": "AbbVie",
          "drug_name": "Venetoclax (Venclyxto®)",
          "earliest": "2017-01-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto",
          "eu_market": "2016-12-04T00:00:00",
          "id": 2557,
          "indication": "Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL)",
          "last_scrape": "2018-12-13T16:53:52",
          "latest": "2018-12-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-05-08, 2018-06-21",
          "rr_end": "2018-06-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "following a resubmission of the rapid review full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies",
          "rr_start": "2018-05-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Venclyxto",
          "url": "http://www.ncpe.ie/drugs/venetoclax-venclyxto/"
         },
         {
          "company": "Roche",
          "drug_name": "Vemurafenib (Zelboraf®)",
          "earliest": "2011-12-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf",
          "eu_market": "2012-02-17T00:00:00",
          "id": 2558,
          "indication": "Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.",
          "last_scrape": "2018-12-13T16:53:58",
          "latest": "2014-09-01T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2011-12-23, 2012-01-04",
          "rr_end": "2012-01-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2011-12-23T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma",
          "trade_name": "Zelboraf",
          "url": "http://www.ncpe.ie/drugs/vermurafenib-zelboraf/"
         },
         {
          "company": "Cardiome",
          "drug_name": "Vernakalant (Brinavess®)",
          "earliest": "2010-10-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess",
          "eu_market": "2010-09-01T00:00:00",
          "id": 2559,
          "indication": "Economic evaluation of Vernakalant (Brinavess®) for haemodynamically stable, symptomatic patients with atrial fibrillation of less than 48 hours duration.",
          "last_scrape": "2018-12-13T16:54:00",
          "latest": "2011-05-04T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2010-10-26, 2010-11-04",
          "rr_end": "2010-11-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2010-10-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Atrial Fibrillation",
          "trade_name": "Brinavess",
          "url": "http://www.ncpe.ie/drugs/vernakalant-brinavess/"
         },
         {
          "company": "Roche",
          "drug_name": "Vismodegib (Erivedge®)",
          "earliest": "2013-05-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge",
          "eu_market": "2013-07-12T00:00:00",
          "id": 2560,
          "indication": "Vismodegib (Erivedge®) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy or metastatic basal cell carcinoma.",
          "last_scrape": "2018-12-13T16:54:04",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2013-05-02, 2013-05-20",
          "rr_end": "2013-05-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2013-05-02T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Basal Cell",
          "trade_name": "Erivedge",
          "url": "http://www.ncpe.ie/drugs/vismodegib-erivedge/"
         },
         {
          "company": "Lundbeck",
          "drug_name": "Vortioxetine (Brintellix®)",
          "earliest": "2014-10-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix",
          "eu_market": "2013-12-18T00:00:00",
          "id": 2561,
          "indication": "Vortioxetine (Brintellix®) is indicated for the treatment of major depressive episodes in adults.",
          "last_scrape": "2018-12-13T16:54:11",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2014-10-01, 2014-11-14",
          "rr_end": "2014-11-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_start": "2014-10-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Depressive Disorder, Major",
          "trade_name": "Brintellix",
          "url": "http://www.ncpe.ie/drugs/vortioxetine-brintellix/"
         }
        ]
       },
       "encoding": {
        "x": {
         "field": "ncpe_year",
         "type": "quantitative"
        },
        "y": {
         "aggregate": "count",
         "type": "quantitative"
        }
       },
       "mark": {
        "color": "green",
        "type": "bar"
       }
      },
      "image/png": "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",
      "text/plain": [
       "<VegaLite 2 object>\n",
       "\n",
       "If you see this message, it means the renderer has not been properly enabled\n",
       "for the frontend that you are using. For more information, see\n",
       "https://altair-viz.github.io/user_guide/troubleshooting.html\n"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "alt.Chart(df).mark_bar(color='green').encode(\n",
    "    x= alt.X('ncpe_year'),\n",
    "    y= 'count()')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Reason for Visualization 1:\n",
    "This graph is important since it provides a rough idea of how many drugs were present in NCPE database for all the years. \n",
    "\n",
    "\n",
    "##### Information obtained from Visualization 1:\n",
    "It is observed that the No.of drugs were inreasing from 2004 to 2018. There is a slight decrease in the year - 2016. The year - 2018 has highest number of drugs found in NCPE Database"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### 2) Top 5 Medical Symptoms for which the manufacturers(pharamaceutical companies) had submitted their medicines for approval by NCPE"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Plotting Type : Seaborn Barplot"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The value - \"Unknown\" is also present in the column - 'ta_list'. Therefore, it is removed while plotting"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 792x576 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sns.set(style=\"whitegrid\")\n",
    "ta_list_count  = df['ta_list'].value_counts()\n",
    "ta_list_count = ta_list_count[:6,]\n",
    "ta_list_count = ta_list_count.drop('Unknown')\n",
    "plt.figure(figsize=(11,8))\n",
    "sns.barplot(ta_list_count.values, ta_list_count.index, alpha=1,palette=(\"Paired\"))\n",
    "plt.title('Top 5 Common diseases for which medicines were submitted to NCPE', fontsize=22)\n",
    "plt.xlabel('Number of Occurrences', size=\"20\")\n",
    "plt.ylabel('Disease Type', size=\"20\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Reason for Visualization 2:\n",
    "When I found the distinct entries in the column - 'ta_list', it looked like a disease names. So, I wanted to see the most common diseases for which the drugs were found in NCPE database.\n",
    "\n",
    "\n",
    "##### Information obtained from Visualization 2:\n",
    "On an overall basis, Many Companies have applied for liscence from NCPE for critical diseases such as Influenza, Radionuclide Imaging, Hepatitis followed by HIV Infections and Multiple Sclerosis. This conveys that those medicines were highly in demand and it led to the spike in the production of new medicines for those diseases and thereby obtain approval from NCPE"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### 3) Company-wise percentage of total drugs in NCPE Database"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Plotting Type : Matplotlib pie chart"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Select Top 8 companies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "company_count = df['company'].value_counts()[:8]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Get rest of the Companies other than top 8"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "top_others_company_count = df['company'].value_counts()[8:]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Taking the Sum of counts of other companies and adding as 'Others' to the series"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "sum_of_others = np.sum(top_others_company_count.values)\n",
    "s1 = pd.Series([sum_of_others], index=['Others'])\n",
    "company_count = company_count.append(s1)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "dropping 'Unknown' company name"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "company_count = company_count.drop('Unknown')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Plotting the company-wise percentage of drugs in NCPE Database"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from matplotlib import cm\n",
    "labels = company_count.index\n",
    "sizes = company_count.values\n",
    "fig1, ax1 = plt.subplots()\n",
    "ax1.pie(sizes, labels=labels, autopct='%1.1f%%',\n",
    "        shadow=True, startangle=90)\n",
    "ax1.axis('equal')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Reason for Visualization 3:\n",
    "I wanted to see the distribution of pharameceutial companies found in NCPE database. This will help to understand the top companies which applied for NCPE liscence.\n",
    "\n",
    "##### Information obtained from Visualization 3:\n",
    "This chart shows that 'Novartis' had the higest number of drugs submitted to NCPE followed by 'GlaxoSmithKline' and 'Pfizer'. Although, 'GlaxoSmithKline' and 'Pfizer' are large companies, they only contribute below 10% of the total drugs in NCPE Database. This denotes that there are many small players (about 58%) in the pharameceutial field who contribute less than 4.4% individually."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### 4) Year-wise Comparision of RR Outcome Results"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Plotting Type : Matplotlib stacked bar chart"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "I wanted to see how many drugs were recommended by NCPE for the different years. </br>\n",
    "\n",
    "<strong>Challenge</strong> - The field 'rr_outcome' has free flow text. Therefore, I used the below logic which will convert them for my graph."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "A new column - 'rr_outcome_type' is added. Below is the logic for populating the new column <br/>\n",
    "\n",
    "If 'rr_outcome' doesn't contain word 'not recommended', the value will be populated as 'True', else 'False'will be populated"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['rr_outcome_type'] = ~df['rr_outcome'].str.contains('not recommended')\n",
    "df['rr_outcome_type'] = df['rr_outcome_type'].replace(False,'Not Recommended').replace(True,'Recommended')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x1a15f41be0>"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df2 = df.groupby(['ncpe_year','rr_outcome_type'])['ncpe_year'].count().unstack('rr_outcome_type').fillna(0)\n",
    "df2.plot(kind='bar', stacked=True, color=['red', 'green'])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Reason for Visualization 4:\n",
    "\n",
    "This is an important chart to understand what is the ratio of drugs that were approved/rejected by NCPE for various years.\n",
    "\n",
    "##### Information obtained from Visualization 4:\n",
    "Higher rejections are found in the years - 2011, 2013 and 2014. There is a gradual decrease in the number of rejections in the recent years. Pharamaceutical companies may have done rigorous tests (for their new drugs) in their labs before applying for NCPE liscence."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### 5) Find the distribution of medicines in NCPE database according to 'rr_status'"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "See the unique values in the column - 'rr_status' before doing the graph"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "HTA recommended at submitted price    224\n",
       "No HTA                                122\n",
       "RR not conducted                       32\n",
       "Reimbursement not recommended           7\n",
       "No HTA at submitted price               7\n",
       "Unknown                                 3\n",
       "Reimbursement without HTA               2\n",
       "No HTA until more evidence              1\n",
       "Name: rr_status, dtype: int64"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['rr_status'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.vegalite.v2+json": {
       "$schema": "https://vega.github.io/schema/vega-lite/v2.6.0.json",
       "config": {
        "view": {
         "height": 300,
         "width": 400
        }
       },
       "data": {
        "name": "data-b61cf69e9b69c7a70a850876fefe805a"
       },
       "datasets": {
        "data-b61cf69e9b69c7a70a850876fefe805a": [
         {
          "company": "",
          "drug_name": "Abatacept (Orencia®)",
          "earliest": "2012-11-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/orencia",
          "eu_market": "2007-05-21T00:00:00",
          "id": 2164,
          "indication": "Subcutaneous Abatacept (Orencia®) in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.",
          "last_scrape": "2018-12-13T16:24:32",
          "latest": "2015-11-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2012-11-28, 2012-12-21",
          "rr_end": "2012-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-11-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Unknown",
          "trade_name": "Orencia",
          "url": "http://www.ncpe.ie/drugs/abatacept-orencia/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Abiraterone acetate (Zytiga®) for mHSPC",
          "earliest": "2018-10-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga",
          "eu_market": "2011-09-05T00:00:00",
          "id": 2165,
          "indication": "Abiraterone acetate (Zytiga®) for the treatment of newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).",
          "last_scrape": "2018-12-13T16:24:36",
          "latest": "2018-11-15T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-10-03, 2018-11-15",
          "rr_end": "2018-11-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-10-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Zytiga",
          "url": "http://www.ncpe.ie/drugs/abiraterone-acetate-zytiga-for-mhspc/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Abiraterone acetate (Zytiga®) for mCRPC post ADT",
          "earliest": "2013-01-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga",
          "eu_market": "2011-09-05T00:00:00",
          "id": 2166,
          "indication": "Pharmacoeconomic evaluation of Abiratone acetate (Zytiga®) for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated",
          "last_scrape": "2018-12-13T16:24:41",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2013-01-03, 2013-02-01",
          "rr_end": "2013-02-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-01-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Zytiga",
          "url": "http://www.ncpe.ie/drugs/abiratone-acetate-zytiga-for-mcrpc-post-adt/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Abiraterone Acetate (Zytiga®) for mCRPC",
          "earliest": "2011-10-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga",
          "eu_market": "2011-09-05T00:00:00",
          "id": 2167,
          "indication": "Pharmacoeconomic evaluation and resource implications of Zytiga ® (abiraterone acetate) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel-based chemotherapy.",
          "last_scrape": "2018-12-13T16:24:46",
          "latest": "2014-04-01T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2011-10-21, 2011-11-02",
          "rr_end": "2011-11-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-10-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Zytiga",
          "url": "http://www.ncpe.ie/drugs/abiratone-acetate-zytiga/"
         },
         {
          "company": "Unknown",
          "drug_name": "Aceclofenac (Vitafen®)",
          "earliest": "2016-07-22T00:00:00",
          "ema_url": "",
          "eu_market": "2014-01-03T00:00:00",
          "id": 2168,
          "indication": "Aceclofenac (Vitafen®) is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.",
          "last_scrape": "2018-12-13T16:24:49",
          "latest": "2017-11-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-12-21, 2017-01-24",
          "rr_end": "2017-01-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "following a resubmission of the rapid review full pharmacoeconomic evaluation is recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-12-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Unknown",
          "trade_name": "Vitafen",
          "url": "http://www.ncpe.ie/drugs/aceclofenac-vitafen/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Aclidinium bromide (Eklira Genuair®)",
          "earliest": "2012-10-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair",
          "eu_market": "2012-07-20T00:00:00",
          "id": 2169,
          "indication": "Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)",
          "last_scrape": "2018-12-13T16:24:56",
          "latest": "2012-10-26T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-10-23, 2012-10-26",
          "rr_end": "2012-10-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2012-10-23T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Pulmonary Disease, Chronic Obstructive",
          "trade_name": "Eklira Genuair",
          "url": "http://www.ncpe.ie/drugs/aclidinium-bromide-eklira-genuair/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Aclidinium bromide / formoterol fumarate dihydrate (Brimica®  Genuair®)",
          "earliest": "2015-01-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair",
          "eu_market": "2014-11-19T00:00:00",
          "id": 2170,
          "indication": "Brimica® Genuair® is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.",
          "last_scrape": "2018-12-13T16:25:00",
          "latest": "2015-02-09T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-01-05, 2015-02-09",
          "rr_end": "2015-02-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-01-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Pulmonary Disease, Chronic Obstructive",
          "trade_name": "Brimica Genuair",
          "url": "http://www.ncpe.ie/drugs/aclidinium-bromide-formoterol-fumarate-dihydrate-brimica-genuair/"
         },
         {
          "company": "AbbVie",
          "drug_name": "Adalimumab (Humira®)",
          "earliest": "2011-05-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/humira",
          "eu_market": "2003-09-07T00:00:00",
          "id": 2171,
          "indication": "Economic evaluation of Adalimumab (Humira®) in combination with methotrexate for polyarticular juvenile idiopathic arthritis in children and adolescents (4-17yrs) in patients who have had an inadequate response to DMARDs.  Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate.",
          "last_scrape": "2018-12-13T16:25:37",
          "latest": "2011-06-02T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-05-20, 2011-06-02",
          "rr_end": "2011-06-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-05-20T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid",
          "trade_name": "Humira",
          "url": "http://www.ncpe.ie/drugs/adalimumab-humira/"
         },
         {
          "company": "Menarini",
          "drug_name": "Adenuric (Febuxostat®)",
          "earliest": "2009-12-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric",
          "eu_market": "2008-04-21T00:00:00",
          "id": 2172,
          "indication": "NCPE review of Adenuric (Febuxostat®) a xanthine oxidase inhibitor for the treatment of gout.",
          "last_scrape": "2018-12-13T16:25:40",
          "latest": "2009-12-08T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "2009-12-08",
          "rr_end": "2009-12-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2009-12-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Gout",
          "trade_name": "Febuxostat",
          "url": "http://www.ncpe.ie/drugs/adenuric-febuxostat/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Afatinib (Giotrif®)",
          "earliest": "2013-10-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif",
          "eu_market": "2013-09-25T00:00:00",
          "id": 2173,
          "indication": "GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).",
          "last_scrape": "2018-12-13T16:25:45",
          "latest": "2013-10-13T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-10-01, 2013-10-13",
          "rr_end": "2013-10-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-10-01T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Giotrif",
          "url": "http://www.ncpe.ie/drugs/afatinib-giotrif/"
         },
         {
          "company": "Bayer",
          "drug_name": "Aflibercept (Eylea®)",
          "earliest": "2012-12-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/eylea",
          "eu_market": "2012-11-21T00:00:00",
          "id": 2174,
          "indication": "Aflibercept (Eylea®) is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).",
          "last_scrape": "2018-12-13T16:25:49",
          "latest": "2012-12-21T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-12-10, 2012-12-21",
          "rr_end": "2012-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-12-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Wet Macular Degeneration; Macular Edema; Diabetes Complications",
          "trade_name": "Eylea",
          "url": "http://www.ncpe.ie/drugs/aflibercept-eylea/"
         },
         {
          "company": "Sanofi-Aventis",
          "drug_name": "Aflibercept (Zaltrap®)",
          "earliest": "2013-03-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zaltrap",
          "eu_market": "2013-02-01T00:00:00",
          "id": 2175,
          "indication": "Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.",
          "last_scrape": "2018-12-13T16:25:52",
          "latest": "2014-02-12T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-03-21, 2013-04-10",
          "rr_end": "2013-04-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-03-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Colorectal Neoplasms",
          "trade_name": "Zaltrap",
          "url": "http://www.ncpe.ie/drugs/aflibercept-zaltrap/"
         },
         {
          "company": "Les",
          "drug_name": "Agomelatine (Valdoxan®)",
          "earliest": "2009-09-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan",
          "eu_market": "2009-02-19T00:00:00",
          "id": 2176,
          "indication": "Economic evaluation of Agomelatine (Valdoxan®) for the treatment of major depressive disorder.",
          "last_scrape": "2018-12-13T16:25:58",
          "latest": "2009-12-11T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-04-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-03-09T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Depressive Disorder, Major",
          "trade_name": "Valdoxan",
          "url": "http://www.ncpe.ie/drugs/agomelatine-valdoxan-4/"
         },
         {
          "company": "Roche",
          "drug_name": "Alectinib (Alecensa®)",
          "earliest": "2017-01-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa",
          "eu_market": "2017-02-16T00:00:00",
          "id": 2177,
          "indication": "Alectinib (Alecensa ®) for the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with crizotinib.",
          "last_scrape": "2018-12-13T16:26:06",
          "latest": "2018-12-05T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04",
          "rr_end": "2017-12-04T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-01-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Alecensa",
          "url": "http://www.ncpe.ie/drugs/alectinib-alecensa/"
         },
         {
          "company": "Sanofi",
          "drug_name": "Alemtuzumab (Lemtrada®)",
          "earliest": "2013-11-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada",
          "eu_market": "2013-09-12T00:00:00",
          "id": 2178,
          "indication": "Alemtuzumab (Lemtrada®) is indicated for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features",
          "last_scrape": "2018-12-13T16:26:12",
          "latest": "2014-06-25T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-11-08, 2013-12-02",
          "rr_end": "2013-12-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-11-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Lemtrada",
          "url": "http://www.ncpe.ie/drugs/alemtuzumab-lemtrada/"
         },
         {
          "company": "sanofi-aventis",
          "drug_name": "Alirocumab (Praluent®)",
          "earliest": "2015-10-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/praluent",
          "eu_market": "2015-09-23T00:00:00",
          "id": 2179,
          "indication": "Praluent® is indicated for both primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.",
          "last_scrape": "2018-12-13T16:26:14",
          "latest": "2018-03-20T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2015-10-13, 2015-11-02",
          "rr_end": "2015-11-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-10-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Dyslipidemias",
          "trade_name": "Praluent",
          "url": "http://www.ncpe.ie/drugs/alirocumab-praluent/"
         },
         {
          "company": "Takeda",
          "drug_name": "Alogliptin (Vipidia®)",
          "earliest": "2013-09-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia",
          "eu_market": "2013-09-18T00:00:00",
          "id": 2180,
          "indication": "Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.",
          "last_scrape": "2018-12-13T16:26:16",
          "latest": "2013-10-30T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-09-27, 2013-10-30",
          "rr_end": "2013-10-30T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-09-27T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Vipidia",
          "url": "http://www.ncpe.ie/drugs/alogliptin-vipidia/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Ambrisentan (Volibris®)",
          "earliest": "2008-10-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/volibris",
          "eu_market": "2008-04-20T00:00:00",
          "id": 2181,
          "indication": "Cost Effectiveness of ambrisentan (Volibris®) in the treatment of patients with Functional Class II or III pulmonary arterial hypertension.",
          "last_scrape": "2018-12-13T16:26:21",
          "latest": "2014-07-04T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-05-27, 2014-07-04",
          "rr_end": "2014-07-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-05-27T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hypertension, Pulmonary",
          "trade_name": "Volibris",
          "url": "http://www.ncpe.ie/drugs/ambrisentan-volibris/"
         },
         {
          "company": "CIS",
          "drug_name": "Amifampridine (Firdapse®)",
          "earliest": "2011-11-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2182,
          "indication": "For Lambert Eaton Myasthenic Syndrome (LEMS).  This high cost drug is likely to require a full HTA due to significant budget impact.",
          "last_scrape": "2018-12-13T16:26:23",
          "latest": "2011-12-09T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-11-07, 2011-12-09",
          "rr_end": "2011-12-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-11-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Firdapse",
          "url": "http://www.ncpe.ie/drugs/amifampridine-firdapse/"
         },
         {
          "company": "Unknown",
          "drug_name": "Amsacrine (Amsidine®)",
          "earliest": "2017-01-10T00:00:00",
          "ema_url": "",
          "eu_market": "2014-01-23T00:00:00",
          "id": 2183,
          "indication": "Amsidine® is indicated for the induction and maintenance of remission in acute leukaemia of adults.",
          "last_scrape": "2018-12-13T16:26:29",
          "latest": "2017-02-15T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-01-10, 2017-02-15",
          "rr_end": "2017-02-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-01-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Amsidine",
          "url": "http://www.ncpe.ie/drugs/amsacrine-amsidine/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Apixaban (Eliquis®) for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and",
          "earliest": "2014-07-29T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis",
          "eu_market": "2011-05-18T00:00:00",
          "id": 2184,
          "indication": "Apixaban (Eliquis®) for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.",
          "last_scrape": "2018-12-13T16:26:35",
          "latest": "2014-08-10T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-07-29, 2014-08-10",
          "rr_end": "2014-08-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-07-29T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Arthroplasty; Venous Thromboembolism",
          "trade_name": "Eliquis",
          "url": "http://www.ncpe.ie/drugs/apixaban-eliquis-for-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe-in-adults/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Apixaban (Eliquis®) for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee",
          "earliest": "2011-10-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis",
          "eu_market": "2011-05-18T00:00:00",
          "id": 2185,
          "indication": "Apixaban (Eliquis®) for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery.",
          "last_scrape": "2018-12-13T16:26:39",
          "latest": "2012-06-19T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-10-19, 2011-11-02",
          "rr_end": "2011-11-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-10-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthroplasty; Venous Thromboembolism",
          "trade_name": "Eliquis",
          "url": "http://www.ncpe.ie/drugs/apixaban-eliquis/"
         },
         {
          "company": "Celgene",
          "drug_name": "Apremilast (Otezla®) for moderate to severe chronic plaque psoriasis.",
          "earliest": "2015-02-24T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/otezla",
          "eu_market": "2015-01-15T00:00:00",
          "id": 2186,
          "indication": "Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light (PUVA).",
          "last_scrape": "2018-12-13T16:26:45",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2015-02-24, 2015-04-03",
          "rr_end": "2015-04-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-02-24T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Psoriatic; Psoriasis",
          "trade_name": "Otezla",
          "url": "http://www.ncpe.ie/drugs/apremilast-otezla-for-moderate-to-severe-chronic-plaque-psoriasis/"
         },
         {
          "company": "Celgene",
          "drug_name": "Apremilast (Otezla®) for psoriatic arthritis.",
          "earliest": "2015-02-24T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/otezla",
          "eu_market": "2015-01-15T00:00:00",
          "id": 2187,
          "indication": "Apremilist (Otezla®), alone or in combination with DMARDs, for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.",
          "last_scrape": "2018-12-13T16:26:47",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2015-02-24, 2015-04-03",
          "rr_end": "2015-04-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-02-24T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Psoriatic; Psoriasis",
          "trade_name": "Otezla",
          "url": "http://www.ncpe.ie/drugs/apremilast-otezla-for-psoriatic-arthritis/"
         },
         {
          "company": "Otsuka",
          "drug_name": "Aripiprazole (Abilify Maintena®)",
          "earliest": "2014-07-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena",
          "eu_market": "2013-11-14T00:00:00",
          "id": 2188,
          "indication": "Aripiprazole (Abilify Maintena®) for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole",
          "last_scrape": "2018-12-13T16:26:49",
          "latest": "2014-08-06T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-07-02, 2014-08-06",
          "rr_end": "2014-08-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-07-02T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Schizophrenia",
          "trade_name": "Abilify Maintena",
          "url": "http://www.ncpe.ie/drugs/aripiprazole-abilify-maintena/"
         },
         {
          "company": "Organon",
          "drug_name": "Asenapine (Sycrest®)",
          "earliest": "2011-08-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/sycrest",
          "eu_market": "2010-09-01T00:00:00",
          "id": 2189,
          "indication": "Asenapine (Sycrest®) for the treatment of moderate to severe manic episodes associated with biopolar 1 disorder in adults.",
          "last_scrape": "2018-12-13T16:26:55",
          "latest": "2011-09-06T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-08-17, 2011-09-06",
          "rr_end": "2011-09-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-08-17T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Bipolar Disorder",
          "trade_name": "Sycrest",
          "url": "http://www.ncpe.ie/drugs/asenapine-sycrest/"
         },
         {
          "company": "Roche",
          "drug_name": "Atezolizumab (Tecentriq®)",
          "earliest": "2017-08-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq",
          "eu_market": "2017-09-21T00:00:00",
          "id": 2190,
          "indication": "Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab.",
          "last_scrape": "2018-12-13T16:27:00",
          "latest": "2018-09-20T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-08-08, 2017-10-09",
          "rr_end": "2017-10-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-08-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Tecentriq",
          "url": "http://www.ncpe.ie/drugs/atezolizumab-tecentriq/"
         },
         {
          "company": "Menarini",
          "drug_name": "Avanafil (Spedra®)",
          "earliest": "2014-02-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/spedra",
          "eu_market": "2013-06-21T00:00:00",
          "id": 2191,
          "indication": "Avanafil (Spedra®) is indicated for the treatment of erectile dysfunction in adult men.",
          "last_scrape": "2018-12-13T16:27:05",
          "latest": "2014-03-12T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-02-19, 2014-03-12",
          "rr_end": "2014-03-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-02-19T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Erectile Dysfunction",
          "trade_name": "Spedra",
          "url": "http://www.ncpe.ie/drugs/avanafil-spedra/"
         },
         {
          "company": "Merck",
          "drug_name": "Avelumab (Bavencio®)",
          "earliest": "2017-10-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio",
          "eu_market": "2017-09-18T00:00:00",
          "id": 2192,
          "indication": "Avelumab (Bavencio®) is indicated for the treatment of adults with metastatic Merkel Cell Carcinoma.",
          "last_scrape": "2018-12-13T16:27:06",
          "latest": "2018-10-08T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-10-17, 2017-11-21",
          "rr_end": "2017-11-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-10-17T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Neuroendocrine Tumors",
          "trade_name": "Bavencio",
          "url": "http://www.ncpe.ie/drugs/avelumab-bavencio/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Aspirin 81mg/Esomeprazole 20mg (Axanum®)",
          "earliest": "2012-04-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2193,
          "indication": "Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.",
          "last_scrape": "2018-12-13T16:27:08",
          "latest": "2012-04-20T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-04-12, 2012-04-20",
          "rr_end": "2012-04-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2012-04-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Axanum",
          "url": "http://www.ncpe.ie/drugs/axanum-aspirin-81mgesomeprazole-20mg/"
         },
         {
          "company": "Kite",
          "drug_name": "Axicabtagene Ciloleucel (Yescarta®)",
          "earliest": "2018-09-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta",
          "eu_market": "2018-08-23T00:00:00",
          "id": 2194,
          "indication": "Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.",
          "last_scrape": "2018-12-13T16:27:14",
          "latest": "2018-10-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-09-10, 2018-10-18",
          "rr_end": "2018-10-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of  axi-cel compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-09-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse",
          "trade_name": "Yescarta",
          "url": "http://www.ncpe.ie/drugs/axicabtagene-ciloleucel-yescarta/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Axitinib (Inlyta®)",
          "earliest": "2012-11-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta",
          "eu_market": "2012-09-03T00:00:00",
          "id": 2195,
          "indication": "For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine",
          "last_scrape": "2018-12-13T16:27:23",
          "latest": "2012-11-19T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-11-07, 2012-11-19",
          "rr_end": "2012-11-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-11-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Renal Cell",
          "trade_name": "Inlyta",
          "url": "http://www.ncpe.ie/drugs/axitinib-inlyta/"
         },
         {
          "company": "Unknown",
          "drug_name": "Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista®)",
          "earliest": "2013-02-12T00:00:00",
          "ema_url": "",
          "eu_market": "2010-02-25T00:00:00",
          "id": 2196,
          "indication": "Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.",
          "last_scrape": "2018-12-13T16:27:24",
          "latest": "2013-02-28T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-02-12, 2013-02-28",
          "rr_end": "2013-02-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-02-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Dymista",
          "url": "http://www.ncpe.ie/drugs/azelastine-hydrochloride-and-fluticasone-propionate-nasal-spray-dymista/"
         },
         {
          "company": "Takeda",
          "drug_name": "Azilsartan (Edarbi®)",
          "earliest": "2012-01-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi",
          "eu_market": "2011-12-07T00:00:00",
          "id": 2197,
          "indication": "Edarbi is indicated for the treatment of essential hypertension in adults.",
          "last_scrape": "2018-12-13T16:27:25",
          "latest": "2012-01-11T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-01-10, 2012-01-11",
          "rr_end": "2012-01-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2012-01-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hypertension",
          "trade_name": "Edarbi",
          "url": "http://www.ncpe.ie/drugs/azilsartan-edarbi/"
         },
         {
          "company": "Eli",
          "drug_name": "Baricitinib (Olumiant®)",
          "earliest": "2017-06-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant",
          "eu_market": "2017-02-12T00:00:00",
          "id": 2198,
          "indication": "Baricitinib (Olumiant®) is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate.",
          "last_scrape": "2018-12-13T16:27:27",
          "latest": "2017-11-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-06-14, 2017-07-13",
          "rr_end": "2017-07-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-06-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Rheumatoid",
          "trade_name": "Olumiant",
          "url": "http://www.ncpe.ie/drugs/baricitinib-olumiant/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Bazedoxifene (Conbriza®)",
          "earliest": "2011-09-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza",
          "eu_market": "2009-04-17T00:00:00",
          "id": 2199,
          "indication": "Bazedoxifene (Conbriza®) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.  A significant reduction in the incidence of verterbral fractures has been demonstrated; efficacy on hip fractures has not been established.",
          "last_scrape": "2018-12-13T16:27:33",
          "latest": "2011-11-02T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-09-20, 2011-11-02",
          "rr_end": "2011-11-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-09-20T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Osteoporosis, Postmenopausal",
          "trade_name": "Conbriza",
          "url": "http://www.ncpe.ie/drugs/bazedoxifene-conbriza/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Bedaquiline (Sirturo®)",
          "earliest": "2015-01-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo",
          "eu_market": "2014-03-05T00:00:00",
          "id": 2200,
          "indication": "Bedaquiline (Sirturo®) is indicated for use as part of an appropriate combination regimen for pulmonary MDR‑TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.",
          "last_scrape": "2018-12-13T16:27:36",
          "latest": "2015-02-20T00:00:00",
          "ncpe_year": 2015,
          "orphan": 1,
          "rr_dates": "2015-01-23, 2015-02-20",
          "rr_end": "2015-02-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-01-23T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Tuberculosis, Multidrug-Resistant",
          "trade_name": "Sirturo",
          "url": "http://www.ncpe.ie/drugs/bedaquiline-sirturo/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Belatacept (Nulojix®)",
          "earliest": "2011-11-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/nulojix",
          "eu_market": "2011-06-17T00:00:00",
          "id": 2201,
          "indication": "Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.\n",
          "last_scrape": "2018-12-13T16:27:37",
          "latest": "2012-01-23T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-11-15, 2012-01-23",
          "rr_end": "2012-01-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-11-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Graft Rejection; Kidney Transplantation",
          "trade_name": "Nulojix",
          "url": "http://www.ncpe.ie/drugs/belatacept-nulojix/"
         },
         {
          "company": "Glaxo",
          "drug_name": "Belimumab (Benlysta®)",
          "earliest": "2011-08-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta",
          "eu_market": "2011-07-13T00:00:00",
          "id": 2202,
          "indication": "Cost-effectiveness of Belimumab (Benlysta®)",
          "last_scrape": "2018-12-13T16:27:40",
          "latest": "2011-08-11T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-08-11, 2011-08-11",
          "rr_end": "2011-08-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-08-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lupus Erythematosus, Systemic",
          "trade_name": "Benlysta",
          "url": "http://www.ncpe.ie/drugs/belimumab-benlysta/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Bendamustine (Levact®)",
          "earliest": "2011-03-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2203,
          "indication": "Bendamustine (Levact®) for the treatment of Chronic Lymphocytic Leukaemia (CLL)",
          "last_scrape": "2018-12-13T16:27:46",
          "latest": "2012-11-20T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-03-21, 2011-03-01",
          "rr_end": "2011-03-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-03-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Levact",
          "url": "http://www.ncpe.ie/drugs/bendamustine-levact/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Benralizumab (Fasenra®)",
          "earliest": "2018-01-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra",
          "eu_market": "2018-01-08T00:00:00",
          "id": 2204,
          "indication": "Benralizumab (Fasenra®) is indicated as add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.",
          "last_scrape": "2018-12-13T16:27:50",
          "latest": "2018-02-14T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-01-15, 2018-02-14",
          "rr_end": "2018-02-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharamcoeconomic assessment recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-01-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Asthma",
          "trade_name": "Fasenra",
          "url": "http://www.ncpe.ie/drugs/benralizumab-fasenra/"
         },
         {
          "company": "Merck",
          "drug_name": "Bezlotoxumab (Zinplava®)",
          "earliest": "2017-05-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava",
          "eu_market": "2017-01-18T00:00:00",
          "id": 2205,
          "indication": "Bezlotoxumab (Zinplava®) is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.",
          "last_scrape": "2018-12-13T16:27:56",
          "latest": "2017-06-14T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-05-11, 2017-06-14",
          "rr_end": "2017-06-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-05-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Enterocolitis, Pseudomembranous",
          "trade_name": "Zinplava",
          "url": "http://www.ncpe.ie/drugs/bezlotoxumab-zinplava/"
         },
         {
          "company": "Gilead",
          "drug_name": "Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®)",
          "earliest": "2018-04-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy",
          "eu_market": "2018-06-21T00:00:00",
          "id": 2206,
          "indication": "Biktarvy® for the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.",
          "last_scrape": "2018-12-13T16:27:58",
          "latest": "2018-12-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-04-30, 2018-06-07",
          "rr_end": "2018-06-07T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended the ncpe recommends that biktarvy® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the health (pricing and supply of medical goods act) 2013",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2018-04-30T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "HIV Infections",
          "trade_name": "Biktarvy",
          "url": "http://www.ncpe.ie/drugs/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy/"
         },
         {
          "company": "CIS",
          "drug_name": "Bilastine (Drynol®)",
          "earliest": "2011-03-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2207,
          "indication": " Bilastine (Drynol®) for the Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria.",
          "last_scrape": "2018-12-13T16:28:01",
          "latest": "2011-03-23T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-03-10, 2011-03-23",
          "rr_end": "2011-03-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-03-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Drynol",
          "url": "http://www.ncpe.ie/drugs/bilastine-drynol/"
         },
         {
          "company": "Amgen",
          "drug_name": "Blinatumomab (Blincyto®)",
          "earliest": "2015-12-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto",
          "eu_market": "2015-11-23T00:00:00",
          "id": 2208,
          "indication": "Blincyto® is indicated for the treatment of adults with Philadelphia chromosome negative (Ph-) relapsed or refractory\nB-precursor acute lymphoblastic leukaemia.",
          "last_scrape": "2018-12-13T16:28:05",
          "latest": "2018-04-16T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2015-12-08, 2015-12-22",
          "rr_end": "2015-12-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended  the ncpe cannot recommend reimbursement of blinctyo® at this point in time",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-12-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
          "trade_name": "Blincyto",
          "url": "http://www.ncpe.ie/drugs/blinatumomab-blincyto/"
         },
         {
          "company": "Merck",
          "drug_name": "Boceprevir (Victrelis®)",
          "earliest": "2011-08-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis",
          "eu_market": "2011-07-18T00:00:00",
          "id": 2209,
          "indication": "Economic evaluation of Boceprevir (Victrelis®) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.",
          "last_scrape": "2018-12-13T16:28:11",
          "latest": "2012-01-17T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2015-12-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-11-20T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Victrelis",
          "url": "http://www.ncpe.ie/drugs/boceprevir-victrelis/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Bosentan (Tracleer®)",
          "earliest": "2014-06-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer",
          "eu_market": "2002-05-14T00:00:00",
          "id": 2210,
          "indication": "Bosentan (Tracleer®) is indicated for the treatment pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO Functional Class (FC) III and WHO FC II.  It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.",
          "last_scrape": "2018-12-13T16:28:16",
          "latest": "2014-07-04T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-06-27, 2014-07-04",
          "rr_end": "2014-07-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-06-27T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Scleroderma, Systemic; Hypertension, Pulmonary",
          "trade_name": "Tracleer",
          "url": "http://www.ncpe.ie/drugs/bosentan-tracleer/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Bosutinib (Bosulif®)",
          "earliest": "2013-08-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif",
          "eu_market": "2013-03-26T00:00:00",
          "id": 2211,
          "indication": "Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.",
          "last_scrape": "2018-12-13T16:28:18",
          "latest": "2013-09-18T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-08-09, 2013-09-18",
          "rr_end": "2013-09-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "at the current price full hta would be required",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-08-09T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid",
          "trade_name": "Bosulif",
          "url": "http://www.ncpe.ie/drugs/bosutinib-bosulif/"
         },
         {
          "company": "Takeda",
          "drug_name": "Brentuximab vedotin (Adcetris®) for CD30+ cutaneous T-cell lymphoma (CTCL)",
          "earliest": "2018-02-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris",
          "eu_market": "2012-10-25T00:00:00",
          "id": 2212,
          "indication": "Brentuximab vedotin (Adcetris®) for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy. This is a license extension.",
          "last_scrape": "2018-12-13T16:28:19",
          "latest": "2018-03-06T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-02-07, 2018-03-06",
          "rr_end": "2018-03-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-02-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lymphoma, Non-Hodgkin; Hodgkin Disease",
          "trade_name": "Adcetris",
          "url": "http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris-for-cd30-cutaneous-t-cell-lymphoma-ctcl/"
         },
         {
          "company": "Takeda",
          "drug_name": "Brentuximab vedotin (Adcetris®)",
          "earliest": "2012-11-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris",
          "eu_market": "2012-10-25T00:00:00",
          "id": 2213,
          "indication": "Brentuximab vedotin (Adcetris®) indicated for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.",
          "last_scrape": "2018-12-13T16:28:23",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 1,
          "rr_dates": "2012-11-28, 2012-12-21",
          "rr_end": "2012-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-11-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lymphoma, Non-Hodgkin; Hodgkin Disease",
          "trade_name": "Adcetris",
          "url": "http://www.ncpe.ie/drugs/brentuximab-vedotin-adcetris/"
         },
         {
          "company": "Takeda",
          "drug_name": "Brigatinib (Alunbrig®)",
          "earliest": "2018-11-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig",
          "eu_market": "2018-11-22T00:00:00",
          "id": 2214,
          "indication": "Brigatinib (Alunbrig ®) is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.",
          "last_scrape": "2018-12-13T16:28:29",
          "latest": "2018-12-11T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-11-19, 2018-12-11",
          "rr_end": "2018-12-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of brigatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-11-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Alunbrig",
          "url": "http://www.ncpe.ie/drugs/brigatinib-alunbrig/"
         },
         {
          "company": "Galderma",
          "drug_name": "Brimonidine 3.3 mg/g gel (Mirvaso®)",
          "earliest": "2014-04-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso",
          "eu_market": "2014-02-20T00:00:00",
          "id": 2215,
          "indication": "Brimonidine 3.3 mg/g gel (Mirvaso®) is indicated for the treatment of facial erythema of rosacea in adult patients.",
          "last_scrape": "2018-12-13T16:28:30",
          "latest": "2014-04-09T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-04-09",
          "rr_end": "2014-04-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-04-09T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Skin Diseases",
          "trade_name": "Mirvaso",
          "url": "http://www.ncpe.ie/drugs/brimonidine-3-3-mgg-gel-mirvaso/"
         },
         {
          "company": "CIS",
          "drug_name": "Brivaracetam (Briviact®)",
          "earliest": "2016-02-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2216,
          "indication": "Brivaracetam (Briviact®) is indicated as adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.",
          "last_scrape": "2018-12-13T16:28:36",
          "latest": "2016-03-22T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-02-15, 2016-03-22",
          "rr_end": "2016-03-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-02-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Briviact",
          "url": "http://www.ncpe.ie/drugs/brivaracetam-briviact/"
         },
         {
          "company": "LEO",
          "drug_name": "Brodalumab (Kyntheum®)",
          "earliest": "2017-07-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum",
          "eu_market": "2017-07-17T00:00:00",
          "id": 2217,
          "indication": "Brodalumab (Kyntheum®) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.",
          "last_scrape": "2018-12-13T16:28:40",
          "latest": "2018-01-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-07-25, 2017-08-29",
          "rr_end": "2017-08-29T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-07-25T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Psoriasis",
          "trade_name": "Kyntheum",
          "url": "http://www.ncpe.ie/drugs/brodalumab-kyntheum/"
         },
         {
          "company": "Pharmaxis",
          "drug_name": "Mannitol Dry Powder (Bronchitol®)",
          "earliest": "2012-09-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol",
          "eu_market": "2012-04-13T00:00:00",
          "id": 2218,
          "indication": "Bronchitol® – Mannitol dry powder for inhalation for the treatment of cystic fibrosis (CF)",
          "last_scrape": "2018-12-13T16:28:44",
          "latest": "2014-08-29T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2012-09-11, 2012-09-21",
          "rr_end": "2012-09-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-09-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystic Fibrosis",
          "trade_name": "Bronchitol",
          "url": "http://www.ncpe.ie/drugs/bronchitol/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar ®)",
          "earliest": "2016-05-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2219,
          "indication": "Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.",
          "last_scrape": "2018-12-13T16:28:46",
          "latest": "2016-06-21T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-05-17, 2016-06-21",
          "rr_end": "2016-06-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2016-05-17T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Enstilar",
          "url": "http://www.ncpe.ie/drugs/c-drugs/calcipotriol-and-betamethasone-dipropionate-cutaneous-foam-enstilar/"
         },
         {
          "company": "Shire",
          "drug_name": "C1inhibitor (human) (Cinryze®)",
          "earliest": "2012-10-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze",
          "eu_market": "2011-06-15T00:00:00",
          "id": 2220,
          "indication": "C1inhibitor (human) (Cinryze® 500 Units powder and solvent for solution for injection)",
          "last_scrape": "2018-12-13T16:28:53",
          "latest": "2012-11-14T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-10-22, 2012-11-14",
          "rr_end": "2012-11-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2012-10-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Angioedemas, Hereditary",
          "trade_name": "Cinryze",
          "url": "http://www.ncpe.ie/drugs/c1inhibitor-human-cinryze/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Cabozantinib (Cabometyx®)",
          "earliest": "2017-03-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2221,
          "indication": "Cabozantinib (Cabometyx®) is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.",
          "last_scrape": "2018-12-13T16:28:55",
          "latest": "2018-07-03T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-03-20, 2017-04-25",
          "rr_end": "2017-04-25T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessmentrecommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-03-20T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Cabometyx",
          "url": "http://www.ncpe.ie/drugs/cabozantinib-cabometyx/"
         },
         {
          "company": "Ipsen",
          "drug_name": "Cabozantinib (Cometriq®)",
          "earliest": "2014-07-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq",
          "eu_market": "2014-03-21T00:00:00",
          "id": 2222,
          "indication": "Cabozantinib (COMETRIQ®) is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.",
          "last_scrape": "2018-12-13T16:28:58",
          "latest": "2014-08-12T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-07-10, 2014-08-12",
          "rr_end": "2014-08-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-07-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Thyroid Neoplasms",
          "trade_name": "Cometriq",
          "url": "http://www.ncpe.ie/drugs/cabozantinib-cometriq/"
         },
         {
          "company": "CIS",
          "drug_name": "Camellia sinensis, folium (green tea leaf) (Catephen 10%®)",
          "earliest": "2015-05-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2223,
          "indication": "Catephen 10%® is indicated for the cutaneous treatment of external genital and perianal warts (condylomataacuminata) in immunocompetent patients from the age of 18 years.",
          "last_scrape": "2018-12-13T16:29:01",
          "latest": "2015-07-10T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-05-26, 2015-07-10",
          "rr_end": "2015-07-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-05-26T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Catephen 10%",
          "url": "http://www.ncpe.ie/drugs/camellia-sinensis-folium-green-tea-leaf-catephen-10/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Canagliflozin (Invokana®)",
          "earliest": "2013-11-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/invokana",
          "eu_market": "2013-11-15T00:00:00",
          "id": 2224,
          "indication": "Canagliflozin (Invokana®) is indicated for the treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin",
          "last_scrape": "2018-12-13T16:29:04",
          "latest": "2014-12-01T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-11-25, 2013-12-02",
          "rr_end": "2013-12-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-11-25T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Invokana",
          "url": "http://www.ncpe.ie/drugs/canagliflozin-invokana/"
         },
         {
          "company": "Grunenthal",
          "drug_name": "Capsaicin 8%w/w patch (Qutenza®)",
          "earliest": "2012-06-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza",
          "eu_market": "2009-05-15T00:00:00",
          "id": 2225,
          "indication": "Capsaicin 8% w/w patch (Qutenza®) for peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.",
          "last_scrape": "2018-12-13T16:29:09",
          "latest": "2012-06-28T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-06-15, 2012-06-28",
          "rr_end": "2012-06-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-06-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Neuralgia",
          "trade_name": "Qutenza",
          "url": "http://www.ncpe.ie/drugs/capsaicin-8ww-patch-qutenza/"
         },
         {
          "company": "sanofi-aventis",
          "drug_name": "Cabazitaxel (Jevtana®)",
          "earliest": "2011-06-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana",
          "eu_market": "2011-03-17T00:00:00",
          "id": 2226,
          "indication": "Economic Evaluation of cabazitaxel (Jevtana®) for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen.",
          "last_scrape": "2018-12-13T16:29:11",
          "latest": "2014-03-01T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2011-06-02, 2011-06-09",
          "rr_end": "2011-06-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-06-02T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Jevtana",
          "url": "http://www.ncpe.ie/drugs/carbazitaxel-jevtana-for-prostate-cancer/"
         },
         {
          "company": "Amgen",
          "drug_name": "Carfilzomib (Kyprolis®)",
          "earliest": "2015-12-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis",
          "eu_market": "2015-11-19T00:00:00",
          "id": 2227,
          "indication": "Kyprolis® (in combination with lenalidomide and dexamethasone) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.",
          "last_scrape": "2018-12-13T16:29:16",
          "latest": "2018-09-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2015-12-07, 2016-01-06",
          "rr_end": "2016-01-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-12-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Myeloma",
          "trade_name": "Kyprolis",
          "url": "http://www.ncpe.ie/drugs/carfilzomib-kyprolis/"
         },
         {
          "company": "Neovii",
          "drug_name": "Catumaxomab (Removab®)",
          "earliest": "2011-08-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/removab",
          "eu_market": "2009-04-20T00:00:00",
          "id": 2228,
          "indication": "Catumazomab (Removab®) for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.",
          "last_scrape": "2018-12-13T16:29:22",
          "latest": "2011-09-06T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-08-05, 2011-09-06",
          "rr_end": "2011-09-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-08-05T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Ascites; Cancer",
          "trade_name": "Removab",
          "url": "http://www.ncpe.ie/drugs/catumaxomab-removab/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Ceftaroline (Zinforo®)",
          "earliest": "2012-10-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo",
          "eu_market": "2012-08-22T00:00:00",
          "id": 2229,
          "indication": "For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP).",
          "last_scrape": "2018-12-13T16:29:25",
          "latest": "2012-10-12T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-10-08, 2012-10-12",
          "rr_end": "2012-10-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2012-10-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia",
          "trade_name": "Zinforo",
          "url": "http://www.ncpe.ie/drugs/ceftaroline-zinforo/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Ceftazidime-avibactam (CEF-AVI)(Zavicefta®)",
          "earliest": "2017-05-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta",
          "eu_market": "2016-06-23T00:00:00",
          "id": 2230,
          "indication": "Ceftazidime-avibactam (CEF-AVI)(Zavicefta®) is indicated for the treatment of CIAI, cUTI, HAP (including VAP) and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.",
          "last_scrape": "2018-12-13T16:29:29",
          "latest": "2017-11-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-05-17, 2017-06-13",
          "rr_end": "2017-06-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-05-17T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections",
          "trade_name": "Zavicefta",
          "url": "http://www.ncpe.ie/drugs/ceftazidime-avibactam-cef-avizavicefta/"
         },
         {
          "company": "Merck",
          "drug_name": "Ceftolozane/tazobactam (Zerbaxa®)",
          "earliest": "2016-03-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa",
          "eu_market": "2015-09-18T00:00:00",
          "id": 2231,
          "indication": "Zerbaxa® is indicated for the treatment of complicated urinary tract infections (cUTI), acute pyelonephritis and complicated intra-abdominal infections (cIAI) in adults.",
          "last_scrape": "2018-12-13T16:29:34",
          "latest": "2016-09-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-03-03, 2016-04-26",
          "rr_end": "2016-04-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-03-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Bacterial Infections",
          "trade_name": "Zerbaxa",
          "url": "http://www.ncpe.ie/drugs/ceftolozanetazobactam-zerbaxa/"
         },
         {
          "company": "Novartis",
          "drug_name": "Ceritinib (Zykadia®)",
          "earliest": "2015-05-29T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia",
          "eu_market": "2015-05-06T00:00:00",
          "id": 2232,
          "indication": "Zykadia® is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.",
          "last_scrape": "2018-12-13T16:29:36",
          "latest": "2015-07-22T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-05-29, 2015-07-22",
          "rr_end": "2015-07-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-05-29T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Zykadia",
          "url": "http://www.ncpe.ie/drugs/ceritinib-zykadia/"
         },
         {
          "company": "BioMarin",
          "drug_name": "Cerliponase alfa (Brineura®)",
          "earliest": "2017-10-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/brineura",
          "eu_market": "2017-05-30T00:00:00",
          "id": 2233,
          "indication": "Cerliponase alfa (Brineura®) is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.",
          "last_scrape": "2018-12-13T16:29:40",
          "latest": "2018-08-02T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-10-11, 2017-11-27",
          "rr_end": "2017-11-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation is recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-10-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Neuronal Ceroid-Lipofuscinoses",
          "trade_name": "Brineura",
          "url": "http://www.ncpe.ie/drugs/cerliponase-alfa-brineura/"
         },
         {
          "company": "UCB",
          "drug_name": "Certolizumab pegol (Cimzia®)",
          "earliest": "2010-03-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0",
          "eu_market": "2009-10-01T00:00:00",
          "id": 2234,
          "indication": "Cost-effectiveness of certolizumab pegol (Cimzia®) for the treatment of moderate to severe rheumatoid arthritis.",
          "last_scrape": "2018-12-13T16:29:44",
          "latest": "2010-09-02T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-11-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-10-26T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Arthritis, Rheumatoid",
          "trade_name": "Cimzia",
          "url": "http://www.ncpe.ie/drugs/certolizumab-pegol-cimzia/"
         },
         {
          "company": "Santen",
          "drug_name": "Ciclosporin 1mg/ml eye drops (Ikervis®)",
          "earliest": "2015-01-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis",
          "eu_market": "2015-03-19T00:00:00",
          "id": 2235,
          "indication": "Ikervis® is indicated for the treatment of severe keratitis in adult patients with dry eye disease (DED), which has not improved despite treatment with tear substitutes.",
          "last_scrape": "2018-12-13T16:29:49",
          "latest": "2016-01-18T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2015-01-07, 2016-01-18",
          "rr_end": "2016-01-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-01-07T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Corneal Diseases",
          "trade_name": "Ikervis",
          "url": "http://www.ncpe.ie/drugs/ciclosporin-1mgml-eye-drops-ikervis/"
         },
         {
          "company": "Merck",
          "drug_name": "Cladribine (Mavenclad®)",
          "earliest": "2017-08-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad",
          "eu_market": "2017-08-22T00:00:00",
          "id": 2236,
          "indication": "Cladribine (Mavenclad®) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features",
          "last_scrape": "2018-12-13T16:29:54",
          "latest": "2018-09-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-08-22, 2017-09-18",
          "rr_end": "2017-09-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-08-22T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Mavenclad",
          "url": "http://www.ncpe.ie/drugs/cladribine-mavenclad/"
         },
         {
          "company": "CIS",
          "drug_name": "Clindamycin 1% with tretinoin 0.025% (Treclinac®)",
          "earliest": "2014-04-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2237,
          "indication": "Clindamycin 1% with tretinoin 0.025% (Treclinac®) is indicated for the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older.",
          "last_scrape": "2018-12-13T16:29:58",
          "latest": "2014-05-06T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-04-08, 2014-05-06",
          "rr_end": "2014-05-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-04-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Treclinac",
          "url": "http://www.ncpe.ie/drugs/clindamycin-1-with-tretinoin-0-025-treclinac/"
         },
         {
          "company": "Roche",
          "drug_name": "Cobimetinib (Cotellic®)",
          "earliest": "2016-04-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic",
          "eu_market": "2015-11-20T00:00:00",
          "id": 2238,
          "indication": "Cotellic® is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
          "last_scrape": "2018-12-13T16:30:02",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-04-19, 2016-04-26",
          "rr_end": "2016-04-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-04-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma",
          "trade_name": "Cotellic",
          "url": "http://www.ncpe.ie/drugs/cobimetinib-cotellic/"
         },
         {
          "company": "Genzyme",
          "drug_name": "Colesevelam (Cholestagel®)",
          "earliest": "2010-10-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cholestagel",
          "eu_market": "2004-03-09T00:00:00",
          "id": 2239,
          "indication": "Cost-effectiveness of Colesevelam (Cholestagel®)",
          "last_scrape": "2018-12-13T16:30:03",
          "latest": "2010-10-22T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-10-19, 2010-10-22",
          "rr_end": "2010-10-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2010-10-19T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hypercholesterolemia",
          "trade_name": "Cholestagel",
          "url": "http://www.ncpe.ie/drugs/colesevelam-cholestagel/"
         },
         {
          "company": "Teva",
          "drug_name": "Colistimethate sodium (Colobreathe®)",
          "earliest": "2013-06-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe",
          "eu_market": "2012-02-13T00:00:00",
          "id": 2240,
          "indication": "Colistimethate sodium (colobreathe®) is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.",
          "last_scrape": "2018-12-13T16:30:06",
          "latest": "2013-06-28T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-06-07, 2013-06-28",
          "rr_end": "2013-06-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-06-07T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Cystic Fibrosis",
          "trade_name": "Colobreathe",
          "url": "http://www.ncpe.ie/drugs/colistimethate-sodium-colobreathe/"
         },
         {
          "company": "Swedish",
          "drug_name": "Collagenase Clostridium Histolyticum (Xiapex®)",
          "earliest": "2011-05-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex",
          "eu_market": "2011-02-28T00:00:00",
          "id": 2241,
          "indication": " Collagenase Clostridium Histolyticum (Xiapex®) is indicated for the treatment of Dupuytren’s contracture in adult patients with a palpable cord.",
          "last_scrape": "2018-12-13T16:30:17",
          "latest": "2011-06-09T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-05-20, 2011-06-09",
          "rr_end": "2011-06-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-05-20T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Dupuytren Contracture",
          "trade_name": "Xiapex",
          "url": "http://www.ncpe.ie/drugs/collagenase-clostridium-histolyticum-xiapex/"
         },
         {
          "company": "Merck",
          "drug_name": "Corifollitropin alfa (Elonva®)",
          "earliest": "2010-09-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/elonva",
          "eu_market": "2010-01-25T00:00:00",
          "id": 2242,
          "indication": "Cost-effectiveness of Corifollitropin alfa (Elonva®).",
          "last_scrape": "2018-12-13T16:30:20",
          "latest": "2010-10-22T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-10-22, 2010-09-01",
          "rr_end": "2010-09-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2010-10-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Reproductive Techniques, Assisted; Ovulation Induction",
          "trade_name": "Elonva",
          "url": "http://www.ncpe.ie/drugs/corifollitropin-alfa-elonva/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Crizotinib (Xalkori®) for first line ALK+ NSCLC",
          "earliest": "2017-02-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori",
          "eu_market": "2012-10-23T00:00:00",
          "id": 2243,
          "indication": "Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
          "last_scrape": "2018-12-13T16:30:24",
          "latest": "2017-04-24T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-02-06, 2017-04-24",
          "rr_end": "2017-04-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-02-06T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Xalkori",
          "url": "http://www.ncpe.ie/drugs/crizotinib-xalkori-for-first-line-alk-nsclc/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Crizotinib (Xalkori®) for ROS1 NSCLC",
          "earliest": "2017-02-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori",
          "eu_market": "2012-10-23T00:00:00",
          "id": 2244,
          "indication": "Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).",
          "last_scrape": "2018-12-13T16:30:29",
          "latest": "2017-04-24T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-02-06, 2017-04-24",
          "rr_end": "2017-04-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-02-06T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Xalkori",
          "url": "http://www.ncpe.ie/drugs/crizotinib-xalkori-for-ros1-nsclc/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Crizotinib (Xalkori®)",
          "earliest": "2013-01-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori",
          "eu_market": "2012-10-23T00:00:00",
          "id": 2245,
          "indication": "For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd–line treatment setting)",
          "last_scrape": "2018-12-13T16:30:34",
          "latest": "2015-08-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2013-01-09, 2013-01-31",
          "rr_end": "2013-01-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-01-09T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Xalkori",
          "url": "http://www.ncpe.ie/drugs/crizotinib-xalkori/"
         },
         {
          "company": "Chiesi",
          "drug_name": "Cysteamine bitartrate delayed-release (Procysbi®)",
          "earliest": "2015-12-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi",
          "eu_market": "2013-09-05T00:00:00",
          "id": 2246,
          "indication": "Procysbi® for the treatment of proven nephropathic cystinosis.",
          "last_scrape": "2018-12-13T16:30:37",
          "latest": "2017-11-15T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2015-12-01, 2015-12-15",
          "rr_end": "2015-12-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-12-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystinosis",
          "trade_name": "Procysbi",
          "url": "http://www.ncpe.ie/drugs/cysteamine-bitartrate-procysbi/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Dabigatran Etexilate (Pradaxa®) for the treatment of DVT and PE",
          "earliest": "2014-05-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa",
          "eu_market": "2008-03-17T00:00:00",
          "id": 2247,
          "indication": "Dabigatran etexilate (Pradaxa®) is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.",
          "last_scrape": "2018-12-13T16:30:43",
          "latest": "2014-06-13T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-05-09, 2014-06-13",
          "rr_end": "2014-06-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-05-09T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Pradaxa",
          "url": "http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-2/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Dabigatran etexilate (Pradaxa®) – for the prevention of stroke and systematic embolisom in atrial fibrillation",
          "earliest": "2010-11-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa",
          "eu_market": "2008-03-17T00:00:00",
          "id": 2248,
          "indication": "Dabigatran etexilate (Pradaxa®) for the Prevention of Stroke and Systemic Embolism in Adult Patients with Atrial Fibrillation",
          "last_scrape": "2018-12-13T16:30:51",
          "latest": "2012-10-03T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2014-06-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-05-12T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Pradaxa",
          "url": "http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-for-the-prevention-of-stroke-and-systematic-embolisom-in-atrial-fibrillation/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Dabigatran Etexilate (Pradaxa®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement",
          "earliest": "2008-07-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa",
          "eu_market": "2008-03-17T00:00:00",
          "id": 2249,
          "indication": "Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate (Pradaxa®) for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have undergone Total Hip Replacement or Total Knee Surgery.",
          "last_scrape": "2018-12-13T16:30:57",
          "latest": "2008-09-01T00:00:00",
          "ncpe_year": 2008,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2014-06-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-05-12T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Pradaxa",
          "url": "http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-vte-prevention/"
         },
         {
          "company": "Novartis",
          "drug_name": "Dabrafenib (Tafinlar®)",
          "earliest": "2013-09-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar",
          "eu_market": "2013-08-26T00:00:00",
          "id": 2250,
          "indication": "Dabrafenib (Tafinlar® ) is indicated for the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation.",
          "last_scrape": "2018-12-13T16:30:59",
          "latest": "2014-06-24T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-09-11, 2013-10-02",
          "rr_end": "2013-10-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-09-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma",
          "trade_name": "Tafinlar",
          "url": "http://www.ncpe.ie/drugs/dabrafenib-tafinlar/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Daclatasvir (Daklinza®)",
          "earliest": "2014-08-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza",
          "eu_market": "2014-08-22T00:00:00",
          "id": 2251,
          "indication": "Daclatasvir (Daklinza®) is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (genotype 1,3 and 4). ",
          "last_scrape": "2018-12-13T16:31:02",
          "latest": "2015-05-29T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-08-05, 2014-09-12",
          "rr_end": "2014-09-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-08-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Daklinza",
          "url": "http://www.ncpe.ie/drugs/daclatasvir-daklinza/"
         },
         {
          "company": "Biogen",
          "drug_name": "Daclizumab (Zinbryta®)",
          "earliest": "2016-09-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta",
          "eu_market": "2016-07-01T00:00:00",
          "id": 2252,
          "indication": "Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.",
          "last_scrape": "2018-12-13T16:31:08",
          "latest": "2018-03-07T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-09-26, 2016-11-23",
          "rr_end": "2016-11-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-09-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Zinbryta",
          "url": "http://www.ncpe.ie/drugs/daclizumab-zinbryta/"
         },
         {
          "company": "Allergan",
          "drug_name": "Dalbavancin (Xydalba®)",
          "earliest": "2017-03-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xydalba",
          "eu_market": "2015-02-19T00:00:00",
          "id": 2253,
          "indication": "Dalbavancin (Xydalba®) is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.",
          "last_scrape": "2018-12-13T16:31:12",
          "latest": "2017-11-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-03-07, 2017-04-28",
          "rr_end": "2017-04-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-03-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Soft Tissue Infections; Skin Diseases, Bacterial",
          "trade_name": "Xydalba",
          "url": "http://www.ncpe.ie/drugs/dalbavancin-xydalba/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Dapagliflozin (Forxiga®)",
          "earliest": "2012-10-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga",
          "eu_market": "2012-11-11T00:00:00",
          "id": 2254,
          "indication": "Dapagliflozin (Forxiga®) is indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as:\nMonotherapy\nWhen diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.\nAdd-on combination therapy\nIn combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.",
          "last_scrape": "2018-12-13T16:31:18",
          "latest": "2013-12-31T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2012-10-10, 2012-10-22",
          "rr_end": "2012-10-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-10-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Forxiga",
          "url": "http://www.ncpe.ie/drugs/dapagliflozin-forxiga/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Daratumumab (Darzalex®)",
          "earliest": "2016-05-31T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex",
          "eu_market": "2017-04-28T00:00:00",
          "id": 2255,
          "indication": "Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.",
          "last_scrape": "2018-12-13T16:31:21",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2016-05-31, 2016-06-14",
          "rr_end": "2016-06-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-05-31T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Myeloma",
          "trade_name": "Darzalex",
          "url": "http://www.ncpe.ie/drugs/daratumumab-darzalex/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza®)",
          "earliest": "2017-09-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza",
          "eu_market": "2017-09-20T00:00:00",
          "id": 2256,
          "indication": "Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza®) is indicated for the treatment of HIV-1 in adults and adolescents.",
          "last_scrape": "2018-12-13T16:31:25",
          "latest": "2017-10-26T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-09-27, 2017-10-26",
          "rr_end": "2017-10-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-09-27T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "HIV Infections",
          "trade_name": "Symtuza",
          "url": "http://www.ncpe.ie/drugs/darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Darunavir & cobicistat (Rezolsta®)",
          "earliest": "2014-12-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta",
          "eu_market": "2014-11-19T00:00:00",
          "id": 2257,
          "indication": "Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.",
          "last_scrape": "2018-12-13T16:31:30",
          "latest": "2015-01-08T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-12-02, 2015-01-08",
          "rr_end": "2015-01-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-12-02T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "HIV Infections",
          "trade_name": "Rezolsta",
          "url": "http://www.ncpe.ie/drugs/darunavir-cobicistat-rezolsta/"
         },
         {
          "company": "Takeda",
          "drug_name": "Darvadstrocel (Alofisel®)",
          "earliest": "2018-06-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel",
          "eu_market": "2018-03-23T00:00:00",
          "id": 2258,
          "indication": "Darvadstrocel (Alofisel®) for the treatment of complex perianal fistulae in adult patients with non-active/ mildly active luminal Crohn’s Disease when fistulae have shown an inadequate response to at least one conventional or biologic therapy and should be used after conditioning of fistula.",
          "last_scrape": "2018-12-13T16:31:35",
          "latest": "2018-07-31T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-06-14, 2018-07-17",
          "rr_end": "2018-07-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of darvadstrocel compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-06-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Rectal Fistula",
          "trade_name": "Alofisel",
          "url": "http://www.ncpe.ie/drugs/darvadstrocel-alofisel/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Decitabine (Dacogen®)",
          "earliest": "2012-11-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen",
          "eu_market": "2012-09-20T00:00:00",
          "id": 2259,
          "indication": "Decitabine (Dacogen®) is indicated for AML in patients who are >65yrs who are not candidates for standard induction therapy",
          "last_scrape": "2018-12-13T16:31:40",
          "latest": "2013-12-05T00:00:00",
          "ncpe_year": 2013,
          "orphan": 1,
          "rr_dates": "2012-11-08, 2012-12-13",
          "rr_end": "2012-12-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-11-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid",
          "trade_name": "Dacogen",
          "url": "http://www.ncpe.ie/drugs/decitabine-dacogen/"
         },
         {
          "company": "Gentium",
          "drug_name": "Defibrotide (Defitelio®)",
          "earliest": "2014-05-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio",
          "eu_market": "2013-10-18T00:00:00",
          "id": 2260,
          "indication": "Defibrotide (Defitelio®) indicated in adults, children and infants (>1month) for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy.",
          "last_scrape": "2018-12-13T16:31:44",
          "latest": "2014-07-10T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-05-12, 2014-07-10",
          "rr_end": "2014-07-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-05-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hepatic Veno-Occlusive Disease",
          "trade_name": "Defitelio",
          "url": "http://www.ncpe.ie/drugs/defibrotide-defitelio/"
         },
         {
          "company": "Ferring",
          "drug_name": "Degarelix (Firmagon®)",
          "earliest": "2009-10-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon",
          "eu_market": "2009-02-17T00:00:00",
          "id": 2261,
          "indication": "Cost-effectiveness of Degarelix (Firmagon®)",
          "last_scrape": "2018-12-13T16:31:47",
          "latest": "2009-10-15T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "2009-10-15",
          "rr_end": "2009-10-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2009-10-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Firmagon",
          "url": "http://www.ncpe.ie/drugs/degarelix-firmagon/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex®)",
          "earliest": "2018-02-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2262,
          "indication": "Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex®) which is indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.",
          "last_scrape": "2018-12-13T16:31:52",
          "latest": "2018-04-20T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-02-12, 2018-04-03",
          "rr_end": "2018-04-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of sativex® compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-02-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Sativex",
          "url": "http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-cannabidiol-thc-cbd-sativex/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex®)",
          "earliest": "2012-12-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2263,
          "indication": "For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy",
          "last_scrape": "2018-12-13T16:31:59",
          "latest": "2014-09-26T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2012-12-05, 2013-01-04",
          "rr_end": "2013-01-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-12-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Sativex",
          "url": "http://www.ncpe.ie/drugs/delta-9-tetrahydrocannabinol-thccannabidiol-cbd-sativex/"
         },
         {
          "company": "Amgen",
          "drug_name": "Denosumab (Prolia®)",
          "earliest": "2010-05-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/prolia",
          "eu_market": "2010-05-26T00:00:00",
          "id": 2264,
          "indication": "The Cost-effectiveness of Denosumab (Prolia®) for the Prevention of Osteoporotic Fractures in Postmenopausal Women.",
          "last_scrape": "2018-12-13T16:32:04",
          "latest": "2010-07-01T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-01-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-12-03T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Bone Resorption; Osteoporosis, Postmenopausal",
          "trade_name": "Prolia",
          "url": "http://www.ncpe.ie/drugs/denosumab-prolia/"
         },
         {
          "company": "Amgen",
          "drug_name": "Denosumab (Xgeva®)",
          "earliest": "2011-08-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva",
          "eu_market": "2011-07-13T00:00:00",
          "id": 2265,
          "indication": "Cost-effectiveness of denosumab (Xgeva®) for the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland.",
          "last_scrape": "2018-12-13T16:32:08",
          "latest": "2011-12-08T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-01-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-12-03T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Fractures, Bone; Neoplasm Metastasis",
          "trade_name": "Xgeva",
          "url": "http://www.ncpe.ie/drugs/denosumab-xgeva-3/"
         },
         {
          "company": "Allergan",
          "drug_name": "Dexamethasone Intravitreal Implant (Ozurdex®)",
          "earliest": "2010-11-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex",
          "eu_market": "2010-07-26T00:00:00",
          "id": 2266,
          "indication": "Cost-effectiveness of Ozurdex® in the treatment of macular oedema following Retinal Vein Occlusion.",
          "last_scrape": "2018-12-13T16:32:12",
          "latest": "2012-03-16T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2010-11-12, 2010-12-16",
          "rr_end": "2010-12-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2010-11-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Macular Edema; Uveitis",
          "trade_name": "Ozurdex",
          "url": "http://www.ncpe.ie/drugs/dexamethasone-intravitreal-implant-ozurdex/"
         },
         {
          "company": "Orion",
          "drug_name": "Dexmedetomidine (Dexdor®)",
          "earliest": "2011-07-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/dexdor",
          "eu_market": "2011-09-15T00:00:00",
          "id": 2267,
          "indication": "Dexmedetomidine (Dexdor®) for the treatemnt of ICU adult patients requiring light to moderate sedation.",
          "last_scrape": "2018-12-13T16:32:15",
          "latest": "2011-09-06T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-07-08, 2011-09-06",
          "rr_end": "2011-09-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-07-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Conscious Sedation",
          "trade_name": "Dexdor",
          "url": "http://www.ncpe.ie/drugs/dexmedetomidine-dexdor/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Dienogest (Visanne®)",
          "earliest": "2010-09-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2268,
          "indication": "Dienogest (Visanne®) for the Treatment of Endometriosis",
          "last_scrape": "2018-12-13T16:32:21",
          "latest": "2010-10-04T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-09-17, 2010-10-04",
          "rr_end": "2010-10-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2010-09-17T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Visanne",
          "url": "http://www.ncpe.ie/drugs/dienogest-visanne/"
         },
         {
          "company": "Almirall",
          "drug_name": "Dimethyl fumarate (Skilarence®)",
          "earliest": "2018-01-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence",
          "eu_market": "2017-06-23T00:00:00",
          "id": 2269,
          "indication": "Dimethyl fumarate (Skilarence®) for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.",
          "last_scrape": "2018-12-13T16:32:24",
          "latest": "2018-02-06T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-01-15, 2018-02-06",
          "rr_end": "2018-02-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-01-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Psoriasis",
          "trade_name": "Skilarence",
          "url": "http://www.ncpe.ie/drugs/dimethyl-fumarate-skilarence/"
         },
         {
          "company": "Biogen",
          "drug_name": "Dimethyl fumarate (Tecfidera®)",
          "earliest": "2014-02-04T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera",
          "eu_market": "2014-01-30T00:00:00",
          "id": 2270,
          "indication": "Dimethyl fumarate (Tecfidera®) is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (MS).",
          "last_scrape": "2018-12-13T16:32:26",
          "latest": "2015-04-14T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-02-04, 2014-03-06",
          "rr_end": "2014-03-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-02-04T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Tecfidera",
          "url": "http://www.ncpe.ie/drugs/dimethyl-fumarate-tecfidera/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Dinutuximab beta (Qarziba®)",
          "earliest": "2017-10-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13",
          "eu_market": "2009-12-09T00:00:00",
          "id": 2271,
          "indication": "Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ≥ 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.",
          "last_scrape": "2018-12-13T16:32:29",
          "latest": "2018-10-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-10-19, 2017-11-23",
          "rr_end": "2017-11-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "following assessment of the applicant’s submission, the ncpe recommends that dinutuximab beta (qarziba®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments this recommendation should be considered while also having regard to the criteria specified in the health (pricing and supply of goods) act 2013",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-10-19T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "Pneumococcal Infections; Immunization",
          "trade_name": "Qarziba",
          "url": "http://www.ncpe.ie/drugs/dinutuximab-beta-dinutuximab-beta-eusa/"
         },
         {
          "company": "ViiV",
          "drug_name": "Dolutegravir/Rilpivirine (Juluca®)",
          "earliest": "2018-06-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/juluca",
          "eu_market": "2018-05-16T00:00:00",
          "id": 2272,
          "indication": "Dolutegravir/rilpivirine (Juluca®)is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.",
          "last_scrape": "2018-12-13T16:32:34",
          "latest": "2018-10-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-06-08, 2018-07-12",
          "rr_end": "2018-07-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is not recommended the ncpe recommends that juluca® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the health (pricing and supply of medical goods) act 2013",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2018-06-08T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "HIV Infections",
          "trade_name": "Juluca",
          "url": "http://www.ncpe.ie/drugs/dolutegravir-rilpivirine-juluca/"
         },
         {
          "company": "ViiV",
          "drug_name": "Dolutegravir (Tivicay®)",
          "earliest": "2014-02-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay",
          "eu_market": "2014-01-16T00:00:00",
          "id": 2273,
          "indication": "Dolutegravir (Tivicay®) is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age.",
          "last_scrape": "2018-12-13T16:32:36",
          "latest": "2014-03-13T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-02-10, 2014-03-13",
          "rr_end": "2014-03-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-02-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "HIV Infections",
          "trade_name": "Tivicay",
          "url": "http://www.ncpe.ie/drugs/dolutegravir-tivicay/"
         },
         {
          "company": "Sanofi-aventis",
          "drug_name": "Dronedarone (Multaq®)",
          "earliest": "2010-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0",
          "eu_market": "2009-11-25T00:00:00",
          "id": 2274,
          "indication": "Rapid Review",
          "last_scrape": "2018-12-13T16:32:39",
          "latest": "2010-01-12T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-01-12, 2010-01-01",
          "rr_end": "2010-01-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2010-01-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Atrial Fibrillation",
          "trade_name": "Multaq",
          "url": "http://www.ncpe.ie/drugs/dronedarone-multaq/"
         },
         {
          "company": "Eli",
          "drug_name": "Dulaglutide (Trulicity®)",
          "earliest": "2015-03-04T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity",
          "eu_market": "2014-11-21T00:00:00",
          "id": 2275,
          "indication": "Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.",
          "last_scrape": "2018-12-13T16:32:42",
          "latest": "2015-04-29T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-03-04, 2015-04-29",
          "rr_end": "2015-04-29T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-03-04T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Trulicity",
          "url": "http://www.ncpe.ie/drugs/dulaglutide-trulicity/"
         },
         {
          "company": "sanofi-aventis",
          "drug_name": "Dupilumab (Dupixent®)",
          "earliest": "2017-11-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent",
          "eu_market": "2017-09-27T00:00:00",
          "id": 2276,
          "indication": "Dupilumab (Dupixent®) is indicated for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.",
          "last_scrape": "2018-12-13T16:32:46",
          "latest": "2018-06-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-11-13, 2017-11-24",
          "rr_end": "2017-11-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-11-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Dermatitis, Atopic",
          "trade_name": "Dupixent",
          "url": "http://www.ncpe.ie/drugs/dupilumab-dupixent/"
         },
         {
          "company": "Alexion",
          "drug_name": "Eculizumab (Soliris®)",
          "earliest": "2010-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/soliris",
          "eu_market": "2007-06-20T00:00:00",
          "id": 2277,
          "indication": "An Economic Evaluation of Eculizumab (Soliris®) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in the Irish healthcare setting.",
          "last_scrape": "2018-12-13T16:32:53",
          "latest": "2013-10-14T00:00:00",
          "ncpe_year": 2013,
          "orphan": 1,
          "rr_dates": "",
          "rr_end": "2017-11-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-10-23T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Hemoglobinuria, Paroxysmal",
          "trade_name": "Soliris",
          "url": "http://www.ncpe.ie/drugs/eculizumab-soliris/"
         },
         {
          "company": "Daiichi",
          "drug_name": "Edoxaban (Lixiana®)",
          "earliest": "2015-06-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2278,
          "indication": "Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.",
          "last_scrape": "2018-12-13T16:32:55",
          "latest": "2015-07-10T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-06-26, 2015-07-10",
          "rr_end": "2015-07-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-06-26T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Stroke; Venous Thromboembolism",
          "trade_name": "Lixiana",
          "url": "http://www.ncpe.ie/drugs/edoxaban-lixiana/"
         },
         {
          "company": "Merck",
          "drug_name": "Elbasvir/Grazoprevir (Zepatier®)",
          "earliest": "2016-08-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier",
          "eu_market": "2016-07-22T00:00:00",
          "id": 2279,
          "indication": "Elbasvir 50mg/100mg grazoprevir (EBR/GZR)(Zepatier®) is indicated for the treatment of genotypes 1 and 4 chronic HCV infection in patients with Child-Turcotte-Pugh score A (CTPA).",
          "last_scrape": "2018-12-13T16:33:00",
          "latest": "2016-10-13T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-08-10, 2016-10-13",
          "rr_end": "2016-10-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2016-08-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Zepatier",
          "url": "http://www.ncpe.ie/drugs/elbasvirgrazoprevir-zepatier-2/"
         },
         {
          "company": "Genzyme",
          "drug_name": "Eliglustat (Cerdelga®)",
          "earliest": "2016-03-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga",
          "eu_market": "2015-01-19T00:00:00",
          "id": 2280,
          "indication": "Eliglustat (Cerdelga®) is indicated for the long-term treatment of adult patients with Gaucher disease type 1.",
          "last_scrape": "2018-12-13T16:33:03",
          "latest": "2018-09-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2016-03-21, 2016-05-17",
          "rr_end": "2016-05-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-03-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Gaucher Disease",
          "trade_name": "Cerdelga",
          "url": "http://www.ncpe.ie/drugs/eliglustat-cerdelga/"
         },
         {
          "company": "BioMarin",
          "drug_name": "Elosulfase alfa (Vimizim®)",
          "earliest": "2015-03-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vimizim",
          "eu_market": "2014-04-27T00:00:00",
          "id": 2281,
          "indication": "Elosulfase alfa (Vimzim®) is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome, MPS IVA) in patients of all ages.",
          "last_scrape": "2018-12-13T16:33:05",
          "latest": "2018-04-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2015-03-30, 2015-05-08",
          "rr_end": "2015-05-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-03-30T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Mucopolysaccharidosis IV",
          "trade_name": "Vimizim",
          "url": "http://www.ncpe.ie/drugs/elosulfase-alfa-vimizim/"
         },
         {
          "company": "Novartis",
          "drug_name": "Eltrombopag (Revolade®) for Thrombocytopenia in HCV",
          "earliest": "2014-01-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/revolade",
          "eu_market": "2010-03-11T00:00:00",
          "id": 2282,
          "indication": "Eltrombopag (Revolade®) is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy",
          "last_scrape": "2018-12-13T16:33:12",
          "latest": "2014-02-13T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-01-10, 2014-02-13",
          "rr_end": "2014-02-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-01-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Purpura, Thrombocytopenic, Idiopathic",
          "trade_name": "Revolade",
          "url": "http://www.ncpe.ie/drugs/eltrombopag-revolade-2/"
         },
         {
          "company": "Novartis",
          "drug_name": "Eltrombopag (Revolade®) for Severe Aplastic Anaemia (SAA)",
          "earliest": "2016-02-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/revolade",
          "eu_market": "2010-03-11T00:00:00",
          "id": 2283,
          "indication": "Revolade® for the treatment adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation.",
          "last_scrape": "2018-12-13T16:33:17",
          "latest": "2016-03-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 1,
          "rr_dates": "2016-02-05, 2016-03-01",
          "rr_end": "2016-03-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2016-02-05T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Purpura, Thrombocytopenic, Idiopathic",
          "trade_name": "Revolade",
          "url": "http://www.ncpe.ie/drugs/eltrombopag-revolade-3/"
         },
         {
          "company": "Novartis",
          "drug_name": "Eltrombopag (Revolade®) for ITP",
          "earliest": "2010-07-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/revolade",
          "eu_market": "2010-03-11T00:00:00",
          "id": 2284,
          "indication": "Cost-effectiveness of eltrombopag (Revolade®) for the treatment of chronic immune thrombocytopenic purpura (ITP).",
          "last_scrape": "2018-12-13T16:33:23",
          "latest": "2018-04-16T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-12-04, 2018-04-16, 2017-12-01",
          "rr_end": "2017-12-01T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with currently available therapies",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-12-04T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Purpura, Thrombocytopenic, Idiopathic",
          "trade_name": "Revolade",
          "url": "http://www.ncpe.ie/drugs/eltrombopag-revolade/"
         },
         {
          "company": "Gilead",
          "drug_name": "Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya®)",
          "earliest": "2015-11-24T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya",
          "eu_market": "2015-11-19T00:00:00",
          "id": 2285,
          "indication": "Genvoya® is indicated for the treatment of adults and adolescents infected with human immunodeficiency virus – 1 (HIV-1).",
          "last_scrape": "2018-12-13T16:33:26",
          "latest": "2016-01-05T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2015-11-24, 2016-01-05",
          "rr_end": "2016-01-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-11-24T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "HIV Infections",
          "trade_name": "Genvoya",
          "url": "http://www.ncpe.ie/drugs/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Empagliflozin (Jardiance®)",
          "earliest": "2014-05-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance",
          "eu_market": "2014-05-22T00:00:00",
          "id": 2286,
          "indication": "Add-on combination therapy ",
          "last_scrape": "2018-12-13T16:33:32",
          "latest": "2014-06-12T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-05-22, 2014-06-12",
          "rr_end": "2014-06-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-05-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Jardiance",
          "url": "http://www.ncpe.ie/drugs/empagliflozin-jardiance/"
         },
         {
          "company": "Gilead",
          "drug_name": "Emtricitabine / tenofovir disoproxil fumarate (Truvada®)",
          "earliest": "2017-06-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/truvada",
          "eu_market": "2005-02-20T00:00:00",
          "id": 2287,
          "indication": "Truvada® is indicated in combination with safer sex practices for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.",
          "last_scrape": "2018-12-13T16:33:37",
          "latest": "2017-07-19T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-06-12, 2017-07-18",
          "rr_end": "2017-07-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-06-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "HIV Infections",
          "trade_name": "Truvada",
          "url": "http://www.ncpe.ie/drugs/emtricitabine-tenofovir-disoproxil-fumarate-truvada/"
         },
         {
          "company": "CIS",
          "drug_name": "Emtricitabine/tenofovir disoproxil (TEVA®)",
          "earliest": "2017-12-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2288,
          "indication": "Emtricitabine/tenofovir disoproxil (TEVA®) for pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk.",
          "last_scrape": "2018-12-13T16:33:43",
          "latest": "2017-12-21T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-12-11, 2017-12-21",
          "rr_end": "2017-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-12-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "TEVA",
          "url": "http://www.ncpe.ie/drugs/emtricitabine-tenovir-disoproxil-teva/"
         },
         {
          "company": "Gilead",
          "drug_name": "Emtricitabine/tenofovir alafenamide (Descovy®)",
          "earliest": "2016-04-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/descovy",
          "eu_market": "2016-04-21T00:00:00",
          "id": 2289,
          "indication": "Descovy® (F/TAF) is licensed in combination with other antiretroviral agents (ARVs) for the treatment of adults and adolescents (≥12 years; body weight ≥35 kg) infected with human immunodeficiency virus (HIV) type 1.",
          "last_scrape": "2018-12-13T16:33:48",
          "latest": "2016-04-26T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-04-26, 2016-04-26",
          "rr_end": "2016-04-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-04-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "HIV Infections",
          "trade_name": "Descovy",
          "url": "http://www.ncpe.ie/drugs/emtricitabinetenofovir-alafenamide-descovy/"
         },
         {
          "company": "Astellas",
          "drug_name": "Enzalutamide (Xtandi®) on or after chemotherapy",
          "earliest": "2013-06-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi",
          "eu_market": "2013-06-21T00:00:00",
          "id": 2290,
          "indication": "Enzalutamide (Xtandi®) is indicated for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.",
          "last_scrape": "2018-12-13T16:33:52",
          "latest": "2014-04-10T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-06-28, 2013-07-10",
          "rr_end": "2013-07-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-06-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Xtandi",
          "url": "http://www.ncpe.ie/drugs/enzalutamide-xtandi/"
         },
         {
          "company": "CIS",
          "drug_name": "Epoprostenol (Veletri®)",
          "earliest": "2016-12-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2291,
          "indication": "Veletri® is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH associated with connective tissue diseases) in patients with WHO FC III–IV symptoms to improve exercise capacity.",
          "last_scrape": "2018-12-13T16:33:59",
          "latest": "2017-02-06T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-12-13, 2017-02-06",
          "rr_end": "2017-02-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2016-12-13T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Veletri",
          "url": "http://www.ncpe.ie/drugs/epoprostenol-veletri/"
         },
         {
          "company": "Novartis",
          "drug_name": "Erenumab (Aimovig®)",
          "earliest": "2018-07-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig",
          "eu_market": "2018-07-26T00:00:00",
          "id": 2292,
          "indication": "Erenumab (Aimovig®)  is indicated for the treatment of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig®.",
          "last_scrape": "2018-12-13T16:34:03",
          "latest": "2018-08-15T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-07-19, 2018-08-15",
          "rr_end": "2018-08-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-07-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Migraine Disorders",
          "trade_name": "Aimovig",
          "url": "http://www.ncpe.ie/drugs/erenumab-aimovig/"
         },
         {
          "company": "Eisai",
          "drug_name": "Eribulin (Halaven®)",
          "earliest": "2011-02-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/halaven",
          "eu_market": "2011-03-17T00:00:00",
          "id": 2293,
          "indication": "Eribulin (Halaven®) for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.",
          "last_scrape": "2018-12-13T16:34:07",
          "latest": "2014-12-01T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2011-03-11, 2011-02-09",
          "rr_end": "2011-02-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-03-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms; Liposarcoma",
          "trade_name": "Halaven",
          "url": "http://www.ncpe.ie/drugs/eribulin-halaven/"
         },
         {
          "company": "BIAL",
          "drug_name": "Eslicarbazepine (Zebinix®)",
          "earliest": "2009-08-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix",
          "eu_market": "2009-04-21T00:00:00",
          "id": 2294,
          "indication": "Eslicarbazepine (Zebinix®) for the treatment of Epilepsy",
          "last_scrape": "2018-12-13T16:34:09",
          "latest": "2009-09-01T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "2009-09-01, 2009-08-01",
          "rr_end": "2009-08-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2009-09-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Epilepsy",
          "trade_name": "Zebinix",
          "url": "http://www.ncpe.ie/drugs/eslicarbazepine-zebinix/"
         },
         {
          "company": "Samsung",
          "drug_name": "Etanercept (Benepali®)",
          "earliest": "2016-03-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/benepali",
          "eu_market": "2016-01-13T00:00:00",
          "id": 2295,
          "indication": "Benepali® is a biosimilar of the TNF-α inhibitor Etanercept (Enbrel®) for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, axial spondylitis and plaque psoriasis.",
          "last_scrape": "2018-12-13T16:34:12",
          "latest": "2016-05-10T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-03-22, 2016-05-10",
          "rr_end": "2016-05-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2016-03-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis",
          "trade_name": "Benepali",
          "url": "http://www.ncpe.ie/drugs/etanercept-benepali/"
         },
         {
          "company": "Amgen",
          "drug_name": "Etelcalcetide (Parsabiv®)",
          "earliest": "2017-06-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv",
          "eu_market": "2016-11-11T00:00:00",
          "id": 2296,
          "indication": "Etelcalcitide (Parsabiv®) is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis.",
          "last_scrape": "2018-12-13T16:34:15",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-06-14, 2017-09-01",
          "rr_end": "2017-09-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-06-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hyperparathyroidism, Secondary",
          "trade_name": "Parsabiv",
          "url": "http://www.ncpe.ie/drugs/etelcalcetide-parsabiv/"
         },
         {
          "company": "Alfasigma",
          "drug_name": "Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim®)",
          "earliest": "2012-05-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/eurartesim",
          "eu_market": "2011-10-27T00:00:00",
          "id": 2297,
          "indication": "Eurartesim® (Piperaquine tetraphosphate/dihidroartemisinin) for uncomplicated malaria caused by the Plasmodium falciparum parasite",
          "last_scrape": "2018-12-13T16:34:21",
          "latest": "2012-05-28T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-05-22, 2012-05-28",
          "rr_end": "2012-05-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2012-05-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Malaria",
          "trade_name": "Eurartesim",
          "url": "http://www.ncpe.ie/drugs/eurartesim-piperaquine-tetraphosphatedihidroartemisinin/"
         },
         {
          "company": "Novartis",
          "drug_name": "Everolimus (Afinitor®)",
          "earliest": "2012-09-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor",
          "eu_market": "2009-08-02T00:00:00",
          "id": 2298,
          "indication": "Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor",
          "last_scrape": "2018-12-13T16:34:24",
          "latest": "2012-10-12T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-09-21, 2012-10-12",
          "rr_end": "2012-10-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-09-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms",
          "trade_name": "Afinitor",
          "url": "http://www.ncpe.ie/drugs/everolimus-afinitor/"
         },
         {
          "company": "Novartis",
          "drug_name": "Everolimus (Votubia ®) for refractory seizures associated with tuberous sclerosis complex (TSC)",
          "earliest": "2017-04-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/votubia",
          "eu_market": "2011-09-02T00:00:00",
          "id": 2299,
          "indication": "Everolimus (Votubia®) is indicated for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC.",
          "last_scrape": "2018-12-13T16:34:26",
          "latest": "2017-04-26T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2017-04-19, 2017-04-26",
          "rr_end": "2017-04-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-04-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Tuberous Sclerosis",
          "trade_name": "Votubia",
          "url": "http://www.ncpe.ie/drugs/everolimus-votubia-for-refractory-seizures-associated-with-tuberous-sclerosis-complex-tsc/"
         },
         {
          "company": "Novartis",
          "drug_name": "Everolimus (Votubia®)",
          "earliest": "2011-09-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/votubia",
          "eu_market": "2011-09-02T00:00:00",
          "id": 2300,
          "indication": "Everolimus (Votubia®) for the treatment of patients aged 3 years and older with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery",
          "last_scrape": "2018-12-13T16:34:29",
          "latest": "2011-10-14T00:00:00",
          "ncpe_year": 2011,
          "orphan": 1,
          "rr_dates": "2011-09-30, 2011-10-14",
          "rr_end": "2011-10-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-09-30T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Tuberous Sclerosis",
          "trade_name": "Votubia",
          "url": "http://www.ncpe.ie/drugs/everolimus-votubia/"
         },
         {
          "company": "Amgen",
          "drug_name": "Evolocumab (Repatha®)",
          "earliest": "2016-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/repatha",
          "eu_market": "2015-07-17T00:00:00",
          "id": 2301,
          "indication": "Evolocumab (Repatha®) is indicated for both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia.",
          "last_scrape": "2018-12-13T16:34:36",
          "latest": "2018-05-16T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2011-10-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-09-12T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Dyslipidemias; Hypercholesterolemia",
          "trade_name": "Repatha",
          "url": "http://www.ncpe.ie/drugs/evolocumab-repatha/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Exenatide (Bydureon®)",
          "earliest": "2011-05-31T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon",
          "eu_market": "2011-06-17T00:00:00",
          "id": 2302,
          "indication": "Exenatide (Bydureon®) for the treatment of type II diabetes mellitus combined with Metformin, Sulphonylurea, Thiazolidinedione, Metform and SU and Metformn and TZD in adults who have not acheived glycaemic control on maximally tolerated doses of these oral therapies.",
          "last_scrape": "2018-12-13T16:34:41",
          "latest": "2011-06-09T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-05-31, 2011-06-09",
          "rr_end": "2011-06-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-05-31T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Bydureon",
          "url": "http://www.ncpe.ie/drugs/exenatide-bydureon/"
         },
         {
          "company": "Blogen",
          "drug_name": "Fampridine (Fampyra®)",
          "earliest": "2011-09-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra",
          "eu_market": "2011-07-20T00:00:00",
          "id": 2303,
          "indication": "Fampridine (Fampyra®) for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).",
          "last_scrape": "2018-12-13T16:34:44",
          "latest": "2012-08-17T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-09-11, 2011-09-01",
          "rr_end": "2011-09-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-09-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Fampyra",
          "url": "http://www.ncpe.ie/drugs/fampridine-fampyra/"
         },
         {
          "company": "Shield",
          "drug_name": "Ferric maltol (Feraccru®)",
          "earliest": "2016-08-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/feraccru",
          "eu_market": "2016-02-18T00:00:00",
          "id": 2304,
          "indication": "Ferric maltol indicated for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients.",
          "last_scrape": "2018-12-13T16:34:48",
          "latest": "2016-09-06T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-08-12, 2016-09-06",
          "rr_end": "2016-09-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "reimbursement not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2016-08-12T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "Anemia, Iron-Deficiency",
          "trade_name": "Feraccru",
          "url": "http://www.ncpe.ie/drugs/ferric-maltol-feraccru_/"
         },
         {
          "company": "Astellas",
          "drug_name": "Fidaxomicin (Dificlir®)",
          "earliest": "2012-03-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir",
          "eu_market": "2011-12-05T00:00:00",
          "id": 2305,
          "indication": "Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.",
          "last_scrape": "2018-12-13T16:34:51",
          "latest": "2013-02-05T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2012-03-09, 2012-03-23",
          "rr_end": "2012-03-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-03-09T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Clostridium Infections",
          "trade_name": "Dificlir",
          "url": "http://www.ncpe.ie/drugs/fidaxomicin-dificlir/"
         },
         {
          "company": "Novartis",
          "drug_name": "Fingolimod (Gilenya®)",
          "earliest": "2010-12-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya",
          "eu_market": "2011-03-17T00:00:00",
          "id": 2306,
          "indication": "Cost effectiveness of Fingolimod (Gilenya®) for the treatment of highly active relapsing-remitting multiple sclerosis.",
          "last_scrape": "2018-12-13T16:34:56",
          "latest": "2011-09-22T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-01-10, 2010-12-03",
          "rr_end": "2010-12-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-01-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Gilenya",
          "url": "http://www.ncpe.ie/drugs/fingolimod-gilenya-4/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Fluocinolone acetonide (Iluvien®)",
          "earliest": "2016-02-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2307,
          "indication": "Iluvien® is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema (DMO) considered insufficiently responsive to available therapies.",
          "last_scrape": "2018-12-13T16:35:01",
          "latest": "2016-03-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-02-15, 2016-03-01",
          "rr_end": "2016-03-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2016-02-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Iluvien",
          "url": "http://www.ncpe.ie/drugs/fluocinolone-acetonide-iluvien/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Fluticasone furoate/ umeclidinium/ vilantero (Trelegy™ Ellipta™)",
          "earliest": "2018-04-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta",
          "eu_market": "2017-11-15T00:00:00",
          "id": 2308,
          "indication": "Trelegy™ Ellipta™ which is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.",
          "last_scrape": "2018-12-13T16:35:05",
          "latest": "2018-06-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-04-30, 2018-06-18",
          "rr_end": "2018-06-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is not recommended the ncpe recommends that trelegy™ ellipta™ be considered for reimbursement in accordance with the criteria specified in the health (pricing and supply of medical goods) act 2013",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2018-04-30T00:00:00",
          "rr_status": "Reimbursement without HTA",
          "ta_list": "Pulmonary Disease, Chronic Obstructive",
          "trade_name": "Trelegy Ellipta",
          "url": "http://www.ncpe.ie/drugs/fluticasone-furoate-umeclidinium-vilantero-trelegy-ellipta/"
         },
         {
          "company": "Ferring",
          "drug_name": "Follitropin delta (Rekovelle®)",
          "earliest": "2017-07-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle",
          "eu_market": "2016-12-12T00:00:00",
          "id": 2309,
          "indication": "Follitropin delta (Rekovelle ®) is indicated for controlled ovarian stimulation (COS) for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle",
          "last_scrape": "2018-12-13T16:35:09",
          "latest": "2019-02-01T00:00:00",
          "ncpe_year": 2019,
          "orphan": 0,
          "rr_dates": "2017-07-25, 2017-08-15",
          "rr_end": "2017-08-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-07-25T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Anovulation",
          "trade_name": "Rekovelle",
          "url": "http://www.ncpe.ie/drugs/follitropin-delta-rekovelle/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Gefitinib (Iressa®)",
          "earliest": "2010-06-16T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/iressa",
          "eu_market": "2009-06-24T00:00:00",
          "id": 2310,
          "indication": "A review of the economic evaluation of oral gefitinib (Iressa®) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR.",
          "last_scrape": "2018-12-13T16:35:12",
          "latest": "2010-11-05T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-08-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-07-14T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Iressa",
          "url": "http://www.ncpe.ie/drugs/gefitinib-iressa/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Gemtuzumab ozogamicin (Mylotarg®)",
          "earliest": "2018-06-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0",
          "eu_market": "2018-04-19T00:00:00",
          "id": 2311,
          "indication": "Gemtuzumab ozogamicin (Mylotarg®) which is indicated for combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia.",
          "last_scrape": "2018-12-13T16:35:15",
          "latest": "2018-07-31T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-06-21, 2018-07-17",
          "rr_end": "2018-07-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of gemtuzumab ozogamicin compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-06-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid, Acute",
          "trade_name": "Mylotarg",
          "url": "http://www.ncpe.ie/drugs/gemtuzumab-ozogamicin-mylotarg/"
         },
         {
          "company": "AbbVie",
          "drug_name": "Glecaprevir/Pibrentasvir (Maviret®)",
          "earliest": "2017-07-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/maviret",
          "eu_market": "2017-07-26T00:00:00",
          "id": 2312,
          "indication": "Glecaprevir/pibrentasvir (Maviret®) is licensed for the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic GT1-6.",
          "last_scrape": "2018-12-13T16:35:19",
          "latest": "2017-08-17T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-07-11, 2017-08-17",
          "rr_end": "2017-08-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-07-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Maviret",
          "url": "http://www.ncpe.ie/drugs/glecaprevirpibrentasvir-maviret/"
         },
         {
          "company": "CIS",
          "drug_name": "Glucosamine sulfate (Dona®)",
          "earliest": "2009-04-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2313,
          "indication": "Economic evalution of glucosamine sulfate (Dona®) for the treatment of oestoarthritis in the Irish Healthcare setting.",
          "last_scrape": "2018-12-13T16:35:25",
          "latest": "2009-06-01T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-08-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-07-16T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Dona",
          "url": "http://www.ncpe.ie/drugs/glucosamine-sulfate-dona/"
         },
         {
          "company": "Horizon",
          "drug_name": "Glycerol Phenylbutyrate (Ravicti®)",
          "earliest": "2018-03-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti",
          "eu_market": "2015-11-26T00:00:00",
          "id": 2314,
          "indication": "Glycerol phenylbutyrate (Ravicti®) which is indicated for use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs).",
          "last_scrape": "2018-12-13T16:35:32",
          "latest": "2018-06-20T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-03-26, 2018-06-20",
          "rr_end": "2018-06-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is not recommended the ncpe recommends that glycerol phenylbutyrate (ravicti®) be considered for reimbursement in accordance with the criteria specified in the health (pricing and supply of medical goods) act 2013",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2018-03-26T00:00:00",
          "rr_status": "Reimbursement without HTA",
          "ta_list": "Urea Cycle Disorders, Inborn",
          "trade_name": "Ravicti",
          "url": "http://www.ncpe.ie/drugs/glycerol-phenylbutyrate-ravicti/"
         },
         {
          "company": "Novartis",
          "drug_name": "Glycopyrronium bromide (Seebri Breezhaler®)",
          "earliest": "2012-08-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler",
          "eu_market": "2012-09-28T00:00:00",
          "id": 2315,
          "indication": "Seebri Breezhaler® is indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).",
          "last_scrape": "2018-12-13T16:35:38",
          "latest": "2012-08-17T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-08-12, 2012-08-17",
          "rr_end": "2012-08-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2012-08-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Pulmonary Disease, Chronic Obstructive",
          "trade_name": "Seebri Breezhaler",
          "url": "http://www.ncpe.ie/drugs/glycopyrronium-bromide-seebri-breezhaler/"
         },
         {
          "company": "Proveca",
          "drug_name": "Glycopyrronium bromide (Sialanar®)",
          "earliest": "2017-03-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar",
          "eu_market": "2016-09-15T00:00:00",
          "id": 2316,
          "indication": "Glycopyrronium bromide (Sialanar®) is indicated for symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders",
          "last_scrape": "2018-12-13T16:35:40",
          "latest": "2017-03-13T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-03-07, 2017-03-13",
          "rr_end": "2017-03-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-03-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Sialorrhea",
          "trade_name": "Sialanar",
          "url": "http://www.ncpe.ie/drugs/glypyrronium-bromide-sialanar/"
         },
         {
          "company": "Janssen",
          "drug_name": "Golimumab (Simponi®) for UC",
          "earliest": "2013-10-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/simponi",
          "eu_market": "2009-10-01T00:00:00",
          "id": 2317,
          "indication": "Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.",
          "last_scrape": "2018-12-13T16:35:47",
          "latest": "2013-10-31T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-10-11, 2013-10-31",
          "rr_end": "2013-10-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-10-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid",
          "trade_name": "Simponi",
          "url": "http://www.ncpe.ie/drugs/golimumab-simponi-2/"
         },
         {
          "company": "Janssen",
          "drug_name": "Golimumab (Simponi®)",
          "earliest": "2009-11-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/simponi",
          "eu_market": "2009-10-01T00:00:00",
          "id": 2318,
          "indication": "Cost-effectiveness of golimumab (Simponi®) in the treatment of moderate to severe rheumatoid arthritis.",
          "last_scrape": "2018-12-13T16:35:54",
          "latest": "2010-06-01T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-10-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-09-29T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid",
          "trade_name": "Simponi",
          "url": "http://www.ncpe.ie/drugs/golimumab-simponi/"
         },
         {
          "company": "Unknown",
          "drug_name": "Grass pollen allergen extract (Oralair®)",
          "earliest": "2011-09-26T00:00:00",
          "ema_url": "",
          "eu_market": "2008-10-23T00:00:00",
          "id": 2319,
          "indication": " Grass pollen allegen extract (Oralair®) for the treatment of allergic grass pollen rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms confirmed by a positive cutaneous test and/or a positive titre of the specific IgE to the grass pollen.",
          "last_scrape": "2018-12-13T16:35:56",
          "latest": "2011-10-01T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-10-11, 2011-09-26",
          "rr_end": "2011-09-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-10-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Oralair",
          "url": "http://www.ncpe.ie/drugs/grass-pollen-allergen-extract-oralair/"
         },
         {
          "company": "Shire",
          "drug_name": "Guanfacine hydrochloride (Intuniv®)",
          "earliest": "2015-12-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv",
          "eu_market": "2015-09-17T00:00:00",
          "id": 2320,
          "indication": "Intuniv® is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.  It must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.",
          "last_scrape": "2018-12-13T16:36:00",
          "latest": "2015-12-18T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-12-01, 2015-12-18",
          "rr_end": "2015-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-12-01T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Attention Deficit Disorder with Hyperactivity",
          "trade_name": "Intuniv",
          "url": "http://www.ncpe.ie/drugs/guanfacine-hydrochloride-intuniv/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Guselkumab (Tremfya®)",
          "earliest": "2017-12-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya",
          "eu_market": "2017-11-10T00:00:00",
          "id": 2321,
          "indication": "Guselkumab (Tremfya®) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.",
          "last_scrape": "2018-12-13T16:36:02",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-12-01, 2018-02-06",
          "rr_end": "2018-02-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-12-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Psoriasis",
          "trade_name": "Tremfya",
          "url": "http://www.ncpe.ie/drugs/guselkumab-tremfya/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Human alpha1-proteinase inhibitor (A1PI) (Prolastin®)",
          "earliest": "2017-05-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2322,
          "indication": "Human A1PI (Prolastin ®)  is indicated for long-term augmentation therapy in subjects with alpha1-proteinase inhibitor deficiency (phenotypes PiZZ, PiZ(null), Pi (null,null) and PiSZ) within the limits of moderate airflow obstruction (FEV1 35-60%) and the evaluation of the clinical condition (disability).",
          "last_scrape": "2018-12-13T16:36:07",
          "latest": "2017-06-08T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-05-05, 2017-06-08",
          "rr_end": "2017-06-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-05-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Prolastin",
          "url": "http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-a1pi-prolastin/"
         },
         {
          "company": "CSL",
          "drug_name": "Human alpha1-proteinase inhibitor (Respreeza®)",
          "earliest": "2016-01-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza",
          "eu_market": "2015-08-20T00:00:00",
          "id": 2323,
          "indication": "Respreeza® is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null, null), PiSZ). Patients are to be under optimal pharmacologic and nonpharmacological treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.",
          "last_scrape": "2018-12-13T16:36:14",
          "latest": "2017-01-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-01-20, 2016-02-05",
          "rr_end": "2016-02-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-01-20T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Genetic Diseases, Inborn; Lung Diseases",
          "trade_name": "Respreeza",
          "url": "http://www.ncpe.ie/drugs/human-alpha1-proteinase-inhibitor-respreeza/"
         },
         {
          "company": "CIS",
          "drug_name": "Hyaluronic acid and co enzyme Q10 (VisuXL®)",
          "earliest": "2017-11-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2324,
          "indication": "Cross linked hyaluronic acid and co enzyme Q10 (VisuXL®) for the treatment of dry eye disease and the treatment of post-surgical intervention following elective surgery and trauma.",
          "last_scrape": "2018-12-13T16:36:17",
          "latest": "2017-11-30T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-11-06, 2017-11-30",
          "rr_end": "2017-11-30T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "reimbursement not recommended at the submitted price",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-11-06T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "VisuXL",
          "url": "http://www.ncpe.ie/drugs/hyaluronic-acid-and-co-enzyme-q10-visuxl/"
         },
         {
          "company": "Shire",
          "drug_name": "Modified Release Hydrocortisone  (Plenadren®)",
          "earliest": "2013-08-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren",
          "eu_market": "2011-11-03T00:00:00",
          "id": 2325,
          "indication": "Modified release hydrocortisone (Plenadren®) for the treatment of adrenal insufficiency in adults.",
          "last_scrape": "2018-12-13T16:36:22",
          "latest": "2018-01-11T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-11-08, 2018-01-11, 2017-11-01",
          "rr_end": "2017-11-01T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "reimbursement not recommended at the submitted price",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-11-08T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "Adrenal Insufficiency",
          "trade_name": "Plenadren",
          "url": "http://www.ncpe.ie/drugs/hydrocortisone-plenadren/"
         },
         {
          "company": "Addmedica",
          "drug_name": "Hydroxycarbamide (Siklos®)",
          "earliest": "2011-08-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/siklos",
          "eu_market": "2007-06-29T00:00:00",
          "id": 2326,
          "indication": " Hydroxycarbamide (Siklos®) is indicated for use in the prevention of painful, recurrent vaso-occlusive crises, including acute chest syndrome, in adults, adolescents and children over 2 years of age suffering from symptomatic sickle-cell disease.",
          "last_scrape": "2018-12-13T16:36:27",
          "latest": "2011-09-06T00:00:00",
          "ncpe_year": 2011,
          "orphan": 1,
          "rr_dates": "2011-08-22, 2011-09-06",
          "rr_end": "2011-09-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-08-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Anemia, Sickle Cell",
          "trade_name": "Siklos",
          "url": "http://www.ncpe.ie/drugs/hydroxcarbamide-siklos/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Ibrutinib (Imbruvica®) for previously untreated CLL",
          "earliest": "2016-08-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica",
          "eu_market": "2014-10-21T00:00:00",
          "id": 2327,
          "indication": "Ibrutinib (Imbruvica®), as a single agent, is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This indication is an extension to the original licence in the relapsed/refractory setting.",
          "last_scrape": "2018-12-13T16:36:32",
          "latest": "2016-08-24T00:00:00",
          "ncpe_year": 2016,
          "orphan": 1,
          "rr_dates": "2016-08-02, 2016-08-24",
          "rr_end": "2016-08-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-08-02T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Imbruvica",
          "url": "http://www.ncpe.ie/drugs/ibrutinib-imbruivca-for-previously-untreated-cll/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Ibrutinib (Imbruvica®) for MCL",
          "earliest": "2014-11-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica",
          "eu_market": "2014-10-21T00:00:00",
          "id": 2328,
          "indication": "Ibrutinib (Imbruvica®) is indicated in the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).",
          "last_scrape": "2018-12-13T16:36:36",
          "latest": "2015-10-06T00:00:00",
          "ncpe_year": 2015,
          "orphan": 1,
          "rr_dates": "2014-11-07, 2014-12-18",
          "rr_end": "2014-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-11-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Imbruvica",
          "url": "http://www.ncpe.ie/drugs/ibrutinib-imbruvica-for-mcl/"
         },
         {
          "company": "Shire",
          "drug_name": "Icatibant (Firazyr®)",
          "earliest": "2013-07-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr",
          "eu_market": "2008-07-11T00:00:00",
          "id": 2329,
          "indication": "Icatibant (Firazyr®) indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (type I and II HAE).",
          "last_scrape": "2018-12-13T16:36:40",
          "latest": "2013-07-01T00:00:00",
          "ncpe_year": 2013,
          "orphan": 1,
          "rr_dates": "2013-07-01, 2013-07-01",
          "rr_end": "2013-07-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-07-01T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Angioedemas, Hereditary",
          "trade_name": "Firazyr",
          "url": "http://www.ncpe.ie/drugs/icatibant-firazyr/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Idarucizumab (Praxbind®)",
          "earliest": "2015-12-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind",
          "eu_market": "2015-11-20T00:00:00",
          "id": 2330,
          "indication": "Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:",
          "last_scrape": "2018-12-13T16:36:43",
          "latest": "2015-12-18T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-12-11, 2015-12-18",
          "rr_end": "2015-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-12-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hemorrhage",
          "trade_name": "Praxbind",
          "url": "http://www.ncpe.ie/drugs/idarucizumab-praxbind/"
         },
         {
          "company": "Santhera",
          "drug_name": "Idebenone (Raxone®)",
          "earliest": "2016-02-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/raxone",
          "eu_market": "2015-09-08T00:00:00",
          "id": 2331,
          "indication": "Raxone® is indicated for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON).",
          "last_scrape": "2018-12-13T16:36:50",
          "latest": "2018-08-28T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2016-02-10, 2016-04-14",
          "rr_end": "2016-04-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-02-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Optic Atrophy, Hereditary, Leber",
          "trade_name": "Raxone",
          "url": "http://www.ncpe.ie/drugs/idebenone-raxone/"
         },
         {
          "company": "Gilead",
          "drug_name": "Idelalisib (Zydelig®)",
          "earliest": "2014-12-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig",
          "eu_market": "2014-09-18T00:00:00",
          "id": 2332,
          "indication": "Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.",
          "last_scrape": "2018-12-13T16:36:56",
          "latest": "2016-12-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2014-12-08, 2014-12-30",
          "rr_end": "2014-12-30T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-12-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Zydelig",
          "url": "http://www.ncpe.ie/drugs/idelalisib-zydelig/"
         },
         {
          "company": "Meda",
          "drug_name": "Imiquimod 3.75% (Zyclara®)",
          "earliest": "2013-09-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara",
          "eu_market": "2012-08-23T00:00:00",
          "id": 2333,
          "indication": "Imiquimod 3.75%(Zyclara®) indicated for topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.",
          "last_scrape": "2018-12-13T16:36:59",
          "latest": "2013-09-18T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-09-10, 2013-09-18",
          "rr_end": "2013-09-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-09-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Keratosis; Keratosis, Actinic",
          "trade_name": "Zyclara",
          "url": "http://www.ncpe.ie/drugs/imiquimod-zyclara/"
         },
         {
          "company": "CIS",
          "drug_name": "Incobotulinum Toxin Type A (Xeomin®)",
          "earliest": "2014-02-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2334,
          "indication": "Incobotulinum Toxin Type A (Xeomin®) is indicated for the symptomatic treatment of blepharospasm, cervical dystonia of a predominantly rotational form (spasmodic torticollis) and of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults.",
          "last_scrape": "2018-12-13T16:37:01",
          "latest": "2014-03-05T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-02-07, 2014-03-05",
          "rr_end": "2014-03-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-02-07T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Xeomin",
          "url": "http://www.ncpe.ie/drugs/incobotulinum-toxin-type-a-xeomin/"
         },
         {
          "company": "Unknown",
          "drug_name": "Indacaterol (Onbrez®)",
          "earliest": "2010-01-15T00:00:00",
          "ema_url": "",
          "eu_market": "2007-01-28T00:00:00",
          "id": 2335,
          "indication": "Review of Indacaterol (Onbrez®) for the treatment of COPD.",
          "last_scrape": "2018-12-13T16:37:04",
          "latest": "2010-01-15T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-01-15",
          "rr_end": "2010-01-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2010-01-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Onbrez",
          "url": "http://www.ncpe.ie/drugs/indacaterol-onbrez/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Infliximab (Inflectra®)",
          "earliest": "2013-09-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra",
          "eu_market": "2013-09-09T00:00:00",
          "id": 2336,
          "indication": "Inflectra® is a biosimilar product indicated for Rheumatoid Arthritis, Adult Crohn’s disease, Paediatric Crohn’s disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis.",
          "last_scrape": "2018-12-13T16:37:07",
          "latest": "2013-09-20T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2010-01-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2009-12-14T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid",
          "trade_name": "Inflectra",
          "url": "http://www.ncpe.ie/drugs/infliximab-inflectra/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Inotuzumab ozogamicin (Besponsa®)",
          "earliest": "2017-07-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa",
          "eu_market": "2017-06-28T00:00:00",
          "id": 2337,
          "indication": "Inotuzumab ozogamicin (Besponsa®) is indicated as monotherapy for the treatment of adults with relapsed or refractory (R/R) CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).",
          "last_scrape": "2018-12-13T16:37:09",
          "latest": "2018-09-14T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-07-03, 2017-09-08",
          "rr_end": "2017-09-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-07-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
          "trade_name": "Besponsa",
          "url": "http://www.ncpe.ie/drugs/inotuzumab-ozogamicin-besponsa/"
         },
         {
          "company": "Novo",
          "drug_name": "Insulin aspart (Fiasp®)",
          "earliest": "2017-05-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/fiasp",
          "eu_market": "2017-01-09T00:00:00",
          "id": 2338,
          "indication": "Insulin aspart (Fiasp®) is indicated for the treatment of diabetes mellitus in adults.",
          "last_scrape": "2018-12-13T16:37:16",
          "latest": "2017-06-14T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-05-17, 2017-06-14",
          "rr_end": "2017-06-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-05-17T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus",
          "trade_name": "Fiasp",
          "url": "http://www.ncpe.ie/drugs/insulin-aspart-fiasp/"
         },
         {
          "company": "Unknown",
          "drug_name": "Insulin aspart (NovoRapid® FlexTouch ®)",
          "earliest": "2014-07-22T00:00:00",
          "ema_url": "",
          "eu_market": "2011-08-04T00:00:00",
          "id": 2339,
          "indication": "Insulin aspart (NovoRapid® FlexTouch ®) is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.",
          "last_scrape": "2018-12-13T16:37:21",
          "latest": "2014-08-28T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-07-22, 2014-08-28",
          "rr_end": "2014-08-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-07-22T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Unknown",
          "trade_name": "NovoRapid FlexTouch",
          "url": "http://www.ncpe.ie/drugs/insulin-aspart-novorapid-flextouch/"
         },
         {
          "company": "Novo",
          "drug_name": "Insulin Degludec (Tresiba®)",
          "earliest": "2012-12-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba",
          "eu_market": "2013-01-20T00:00:00",
          "id": 2340,
          "indication": "Treatment of diabetes mellitus",
          "last_scrape": "2018-12-13T16:37:25",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2012-12-17, 2013-01-04",
          "rr_end": "2013-01-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-12-17T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Diabetes Mellitus",
          "trade_name": "Tresiba",
          "url": "http://www.ncpe.ie/drugs/insulin-degludec-tresiba/"
         },
         {
          "company": "Novo",
          "drug_name": "Insulin degludec/liraglutide (IDegLira) (Xultophy®)",
          "earliest": "2016-09-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy",
          "eu_market": "2014-09-18T00:00:00",
          "id": 2341,
          "indication": "IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.",
          "last_scrape": "2018-12-13T16:37:30",
          "latest": "2016-10-17T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-09-19, 2016-10-17",
          "rr_end": "2016-10-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-09-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Xultophy",
          "url": "http://www.ncpe.ie/drugs/insulin-degludecliraglutide-ideglira-xultophy/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Insulin Glargine (Abasaglar®)",
          "earliest": "2015-09-04T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2342,
          "indication": "Abasaglar® is indicated in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.",
          "last_scrape": "2018-12-13T16:37:36",
          "latest": "2015-10-12T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-09-04, 2015-10-12",
          "rr_end": "2015-10-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-09-04T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Abasaglar",
          "url": "http://www.ncpe.ie/drugs/insulin-glargine-abasaglar/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Insulin Glargine U300 (Toujeo®)",
          "earliest": "2015-05-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2343,
          "indication": "Toujeo® is indicated for the treatment of diabetes mellitus in adults.",
          "last_scrape": "2018-12-13T16:37:40",
          "latest": "2015-07-02T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-05-14, 2015-07-02",
          "rr_end": "2015-07-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-05-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Toujeo",
          "url": "http://www.ncpe.ie/drugs/insulin-glargine-u300-toujeo/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Ipilimumab (Yervoy®)",
          "earliest": "2011-05-31T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy",
          "eu_market": "2011-07-12T00:00:00",
          "id": 2344,
          "indication": "Pharmacoeconomic evaluation of Ipilimumab (Yervoy®) for the treatment of advanced (unresectable or metastatic) melanoma in adult patients who have received prior therapy.",
          "last_scrape": "2018-12-13T16:37:43",
          "latest": "2013-09-01T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2011-05-31, 2011-06-09",
          "rr_end": "2011-06-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-05-31T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma",
          "trade_name": "Yervoy",
          "url": "http://www.ncpe.ie/drugs/ipilimumab-yervoy/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Iron (III) isomaltoside 1000 (Diafer®)",
          "earliest": "2015-10-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2345,
          "indication": "Diafer® is indicated in adults for the treatment of iron deficiency in patients with chronic kidney disease on dialysis, when oral iron preparations are ineffective or cannot be used.",
          "last_scrape": "2018-12-13T16:37:49",
          "latest": "2015-11-18T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-10-10, 2015-11-18",
          "rr_end": "2015-11-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-10-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Diafer",
          "url": "http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-diafer/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Iron (III) isomaltoside 1000 (Monover®)",
          "earliest": "2015-10-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2346,
          "indication": "Monover® is indicated in the treatment of Iron deficiency anaemia when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.",
          "last_scrape": "2018-12-13T16:37:52",
          "latest": "2015-11-18T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-10-10, 2015-11-18",
          "rr_end": "2015-11-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-10-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Monover",
          "url": "http://www.ncpe.ie/drugs/iron-iii-isomaltoside-1000-monover/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Iron isomaltoside 1000 (MonoVer®)",
          "earliest": "2011-01-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2347,
          "indication": "MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.",
          "last_scrape": "2018-12-13T16:38:02",
          "latest": "2011-02-02T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-01-10, 2011-02-02",
          "rr_end": "2011-02-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-01-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "MonoVer",
          "url": "http://www.ncpe.ie/drugs/iron-isomaltoside-1000-monover/"
         },
         {
          "company": "Basilea",
          "drug_name": "Isavuconazole (Cresemba®) for the treatment of invasive aspergillosis.",
          "earliest": "2016-04-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba",
          "eu_market": "2015-10-15T00:00:00",
          "id": 2348,
          "indication": "Isavuconazole (Cresemba®) is indicated for the treatment of invasive aspergillosis",
          "last_scrape": "2018-12-13T16:38:07",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2016-04-11, 2016-05-11",
          "rr_end": "2016-05-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-04-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Aspergillosis",
          "trade_name": "Cresemba",
          "url": "http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-invasive-aspergillosis/"
         },
         {
          "company": "Basilea",
          "drug_name": "Isavuconazole (Cresemba®) for the treatment of mucormycosis",
          "earliest": "2016-04-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba",
          "eu_market": "2015-10-15T00:00:00",
          "id": 2349,
          "indication": "Isavuconazole (Cresemba®) is indicated in adults for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate.",
          "last_scrape": "2018-12-13T16:38:09",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2016-04-11, 2016-05-11",
          "rr_end": "2016-05-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2016-04-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Aspergillosis",
          "trade_name": "Cresemba",
          "url": "http://www.ncpe.ie/drugs/isavuconazole-cresemba-for-the-treatment-of-mucormycosis/"
         },
         {
          "company": "Vertex",
          "drug_name": "Ivacaftor (Kalydeco®)",
          "earliest": "2012-08-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco",
          "eu_market": "2012-07-22T00:00:00",
          "id": 2350,
          "indication": "For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation",
          "last_scrape": "2018-12-13T16:38:15",
          "latest": "2013-01-21T00:00:00",
          "ncpe_year": 2013,
          "orphan": 1,
          "rr_dates": "2012-08-13, 2012-08-22",
          "rr_end": "2012-08-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-08-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystic Fibrosis",
          "trade_name": "Kalydeco",
          "url": "http://www.ncpe.ie/drugs/ivacaftor-kaldeco/"
         },
         {
          "company": "Vertex",
          "drug_name": "Ivacaftor (Kalydeco®) for patients with CF 2 years +",
          "earliest": "2015-11-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco",
          "eu_market": "2012-07-22T00:00:00",
          "id": 2351,
          "indication": "Kalydeco® is indicated for the treatment of children with CF aged 2 years and older and weighing less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.",
          "last_scrape": "2018-12-13T16:38:21",
          "latest": "2016-10-12T00:00:00",
          "ncpe_year": 2016,
          "orphan": 1,
          "rr_dates": "2015-11-19, 2015-12-18",
          "rr_end": "2015-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmaoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-11-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystic Fibrosis",
          "trade_name": "Kalydeco",
          "url": "http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-patients-with-cf-2-years/"
         },
         {
          "company": "Vertex",
          "drug_name": "Ivacaftor (Kalydeco®) for the treatment of CF patients with the R117H mutation.",
          "earliest": "2016-01-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco",
          "eu_market": "2012-07-22T00:00:00",
          "id": 2352,
          "indication": "Kalydeco® for the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene.",
          "last_scrape": "2018-12-13T16:38:24",
          "latest": "2017-01-05T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2016-01-14, 2016-02-10",
          "rr_end": "2016-02-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-01-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystic Fibrosis",
          "trade_name": "Kalydeco",
          "url": "http://www.ncpe.ie/drugs/ivacaftor-kalydeco-for-the-treatment-of-cf-patients-with-the-r117h-mutation/"
         },
         {
          "company": "Takeda",
          "drug_name": "Ixazomib (Ninlaro®)",
          "earliest": "2016-11-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro",
          "eu_market": "2016-11-21T00:00:00",
          "id": 2353,
          "indication": "Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.",
          "last_scrape": "2018-12-13T16:38:29",
          "latest": "2018-12-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2016-11-23, 2017-01-16",
          "rr_end": "2017-01-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-11-23T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Myeloma",
          "trade_name": "Ninlaro",
          "url": "http://www.ncpe.ie/drugs/ixazomib-ninlaro/"
         },
         {
          "company": "Eli",
          "drug_name": "Ixekizumab (Taltz®) for psoriatic arthritis",
          "earliest": "2018-10-16T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/taltz",
          "eu_market": "2016-04-25T00:00:00",
          "id": 2354,
          "indication": "Ixekizumab (Taltz®) is indicated for the treatment of active PsA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.",
          "last_scrape": "2018-12-13T16:38:34",
          "latest": "2018-11-19T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-10-16, 2018-11-19",
          "rr_end": "2018-11-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is not recommended the ncpe recommends that ixekizumab not be considered for reimbursement at the submitted price this recommendation should be considered while also having regard to the criteria specified in the health (pricing and supply of medical goods act) 2013",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2018-10-16T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "Psoriasis",
          "trade_name": "Taltz",
          "url": "http://www.ncpe.ie/drugs/ixekizumab-taltz-for-psoriatic-arthritis/"
         },
         {
          "company": "Eli",
          "drug_name": "Ixekizumab (Taltz®)",
          "earliest": "2016-06-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/taltz",
          "eu_market": "2016-04-25T00:00:00",
          "id": 2355,
          "indication": "Taltz® is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.",
          "last_scrape": "2018-12-13T16:38:37",
          "latest": "2016-09-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-06-28, 2016-07-26",
          "rr_end": "2016-07-26T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-06-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Psoriasis",
          "trade_name": "Taltz",
          "url": "http://www.ncpe.ie/drugs/ixekizumab-taltz/"
         },
         {
          "company": "CIS",
          "drug_name": "Lisdexamfetamine dimesylate (Tyvense®)",
          "earliest": "2013-02-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2356,
          "indication": "Lisdexamfetamine dimesylate (Tyvense®) for Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.",
          "last_scrape": "2018-12-13T16:38:39",
          "latest": "2013-02-28T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-02-09, 2013-02-28",
          "rr_end": "2013-02-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-02-09T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Tyvense",
          "url": "http://www.ncpe.ie/drugs/l/lisdexamfetamine-dimesylate-tyvense/"
         },
         {
          "company": "UCB",
          "drug_name": "Lacosamide (Vimpat ®)",
          "earliest": "2017-09-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat",
          "eu_market": "2008-08-29T00:00:00",
          "id": 2357,
          "indication": "Vimpat ® is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.  The Applicant is seeking reimbursement for an extension to the product license to cover children (≥4 years of age) and adolescents (≤ 15 years of age).",
          "last_scrape": "2018-12-13T16:38:44",
          "latest": "2017-10-31T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-09-11, 2017-10-31",
          "rr_end": "2017-10-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation is recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-09-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Epilepsy",
          "trade_name": "Vimpat",
          "url": "http://www.ncpe.ie/drugs/lacosamide-vimpat/"
         },
         {
          "company": "Novartis",
          "drug_name": "Lapatinib (Tyverb®)",
          "earliest": "2008-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb",
          "eu_market": "2008-06-10T00:00:00",
          "id": 2358,
          "indication": "Cost-effectiveness of Lapatinib (Tyverb®) for the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer.",
          "last_scrape": "2018-12-13T16:38:50",
          "latest": "2008-01-01T00:00:00",
          "ncpe_year": 2008,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-10-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-09-29T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Tyverb",
          "url": "http://www.ncpe.ie/drugs/lapatinib-tyverb/"
         },
         {
          "company": "Gilead",
          "drug_name": "Ledipasvir/sofosbuvir (Harvoni®)",
          "earliest": "2014-11-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni",
          "eu_market": "2014-11-17T00:00:00",
          "id": 2359,
          "indication": "Ledipasvir/sofosbuvir (Harvoni®) is indicated for the treatment of Chronic Hepatitis C (CHC) infection (Genotye 1, 3 and 4)  in adults.",
          "last_scrape": "2018-12-13T16:38:56",
          "latest": "2015-11-20T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-11-14, 2014-12-18",
          "rr_end": "2014-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-11-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Harvoni",
          "url": "http://www.ncpe.ie/drugs/ledipasvirsofosbuvir-harvoni/"
         },
         {
          "company": "Celgene",
          "drug_name": "Lenalidomide (Revlimid®)",
          "earliest": "2015-10-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid",
          "eu_market": "2007-06-14T00:00:00",
          "id": 2360,
          "indication": "Revlimid® for the treatment of adult patients with previously untreated multiple myelomas (MM) who are not eligible for transplant (licence extension).",
          "last_scrape": "2018-12-13T16:39:05",
          "latest": "2018-01-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2015-10-05, 2015-11-20",
          "rr_end": "2015-11-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-10-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes",
          "trade_name": "Revlimid",
          "url": "http://www.ncpe.ie/drugs/lenalidomide-revlimid/"
         },
         {
          "company": "Eisai",
          "drug_name": "Lenvatinib (Kisplyx®)",
          "earliest": "2017-05-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx",
          "eu_market": "2016-08-25T00:00:00",
          "id": 2361,
          "indication": "Lenvatinib (Kisplyx®) is Indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.",
          "last_scrape": "2018-12-13T16:39:07",
          "latest": "2017-05-18T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-05-05, 2017-05-18",
          "rr_end": "2017-05-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-05-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Renal Cell",
          "trade_name": "Kisplyx",
          "url": "http://www.ncpe.ie/drugs/lenvatinib-kisplyx/"
         },
         {
          "company": "Eisai",
          "drug_name": "Lenvatinib (Lenvima®) for HCC",
          "earliest": "2018-08-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima",
          "eu_market": "2015-05-28T00:00:00",
          "id": 2362,
          "indication": "Lenvatinib (Lenvima®) which is indicated as monotherapy for the treatment of adult patients with advanced or unresectable HCC who have received no prior systemic therapy.",
          "last_scrape": "2018-12-13T16:39:11",
          "latest": "2018-08-16T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-08-07, 2018-08-16",
          "rr_end": "2018-08-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-08-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Thyroid Neoplasms",
          "trade_name": "Lenvima",
          "url": "http://www.ncpe.ie/drugs/lenvatinib-lenvima-2/"
         },
         {
          "company": "Eisai",
          "drug_name": "Lenvatinib (Lenvima®)",
          "earliest": "2015-05-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima",
          "eu_market": "2015-05-28T00:00:00",
          "id": 2363,
          "indication": "Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.",
          "last_scrape": "2018-12-13T16:39:15",
          "latest": "2015-07-09T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-05-05, 2015-07-09",
          "rr_end": "2015-07-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-05-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Thyroid Neoplasms",
          "trade_name": "Lenvima",
          "url": "http://www.ncpe.ie/drugs/lenvatinib-lenvima/"
         },
         {
          "company": "Grünenthal",
          "drug_name": "Lesinurad (Zurampic®)",
          "earliest": "2017-03-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic",
          "eu_market": "2016-02-18T00:00:00",
          "id": 2364,
          "indication": "Lesinurad (Zurampic®) for the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor.",
          "last_scrape": "2018-12-13T16:39:20",
          "latest": "2018-12-06T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-03-15, 2017-03-20",
          "rr_end": "2017-03-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-03-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hyperuricemia",
          "trade_name": "Zurampic",
          "url": "http://www.ncpe.ie/drugs/lesinurad-zurampic/"
         },
         {
          "company": "Merck",
          "drug_name": "Letermovir (Prevymis®)",
          "earliest": "2018-03-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis",
          "eu_market": "2018-01-08T00:00:00",
          "id": 2365,
          "indication": "Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).",
          "last_scrape": "2018-12-13T16:39:25",
          "latest": "2018-05-10T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-03-12, 2018-05-10",
          "rr_end": "2018-05-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-03-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cytomegalovirus Infections",
          "trade_name": "Prevymis",
          "url": "http://www.ncpe.ie/drugs/letermovir-prevymis/"
         },
         {
          "company": "Unknown",
          "drug_name": "Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa®)",
          "earliest": "2013-03-13T00:00:00",
          "ema_url": "",
          "eu_market": "2010-03-26T00:00:00",
          "id": 2366,
          "indication": "For the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa® administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.",
          "last_scrape": "2018-12-13T16:39:28",
          "latest": "2018-12-05T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2013-03-13, 2013-04-16",
          "rr_end": "2013-04-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-03-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Unknown",
          "trade_name": "Duodopa",
          "url": "http://www.ncpe.ie/drugs/levodopa-20mgml-carbidopa-monohydrate-5mg-intestinal-gel-duodopa/"
         },
         {
          "company": "Horizon",
          "drug_name": "Levofloxacin (Quinsair®)",
          "earliest": "2016-02-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair",
          "eu_market": "2015-03-25T00:00:00",
          "id": 2367,
          "indication": "Levofloxacin (Quinsair®) is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with Cystic Fibrosis.",
          "last_scrape": "2018-12-13T16:39:34",
          "latest": "2016-03-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-02-10, 2016-03-01",
          "rr_end": "2016-03-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-02-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystic Fibrosis; Respiratory Tract Infections",
          "trade_name": "Quinsair",
          "url": "http://www.ncpe.ie/drugs/levofloxacin-quinsair/"
         },
         {
          "company": "CIS",
          "drug_name": "Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena®)",
          "earliest": "2017-02-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2368,
          "indication": "Kyleena® (19.5mg levonorgestrel intrauterine delivery system; LNG IUS 12)  which is indicated for contraception for up to 5 years.",
          "last_scrape": "2018-12-13T16:39:39",
          "latest": "2017-03-16T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-02-08, 2017-03-16",
          "rr_end": "2017-03-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-02-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Kyleena",
          "url": "http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-delivery-system-lng-ius-12-kyleena/"
         },
         {
          "company": "Unknown",
          "drug_name": "Levonorgestrel intrauterine system LNG-IUS (Jaydess®)",
          "earliest": "2013-03-07T00:00:00",
          "ema_url": "",
          "eu_market": "2010-03-20T00:00:00",
          "id": 2369,
          "indication": "Levonorgestrel Intrauterine System LNG-IUS (Jaydess®) for contraception for up to three years.",
          "last_scrape": "2018-12-13T16:39:44",
          "latest": "2013-03-25T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-03-07, 2013-03-25",
          "rr_end": "2013-03-25T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-03-07T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Jaydess",
          "url": "http://www.ncpe.ie/drugs/levonorgestrel-intrauterine-system-lng-ius-jaydess/"
         },
         {
          "company": "Unknown",
          "drug_name": "Lidocaine 5% plasters (Versatis®)",
          "earliest": "2010-09-09T00:00:00",
          "ema_url": "",
          "eu_market": "2007-09-22T00:00:00",
          "id": 2370,
          "indication": "Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).",
          "last_scrape": "2018-12-13T16:39:46",
          "latest": "2015-09-24T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2010-09-09, 2010-10-22",
          "rr_end": "2010-10-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2010-09-09T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Unknown",
          "trade_name": "Versatis",
          "url": "http://www.ncpe.ie/drugs/lidocaine-5-plasters-versatis/"
         },
         {
          "company": "Allergan",
          "drug_name": "Linaclotide (Constella®)",
          "earliest": "2013-05-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/constella",
          "eu_market": "2012-11-26T00:00:00",
          "id": 2371,
          "indication": "Linaclotide (Constella®) is indicated for the treatment of symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.",
          "last_scrape": "2018-12-13T16:39:51",
          "latest": "2013-06-28T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-05-28, 2013-06-28",
          "rr_end": "2013-06-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-05-28T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Irritable Bowel Syndrome",
          "trade_name": "Constella",
          "url": "http://www.ncpe.ie/drugs/linaclotide-clonstella/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Linagliptin (Trajenta®)",
          "earliest": "2011-08-18T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta",
          "eu_market": "2011-08-23T00:00:00",
          "id": 2372,
          "indication": "Lingagliptin (Trajenta®) for treatment of type 2 diabetes mellitus to improve glycaemic control in adults, as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment, as combination therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control, in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.",
          "last_scrape": "2018-12-13T16:39:54",
          "latest": "2011-09-06T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-08-18, 2011-09-06",
          "rr_end": "2011-09-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-08-18T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Trajenta",
          "url": "http://www.ncpe.ie/drugs/linagliptin-trajenta/"
         },
         {
          "company": "Sicor",
          "drug_name": "Lipegfilgrastim (Lonquex®)",
          "earliest": "2013-08-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex",
          "eu_market": "2013-07-25T00:00:00",
          "id": 2373,
          "indication": "Lonquex® is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).",
          "last_scrape": "2018-12-13T16:39:57",
          "latest": "2013-09-20T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-08-20, 2013-09-20",
          "rr_end": "2013-09-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-08-20T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Neutropenia",
          "trade_name": "Lonquex",
          "url": "http://www.ncpe.ie/drugs/lipegfilgrastim-lonquex/"
         },
         {
          "company": "Jazz",
          "drug_name": "Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos®)",
          "earliest": "2018-09-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos",
          "eu_market": "2018-08-23T00:00:00",
          "id": 2374,
          "indication": "Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos®) for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes.",
          "last_scrape": "2018-12-13T16:40:00",
          "latest": "2018-11-08T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-09-28, 2018-11-08",
          "rr_end": "2018-11-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-09-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid, Acute",
          "trade_name": "Vyxeos",
          "url": "http://www.ncpe.ie/drugs/liposomal-daunorubicin-and-cytarabine-cpx-351vyxeos/"
         },
         {
          "company": "Baxalta",
          "drug_name": "Liposomal irinotecan (Onivyde®)",
          "earliest": "2017-06-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-0",
          "eu_market": "2016-10-14T00:00:00",
          "id": 2375,
          "indication": "Liposomal irinotecan (Onivyde®) is indicated for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin in adult patients who have progressed following gemcitabine based therapy.",
          "last_scrape": "2018-12-13T16:40:06",
          "latest": "2017-07-13T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2017-06-13, 2017-07-13",
          "rr_end": "2017-07-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-06-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Pancreatic Neoplasms",
          "trade_name": "Onivyde",
          "url": "http://www.ncpe.ie/drugs/liposomal-irinotecan-nal-iri-onivyde/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Liquid Paraffin Ointment (VitA-POS Opthalmic®)",
          "earliest": "2014-01-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2376,
          "indication": "Liquid Paraffin Ointment (VitA-POS Opthalmic®) is indicated for the treatment of mild to moderate form of dry eye.",
          "last_scrape": "2018-12-13T16:40:09",
          "latest": "2014-01-27T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-01-15, 2014-01-27",
          "rr_end": "2014-01-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-01-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "VitA-POS Opthalmic",
          "url": "http://www.ncpe.ie/drugs/liquid-paraffin-ointment-vita-pos-opthalmic/"
         },
         {
          "company": "Novo",
          "drug_name": "Liraglutide (Victoza®)",
          "earliest": "2009-09-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/victoza",
          "eu_market": "2009-06-30T00:00:00",
          "id": 2377,
          "indication": "Victoza®  is indicated for treatment of adults with type 2 diabetes mellitus.",
          "last_scrape": "2018-12-13T16:40:13",
          "latest": "2018-10-30T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2009-09-01, 2009-10-07",
          "rr_end": "2009-10-07T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2009-09-01T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Diabetes Mellitus, Type 2",
          "trade_name": "Victoza",
          "url": "http://www.ncpe.ie/drugs/liraglutide-victoza/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Lixisenatide (Lyxumia®)",
          "earliest": "2013-03-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13",
          "eu_market": "2009-12-09T00:00:00",
          "id": 2378,
          "indication": "Lixisenatide (Lyxumia®) for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.",
          "last_scrape": "2018-12-13T16:40:17",
          "latest": "2014-08-07T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-03-21, 2013-04-10",
          "rr_end": "2013-04-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-03-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Pneumococcal Infections; Immunization",
          "trade_name": "Lyxumia",
          "url": "http://www.ncpe.ie/drugs/lixisenatide-lyxumia/"
         },
         {
          "company": "Amryt",
          "drug_name": "Lomitapide (Lojuxta®)",
          "earliest": "2014-09-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta",
          "eu_market": "2013-07-31T00:00:00",
          "id": 2379,
          "indication": "Lojuxta® is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH).",
          "last_scrape": "2018-12-13T16:40:19",
          "latest": "2014-09-15T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-09-09, 2014-09-15",
          "rr_end": "2014-09-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-09-09T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hypercholesterolemia",
          "trade_name": "Lojuxta",
          "url": "http://www.ncpe.ie/drugs/lomitapide-lojuxta/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Lornoxicam (Xefo®)",
          "earliest": "2011-06-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13",
          "eu_market": "2009-12-09T00:00:00",
          "id": 2380,
          "indication": " Lornoxicam (Xefo®) for the Short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis",
          "last_scrape": "2018-12-13T16:40:22",
          "latest": "2011-07-07T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-06-23, 2011-07-07",
          "rr_end": "2011-07-07T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-06-23T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Pneumococcal Infections; Immunization",
          "trade_name": "Xefo",
          "url": "http://www.ncpe.ie/drugs/lornoxicam-xefo/"
         },
         {
          "company": "Unknown",
          "drug_name": "Lotemax 0.5% eye drops suspension (Loteprednol)",
          "earliest": "2011-11-15T00:00:00",
          "ema_url": "",
          "eu_market": "2008-11-27T00:00:00",
          "id": 2381,
          "indication": " Indicated for treatment of post-operative inflammation following ocular surgery.",
          "last_scrape": "2018-12-13T16:40:24",
          "latest": "2011-12-05T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-11-15, 2011-12-05",
          "rr_end": "2011-12-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-11-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Loteprednol",
          "url": "http://www.ncpe.ie/drugs/lotemax-0-5-eye-drops-suspension-loteprednol/"
         },
         {
          "company": "Ferrer",
          "drug_name": "Loxapine inhalation powder (Adasuve®)",
          "earliest": "2016-06-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve",
          "eu_market": "2013-02-20T00:00:00",
          "id": 2382,
          "indication": "Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.",
          "last_scrape": "2018-12-13T16:40:30",
          "latest": "2016-07-28T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-06-21, 2016-07-28",
          "rr_end": "2016-07-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-06-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Schizophrenia; Bipolar Disorder",
          "trade_name": "Adasuve",
          "url": "http://www.ncpe.ie/drugs/loxapine-inhalation-powder-adasuve/"
         },
         {
          "company": "Vertex",
          "drug_name": "Lumacaftor/ivacaftor (Orkambi®)",
          "earliest": "2015-11-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi",
          "eu_market": "2015-11-19T00:00:00",
          "id": 2383,
          "indication": "Orkambi® is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene.",
          "last_scrape": "2018-12-13T16:40:34",
          "latest": "2016-06-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2015-11-26, 2015-12-15",
          "rr_end": "2015-12-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-11-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Cystic Fibrosis",
          "trade_name": "Orkambi",
          "url": "http://www.ncpe.ie/drugs/lumacaftorivacaftor-orkambi/"
         },
         {
          "company": "Advanced",
          "drug_name": "Lutetium (177Lu) Oxodotreotide (Lutathera®)",
          "earliest": "2018-10-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera",
          "eu_market": "2017-09-26T00:00:00",
          "id": 2384,
          "indication": "Lutetium (177Lu) Oxodotreotide (Lutathera®) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.",
          "last_scrape": "2018-12-13T16:40:36",
          "latest": "2018-11-16T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-10-23, 2018-11-16",
          "rr_end": "2018-11-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-10-23T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Neuroendocrine Tumors",
          "trade_name": "Lutathera",
          "url": "http://www.ncpe.ie/drugs/lutetium-177lu-oxodotreotide-lutathera/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Macitentan (Opsumit®)",
          "earliest": "2014-01-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit",
          "eu_market": "2013-12-20T00:00:00",
          "id": 2385,
          "indication": "Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.",
          "last_scrape": "2018-12-13T16:40:41",
          "latest": "2014-01-27T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-01-10, 2014-01-27",
          "rr_end": "2014-01-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-01-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hypertension, Pulmonary",
          "trade_name": "Opsumit",
          "url": "http://www.ncpe.ie/drugs/macitentan-opsumit/"
         },
         {
          "company": "RAD",
          "drug_name": "Melatonin (Circadin®)",
          "earliest": "2008-08-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/circadin",
          "eu_market": "2007-06-29T00:00:00",
          "id": 2386,
          "indication": "A Review of the Economic Evaluation of Prolonged Release Melatonin (Circadin®) For The Short-Term Treatment of Primary Insomnia.",
          "last_scrape": "2018-12-13T16:40:43",
          "latest": "2008-10-01T00:00:00",
          "ncpe_year": 2008,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2014-01-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-12-26T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Sleep Initiation and Maintenance Disorders",
          "trade_name": "Circadin",
          "url": "http://www.ncpe.ie/drugs/melatonin-circadin/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Mepolizumab (Nucala®)",
          "earliest": "2016-03-16T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/nucala",
          "eu_market": "2015-12-01T00:00:00",
          "id": 2387,
          "indication": "Mepolizumab (Nucala®) is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.",
          "last_scrape": "2018-12-13T16:40:45",
          "latest": "2018-04-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-03-16, 2016-04-04",
          "rr_end": "2016-04-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-03-16T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Asthma",
          "trade_name": "Nucala",
          "url": "http://www.ncpe.ie/drugs/mepolizumab-nucala/"
         },
         {
          "company": "Unknown",
          "drug_name": "Methoxyflurane (Penthrox®)",
          "earliest": "2015-11-23T00:00:00",
          "ema_url": "",
          "eu_market": "2012-12-05T00:00:00",
          "id": 2388,
          "indication": "Penthrox® is indicated for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  It is an inhaled anesthetic with analgesic effects at sub-anesthetic doses.",
          "last_scrape": "2018-12-13T16:40:51",
          "latest": "2015-12-18T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-11-23, 2015-12-18",
          "rr_end": "2015-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-11-23T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Unknown",
          "trade_name": "Penthrox",
          "url": "http://www.ncpe.ie/drugs/methoxyflurane-penthrox/"
         },
         {
          "company": "Novartis",
          "drug_name": "Midostaurin (Rydapt®) for AML",
          "earliest": "2018-08-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt",
          "eu_market": "2017-09-18T00:00:00",
          "id": 2389,
          "indication": "Midostaurin (Rydapt®) is indicated in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.",
          "last_scrape": "2018-12-13T16:40:56",
          "latest": "2018-09-10T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-08-13, 2018-09-10",
          "rr_end": "2018-09-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-08-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid, Acute; Mastocytosis",
          "trade_name": "Rydapt",
          "url": "http://www.ncpe.ie/drugs/midostaurin-rydapt-for-aml/"
         },
         {
          "company": "Novartis",
          "drug_name": "Midostaurin (Rydapt®) for ASM",
          "earliest": "2018-08-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt",
          "eu_market": "2017-09-18T00:00:00",
          "id": 2390,
          "indication": "Midostaurin (Rydapt®) is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL).",
          "last_scrape": "2018-12-13T16:41:02",
          "latest": "2018-09-10T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-08-13, 2018-09-10",
          "rr_end": "2018-09-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-08-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid, Acute; Mastocytosis",
          "trade_name": "Rydapt",
          "url": "http://www.ncpe.ie/drugs/midostaurin-rydapt-for-asm/"
         },
         {
          "company": "Takeda",
          "drug_name": "Mifamurtide (Mepact®)",
          "earliest": "2010-06-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mepact",
          "eu_market": "2009-03-06T00:00:00",
          "id": 2391,
          "indication": "Mifamurtide (Meptact®) for the treatment of osteosarcoma.",
          "last_scrape": "2018-12-13T16:41:04",
          "latest": "2010-07-13T00:00:00",
          "ncpe_year": 2010,
          "orphan": 1,
          "rr_dates": "2010-06-22, 2010-07-13",
          "rr_end": "2010-07-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2010-06-22T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Osteosarcoma",
          "trade_name": "Mepact",
          "url": "http://www.ncpe.ie/drugs/mifamurtide-mepact/"
         },
         {
          "company": "Amicus",
          "drug_name": "Migalastat (Galafold®)",
          "earliest": "2016-07-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/galafold",
          "eu_market": "2016-05-25T00:00:00",
          "id": 2392,
          "indication": "Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.",
          "last_scrape": "2018-12-13T16:41:06",
          "latest": "2017-06-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2016-07-14, 2016-08-18",
          "rr_end": "2016-08-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-07-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Fabry Disease",
          "trade_name": "Galafold",
          "url": "http://www.ncpe.ie/drugs/migalastat-galafold/"
         },
         {
          "company": "Astellas",
          "drug_name": "Mirabegron (Betmiga®)",
          "earliest": "2012-12-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga",
          "eu_market": "2012-12-20T00:00:00",
          "id": 2393,
          "indication": "Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome",
          "last_scrape": "2018-12-13T16:41:13",
          "latest": "2013-03-12T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2012-12-19, 2013-03-12",
          "rr_end": "2013-03-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2012-12-19T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Urinary Bladder, Overactive",
          "trade_name": "Betmiga",
          "url": "http://www.ncpe.ie/drugs/mirabegron-betmiga/"
         },
         {
          "company": "Celgene",
          "drug_name": "Nab-paclitaxel (Abraxane®)",
          "earliest": "2014-01-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane",
          "eu_market": "2008-01-10T00:00:00",
          "id": 2394,
          "indication": "Nab-paclitaxel (Abraxane®) in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.",
          "last_scrape": "2018-12-13T16:41:15",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-01-23, 2014-03-02",
          "rr_end": "2014-03-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-01-23T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Abraxane",
          "url": "http://www.ncpe.ie/drugs/nab-paclitaxel-abraxane/"
         },
         {
          "company": "Lundbeck",
          "drug_name": "Nalmefene (Selincro®)",
          "earliest": "2013-06-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/selincro",
          "eu_market": "2013-02-24T00:00:00",
          "id": 2395,
          "indication": "Nalmefene (Selincro®) is indicated for the reduction of alcohol consumption in those aged ≥18 years with alcohol dependence, who do not require immediate detoxification.",
          "last_scrape": "2018-12-13T16:41:18",
          "latest": "2014-04-08T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-06-07, 2013-06-28",
          "rr_end": "2013-06-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-06-07T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Alcohol-Related Disorders",
          "trade_name": "Selincro",
          "url": "http://www.ncpe.ie/drugs/nalmefene-selincro/"
         },
         {
          "company": "Kyowa",
          "drug_name": "Naloxegel (Moventig®)",
          "earliest": "2015-02-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/moventig",
          "eu_market": "2014-12-07T00:00:00",
          "id": 2396,
          "indication": "Naloxegel (Moventiq®) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).",
          "last_scrape": "2018-12-13T16:41:24",
          "latest": "2015-04-13T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-02-10, 2015-04-13",
          "rr_end": "2015-04-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-02-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Constipation; Opioid-Related Disorders",
          "trade_name": "Moventig",
          "url": "http://www.ncpe.ie/drugs/naloxegel-moventig/"
         },
         {
          "company": "Orexigen",
          "drug_name": "Naltrexone / bupropion (Mysimba®)",
          "earliest": "2017-03-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba",
          "eu_market": "2015-03-26T00:00:00",
          "id": 2397,
          "indication": "Naltrexone / bupropion (Mysimba®) is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities.",
          "last_scrape": "2018-12-13T16:41:26",
          "latest": "2018-05-09T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-03-12, 2017-03-28",
          "rr_end": "2017-03-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-03-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Obesity; Overweight",
          "trade_name": "Mysimba",
          "url": "http://www.ncpe.ie/drugs/naltrexone-bupropion-mysimba/"
         },
         {
          "company": "Biogen",
          "drug_name": "Natalizumab (Tysabri®)",
          "earliest": "2007-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri",
          "eu_market": "2006-06-27T00:00:00",
          "id": 2398,
          "indication": " Economic Evaluation of Natalizumab (Tysabri®) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated.",
          "last_scrape": "2018-12-13T16:41:30",
          "latest": "2007-03-01T00:00:00",
          "ncpe_year": 2007,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-03-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-02-24T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Tysabri",
          "url": "http://www.ncpe.ie/drugs/natalizumab-tysabri/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Inhaled insulin (Exubera®)",
          "earliest": "2006-03-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/exubera",
          "eu_market": "2006-01-24T00:00:00",
          "id": 2399,
          "indication": "In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera®) versus sub-cutaneous insulin in patients with diabetes mellitus in support of their application for reimbursement under the Community Drug Schemes. The following reports were prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.",
          "last_scrape": "2018-12-13T16:41:35",
          "latest": "2006-03-01T00:00:00",
          "ncpe_year": 2006,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-03-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-02-24T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Diabetes Mellitus",
          "trade_name": "Exubera",
          "url": "http://www.ncpe.ie/drugs/ncpe-inhaled-insulin-exubera-assessment/"
         },
         {
          "company": "Novartis",
          "drug_name": "Nepafenac (Nevanac®)",
          "earliest": "2011-06-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac",
          "eu_market": "2007-12-11T00:00:00",
          "id": 2400,
          "indication": "Nepafenac (Nevanac®) for the prevention and treatment of postoperative pain and inflammation associated with cataract surgery.",
          "last_scrape": "2018-12-13T16:41:38",
          "latest": "2011-06-27T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-06-14, 2011-06-27",
          "rr_end": "2011-06-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-06-14T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Pain, Postoperative; Ophthalmologic Surgical Procedures",
          "trade_name": "Nevanac",
          "url": "http://www.ncpe.ie/drugs/nepafenac-nevanac-2/"
         },
         {
          "company": "Helsinn",
          "drug_name": "Netupitant/palonosetron (Akynzeo®)",
          "earliest": "2015-08-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo",
          "eu_market": "2015-05-27T00:00:00",
          "id": 2401,
          "indication": "Akynzeo® is indicated for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.",
          "last_scrape": "2018-12-13T16:41:41",
          "latest": "2015-10-13T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-08-26, 2015-10-13",
          "rr_end": "2015-10-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-08-26T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Vomiting; Cancer; Nausea",
          "trade_name": "Akynzeo",
          "url": "http://www.ncpe.ie/drugs/netupitantpalonosetron-akynzeo/"
         },
         {
          "company": "Novartis",
          "drug_name": "Nilotinib (Tasigna®) newly diagnosed CML",
          "earliest": "2010-10-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna",
          "eu_market": "2007-11-19T00:00:00",
          "id": 2402,
          "indication": "Nilotinib (Tasigna®) for the newly diagnosed Chronic Phase Philadelpha Chromosone positive CML.",
          "last_scrape": "2018-12-13T16:41:44",
          "latest": "2010-10-22T00:00:00",
          "ncpe_year": 2010,
          "orphan": 1,
          "rr_dates": "2010-10-06, 2010-10-22",
          "rr_end": "2010-10-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2010-10-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
          "trade_name": "Tasigna",
          "url": "http://www.ncpe.ie/drugs/nilotinib-tasigna-newly-diagnosed-cml/"
         },
         {
          "company": "Novartis",
          "drug_name": "Nilotinib (Tasigna®) CML resistant/intolerant to imatinib",
          "earliest": "2008-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna",
          "eu_market": "2007-11-19T00:00:00",
          "id": 2403,
          "indication": "Cost-effectiveness of Nilotinib (Tasigna®) for the treatment of chronic phase CML.",
          "last_scrape": "2018-12-13T16:41:51",
          "latest": "2008-02-01T00:00:00",
          "ncpe_year": 2008,
          "orphan": 1,
          "rr_dates": "",
          "rr_end": "2010-10-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2010-09-20T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
          "trade_name": "Tasigna",
          "url": "http://www.ncpe.ie/drugs/nilotinib-tasigna/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Nintedanib (Ofev®)",
          "earliest": "2015-01-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ofev",
          "eu_market": "2015-01-14T00:00:00",
          "id": 2404,
          "indication": "Nintedanib (Ofev®) indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).",
          "last_scrape": "2018-12-13T16:41:53",
          "latest": "2017-06-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2015-01-30, 2015-02-18",
          "rr_end": "2015-02-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-01-30T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Idiopathic Pulmonary Fibrosis",
          "trade_name": "Ofev",
          "url": "http://www.ncpe.ie/drugs/nintedanib-ofev/"
         },
         {
          "company": "Boehringer",
          "drug_name": "Nintedanib (Vargatef®)",
          "earliest": "2015-01-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef",
          "eu_market": "2014-11-21T00:00:00",
          "id": 2405,
          "indication": "Nintedanib (Vargatef®) indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.",
          "last_scrape": "2018-12-13T16:41:56",
          "latest": "2017-02-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2015-01-02, 2015-02-10",
          "rr_end": "2015-02-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-01-02T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Vargatef",
          "url": "http://www.ncpe.ie/drugs/nintedanib-vargatef/"
         },
         {
          "company": "Tesaro",
          "drug_name": "Niraparib (Zejula®)",
          "earliest": "2018-06-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zejula",
          "eu_market": "2017-11-16T00:00:00",
          "id": 2406,
          "indication": "Niraparib (Zejula®) which is indicated as monotherapy for maintenance treatment of adult patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response [CR] or partial response [PR]) to platinum-based chemotherapy.",
          "last_scrape": "2018-12-13T16:42:00",
          "latest": "2018-06-27T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-06-01, 2018-06-21",
          "rr_end": "2018-06-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of niraparib compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-06-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms",
          "trade_name": "Zejula",
          "url": "http://www.ncpe.ie/drugs/niraparib-zejula/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for Melanoma",
          "earliest": "2015-05-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2407,
          "indication": "Opdivo® is indicated as for monotherapy treatment for patients diagnosed with unresectable metastatic melanoma.",
          "last_scrape": "2018-12-13T16:42:06",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2015-05-28, 2015-07-16",
          "rr_end": "2015-07-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-05-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivio-for-melanoma/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for non-squamous NSCLC",
          "earliest": "2016-03-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2408,
          "indication": "Nivolumab (Opdivo®) is indicated for the treatment of adults with locally advanced or metastatic non-squamous NSCLC after prior chemotherapy.",
          "last_scrape": "2018-12-13T16:42:13",
          "latest": "2018-09-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-03-03, 2016-04-04",
          "rr_end": "2016-04-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-03-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivio-for-non-squamous-nsclc/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for NSCLC",
          "earliest": "2015-07-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2409,
          "indication": "Opdivo® is indicated for the treatment of locally advanced or metastatic squamous NSCLC after prior chemotherapy in adults.",
          "last_scrape": "2018-12-13T16:42:20",
          "latest": "2018-09-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2015-07-02, 2015-07-16",
          "rr_end": "2015-07-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-07-02T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivio-for-nsclc/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of adults with melanoma",
          "earliest": "2018-07-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2410,
          "indication": "Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of adults with melanoma  with involvement of lymph nodes or metastatic disease who have undergone complete resection.",
          "last_scrape": "2018-12-13T16:42:26",
          "latest": "2018-11-30T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-07-09, 2018-07-27",
          "rr_end": "2018-07-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-07-09T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivo-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-melanoma/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for advanced renal cell carcinoma",
          "earliest": "2016-04-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2411,
          "indication": "Nivolumab (Opdivo®) is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults.",
          "last_scrape": "2018-12-13T16:42:31",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-04-27, 2016-05-16",
          "rr_end": "2016-05-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-04-27T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivo-for-advanced-renal-cell-carcinoma/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for classical Hodgkin Lymphoma",
          "earliest": "2016-11-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2412,
          "indication": "Nivolumab (Opdivo®) as monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.",
          "last_scrape": "2018-12-13T16:42:33",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-11-22, 2017-01-18",
          "rr_end": "2017-01-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-11-22T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivo-for-classical-hodgkin-lymphoma/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for head and neck cancer",
          "earliest": "2017-05-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2413,
          "indication": "Nivolumab (Opdivo®) for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy.",
          "last_scrape": "2018-12-13T16:42:36",
          "latest": "2018-04-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-05-03, 2017-05-30",
          "rr_end": "2017-05-30T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-05-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivo-for-head-and-neck-cancer/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) for urothelial carcinoma",
          "earliest": "2017-06-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo",
          "eu_market": "2015-06-19T00:00:00",
          "id": 2414,
          "indication": "Nivolumab (Opdivo®) as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.",
          "last_scrape": "2018-12-13T16:42:41",
          "latest": "2018-09-12T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-06-28, 2017-08-10",
          "rr_end": "2017-08-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-06-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Opdivo",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivo-for-urothelial-carcinoma/"
         },
         {
          "company": "Bristol-Myers",
          "drug_name": "Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®)",
          "earliest": "2018-11-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy",
          "eu_market": "2011-07-12T00:00:00",
          "id": 2415,
          "indication": "Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).",
          "last_scrape": "2018-12-13T16:42:46",
          "latest": "2018-12-11T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-11-28, 2018-12-11",
          "rr_end": "2018-12-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-11-28T00:00:00",
          "rr_status": "Unknown",
          "ta_list": "Melanoma",
          "trade_name": "Yervoy",
          "url": "http://www.ncpe.ie/drugs/nivolumab-opdivo-in-combination-with-ipilimumab-yervoy/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Nivolumab plus ipilimumab (Opdivo® plus Yervoy®)",
          "earliest": "2016-06-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2416,
          "indication": "Opdivo® plus Yervoy® Is indicated for the treatment of advanced melanoma.",
          "last_scrape": "2018-12-13T16:42:51",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2018-12-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-11-09T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Opdivo plus Yervoy",
          "url": "http://www.ncpe.ie/drugs/nivolumab-plus-ipilimumab-opdivio-plus-yervoy/"
         },
         {
          "company": "Teva",
          "drug_name": "Nomegestrol acetate/estradiol (Zoely®)",
          "earliest": "2011-12-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zoely",
          "eu_market": "2011-07-26T00:00:00",
          "id": 2417,
          "indication": "Nomegestrol acetate/estradiol (Zoely®) oral contraception",
          "last_scrape": "2018-12-13T16:42:56",
          "latest": "2012-01-03T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-12-08, 2012-01-03",
          "rr_end": "2012-01-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-12-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Contraception",
          "trade_name": "Zoely",
          "url": "http://www.ncpe.ie/drugs/nomace2-zoely/"
         },
         {
          "company": "Biogen",
          "drug_name": "Nusinersin (Spinraza®)",
          "earliest": "2017-07-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza",
          "eu_market": "2017-05-30T00:00:00",
          "id": 2418,
          "indication": "Nusinersen (Spinraza®) is indicated for the treatment of 5q spinal muscular atrophy (SMA)",
          "last_scrape": "2018-12-13T16:43:02",
          "latest": "2017-12-19T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2017-07-11, 2017-08-02",
          "rr_end": "2017-08-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-07-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Muscular Atrophy, Spinal",
          "trade_name": "Spinraza",
          "url": "http://www.ncpe.ie/drugs/nusinersin-spinraza/"
         },
         {
          "company": "Intercept",
          "drug_name": "Obeticholic acid (Ocaliva®)",
          "earliest": "2016-11-18T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva",
          "eu_market": "2016-12-12T00:00:00",
          "id": 2419,
          "indication": "Obeticholic acid is indicated for the treatment of primary biliary cirrhosis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.",
          "last_scrape": "2018-12-13T16:43:07",
          "latest": "2017-10-31T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2016-11-18, 2016-12-21",
          "rr_end": "2016-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-11-18T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Liver Cirrhosis, Biliary",
          "trade_name": "Ocaliva",
          "url": "http://www.ncpe.ie/drugs/obeticholic-acid-ocaliva/"
         },
         {
          "company": "Roche",
          "drug_name": "Obinutuzumab (Gazyvaro®) for Follicular Lymphoma",
          "earliest": "2016-05-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro",
          "eu_market": "2014-07-22T00:00:00",
          "id": 2420,
          "indication": "Obinutuzumab (in combination with bendamustine) followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.",
          "last_scrape": "2018-12-13T16:43:10",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2016-05-11, 2016-05-31",
          "rr_end": "2016-05-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-05-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Gazyvaro",
          "url": "http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-follicular-lymphoma/"
         },
         {
          "company": "Roche",
          "drug_name": "Obinutuzumab (Gazyvaro®) for previously untreated advanced follicular lymphoma",
          "earliest": "2017-08-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro",
          "eu_market": "2014-07-22T00:00:00",
          "id": 2421,
          "indication": "Obinutuzumab (Gazyvaro®) in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.",
          "last_scrape": "2018-12-13T16:43:15",
          "latest": "2018-05-03T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-08-08, 2017-09-13",
          "rr_end": "2017-09-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-08-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Gazyvaro",
          "url": "http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro-for-previously-untreated-advanced-follicular-lymphoma/"
         },
         {
          "company": "Roche",
          "drug_name": "Obinutuzumab (Gazyvaro®) for Lymphocytic Leukaemia",
          "earliest": "2014-08-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro",
          "eu_market": "2014-07-22T00:00:00",
          "id": 2422,
          "indication": "Obinutuzumab (Gazyvaro®) in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia and with comorbidities making them unsuitable for full-dose fludarabine based therapy.",
          "last_scrape": "2018-12-13T16:43:21",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 1,
          "rr_dates": "2014-08-08, 2014-09-11",
          "rr_end": "2014-09-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-08-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Gazyvaro",
          "url": "http://www.ncpe.ie/drugs/obinutuzumab-gazyvaro/"
         },
         {
          "company": "Roche",
          "drug_name": "Ocrelizumab (Ocrevus®) for PPMS",
          "earliest": "2017-11-29T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus",
          "eu_market": "2018-01-08T00:00:00",
          "id": 2423,
          "indication": "Ocrelizumab (Ocrevus®) is indicated for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.",
          "last_scrape": "2018-12-13T16:43:24",
          "latest": "2018-10-04T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-11-29, 2017-12-14",
          "rr_end": "2017-12-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-11-29T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Ocrevus",
          "url": "http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-ppms/"
         },
         {
          "company": "Roche",
          "drug_name": "Ocrelizumab (Ocrevus®) for RMS",
          "earliest": "2017-11-29T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus",
          "eu_market": "2018-01-08T00:00:00",
          "id": 2424,
          "indication": "Ocrelizumab (Ocrevus®) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.",
          "last_scrape": "2018-12-13T16:43:30",
          "latest": "2018-08-29T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-11-29, 2017-12-14",
          "rr_end": "2017-12-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-11-29T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Ocrevus",
          "url": "http://www.ncpe.ie/drugs/ocrelizumab-ocrevus-for-rms/"
         },
         {
          "company": "ThromboGenics",
          "drug_name": "Ocriplasmin (Jetrea®)",
          "earliest": "2013-06-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea",
          "eu_market": "2013-03-13T00:00:00",
          "id": 2425,
          "indication": "Ocriplasmin (Jetrea®) is a hospital only product licensed in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.",
          "last_scrape": "2018-12-13T16:43:34",
          "latest": "2013-07-09T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-06-12, 2013-07-09",
          "rr_end": "2013-07-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-06-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Retinal Diseases",
          "trade_name": "Jetrea",
          "url": "http://www.ncpe.ie/drugs/ocriplasmin-jetrea/"
         },
         {
          "company": "Novartis",
          "drug_name": "Ofatumumab (Arzerra®) (Previously untreated Chronic Lymphocytic Leukaemia)",
          "earliest": "2014-10-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra",
          "eu_market": "2010-04-19T00:00:00",
          "id": 2426,
          "indication": "Ofatumumab (Arzerra®) in combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.",
          "last_scrape": "2018-12-13T16:43:39",
          "latest": "2014-12-18T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-10-13, 2014-12-18",
          "rr_end": "2014-12-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-10-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Arzerra",
          "url": "http://www.ncpe.ie/drugs/ofatumumab-arzerra-previously-untreated-chronic-lymphocytic-leukaemia/"
         },
         {
          "company": "Novartis",
          "drug_name": "Ofatumumab (Arzerra®) (Refractory CLL)",
          "earliest": "2010-06-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra",
          "eu_market": "2010-04-19T00:00:00",
          "id": 2427,
          "indication": "Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.",
          "last_scrape": "2018-12-13T16:43:46",
          "latest": "2010-06-22T00:00:00",
          "ncpe_year": 2010,
          "orphan": 1,
          "rr_dates": "2010-06-22, 2010-06-01",
          "rr_end": "2010-06-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2010-06-22T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Arzerra",
          "url": "http://www.ncpe.ie/drugs/ofatumumab-arzerra/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Oladaterol (Striverdi®, Respimat®)",
          "earliest": "2014-04-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2428,
          "indication": "Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).",
          "last_scrape": "2018-12-13T16:43:52",
          "latest": "2014-05-02T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-04-07, 2014-05-02",
          "rr_end": "2014-05-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-04-07T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Striverdi, Respimat",
          "url": "http://www.ncpe.ie/drugs/oladaterol-striverdi-respimat/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Olaparib (Lynparza®)",
          "earliest": "2015-01-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza",
          "eu_market": "2014-12-16T00:00:00",
          "id": 2429,
          "indication": "Lynparza® is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.",
          "last_scrape": "2018-12-13T16:43:57",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2015-01-05, 2015-02-19",
          "rr_end": "2015-02-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-01-05T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Ovarian Neoplasms",
          "trade_name": "Lynparza",
          "url": "http://www.ncpe.ie/drugs/olaparib-lynparza-2/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Olaparib (Lynparza®) for platinum sensitive relapsed ovarian cancer",
          "earliest": "2018-09-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza",
          "eu_market": "2014-12-16T00:00:00",
          "id": 2430,
          "indication": "Olaparib (Lynparza®) monotherapy for the maintenance treatment of adult patients with PSR high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
          "last_scrape": "2018-12-13T16:44:03",
          "latest": "2018-10-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-09-19, 2018-10-01",
          "rr_end": "2018-10-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "the ncpe recommend  full hta to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-09-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Ovarian Neoplasms",
          "trade_name": "Lynparza",
          "url": "http://www.ncpe.ie/drugs/olaparib-lynparza-for-platinum-sensitive-relapsed-ovarian-cancer/"
         },
         {
          "company": "Novartis",
          "drug_name": "Omalizumab (Xolair®) for the treatment of severe allergic asthma",
          "earliest": "2014-08-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xolair",
          "eu_market": "2005-10-25T00:00:00",
          "id": 2431,
          "indication": "Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1<80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.",
          "last_scrape": "2018-12-13T16:44:08",
          "latest": "2015-06-25T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2018-10-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-08-30T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Asthma; Urticaria",
          "trade_name": "Xolair",
          "url": "http://www.ncpe.ie/drugs/omalizumab-xolair-for-the-treatment-of-severe-allergic-asthma/"
         },
         {
          "company": "Novartis",
          "drug_name": "Omalizumab (Xolair®)",
          "earliest": "2014-03-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xolair",
          "eu_market": "2005-10-25T00:00:00",
          "id": 2432,
          "indication": "Omalizumab (Xolair®) is indicated as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment. ",
          "last_scrape": "2018-12-13T16:44:14",
          "latest": "2014-04-25T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-03-25, 2014-04-25",
          "rr_end": "2014-04-25T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended for this indication",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-03-25T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Asthma; Urticaria",
          "trade_name": "Xolair",
          "url": "http://www.ncpe.ie/drugs/omalizumab-xolair/"
         },
         {
          "company": "CIS",
          "drug_name": "Oxycodone/naloxone (Targin®)",
          "earliest": "2010-05-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2433,
          "indication": "Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin®) for severe pain, which can be adequately managed only with opioid analgesics.",
          "last_scrape": "2018-12-13T16:44:19",
          "latest": "2010-10-19T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2014-04-25T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-03-24T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Targin",
          "url": "http://www.ncpe.ie/drugs/oral-oxycodonenaloxone-targin/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Osimertinib (Tagrisso®) for the first-line treatment of metastatic NSCLC",
          "earliest": "2018-07-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso",
          "eu_market": "2016-02-01T00:00:00",
          "id": 2434,
          "indication": "Osimertinib (Tagrisso®) as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.",
          "last_scrape": "2018-12-13T16:44:22",
          "latest": "2018-08-07T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-07-19, 2018-08-07",
          "rr_end": "2018-08-07T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib for the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-07-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Tagrisso",
          "url": "http://www.ncpe.ie/drugs/osimertinib-tagrisso-for-the-first-line-treatment-of-metastatic-nsclc/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Osimertinib (Tagrisso®)",
          "earliest": "2016-02-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso",
          "eu_market": "2016-02-01T00:00:00",
          "id": 2435,
          "indication": "Osimertinib (Tagrisso®) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor [EGFR] T790M mutation positive non-small cell lung cancer [NSCLC].",
          "last_scrape": "2018-12-13T16:44:39",
          "latest": "2018-05-03T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-02-26, 2016-03-22, 2017-01-10",
          "rr_end": "2017-01-10T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-02-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Tagrisso",
          "url": "http://www.ncpe.ie/drugs/osimertinib-tagrisso/"
         },
         {
          "company": "Unknown",
          "drug_name": "Ozenoxacin (Dubine®)",
          "earliest": "2018-11-12T00:00:00",
          "ema_url": "",
          "eu_market": "2015-11-25T00:00:00",
          "id": 2436,
          "indication": "Ozenoxacin (Dubine®) 10mg/g cream for the short term treatment of non-bullous impetigo in adults, adolescents, children, and infants aged 6 months and older.",
          "last_scrape": "2018-12-13T16:44:40",
          "latest": "2018-12-13T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-11-12, 2018-12-13",
          "rr_end": "2018-12-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is not recommended the ncpe recommends that ozenoxacin cream not be considered for reimbursement at the submitted price  this recommendation should be considered while also having regard to the criteria specified in the health (pricing and supply of medical goods act) 2013",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2018-11-12T00:00:00",
          "rr_status": "Unknown",
          "ta_list": "Unknown",
          "trade_name": "Dubine",
          "url": "http://www.ncpe.ie/drugs/ozenoxacin-dubine/"
         },
         {
          "company": "Biogen",
          "drug_name": "Pegylated Interferon beta-1a (Plegridy ®)",
          "earliest": "2014-11-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy",
          "eu_market": "2014-07-17T00:00:00",
          "id": 2437,
          "indication": "Treatment of adult patients with relapsing remitting multiple sclerosis",
          "last_scrape": "2018-12-13T16:44:43",
          "latest": "2014-12-22T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-11-25, 2014-12-22",
          "rr_end": "2014-12-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-11-25T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Plegridy",
          "url": "http://www.ncpe.ie/drugs/p-drugs/pegylated-interferon-b-1a-plegridy/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Palbociclib (Ibrance®)",
          "earliest": "2016-09-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance",
          "eu_market": "2016-11-09T00:00:00",
          "id": 2438,
          "indication": "Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.",
          "last_scrape": "2018-12-13T16:44:47",
          "latest": "2017-07-28T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-09-10, 2016-09-28",
          "rr_end": "2016-09-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-09-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Ibrance",
          "url": "http://www.ncpe.ie/drugs/palbociclib-ibrance/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Paliperidone palmitate (Xeplion®)",
          "earliest": "2011-03-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xeplion",
          "eu_market": "2011-03-04T00:00:00",
          "id": 2439,
          "indication": "Paliperidone palmitate (Xeplion®) is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate, and a long acting injectable treatment is needed.",
          "last_scrape": "2018-12-13T16:44:53",
          "latest": "2011-03-23T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-03-11, 2011-03-23",
          "rr_end": "2011-03-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-03-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Schizophrenia",
          "trade_name": "Xeplion",
          "url": "http://www.ncpe.ie/drugs/paliperidone-palmitate-xeplion/"
         },
         {
          "company": "Novartis",
          "drug_name": "Panobinostat (Farydak®)",
          "earliest": "2016-01-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/farydak",
          "eu_market": "2015-08-28T00:00:00",
          "id": 2440,
          "indication": "Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.",
          "last_scrape": "2018-12-13T16:44:57",
          "latest": "2016-02-09T00:00:00",
          "ncpe_year": 2016,
          "orphan": 1,
          "rr_dates": "2016-01-26, 2016-02-09",
          "rr_end": "2016-02-09T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-01-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Myeloma",
          "trade_name": "Farydak",
          "url": "http://www.ncpe.ie/drugs/panobinostat-farydak/"
         },
         {
          "company": "AbbVie",
          "drug_name": "Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax®) with or without dasabuvir (Exviera®)",
          "earliest": "2014-12-21T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/exviera",
          "eu_market": "2015-01-14T00:00:00",
          "id": 2441,
          "indication": "Exviera® is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (CHC) in adults. Exviera® must not be administered as monotherapy. Depending on the patient population The recommended co-administered medicinal products for exviera® combination therapy are viekirax® or viekirax®   and ribavirin.",
          "last_scrape": "2018-12-13T16:45:01",
          "latest": "2016-02-10T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2014-12-21, 2015-01-13",
          "rr_end": "2015-01-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-12-21T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Exviera",
          "url": "http://www.ncpe.ie/drugs/paritaprevir-boosted-with-ritonavir-and-ombitasvir-vierkirax-with-or-without-dasabuvir-exviera/"
         },
         {
          "company": "Vifor",
          "drug_name": "Patiromer (Veltassa®)",
          "earliest": "2017-10-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/veltassa",
          "eu_market": "2017-07-19T00:00:00",
          "id": 2442,
          "indication": "Patiromer (Veltassa®) is indicated for the treatment of hyperkalaemia in adults.",
          "last_scrape": "2018-12-13T16:45:07",
          "latest": "2018-11-13T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-10-11, 2017-11-17",
          "rr_end": "2017-11-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessmentrecommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-10-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hyperkalemia",
          "trade_name": "Veltassa",
          "url": "http://www.ncpe.ie/drugs/patiromer-veltassa/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda®) 1L NSCLC with chemotherapy",
          "earliest": "2018-08-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2443,
          "indication": "Pembrolizumab (Keytruda®) is indicated in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.",
          "last_scrape": "2018-12-13T16:45:10",
          "latest": "2018-08-29T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-08-14, 2018-08-29",
          "rr_end": "2018-08-29T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-08-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-1l-nsclc-with-chemotherapy/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda®) for Adjuvant melanoma",
          "earliest": "2018-11-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2444,
          "indication": "Pembrolizuma (Keytruda®) as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.",
          "last_scrape": "2018-12-13T16:45:15",
          "latest": "2018-12-07T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-11-19, 2018-12-07",
          "rr_end": "2018-12-07T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-11-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-adjuvant-melanoma/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda ®) for Classical Hodgkin Lymphoma",
          "earliest": "2017-12-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2445,
          "indication": "Pembrolizumab (Keytruda®) is indicated as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.",
          "last_scrape": "2018-12-13T16:45:18",
          "latest": "2018-11-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-12-06, 2017-12-21",
          "rr_end": "2017-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-12-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-classical-hodgkin-lymphoma/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda®) for NSCLC (first line)",
          "earliest": "2016-12-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2446,
          "indication": "Keytruda® for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 (tumour proportion score [TPS] ≥ 50%) with no EGFR or ALK positive tumour mutations and no prior systemic therapy for advanced disease.",
          "last_scrape": "2018-12-13T16:45:23",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-12-19, 2017-01-10",
          "rr_end": "2017-01-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-12-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-first-line-nsclc/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda®) for NSCLC (second line)",
          "earliest": "2016-08-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2447,
          "indication": "Pembrolizumab (Keytruda®) is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving pembrolizumab.",
          "last_scrape": "2018-12-13T16:45:28",
          "latest": "2018-11-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-08-03, 2016-08-24",
          "rr_end": "2016-08-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-08-03T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-nsclc/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda®) for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.",
          "earliest": "2015-08-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2448,
          "indication": "Keytruda® for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.",
          "last_scrape": "2018-12-13T16:45:31",
          "latest": "2016-06-01T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2015-08-06, 2015-08-13",
          "rr_end": "2015-08-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-08-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-the-treatment-of-unresectable-or-advanced-metastatic-melanoma-in-adults-refractory-to-ipilimumab/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda ®) for Urothelial  Carcinoma 1L",
          "earliest": "2017-12-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2449,
          "indication": "Pembrolizumab (Keytruda®) is indicated for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.",
          "last_scrape": "2018-12-13T16:45:36",
          "latest": "2018-07-27T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27",
          "rr_end": "2018-07-27T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-12-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-uc-1l/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda ®) for Urothelial Carcinoma 2L",
          "earliest": "2017-12-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2450,
          "indication": "Pembrolizumab (Keytruda ®) is indicated as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.",
          "last_scrape": "2018-12-13T16:45:38",
          "latest": "2018-12-05T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-12-06, 2017-12-21",
          "rr_end": "2017-12-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-12-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda-for-urothelial-carcinoma-2l/"
         },
         {
          "company": "Merck",
          "drug_name": "Pembrolizumab (Keytruda®) for the first line treatment of unresectable or advanced metastatic melanoma in adults.",
          "earliest": "2015-08-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda",
          "eu_market": "2015-07-16T00:00:00",
          "id": 2451,
          "indication": "Keytruda® is indicated for the first line treatment of unresectable or advanced metastatic melanoma in adults.",
          "last_scrape": "2018-12-13T16:45:45",
          "latest": "2016-02-08T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2015-08-06, 2015-08-13",
          "rr_end": "2015-08-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-08-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung",
          "trade_name": "Keytruda",
          "url": "http://www.ncpe.ie/drugs/pembrolizumab-keytruda/"
         },
         {
          "company": "Eisai",
          "drug_name": "Perampanel (Fycompa®)",
          "earliest": "2013-07-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa",
          "eu_market": "2012-07-23T00:00:00",
          "id": 2452,
          "indication": "Perampanel (Fycompa®) indicated for treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. ",
          "last_scrape": "2018-12-13T16:45:50",
          "latest": "2013-07-01T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-07-01, 2013-07-01",
          "rr_end": "2013-07-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-07-01T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Epilepsies, Partial",
          "trade_name": "Fycompa",
          "url": "http://www.ncpe.ie/drugs/perampanel-fycompa/"
         },
         {
          "company": "Roche",
          "drug_name": "Pertuzumab  (Perjeta®) for Adjuvant HER2 positive breast cancer",
          "earliest": "2018-06-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta",
          "eu_market": "2013-03-04T00:00:00",
          "id": 2453,
          "indication": "Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.",
          "last_scrape": "2018-12-13T16:45:56",
          "latest": "2018-12-03T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-06-01, 2018-06-22",
          "rr_end": "2018-06-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of pertuzumab compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-06-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Perjeta",
          "url": "http://www.ncpe.ie/drugs/pertuzumab-perjeta-for-her2-positive-breast-cancer/"
         },
         {
          "company": "Roche",
          "drug_name": "Pertuzumab (Perjeta®) in neoadjuvant HER2 positive breast cancer",
          "earliest": "2015-08-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta",
          "eu_market": "2013-03-04T00:00:00",
          "id": 2454,
          "indication": "Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.",
          "last_scrape": "2018-12-13T16:46:02",
          "latest": "2016-05-10T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2015-08-10, 2015-09-01",
          "rr_end": "2015-09-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-08-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Perjeta",
          "url": "http://www.ncpe.ie/drugs/pertuzumab-perjeta-in-neoadjuvant-her2-positive-breast-cancer/"
         },
         {
          "company": "Roche",
          "drug_name": "Pertuzumab (Perjeta®)",
          "earliest": "2013-01-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta",
          "eu_market": "2013-03-04T00:00:00",
          "id": 2455,
          "indication": "The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. ",
          "last_scrape": "2018-12-13T16:46:04",
          "latest": "2013-08-28T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-01-14, 2013-01-31",
          "rr_end": "2013-01-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-01-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Perjeta",
          "url": "http://www.ncpe.ie/drugs/pertuzumab-perjeta/"
         },
         {
          "company": "Unknown",
          "drug_name": "Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane®)",
          "earliest": "2016-11-18T00:00:00",
          "ema_url": "",
          "eu_market": "2013-12-01T00:00:00",
          "id": 2456,
          "indication": "Fydrane® is indicated for cataract surgery to obtain mydriasis and intraocular anaesthesia, during the surgical procedure.",
          "last_scrape": "2018-12-13T16:46:09",
          "latest": "2016-12-19T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-11-18, 2016-12-19",
          "rr_end": "2016-12-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "reimbursement not recommended at the submitted price",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2016-11-18T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "Unknown",
          "trade_name": "Fydrane",
          "url": "http://www.ncpe.ie/drugs/phenylephrine-hydrochloride-tropicamide-lidocaine-hydrochloride-fydrane/"
         },
         {
          "company": "Roche",
          "drug_name": "Pirfenidone (Esbriet®)",
          "earliest": "2011-12-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet",
          "eu_market": "2011-02-27T00:00:00",
          "id": 2457,
          "indication": "Pirfenidone has been licensed by the European Medicines Agency (EMA) for the treatment of mild to moderate idiopathic pulmonary fibrosis.",
          "last_scrape": "2018-12-13T16:46:11",
          "latest": "2015-03-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 1,
          "rr_dates": "2011-12-15, 2012-01-05",
          "rr_end": "2012-01-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-12-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Idiopathic Pulmonary Fibrosis",
          "trade_name": "Esbriet",
          "url": "http://www.ncpe.ie/drugs/pirfenidone-esbriet/"
         },
         {
          "company": "CIS",
          "drug_name": "Pitavastatin (Livazo®)",
          "earliest": "2010-12-22T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2458,
          "indication": "Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.",
          "last_scrape": "2018-12-13T16:46:14",
          "latest": "2010-12-24T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-12-22, 2010-12-24",
          "rr_end": "2010-12-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2010-12-22T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Livazo",
          "url": "http://www.ncpe.ie/drugs/pitavastatin-livazo/"
         },
         {
          "company": "Bioprojet",
          "drug_name": "Pitolisant hydrochloride (Wakix®)",
          "earliest": "2017-06-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/wakix",
          "eu_market": "2016-03-31T00:00:00",
          "id": 2459,
          "indication": "Pitolisant hydrochloride (Wakix®) is indicated for the treatment of narcolepsy with or without cataplexy and should be initiated by a physician experienced in the treatment of sleep disorders.",
          "last_scrape": "2018-12-13T16:46:20",
          "latest": "2017-06-15T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2017-06-12, 2017-06-15",
          "rr_end": "2017-06-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-06-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Narcolepsy",
          "trade_name": "Wakix",
          "url": "http://www.ncpe.ie/drugs/pitolisant-wakix/"
         },
         {
          "company": "CTI",
          "drug_name": "Pixantrone (Pixuvri®)",
          "earliest": "2015-02-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri",
          "eu_market": "2012-05-10T00:00:00",
          "id": 2460,
          "indication": "Pixurvi® is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas (NHL).",
          "last_scrape": "2018-12-13T16:46:24",
          "latest": "2015-03-20T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-02-10, 2015-03-20",
          "rr_end": "2015-03-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-02-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Lymphoma, Non-Hodgkin",
          "trade_name": "Pixuvri",
          "url": "http://www.ncpe.ie/drugs/pixantrone-pixuvri/"
         },
         {
          "company": "Vifor",
          "drug_name": "Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro®)",
          "earliest": "2014-09-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro",
          "eu_market": "2014-08-26T00:00:00",
          "id": 2461,
          "indication": "Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro™) is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD).",
          "last_scrape": "2018-12-13T16:46:27",
          "latest": "2014-10-08T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-09-12, 2014-10-08",
          "rr_end": "2014-10-08T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-09-12T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hyperphosphatemia; Renal Dialysis",
          "trade_name": "Velphoro",
          "url": "http://www.ncpe.ie/drugs/polynuclear-ironiii-oxyhydroxide-pn-feooh-velphoro/"
         },
         {
          "company": "CIS",
          "drug_name": "Pomalidomide (Imnovid®)",
          "earliest": "2013-09-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2462,
          "indication": "Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.",
          "last_scrape": "2018-12-13T16:46:30",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2013-09-20, 2013-10-02",
          "rr_end": "2013-10-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-09-20T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Imnovid",
          "url": "http://www.ncpe.ie/drugs/pomalidomide-imnovid/"
         },
         {
          "company": "Incyte",
          "drug_name": "Ponatinib (Iclusig®)",
          "earliest": "2013-10-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig",
          "eu_market": "2013-07-01T00:00:00",
          "id": 2463,
          "indication": "Ponatinib (Iclusig®) Is indicated for patients in chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation and for Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) patients who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.",
          "last_scrape": "2018-12-13T16:46:32",
          "latest": "2016-01-05T00:00:00",
          "ncpe_year": 2016,
          "orphan": 1,
          "rr_dates": "2013-10-02, 2013-12-01",
          "rr_end": "2013-12-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-10-02T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Myeloid; Leukemia, Lymphoid",
          "trade_name": "Iclusig",
          "url": "http://www.ncpe.ie/drugs/ponatinib-iclusig/"
         },
         {
          "company": "Daiichi",
          "drug_name": "Prasugrel (Efient®)",
          "earliest": "2009-07-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/efient",
          "eu_market": "2009-02-24T00:00:00",
          "id": 2464,
          "indication": "Economic Evaluation of Prasugrel (Efient®) for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.",
          "last_scrape": "2018-12-13T16:46:38",
          "latest": "2010-02-01T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-12-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-10-30T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction",
          "trade_name": "Efient",
          "url": "http://www.ncpe.ie/drugs/prasugrel-efient/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Pregabalin (Lyrica®) for the treatment of neuropathic pain",
          "earliest": "2013-09-30T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica",
          "eu_market": "2004-07-05T00:00:00",
          "id": 2465,
          "indication": "Lyrica® is indicated for the treatment of peripheral and central neuropathic pain, generalised anxiety disorder and as adjunctive therapy for epilepsy.",
          "last_scrape": "2018-12-13T16:46:46",
          "latest": "2015-06-12T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-12-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-10-30T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Epilepsy; Anxiety Disorders; Neuralgia",
          "trade_name": "Lyrica",
          "url": "http://www.ncpe.ie/drugs/pregabalin-lyrica-2/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Pregabalin (Lyrica®) for the treatment of Generalised Anxiety Disorder",
          "earliest": "2014-09-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica",
          "eu_market": "2004-07-05T00:00:00",
          "id": 2466,
          "indication": "Pregabalin (Lyrica®) for the treatment of Generalised Anxiety Disorder.",
          "last_scrape": "2018-12-13T16:46:52",
          "latest": "2014-12-15T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-12-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-10-30T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Epilepsy; Anxiety Disorders; Neuralgia",
          "trade_name": "Lyrica",
          "url": "http://www.ncpe.ie/drugs/pregabalin-lyrica-for-the-treatment-of-generalised-anxiety-disorder/"
         },
         {
          "company": "Shire",
          "drug_name": "Prucalopride (Resolor®)",
          "earliest": "2011-01-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/resolor",
          "eu_market": "2009-10-14T00:00:00",
          "id": 2467,
          "indication": "Prucalopride (Resolor®) for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.",
          "last_scrape": "2018-12-13T16:46:58",
          "latest": "2011-03-01T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-03-11, 2011-01-17",
          "rr_end": "2011-01-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-03-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Constipation",
          "trade_name": "Resolor",
          "url": "http://www.ncpe.ie/drugs/prucalopride-resolor/"
         },
         {
          "company": "Bayer",
          "drug_name": "Radium-223 (Xofigo®)",
          "earliest": "2013-11-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo",
          "eu_market": "2013-11-13T00:00:00",
          "id": 2468,
          "indication": "Radium-223 (Xofigo®) is indicated for the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.  It is for use in the hospital setting.",
          "last_scrape": "2018-12-13T16:47:00",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2013-11-28, 2013-12-23",
          "rr_end": "2013-12-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-11-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Prostatic Neoplasms",
          "trade_name": "Xofigo",
          "url": "http://www.ncpe.ie/drugs/radium-223-xofigo/"
         },
         {
          "company": "Eli",
          "drug_name": "Ramucirumab (Cyramza®)",
          "earliest": "2014-12-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza",
          "eu_market": "2014-12-19T00:00:00",
          "id": 2469,
          "indication": "Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.",
          "last_scrape": "2018-12-13T16:47:03",
          "latest": "2016-07-26T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2014-12-20, 2014-12-23",
          "rr_end": "2014-12-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-12-20T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Stomach Neoplasms",
          "trade_name": "Cyramza",
          "url": "http://www.ncpe.ie/drugs/ramucirumab-cyramza/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Ranolazine (Ranexa®)",
          "earliest": "2009-11-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2470,
          "indication": "Cost-effectiveness of Ranolazine (Ranexa®)",
          "last_scrape": "2018-12-13T16:47:06",
          "latest": "2009-11-19T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "2009-11-19",
          "rr_end": "2009-11-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2009-11-19T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Ranexa",
          "url": "http://www.ncpe.ie/drugs/ranolazine-ranexa/"
         },
         {
          "company": "GE",
          "drug_name": "Regadenoson (Rapiscan®)",
          "earliest": "2011-09-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan",
          "eu_market": "2010-09-06T00:00:00",
          "id": 2471,
          "indication": "Cost-effectiveness of Regadenoson (Rapiscan®)",
          "last_scrape": "2018-12-13T16:47:13",
          "latest": "2011-11-02T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-09-19, 2011-11-02",
          "rr_end": "2011-11-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-09-19T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Myocardial Perfusion Imaging",
          "trade_name": "Rapiscan",
          "url": "http://www.ncpe.ie/drugs/regadenoson-rapiscan/"
         },
         {
          "company": "Bayer",
          "drug_name": "Regorafenib (Stivarga®) for GIST",
          "earliest": "2014-09-18T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga",
          "eu_market": "2013-08-26T00:00:00",
          "id": 2472,
          "indication": "Regorafenib (Stivarga®) indicated for the treatment of patients with gastrointestinal stromal tumours (GIST) who have been previously treated with two tyrosine kinase inhibitors and have progressed or are intolerant to prior treatment with two TKI’s.",
          "last_scrape": "2018-12-13T16:47:17",
          "latest": "2014-10-06T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-09-18, 2014-10-06",
          "rr_end": "2014-10-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-09-18T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Colorectal Neoplasms",
          "trade_name": "Stivarga",
          "url": "http://www.ncpe.ie/drugs/regorafenib-stivarga-for-gist/"
         },
         {
          "company": "Teva",
          "drug_name": "Reslizumab (Cinqaero®)",
          "earliest": "2017-01-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero",
          "eu_market": "2016-08-15T00:00:00",
          "id": 2473,
          "indication": "Cinqaero® is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.",
          "last_scrape": "2018-12-13T16:47:23",
          "latest": "2017-03-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-01-23, 2017-03-01",
          "rr_end": "2017-03-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-01-23T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Asthma",
          "trade_name": "Cinqaero",
          "url": "http://www.ncpe.ie/drugs/reslizumab-cinqaero/"
         },
         {
          "company": "Glaxo",
          "drug_name": "Retigabine (Trobalt®)",
          "earliest": "2011-03-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt",
          "eu_market": "2011-03-27T00:00:00",
          "id": 2474,
          "indication": "Cost-effectiveness of Retigabine (Trobalt®)",
          "last_scrape": "2018-12-13T16:47:27",
          "latest": "2011-04-06T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-04-06, 2011-03-01",
          "rr_end": "2011-03-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-04-06T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Epilepsy",
          "trade_name": "Trobalt",
          "url": "http://www.ncpe.ie/drugs/retigabine-trobalt/"
         },
         {
          "company": "Novartis",
          "drug_name": "Ribociclib (Kisqali®)",
          "earliest": "2017-09-04T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali",
          "eu_market": "2017-08-22T00:00:00",
          "id": 2475,
          "indication": "Ribociclib (Kisqali®) in combination with an aromatase inhibitor (AI) is indicated for the treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine based therapy.",
          "last_scrape": "2018-12-13T16:47:29",
          "latest": "2018-08-13T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2017-09-04, 2017-09-19",
          "rr_end": "2017-09-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "following ncpe assessment of the company submission, the ncpe recommends that ribociclib (in combination with an aromatase inhibitor) for the treatment of postmenopausal women with hr+/her2- locally advanced or metastatic bc as initial endocrine-based therapy, not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments this recommendation should be considered while also having regard to the criteria specified in the health (pricing and supply of medical goods) act 2013",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-09-04T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Kisqali",
          "url": "http://www.ncpe.ie/drugs/ribociclib-kisqali/"
         },
         {
          "company": "CIS",
          "drug_name": "Rifaximin (Targaxan®)",
          "earliest": "2013-07-09T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2476,
          "indication": "Rifaximin (Targaxan®) is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age. ",
          "last_scrape": "2018-12-13T16:47:35",
          "latest": "2013-08-06T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-07-09, 2013-08-06",
          "rr_end": "2013-08-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-07-09T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Targaxan",
          "url": "http://www.ncpe.ie/drugs/rifaximin-targaxan-2/"
         },
         {
          "company": "Bayer",
          "drug_name": "Regorafenib (Stivarga®) for mCRC",
          "earliest": "2013-09-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga",
          "eu_market": "2013-08-26T00:00:00",
          "id": 2477,
          "indication": "Regorafenib (Stivarga®) is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.",
          "last_scrape": "2018-12-13T16:47:38",
          "latest": "2014-06-30T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-09-12, 2013-10-02",
          "rr_end": "2013-10-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-09-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Colorectal Neoplasms",
          "trade_name": "Stivarga",
          "url": "http://www.ncpe.ie/drugs/rigorafenib-stivarga/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Rilpivirine (Edurant®)",
          "earliest": "2011-12-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/edurant",
          "eu_market": "2011-11-28T00:00:00",
          "id": 2478,
          "indication": "Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml.",
          "last_scrape": "2018-12-13T16:47:42",
          "latest": "2012-01-06T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-12-14, 2012-01-06",
          "rr_end": "2012-01-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-12-14T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "HIV Infections",
          "trade_name": "Edurant",
          "url": "http://www.ncpe.ie/drugs/rilpivirine-edurant/"
         },
         {
          "company": "Gilead",
          "drug_name": "Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey®)",
          "earliest": "2016-06-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey",
          "eu_market": "2016-06-21T00:00:00",
          "id": 2479,
          "indication": "Odefsey® (R/F/TAF) is indicated for the treatment of adults and adolescents (≥ 12 years, body weight ≥35 kg) infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/ml.",
          "last_scrape": "2018-12-13T16:47:45",
          "latest": "2016-10-04T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-06-28, 2016-07-11",
          "rr_end": "2016-07-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "reimbursement not recommeded",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-06-28T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "HIV Infections",
          "trade_name": "Odefsey",
          "url": "http://www.ncpe.ie/drugs/rilpivirine-r-emtricitabine-f-tenofovir-alafenamide-taf-odefsey/"
         },
         {
          "company": "sanofi-aventis",
          "drug_name": "Rimonabant (Acomplia®)",
          "earliest": "2006-06-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia",
          "eu_market": "2006-06-19T00:00:00",
          "id": 2480,
          "indication": "In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant (in addition to diet and exercise) in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.",
          "last_scrape": "2018-12-13T16:47:48",
          "latest": "2006-06-01T00:00:00",
          "ncpe_year": 2006,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2016-07-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-06-09T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Obesity",
          "trade_name": "Acomplia",
          "url": "http://www.ncpe.ie/drugs/rimonabant-acomplia-2/"
         },
         {
          "company": "Bayer",
          "drug_name": "Riociguat (Adempas®)",
          "earliest": "2014-04-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adempas",
          "eu_market": "2014-03-27T00:00:00",
          "id": 2481,
          "indication": "Riociguat (Adempas®) is indicated for the treatment of Pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH).",
          "last_scrape": "2018-12-13T16:47:53",
          "latest": "2014-05-16T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-04-11, 2014-05-16",
          "rr_end": "2014-05-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta recommended at the current price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-04-11T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hypertension, Pulmonary",
          "trade_name": "Adempas",
          "url": "http://www.ncpe.ie/drugs/riociguat-adempas/"
         },
         {
          "company": "Roche",
          "drug_name": "Rituximab (MabThera®)",
          "earliest": "2014-05-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera",
          "eu_market": "1998-06-02T00:00:00",
          "id": 2482,
          "indication": "Rituximab (MabThera®) subcutaneous formulation is indicated in adults for Non-Hodgkin’s lymphoma (NHL):",
          "last_scrape": "2018-12-13T16:47:59",
          "latest": "2014-09-22T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-05-26, 2014-09-22",
          "rr_end": "2014-09-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-05-26T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "MabThera",
          "url": "http://www.ncpe.ie/drugs/rituximab-mabthera/"
         },
         {
          "company": "Bayer",
          "drug_name": "Rivaroxaban (Xarelto®) for Atrial Fibrillation patients undergoing PCI",
          "earliest": "2017-11-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto",
          "eu_market": "2008-09-30T00:00:00",
          "id": 2483,
          "indication": "Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.",
          "last_scrape": "2018-12-13T16:48:05",
          "latest": "2017-11-21T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-11-20, 2017-11-21",
          "rr_end": "2017-11-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-11-20T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Xarelto",
          "url": "http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-atrial-fibrillation-patients-undergoing-pci/"
         },
         {
          "company": "Bayer",
          "drug_name": "Rivaroxaban (Xarelto®) for the Treatment of Deep Vein Thrombosis",
          "earliest": "2011-08-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto",
          "eu_market": "2008-09-30T00:00:00",
          "id": 2484,
          "indication": "Economic evaluation of Rivaroxaban (Xarelto®) for the Treatment of Deep Vein Thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.",
          "last_scrape": "2018-12-13T16:48:10",
          "latest": "2012-02-24T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-08-17, 2011-08-31",
          "rr_end": "2011-08-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-08-17T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Xarelto",
          "url": "http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-dvt/"
         },
         {
          "company": "Bayer",
          "drug_name": "Rivaroxaban (Xarelto®) for the Prevention of Stroke in Atrial Fibrillation",
          "earliest": "2011-08-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto",
          "eu_market": "2008-09-30T00:00:00",
          "id": 2485,
          "indication": "Cost Effectiveness of Rivaroxaban (Xarelto®) for the prevention of stroke in atrial fibrillation.",
          "last_scrape": "2018-12-13T16:48:15",
          "latest": "2012-06-19T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-08-17, 2011-08-31",
          "rr_end": "2011-08-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-08-17T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Xarelto",
          "url": "http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-spaf-2/"
         },
         {
          "company": "Bayer",
          "drug_name": "Rivaroxaban (Xarelto®) for the prevention of atherothrombotic events",
          "earliest": "2018-09-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto",
          "eu_market": "2008-09-30T00:00:00",
          "id": 2486,
          "indication": "Rivaroxaban (Xarelto®) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.",
          "last_scrape": "2018-12-13T16:48:18",
          "latest": "2018-10-11T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-09-26, 2018-10-11",
          "rr_end": "2018-10-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of rivaroxaban compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-09-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Xarelto",
          "url": "http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-the-prevention-of-atherothrombotic-events/"
         },
         {
          "company": "Bayer",
          "drug_name": "Rivaroxaban (Xarelto®) low dose for prevention of recurrent venous thromboembolism",
          "earliest": "2017-11-20T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto",
          "eu_market": "2008-09-30T00:00:00",
          "id": 2487,
          "indication": "Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.",
          "last_scrape": "2018-12-13T16:48:25",
          "latest": "2017-11-21T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-11-20, 2017-11-21",
          "rr_end": "2017-11-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-11-20T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Xarelto",
          "url": "http://www.ncpe.ie/drugs/rivaroxaban-xarelto-low-dose-for-prevention-of-recurrent-venous-thromboembolism/"
         },
         {
          "company": "Bayer",
          "drug_name": "Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement",
          "earliest": "2008-04-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto",
          "eu_market": "2008-09-30T00:00:00",
          "id": 2488,
          "indication": "Cost Effectiveness of Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement.",
          "last_scrape": "2018-12-13T16:48:30",
          "latest": "2008-09-01T00:00:00",
          "ncpe_year": 2008,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-11-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-10-20T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Arthroplasty, Replacement; Venous Thromboembolism",
          "trade_name": "Xarelto",
          "url": "http://www.ncpe.ie/drugs/rivaroxaban-xarelto/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Roflumilast (Daxas®)",
          "earliest": "2010-06-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/daxas",
          "eu_market": "2010-07-05T00:00:00",
          "id": 2489,
          "indication": "Cost Effectiveness of Roflumilast (Daxas®) for the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.",
          "last_scrape": "2018-12-13T16:48:33",
          "latest": "2010-11-03T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-11-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-10-20T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Pulmonary Disease, Chronic Obstructive",
          "trade_name": "Daxas",
          "url": "http://www.ncpe.ie/drugs/roflumilast-daxas/"
         },
         {
          "company": "Tesaro",
          "drug_name": "Rolapitant (Varuby®)",
          "earliest": "2017-05-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/varuby",
          "eu_market": "2017-04-19T00:00:00",
          "id": 2490,
          "indication": "Rolapitant (Varuby®)is indicated for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.",
          "last_scrape": "2018-12-13T16:48:40",
          "latest": "2017-06-12T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-05-15, 2017-06-12",
          "rr_end": "2017-06-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-05-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Vomiting; Nausea; Cancer",
          "trade_name": "Varuby",
          "url": "http://www.ncpe.ie/drugs/rolapitant-varuby/"
         },
         {
          "company": "Amgen",
          "drug_name": "Romiplostim (Nplate®)",
          "earliest": "2015-04-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/nplate",
          "eu_market": "2009-02-04T00:00:00",
          "id": 2491,
          "indication": "Romiplostim (Nplate®) is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.",
          "last_scrape": "2018-12-13T16:48:43",
          "latest": "2015-05-27T00:00:00",
          "ncpe_year": 2015,
          "orphan": 1,
          "rr_dates": "",
          "rr_end": "2017-06-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-05-11T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Purpura, Thrombocytopenic, Idiopathic",
          "trade_name": "Nplate",
          "url": "http://www.ncpe.ie/drugs/romiplostim-nplate/"
         },
         {
          "company": "Unknown",
          "drug_name": "Ropivacaine Readyfusor®",
          "earliest": "2018-11-09T00:00:00",
          "ema_url": "",
          "eu_market": "2015-11-22T00:00:00",
          "id": 2492,
          "indication": "Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.",
          "last_scrape": "2018-12-13T16:48:47",
          "latest": "2018-12-13T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-11-09, 2018-12-13",
          "rr_end": "2018-12-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is not recommended the ncpe recommends that ropivicaine readyfusor not be considered for reimbursement at the submitted price  this recommendation should be considered while also having regard to the criteria specified in the health (pricing and supply of medical goods act) 2013",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2018-11-09T00:00:00",
          "rr_status": "Unknown",
          "ta_list": "Unknown",
          "trade_name": "Ropivacaine Readyfusor",
          "url": "http://www.ncpe.ie/drugs/ropivacaine-readyfusor/"
         },
         {
          "company": "Novartis",
          "drug_name": "Ruxolitinib (Jakavi®) for Polycythaemia Vera",
          "earliest": "2015-04-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi",
          "eu_market": "2012-08-23T00:00:00",
          "id": 2493,
          "indication": "Jakavi® is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.",
          "last_scrape": "2018-12-13T16:48:50",
          "latest": "2016-08-16T00:00:00",
          "ncpe_year": 2016,
          "orphan": 1,
          "rr_dates": "2015-04-15, 2015-05-28",
          "rr_end": "2015-05-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-04-15T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Myeloproliferative Disorders",
          "trade_name": "Jakavi",
          "url": "http://www.ncpe.ie/drugs/ruxolitinib-jakavi-for-polycythaemia-vera/"
         },
         {
          "company": "Novartis",
          "drug_name": "Ruxolitinib (Jakavi®)",
          "earliest": "2012-08-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi",
          "eu_market": "2012-08-23T00:00:00",
          "id": 2494,
          "indication": "Ruxolitinib (Jakavi®) for the treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.",
          "last_scrape": "2018-12-13T16:48:55",
          "latest": "2013-07-09T00:00:00",
          "ncpe_year": 2013,
          "orphan": 1,
          "rr_dates": "2012-08-01, 2012-08-10",
          "rr_end": "2012-08-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2012-08-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Myeloproliferative Disorders",
          "trade_name": "Jakavi",
          "url": "http://www.ncpe.ie/drugs/ruxolitinib-jakavi/"
         },
         {
          "company": "Novartis",
          "drug_name": "Sacubitril/valsartan (Entresto®)",
          "earliest": "2015-11-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/entresto",
          "eu_market": "2015-11-19T00:00:00",
          "id": 2495,
          "indication": "Entresto® for the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients.",
          "last_scrape": "2018-12-13T16:48:58",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2015-11-06, 2015-11-30",
          "rr_end": "2015-11-30T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-11-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Heart Failure",
          "trade_name": "Entresto",
          "url": "http://www.ncpe.ie/drugs/sacubitrilvalsartan-entresto/"
         },
         {
          "company": "Zambon",
          "drug_name": "Safinamide methansulfonate (Xadago®)",
          "earliest": "2016-06-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xadago",
          "eu_market": "2015-02-23T00:00:00",
          "id": 2496,
          "indication": "Xadago® for the treatment of adult patients with idiopathic Parkinson’s disease.",
          "last_scrape": "2018-12-13T16:49:04",
          "latest": "2016-07-06T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-06-14, 2016-07-06",
          "rr_end": "2016-07-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "reimbursement not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2016-06-14T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "Parkinson Disease",
          "trade_name": "Xadago",
          "url": "http://www.ncpe.ie/drugs/safinamide-methansulfonate-xadago/"
         },
         {
          "company": "BioMarin",
          "drug_name": "Sapropterin (Kuvan®)",
          "earliest": "2009-01-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan",
          "eu_market": "2008-12-02T00:00:00",
          "id": 2497,
          "indication": "Sapropterin (Kuvan®) for the treatment of phenylketonuria (PKU).",
          "last_scrape": "2018-12-13T16:49:07",
          "latest": "2017-09-15T00:00:00",
          "ncpe_year": 2017,
          "orphan": 1,
          "rr_dates": "2015-07-14, 2015-08-14, 2015-07-01",
          "rr_end": "2015-07-01T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-07-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Phenylketonurias",
          "trade_name": "Kuvan",
          "url": "http://www.ncpe.ie/drugs/sapropterin-kuvan/"
         },
         {
          "company": "sanofi-aventis",
          "drug_name": "Sarilumab (Kevzara®)",
          "earliest": "2017-08-18T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara",
          "eu_market": "2017-06-23T00:00:00",
          "id": 2498,
          "indication": "Sarilumab (Kevzara®) in combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARD). Sarilumab can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.",
          "last_scrape": "2018-12-13T16:49:11",
          "latest": "2017-10-04T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-08-18, 2017-10-04",
          "rr_end": "2017-10-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-08-18T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Rheumatoid",
          "trade_name": "Kevzara",
          "url": "http://www.ncpe.ie/drugs/sarilumab-kevzara/"
         },
         {
          "company": "Alexion",
          "drug_name": "Sebelipase alfa (Kanuma®)",
          "earliest": "2017-02-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kanuma",
          "eu_market": "2015-08-28T00:00:00",
          "id": 2499,
          "indication": "Sebelipase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.",
          "last_scrape": "2018-12-13T16:49:16",
          "latest": "2018-06-08T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-02-08, 2017-03-13",
          "rr_end": "2017-03-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-02-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Lipid Metabolism, Inborn Errors",
          "trade_name": "Kanuma",
          "url": "http://www.ncpe.ie/drugs/sebelipase-alfa-kanuma/"
         },
         {
          "company": "Novartis",
          "drug_name": "Secukinumab (Cosentyx®) for Ankylosing Spondylitis",
          "earliest": "2015-12-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx",
          "eu_market": "2015-01-14T00:00:00",
          "id": 2500,
          "indication": "Cosentyx® is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy",
          "last_scrape": "2018-12-13T16:49:20",
          "latest": "2015-12-14T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-12-02, 2015-12-14",
          "rr_end": "2015-12-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-12-02T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing",
          "trade_name": "Cosentyx",
          "url": "http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-ankylosing-spondylitis/"
         },
         {
          "company": "Novartis",
          "drug_name": "Secukinumab (Cosentyx®) for Psoriatic Arthritis",
          "earliest": "2015-12-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx",
          "eu_market": "2015-01-14T00:00:00",
          "id": 2501,
          "indication": "Cosentyx® alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.",
          "last_scrape": "2018-12-13T16:49:25",
          "latest": "2015-12-15T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-12-02, 2015-12-15",
          "rr_end": "2015-12-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-12-02T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing",
          "trade_name": "Cosentyx",
          "url": "http://www.ncpe.ie/drugs/secukinumab-cosentyx-for-psoriatic-arthritis/"
         },
         {
          "company": "Novartis",
          "drug_name": "Secukinumab (Cosentyx®)",
          "earliest": "2014-12-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx",
          "eu_market": "2015-01-14T00:00:00",
          "id": 2502,
          "indication": "Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.",
          "last_scrape": "2018-12-13T16:49:31",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-12-19, 2015-02-05",
          "rr_end": "2015-02-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-12-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing",
          "trade_name": "Cosentyx",
          "url": "http://www.ncpe.ie/drugs/secukinumab-cosentyx/"
         },
         {
          "company": "Janssen",
          "drug_name": "Selexipag (Uptravi®)",
          "earliest": "2016-11-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi",
          "eu_market": "2016-05-12T00:00:00",
          "id": 2503,
          "indication": "Selexipag (Uptravi®) is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.",
          "last_scrape": "2018-12-13T16:49:34",
          "latest": "2018-05-21T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-11-01, 2016-12-05",
          "rr_end": "2016-12-05T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-11-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hypertension, Pulmonary",
          "trade_name": "Uptravi",
          "url": "http://www.ncpe.ie/drugs/selexipag-uptravi/"
         },
         {
          "company": "Novo",
          "drug_name": "Semaglutide (Ozempic®)",
          "earliest": "2018-03-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic",
          "eu_market": "2018-02-08T00:00:00",
          "id": 2504,
          "indication": "Semaglutide (Ozempic®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:",
          "last_scrape": "2018-12-13T16:49:39",
          "latest": "2018-04-10T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-03-12, 2018-04-10",
          "rr_end": "2018-04-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is recommended on the basis of the proposed price, relative to currently available therapies",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-03-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Diabetes Mellitus",
          "trade_name": "Ozempic",
          "url": "http://www.ncpe.ie/drugs/semaglutide-ozempic/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Sildenafil (Revatio®)",
          "earliest": "2014-04-16T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/revatio",
          "eu_market": "2005-10-28T00:00:00",
          "id": 2505,
          "indication": "Sildenafil (Revatio®) is indicated for:",
          "last_scrape": "2018-12-13T16:49:44",
          "latest": "2014-05-23T00:00:00",
          "ncpe_year": 2014,
          "orphan": 1,
          "rr_dates": "2014-04-16, 2014-05-23",
          "rr_end": "2014-05-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-04-16T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hypertension, Pulmonary",
          "trade_name": "Revatio",
          "url": "http://www.ncpe.ie/drugs/sildenafil-revatio/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Simeprevir (Olysio®) in combination with Sofosbuvir",
          "earliest": "2014-05-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/olysio",
          "eu_market": "2014-05-14T00:00:00",
          "id": 2506,
          "indication": "Simeprevir (Olysio®) in combination with Sofosbuvir for the treatment of chronic hepatitis C (CHC) in adult patients who are intolerant to or ineligible for interferon therapy, and are in urgent need of treatment.",
          "last_scrape": "2018-12-13T16:49:49",
          "latest": "2015-03-13T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-05-27, 2014-07-11",
          "rr_end": "2014-07-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-05-27T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Olysio",
          "url": "http://www.ncpe.ie/drugs/simeprevir-olysio-in-combination-with-sofosbuvir/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Simeprevir (Olysio®)",
          "earliest": "2014-05-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/olysio",
          "eu_market": "2014-05-14T00:00:00",
          "id": 2507,
          "indication": "Simeprevir (Olysio®) is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients as part of a triple therapy regimen (co-administered with PegInterferon + Ribavirin) to treat hepatitis C virus (HCV) Genotypes 1 and 4 who are treatment naïve or have previously been treated.",
          "last_scrape": "2018-12-13T16:49:53",
          "latest": "2014-07-11T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-05-27, 2014-07-11",
          "rr_end": "2014-07-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended when used in triple therapy with peg-interferon and ribavirin",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-05-27T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Olysio",
          "url": "http://www.ncpe.ie/drugs/simeprevir-olysio/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb®)",
          "earliest": "2014-02-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2508,
          "indication": "Hyaneb® is particularly indicated in patients with cystic fibrosis and in patients with bronchiectasis.  Hyaneb® is classified as a medical device and carries a CE mark.",
          "last_scrape": "2018-12-13T16:50:00",
          "latest": "2014-03-19T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-02-10, 2014-03-19",
          "rr_end": "2014-03-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-02-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Hyaneb",
          "url": "http://www.ncpe.ie/drugs/sodium-chloride-70mgml-sodium-hyaluronate-1mgml-hyaneb/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Sodium Hyaluronate (Hyloforte® 0.2%)",
          "earliest": "2014-01-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2509,
          "indication": "Sodium Hyaluronate (Hyloforte® 0.2%) is indicated for the treatment of mild to moderate form of dry eye.",
          "last_scrape": "2018-12-13T16:50:06",
          "latest": "2014-01-27T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-01-15, 2014-01-27",
          "rr_end": "2014-01-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-01-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Hyloforte 0.2%",
          "url": "http://www.ncpe.ie/drugs/sodium-hyaluronate-hyloforte-0-2/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Sodium Hyaluronate (Hylotear® 0.1%)",
          "earliest": "2014-01-15T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2510,
          "indication": "Sodium Hyaluronate (Hylotear® 0.1%) is indicated for the treatment of mild to moderate form of dry eye.",
          "last_scrape": "2018-12-13T16:50:09",
          "latest": "2014-01-27T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-01-15, 2014-01-27",
          "rr_end": "2014-01-27T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-01-15T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Hylotear 0.1%",
          "url": "http://www.ncpe.ie/drugs/sodium-hyaluronate-hylotear-0-1/"
         },
         {
          "company": "Lucane",
          "drug_name": "Sodium phenylbutyrate (Pheburane®)",
          "earliest": "2013-07-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane",
          "eu_market": "2013-07-30T00:00:00",
          "id": 2511,
          "indication": "Sodium phenylbutyrate (Pheburane®) is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.",
          "last_scrape": "2018-12-13T16:50:15",
          "latest": "2013-08-06T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-07-17, 2013-08-06",
          "rr_end": "2013-08-06T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-07-17T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Carbamoyl-Phosphate Synthase I Deficiency Disease",
          "trade_name": "Pheburane",
          "url": "http://www.ncpe.ie/drugs/sodium-phenylbutyrate-pheburane/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Sofosbuvir (Solvaldi®)",
          "earliest": "2014-02-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13",
          "eu_market": "2009-12-09T00:00:00",
          "id": 2512,
          "indication": "Sofosbuvir (Solvaldi®) is indicated in combination with other medicinal products for the treatment of Chronic Hepatitis C in adults.",
          "last_scrape": "2018-12-13T16:50:18",
          "latest": "2014-10-24T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-02-12, 2014-03-10",
          "rr_end": "2014-03-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-02-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Pneumococcal Infections; Immunization",
          "trade_name": "Solvaldi",
          "url": "http://www.ncpe.ie/drugs/sofosbuvir-solvaldi/"
         },
         {
          "company": "Gilead",
          "drug_name": "Sofosbuvir/Velpatasvir (Epclusa®) chronic hepatitis C virus (HCV) – pangenotypic",
          "earliest": "2017-09-05T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa",
          "eu_market": "2016-07-06T00:00:00",
          "id": 2513,
          "indication": "Sofosbuvir/velpatasvir (Epclusa®) for the treatment of chronic hepatitis C virus (HCV) infection in adults. This indication covers all genotypes (GT1, 2, 3, 4, 5 and 6) i.e. pangenotypic.",
          "last_scrape": "2018-12-13T16:50:22",
          "latest": "2017-10-19T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-09-05, 2017-10-19",
          "rr_end": "2017-10-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-09-05T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Epclusa",
          "url": "http://www.ncpe.ie/drugs/sofosbuvirvelpatasvir-epclusa-chronic-hepatitis-c-virus-hcv-pangenotypic/"
         },
         {
          "company": "Gilead",
          "drug_name": "Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®)",
          "earliest": "2017-09-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi",
          "eu_market": "2017-07-26T00:00:00",
          "id": 2514,
          "indication": "Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®) is indicated the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic i.e. all genotypes (GT1, 2, 3, 4, 5 and 6).",
          "last_scrape": "2018-12-13T16:50:26",
          "latest": "2017-11-15T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-09-19, 2017-11-15",
          "rr_end": "2017-11-15T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-09-19T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Vosevi",
          "url": "http://www.ncpe.ie/drugs/sofosbuvirvelpatasvirvoxilaprevir-vosevi/"
         },
         {
          "company": "CIS",
          "drug_name": "St Johns Wort (Pacifa®)",
          "earliest": "2015-04-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2515,
          "indication": "Pacifa® is indicated for the short term treatment of mild depressive symptoms.",
          "last_scrape": "2018-12-13T16:50:32",
          "latest": "2015-05-29T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-04-14, 2015-05-29",
          "rr_end": "2015-05-29T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-04-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Pacifa",
          "url": "http://www.ncpe.ie/drugs/st-johns-wort-pafica/"
         },
         {
          "company": "Biocodex",
          "drug_name": "Stiripentol (Diacomit®)",
          "earliest": "2017-07-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit",
          "eu_market": "2007-01-03T00:00:00",
          "id": 2516,
          "indication": "Stiripentol (Diacomit®) for use in conjunction with clobazam and valproate as adjunctive therapy of\nrefractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy\n(SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and\nvalproate",
          "last_scrape": "2018-12-13T16:50:38",
          "latest": "2018-10-19T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-07-06, 2017-08-10",
          "rr_end": "2017-08-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-07-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Myoclonic Epilepsy, Juvenile",
          "trade_name": "Diacomit",
          "url": "http://www.ncpe.ie/drugs/stiripentol-diacomit/"
         },
         {
          "company": "Gilead",
          "drug_name": "Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild®)",
          "earliest": "2013-04-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/stribild",
          "eu_market": "2013-05-24T00:00:00",
          "id": 2517,
          "indication": "Indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®.",
          "last_scrape": "2018-12-13T16:50:43",
          "latest": "2013-12-06T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-04-28, 2013-05-17",
          "rr_end": "2013-05-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-04-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "HIV Infections",
          "trade_name": "Stribild",
          "url": "http://www.ncpe.ie/drugs/stribild-elvitegravircobicistatemtricitabinetenofovir-disoproxil-as-fumarate/"
         },
         {
          "company": "CIS",
          "drug_name": "Sublingual Immunotherapy (Grazax®)",
          "earliest": "2007-09-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2518,
          "indication": "A Review of the Cost-Effectiveness of Sublingual Immunotherapy (Grazax®) for the Prevention of Seasonal Grass Pollen-Induced Rhinoconjunctivitis.",
          "last_scrape": "2018-12-13T16:50:49",
          "latest": "2007-09-01T00:00:00",
          "ncpe_year": 2007,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-05-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-04-15T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Grazax",
          "url": "http://www.ncpe.ie/drugs/sublingual-immunotherapy-grazax/"
         },
         {
          "company": "Indivior",
          "drug_name": "Buprenorphine/naloxone (Suboxone®)",
          "earliest": "2007-11-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone",
          "eu_market": "2006-09-26T00:00:00",
          "id": 2519,
          "indication": "An economic evaluation of suboxone for the management of opiate addiction.",
          "last_scrape": "2018-12-13T16:50:50",
          "latest": "2014-05-22T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2013-05-17T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-04-15T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Opioid-Related Disorders",
          "trade_name": "Suboxone",
          "url": "http://www.ncpe.ie/drugs/suboxone-buprenorphinenaloxone/"
         },
         {
          "company": "Grünenthal",
          "drug_name": "Sufentanil (Zalviso®)",
          "earliest": "2016-03-14T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zalviso",
          "eu_market": "2015-09-18T00:00:00",
          "id": 2520,
          "indication": "Sufentanil (Zalviso®) is indicated for the management of acute moderate to severe post-operative pain in adult patients.",
          "last_scrape": "2018-12-13T16:50:54",
          "latest": "2018-06-27T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-03-14, 2016-03-22",
          "rr_end": "2016-03-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-03-14T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Pain, Postoperative",
          "trade_name": "Zalviso",
          "url": "http://www.ncpe.ie/drugs/sufentanil-zalviso/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Sunitinib (Sutent®)",
          "earliest": "2006-09-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/sutent",
          "eu_market": "2006-07-19T00:00:00",
          "id": 2521,
          "indication": "In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours (GIST). Data on the cost-effectiveness and budget impact of sutinitinib as second line treatment for patients with metastatic renal cell carcinoma (mRCC) was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.",
          "last_scrape": "2018-12-13T16:50:59",
          "latest": "2006-09-01T00:00:00",
          "ncpe_year": 2006,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2016-03-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-02-19T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors",
          "trade_name": "Sutent",
          "url": "http://www.ncpe.ie/drugs/sunitinib-sutent/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Tadalafil (Adcirca®)",
          "earliest": "2011-07-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2522,
          "indication": "Tadalafil (Adcirca®) is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as World Health Organisation (WHO) Functional Class (FC) II and III, to improve exercise capacity.",
          "last_scrape": "2018-12-13T16:51:04",
          "latest": "2014-05-23T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23",
          "rr_end": "2014-05-23T00:00:00",
          "rr_multiple": 1,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-07-13T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Adcirca",
          "url": "http://www.ncpe.ie/drugs/tadalafil-adcirca-2/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Tafamadis meglumine (Vyndaqel®)",
          "earliest": "2018-03-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel",
          "eu_market": "2011-11-16T00:00:00",
          "id": 2523,
          "indication": "Tafamadis meglumine (Vyndaqel®) for the treatment of transthyretin amyloidosis in adult patients with stage I symptomatic polyneuropathy to delay peripheral neurologic impairment.",
          "last_scrape": "2018-12-13T16:51:09",
          "latest": "2018-05-10T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-03-12, 2018-05-10",
          "rr_end": "2018-05-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is not recommended until additional efficacy and/or safety data is submitted on the basis of current evidence, the ncpe recommends that tafamidis not be considered for reimbursement in accordance with the criteria specified in the health (pricing and supply of medical goods) act 2013",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2018-03-12T00:00:00",
          "rr_status": "No HTA until more evidence",
          "ta_list": "Amyloidosis",
          "trade_name": "Vyndaqel",
          "url": "http://www.ncpe.ie/drugs/tafamadis-meglumine-vyndaqel/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Tafluprost (Saflutan®)",
          "earliest": "2011-03-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2524,
          "indication": "Tafluoprost (Salflutan®) for the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension.",
          "last_scrape": "2018-12-13T16:51:15",
          "latest": "2011-03-25T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-03-11, 2011-03-25",
          "rr_end": "2011-03-25T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2011-03-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Saflutan",
          "url": "http://www.ncpe.ie/drugs/tafluprost-saflutan/"
         },
         {
          "company": "Amgen",
          "drug_name": "Talimogene Laherparepvec (Imlygic®)",
          "earliest": "2016-02-16T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic",
          "eu_market": "2015-12-16T00:00:00",
          "id": 2525,
          "indication": "Talimogene laherparepvec (Imlygic®) is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.",
          "last_scrape": "2018-12-13T16:51:24",
          "latest": "2016-03-14T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-02-16, 2016-03-14",
          "rr_end": "2016-03-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-02-16T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma",
          "trade_name": "Imlygic",
          "url": "http://www.ncpe.ie/drugs/talimogene-laherparepvec-imlygic/"
         },
         {
          "company": "GlaxoSmithKline",
          "drug_name": "Tapentadol (Palexia®)",
          "earliest": "2010-10-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/adjupanrix-previously-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted",
          "eu_market": "2009-10-10T00:00:00",
          "id": 2526,
          "indication": "Economic evaluation of oral tapentadol (Palexia®) for the management of adult patients with severe chronic/acute pain.",
          "last_scrape": "2018-12-13T16:51:28",
          "latest": "2011-04-08T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2010-10-19, 2010-10-22",
          "rr_end": "2010-10-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2010-10-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Influenza, Human; Immunization; Disease Outbreaks",
          "trade_name": "Palexia",
          "url": "http://www.ncpe.ie/drugs/tapentadol-palexia/"
         },
         {
          "company": "Merck",
          "drug_name": "Tedizolid phosphate (Sivextro®)",
          "earliest": "2015-05-07T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro",
          "eu_market": "2015-03-23T00:00:00",
          "id": 2527,
          "indication": "Tedizolid phosphate (Sivextro®) is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults",
          "last_scrape": "2018-12-13T16:51:34",
          "latest": "2015-07-07T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2015-05-07, 2015-07-07",
          "rr_end": "2015-07-07T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2015-05-07T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Soft Tissue Infections; Skin Diseases, Bacterial",
          "trade_name": "Sivextro",
          "url": "http://www.ncpe.ie/drugs/tedizolid-phosphate-sivextro/"
         },
         {
          "company": "Shire",
          "drug_name": "Teduglutide (Revestive®)",
          "earliest": "2017-03-13T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/revestive",
          "eu_market": "2012-08-30T00:00:00",
          "id": 2528,
          "indication": "Teduglutide (Revestive®) is indicated for the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation.",
          "last_scrape": "2018-12-13T16:51:38",
          "latest": "2018-03-16T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2017-03-13, 2017-04-12",
          "rr_end": "2017-04-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-03-13T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Malabsorption Syndromes",
          "trade_name": "Revestive",
          "url": "http://www.ncpe.ie/drugs/teduglutide-revestive/"
         },
         {
          "company": "Nordic",
          "drug_name": "Tegafur/Gimeracil/Oteracil (Teysuno®)",
          "earliest": "2012-02-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno",
          "eu_market": "2011-03-14T00:00:00",
          "id": 2529,
          "indication": "Teysuno is indicated in adults for the treatment of advanced gastric cancer.",
          "last_scrape": "2018-12-13T16:51:44",
          "latest": "2012-03-23T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2012-02-27, 2012-03-23",
          "rr_end": "2012-03-23T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2012-02-27T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Stomach Neoplasms",
          "trade_name": "Teysuno",
          "url": "http://www.ncpe.ie/drugs/tegafurgimeraciloteracil-teysuno/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Telaprevir (Incivo®)",
          "earliest": "2011-10-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/incivo",
          "eu_market": "2011-09-19T00:00:00",
          "id": 2530,
          "indication": "Economic evaluation of Telaprevir (Incivo®) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.",
          "last_scrape": "2018-12-13T16:51:48",
          "latest": "2012-01-19T00:00:00",
          "ncpe_year": 2012,
          "orphan": 0,
          "rr_dates": "2011-10-28, 2011-11-02",
          "rr_end": "2011-11-02T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-10-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Hepatitis C, Chronic",
          "trade_name": "Incivo",
          "url": "http://www.ncpe.ie/drugs/telapravir/"
         },
         {
          "company": "Theravance",
          "drug_name": "Telavancin (Vibativ®)",
          "earliest": "2014-12-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/vibativ-0",
          "eu_market": "2011-09-02T00:00:00",
          "id": 2531,
          "indication": "Indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA).  Vabitiv® should be used only in situations where it is known or suspected that other alternatives are not suitable.",
          "last_scrape": "2018-12-13T16:51:52",
          "latest": "2015-01-13T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2014-12-08, 2015-01-13",
          "rr_end": "2015-01-13T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-12-08T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Pneumonia, Bacterial; Cross Infection",
          "trade_name": "Vibativ",
          "url": "http://www.ncpe.ie/drugs/telavancin-vibativ/"
         },
         {
          "company": "Sanofi-aventis",
          "drug_name": "Teriflunomide (Aubagio®)",
          "earliest": "2013-08-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio",
          "eu_market": "2013-08-26T00:00:00",
          "id": 2532,
          "indication": "Aubagio® is indicated for the first line treatment of adult patients with relapsing remitting multiple sclerosis (MS).",
          "last_scrape": "2018-12-13T16:51:56",
          "latest": "2014-09-05T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2013-08-27, 2013-09-20",
          "rr_end": "2013-09-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-08-27T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Multiple Sclerosis",
          "trade_name": "Aubagio",
          "url": "http://www.ncpe.ie/drugs/teriflunomide-aubagio/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Ticagrelor (Brilique®)",
          "earliest": "2016-02-29T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/brilique",
          "eu_market": "2010-12-03T00:00:00",
          "id": 2533,
          "indication": "Ticagrelor (Brilique®) 60mg, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.",
          "last_scrape": "2018-12-13T16:51:58",
          "latest": "2016-05-04T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-02-29, 2016-05-04",
          "rr_end": "2016-05-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-02-29T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Peripheral Vascular Diseases; Acute Coronary Syndrome",
          "trade_name": "Brilique",
          "url": "http://www.ncpe.ie/drugs/ticagrelor-brilique-2/"
         },
         {
          "company": "AstraZeneca",
          "drug_name": "Ticagrelor (Brilique®)",
          "earliest": "2010-11-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/brilique",
          "eu_market": "2010-12-03T00:00:00",
          "id": 2534,
          "indication": "Economic Evaluation of Ticagrelor (Brilique®) for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndrome (ACS) including patients managed medically, and those who are managed with PCI (Percutaneous Coronary Intervention) or CABG (Coronary Artery Bypass Graft).",
          "last_scrape": "2018-12-13T16:52:01",
          "latest": "2011-10-10T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2010-11-25, 2011-01-20",
          "rr_end": "2011-01-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2010-11-25T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Peripheral Vascular Diseases; Acute Coronary Syndrome",
          "trade_name": "Brilique",
          "url": "http://www.ncpe.ie/drugs/ticagrelor-brilique/"
         },
         {
          "company": "Novartis",
          "drug_name": "Tisagenlecleucel (Kymriah®) for ALL",
          "earliest": "2018-09-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah",
          "eu_market": "2018-08-22T00:00:00",
          "id": 2535,
          "indication": "Tisagenlecleucel (Kymriah®) for the treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.",
          "last_scrape": "2018-12-13T16:52:07",
          "latest": "2018-10-19T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-09-19, 2018-10-19",
          "rr_end": "2018-10-19T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-09-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse",
          "trade_name": "Kymriah",
          "url": "http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-all/"
         },
         {
          "company": "Novartis",
          "drug_name": "Tisagenlecleucel (Kymriah®) for DLBCL",
          "earliest": "2018-09-19T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah",
          "eu_market": "2018-08-22T00:00:00",
          "id": 2536,
          "indication": "Tisagenlecleucel (Kymriah®) which is licensed for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.",
          "last_scrape": "2018-12-13T16:52:13",
          "latest": "2018-10-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-09-19, 2018-10-18",
          "rr_end": "2018-10-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-09-19T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse",
          "trade_name": "Kymriah",
          "url": "http://www.ncpe.ie/drugs/tisagenlecleucel-kymriah-for-dlbcl/"
         },
         {
          "company": "CIS",
          "drug_name": "Tobramycin (TOBI Podhaler®)",
          "earliest": "2010-11-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2537,
          "indication": "Tobramycin (TOBI Podhaler®) for the suppressive therapy of chronic pulmonary infection due to Ps aeruginosa in adults and children aged 6 years and older with CF.",
          "last_scrape": "2018-12-13T16:52:19",
          "latest": "2010-11-03T00:00:00",
          "ncpe_year": 2010,
          "orphan": 0,
          "rr_dates": "2010-11-10, 2010-11-03",
          "rr_end": "2010-11-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2010-11-10T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "TOBI Podhaler",
          "url": "http://www.ncpe.ie/drugs/tobramycin-tobi-podhaler/"
         },
         {
          "company": "Roche",
          "drug_name": "Tocilizumab SC (RoActemra®)",
          "earliest": "2014-04-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra",
          "eu_market": "2009-01-15T00:00:00",
          "id": 2538,
          "indication": "It is licensed for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.",
          "last_scrape": "2018-12-13T16:52:24",
          "latest": "2014-07-16T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-04-28, 2014-07-16",
          "rr_end": "2014-07-16T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at thesubmitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-04-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid",
          "trade_name": "RoActemra",
          "url": "http://www.ncpe.ie/drugs/tocilizumab-sc-roactemra/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Tofacitinib (Xeljanz®) for Ulcerative Colitis",
          "earliest": "2018-07-16T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz",
          "eu_market": "2017-03-21T00:00:00",
          "id": 2539,
          "indication": "Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor).",
          "last_scrape": "2018-12-13T16:52:30",
          "latest": "2018-09-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-07-16, 2018-09-18",
          "rr_end": "2018-09-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of tofacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-07-16T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Rheumatoid",
          "trade_name": "Xeljanz",
          "url": "http://www.ncpe.ie/drugs/tofacitinib-xeljanz-for-ulcerative-colitis/"
         },
         {
          "company": "Pfizer",
          "drug_name": "Tofacitinib (Xeljanz®)",
          "earliest": "2017-03-08T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz",
          "eu_market": "2017-03-21T00:00:00",
          "id": 2540,
          "indication": "Tofacitinib (Xeljanz®) in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drug. Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.",
          "last_scrape": "2018-12-13T16:52:35",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-03-08, 2017-04-28",
          "rr_end": "2017-04-28T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2017-03-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Arthritis, Rheumatoid",
          "trade_name": "Xeljanz",
          "url": "http://www.ncpe.ie/drugs/tofacitinib-xeljanz/"
         },
         {
          "company": "Otsuka",
          "drug_name": "Tolvaptan (Jinarc®)",
          "earliest": "2016-01-04T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc",
          "eu_market": "2015-05-27T00:00:00",
          "id": 2541,
          "indication": "Jinarc®) to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1-3 at initiation of treatment with evidence of rapidly progressing disease.",
          "last_scrape": "2018-12-13T16:52:40",
          "latest": "2018-09-13T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2016-01-04, 2016-01-12",
          "rr_end": "2016-01-12T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-01-04T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Polycystic Kidney, Autosomal Dominant",
          "trade_name": "Jinarc",
          "url": "http://www.ncpe.ie/drugs/tolvaptan-jinarc/"
         },
         {
          "company": "CIS",
          "drug_name": "Tramadol hydrochloride/dexketoprofen (Skudexa®)",
          "earliest": "2017-10-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2542,
          "indication": "Tramadol hydrochloride/dexketoprofen (Skudexa ®) for the symptomatic short-term treatment of moderate to severe acute pain in adult patients whose pain is considered to require a combination of tramadol and dexketoprofen.",
          "last_scrape": "2018-12-13T16:52:45",
          "latest": "2017-12-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2017-10-17, 2017-12-01",
          "rr_end": "2017-12-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "reimursement not recommended at the submitted price",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2017-10-17T00:00:00",
          "rr_status": "Reimbursement not recommended",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Skudexa",
          "url": "http://www.ncpe.ie/drugs/tramadol-hydrochloridedexketoprofen-skudexa/"
         },
         {
          "company": "Novartis",
          "drug_name": "Trametinib (Mekinist®)",
          "earliest": "2015-11-27T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist",
          "eu_market": "2014-06-30T00:00:00",
          "id": 2543,
          "indication": "Mekinist® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
          "last_scrape": "2018-12-13T16:52:51",
          "latest": "2018-03-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2015-11-27, 2015-12-22",
          "rr_end": "2015-12-22T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2015-11-27T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma",
          "trade_name": "Mekinist",
          "url": "http://www.ncpe.ie/drugs/trametinib-mekinist/"
         },
         {
          "company": "Roche",
          "drug_name": "Trastuzumab emtansine (Kadcyla®)",
          "earliest": "2013-09-25T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla",
          "eu_market": "2013-11-15T00:00:00",
          "id": 2544,
          "indication": "Trastuzumab emtansine (Kadcyla®) is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination.",
          "last_scrape": "2018-12-13T16:52:56",
          "latest": "2015-12-01T00:00:00",
          "ncpe_year": 2015,
          "orphan": 0,
          "rr_dates": "2013-09-25, 2013-10-24",
          "rr_end": "2013-10-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-09-25T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Breast Neoplasms",
          "trade_name": "Kadcyla",
          "url": "http://www.ncpe.ie/drugs/trastuzumab-emtansine-kadcyla/"
         },
         {
          "company": "Les",
          "drug_name": "Trifluridine/tipiracil (Lonsurf®)",
          "earliest": "2016-06-10T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf",
          "eu_market": "2016-04-25T00:00:00",
          "id": 2545,
          "indication": "Trifluridine/tipiracil (Lonsurf®) is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.",
          "last_scrape": "2018-12-13T16:53:00",
          "latest": "2016-07-11T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-06-10, 2016-07-11",
          "rr_end": "2016-07-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-06-10T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Colorectal Neoplasms",
          "trade_name": "Lonsurf",
          "url": "http://www.ncpe.ie/drugs/trifluridinetipiracil-lonsurf/"
         },
         {
          "company": "Gedeon",
          "drug_name": "Ulipristal acetate (Esmya ®) intermittent treatment",
          "earliest": "2016-05-17T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/esmya",
          "eu_market": "2012-02-22T00:00:00",
          "id": 2546,
          "indication": "Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.",
          "last_scrape": "2018-12-13T16:53:04",
          "latest": "2016-05-31T00:00:00",
          "ncpe_year": 2016,
          "orphan": 0,
          "rr_dates": "2016-05-17, 2016-05-31",
          "rr_end": "2016-05-31T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2016-05-17T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Leiomyoma",
          "trade_name": "Esmya",
          "url": "http://www.ncpe.ie/drugs/ulipristal-acetate-esmya-2/"
         },
         {
          "company": "Gedeon",
          "drug_name": "Ulipristal acetate (Esmya®) single course treatment",
          "earliest": "2013-09-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/esmya",
          "eu_market": "2012-02-22T00:00:00",
          "id": 2547,
          "indication": "Ulipristal acetate (Esmya®) is indicated for the pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.",
          "last_scrape": "2018-12-13T16:53:08",
          "latest": "2013-10-18T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-09-03, 2013-10-18",
          "rr_end": "2013-10-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2013-09-03T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Leiomyoma",
          "trade_name": "Esmya",
          "url": "http://www.ncpe.ie/drugs/ulipristal-acetate-esmya/"
         },
         {
          "company": "CIS",
          "drug_name": "Umeclidinium/vilanterol (Anoro®)",
          "earliest": "2014-06-11T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2548,
          "indication": "Umeclidinium/vilanterol (Anoro®) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.",
          "last_scrape": "2018-12-13T16:53:10",
          "latest": "2014-07-10T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2014-06-11, 2014-07-10",
          "rr_end": "2014-07-10T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation not recommended",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2014-06-11T00:00:00",
          "rr_status": "No HTA",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "Anoro",
          "url": "http://www.ncpe.ie/drugs/umeclidiniumvilanterol-anoro/"
         },
         {
          "company": "Unknown",
          "drug_name": "Urea (GlucoRx Allpresan®)",
          "earliest": "2018-07-09T00:00:00",
          "ema_url": "",
          "eu_market": "2015-07-22T00:00:00",
          "id": 2549,
          "indication": "GlucoRx Allpresan® Diabetic Foam Cream for the treatment of dry and sensitive foot skin (Basic) and very dry to chapped foot skin (Intensive) in patients with Diabetes Mellitus.",
          "last_scrape": "2018-12-13T16:53:12",
          "latest": "2018-07-24T00:00:00",
          "ncpe_year": 2018,
          "orphan": 0,
          "rr_dates": "2018-07-09, 2018-07-24",
          "rr_end": "2018-07-24T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic assessment is not recommended the ncpe recommends that glucorx allpresan diabetic foam cream not be considered for reimbursement at the submitted price in accordance with the criteria specified in the health (pricing and supply of medical goods) act 2013",
          "rr_outcome_type": "Not Recommended",
          "rr_start": "2018-07-09T00:00:00",
          "rr_status": "No HTA at submitted price",
          "ta_list": "Unknown",
          "trade_name": "GlucoRx Allpresan",
          "url": "http://www.ncpe.ie/drugs/urea-glucorx-allpresan/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Ustekinumab (Stelara®) for Crohn’s Disease",
          "earliest": "2016-11-28T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/stelara",
          "eu_market": "2009-01-15T00:00:00",
          "id": 2550,
          "indication": "Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist or have medical contraindications to such therapies",
          "last_scrape": "2018-12-13T16:53:17",
          "latest": "2017-11-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2016-11-28, 2017-01-11",
          "rr_end": "2017-01-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended at the submitted price",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-11-28T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Psoriasis; Arthritis, Psoriatic; Crohn Disease",
          "trade_name": "Stelara",
          "url": "http://www.ncpe.ie/drugs/ustekinumab-stelara-2/"
         },
         {
          "company": "Janssen-Cilag",
          "drug_name": "Ustekinumab (Stelara®)",
          "earliest": "2009-07-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/stelara",
          "eu_market": "2009-01-15T00:00:00",
          "id": 2551,
          "indication": "Cost-effectiveness of Ustekinumab (Stelara®) in the treament of moderate to severe psoriasis.",
          "last_scrape": "2018-12-13T16:53:23",
          "latest": "2009-11-01T00:00:00",
          "ncpe_year": 2009,
          "orphan": 0,
          "rr_dates": "",
          "rr_end": "2017-01-11T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "",
          "rr_outcome_type": "Recommended",
          "rr_start": "2016-12-10T00:00:00",
          "rr_status": "RR not conducted",
          "ta_list": "Psoriasis; Arthritis, Psoriatic; Crohn Disease",
          "trade_name": "Stelara",
          "url": "http://www.ncpe.ie/drugs/ustekinumab-stelara/"
         },
         {
          "company": "Genzyme",
          "drug_name": "Vandetanib (Caprelsa®)",
          "earliest": "2013-06-06T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa",
          "eu_market": "2012-02-16T00:00:00",
          "id": 2552,
          "indication": "Vandetanib (Caprelsa®) for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.",
          "last_scrape": "2018-12-13T16:53:29",
          "latest": "2013-07-03T00:00:00",
          "ncpe_year": 2013,
          "orphan": 0,
          "rr_dates": "2013-06-06, 2013-07-03",
          "rr_end": "2013-07-03T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-06-06T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Thyroid Neoplasms",
          "trade_name": "Caprelsa",
          "url": "http://www.ncpe.ie/drugs/vandetanib-caprelsa/"
         },
         {
          "company": "Takeda",
          "drug_name": "Vedolizumab (Entyvio®) in Crohn’s Disease",
          "earliest": "2014-09-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio",
          "eu_market": "2014-05-22T00:00:00",
          "id": 2553,
          "indication": "Vedolizumab (Entyvio®) indicated for the treatment of adult patients with moderately toseverely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.",
          "last_scrape": "2018-12-13T16:53:32",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2014-09-12, 2014-10-01",
          "rr_end": "2014-10-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-09-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Colitis, Ulcerative; Crohn Disease",
          "trade_name": "Entyvio",
          "url": "http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-crohns-disease/"
         },
         {
          "company": "Takeda",
          "drug_name": "Vedolizumab (Entyvio®) in Ulcerative Colitis",
          "earliest": "2014-09-12T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio",
          "eu_market": "2014-05-22T00:00:00",
          "id": 2554,
          "indication": "Vedolizumab (Entyvio®) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.",
          "last_scrape": "2018-12-13T16:53:39",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2014-09-12, 2014-10-01",
          "rr_end": "2014-10-01T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-09-12T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Colitis, Ulcerative; Crohn Disease",
          "trade_name": "Entyvio",
          "url": "http://www.ncpe.ie/drugs/vedolizumab-entyvio-in-ulcerative-colitis/"
         },
         {
          "company": "CIS",
          "drug_name": "Velaglucerase Alfa (VPRIV®)",
          "earliest": "2011-04-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125",
          "eu_market": "1996-10-04T00:00:00",
          "id": 2555,
          "indication": "VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.",
          "last_scrape": "2018-12-13T16:53:45",
          "latest": "2011-06-20T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2011-04-26, 2011-06-20",
          "rr_end": "2011-06-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-04-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Radionuclide Imaging; Ovarian Neoplasms",
          "trade_name": "VPRIV",
          "url": "http://www.ncpe.ie/drugs/velaglucerase-alfa-vpriv-2/"
         },
         {
          "company": "AbbVie",
          "drug_name": "Venetoclax (Venclyxto®) in combination with rituximab",
          "earliest": "2018-09-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto",
          "eu_market": "2016-12-04T00:00:00",
          "id": 2556,
          "indication": "Venetoclax (Venclyxto®) in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.",
          "last_scrape": "2018-12-13T16:53:49",
          "latest": "2018-10-18T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-09-26, 2018-10-18",
          "rr_end": "2018-10-18T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full hta is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax compared with the current standard of care",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-09-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Venclyxto",
          "url": "http://www.ncpe.ie/drugs/venetoclax-venclyxto-in-combination-with-rituximab/"
         },
         {
          "company": "AbbVie",
          "drug_name": "Venetoclax (Venclyxto®)",
          "earliest": "2017-01-03T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto",
          "eu_market": "2016-12-04T00:00:00",
          "id": 2557,
          "indication": "Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL)",
          "last_scrape": "2018-12-13T16:53:52",
          "latest": "2018-12-01T00:00:00",
          "ncpe_year": 2018,
          "orphan": 1,
          "rr_dates": "2018-05-08, 2018-06-21",
          "rr_end": "2018-06-21T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "following a resubmission of the rapid review full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies",
          "rr_outcome_type": "Recommended",
          "rr_start": "2018-05-08T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Leukemia, Lymphocytic, Chronic, B-Cell",
          "trade_name": "Venclyxto",
          "url": "http://www.ncpe.ie/drugs/venetoclax-venclyxto/"
         },
         {
          "company": "Roche",
          "drug_name": "Vemurafenib (Zelboraf®)",
          "earliest": "2011-12-23T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf",
          "eu_market": "2012-02-17T00:00:00",
          "id": 2558,
          "indication": "Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.",
          "last_scrape": "2018-12-13T16:53:58",
          "latest": "2014-09-01T00:00:00",
          "ncpe_year": 2014,
          "orphan": 0,
          "rr_dates": "2011-12-23, 2012-01-04",
          "rr_end": "2012-01-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2011-12-23T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Melanoma",
          "trade_name": "Zelboraf",
          "url": "http://www.ncpe.ie/drugs/vermurafenib-zelboraf/"
         },
         {
          "company": "Cardiome",
          "drug_name": "Vernakalant (Brinavess®)",
          "earliest": "2010-10-26T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess",
          "eu_market": "2010-09-01T00:00:00",
          "id": 2559,
          "indication": "Economic evaluation of Vernakalant (Brinavess®) for haemodynamically stable, symptomatic patients with atrial fibrillation of less than 48 hours duration.",
          "last_scrape": "2018-12-13T16:54:00",
          "latest": "2011-05-04T00:00:00",
          "ncpe_year": 2011,
          "orphan": 0,
          "rr_dates": "2010-10-26, 2010-11-04",
          "rr_end": "2010-11-04T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2010-10-26T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Atrial Fibrillation",
          "trade_name": "Brinavess",
          "url": "http://www.ncpe.ie/drugs/vernakalant-brinavess/"
         },
         {
          "company": "Roche",
          "drug_name": "Vismodegib (Erivedge®)",
          "earliest": "2013-05-02T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge",
          "eu_market": "2013-07-12T00:00:00",
          "id": 2560,
          "indication": "Vismodegib (Erivedge®) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy or metastatic basal cell carcinoma.",
          "last_scrape": "2018-12-13T16:54:04",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2013-05-02, 2013-05-20",
          "rr_end": "2013-05-20T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2013-05-02T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Carcinoma, Basal Cell",
          "trade_name": "Erivedge",
          "url": "http://www.ncpe.ie/drugs/vismodegib-erivedge/"
         },
         {
          "company": "Lundbeck",
          "drug_name": "Vortioxetine (Brintellix®)",
          "earliest": "2014-10-01T00:00:00",
          "ema_url": "https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix",
          "eu_market": "2013-12-18T00:00:00",
          "id": 2561,
          "indication": "Vortioxetine (Brintellix®) is indicated for the treatment of major depressive episodes in adults.",
          "last_scrape": "2018-12-13T16:54:11",
          "latest": "2017-10-01T00:00:00",
          "ncpe_year": 2017,
          "orphan": 0,
          "rr_dates": "2014-10-01, 2014-11-14",
          "rr_end": "2014-11-14T00:00:00",
          "rr_multiple": 0,
          "rr_outcome": "full pharmacoeconomic evaluation recommended",
          "rr_outcome_type": "Recommended",
          "rr_start": "2014-10-01T00:00:00",
          "rr_status": "HTA recommended at submitted price",
          "ta_list": "Depressive Disorder, Major",
          "trade_name": "Brintellix",
          "url": "http://www.ncpe.ie/drugs/vortioxetine-brintellix/"
         }
        ]
       },
       "encoding": {
        "color": {
         "field": "rr_status",
         "type": "nominal"
        },
        "x": {
         "field": "rr_status",
         "type": "nominal"
        },
        "y": {
         "aggregate": "count",
         "type": "quantitative"
        }
       },
       "height": 250,
       "mark": "bar",
       "selection": {
        "selector001": {
         "bind": "scales",
         "encodings": [
          "x",
          "y"
         ],
         "mark": {
          "fill": "#333",
          "fillOpacity": 0.125,
          "stroke": "white"
         },
         "on": "[mousedown, window:mouseup] > window:mousemove!",
         "resolve": "global",
         "translate": "[mousedown, window:mouseup] > window:mousemove!",
         "type": "interval",
         "zoom": "wheel!"
        }
       },
       "width": 500
      },
      "image/png": "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",
      "text/plain": [
       "<VegaLite 2 object>\n",
       "\n",
       "If you see this message, it means the renderer has not been properly enabled\n",
       "for the frontend that you are using. For more information, see\n",
       "https://altair-viz.github.io/user_guide/troubleshooting.html\n"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "alt.Chart(df).mark_bar().encode(\n",
    "    x='rr_status',\n",
    "    y='count()',\n",
    "    color='rr_status',).properties(\n",
    "    width=500,\n",
    "    height=250\n",
    ").interactive()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Reason for Visualization 5:\n",
    "\n",
    "This chart displays the ratio of 'rr_status' for all the drugs in the NCPE database. This helps us to identify the no.of drugs for each 'rr_status' an overall basis.\n",
    "\n",
    "##### Information obtained from Visualization 5:\n",
    "\n",
    "Maximum drugs belong to 'The HTA recommended at submitted price' (around 220 drugs) followed by 'No HTA' (120 drugs). There are few drugs that belong to 'RR not conducted' (30 drugs). Other statuses are very minimum compared to the above mentioned major ones."
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
